

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 471 236 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (43) Date of publication of patent specification: 15.03.95 (51) Int. Cl.⁶: **A61K 31/435, A61K 31/44, C07D 471/04**
- (21) Application number: 91112798.3
- (22) Date of filing: 30.07.91

(54) Imidazopyridine derivatives and their use.

- (30) Priority: 30.07.90 JP 202963/90
30.07.90 JP 202964/90
27.05.91 JP 121277/91
12.06.91 JP 140186/91
- (43) Date of publication of application: 19.02.92 Bulletin 92/08
- (45) Publication of the grant of the patent: 15.03.95 Bulletin 95/11
- (84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE
- (56) References cited:
EP-A- 0 006 614
EP-A- 0 185 345
EP-A- 0 249 170
DE-A- 2 820 938
US-A- 4 833 149

Hawley's Condensed Chemical Dictionary,
11th Edition, 1981, Van Nostrand Reinhold
Company, New York, pages 36, 100, 613 and
614.

- (73) Proprietor: **TAKEDA CHEMICAL INDUSTRIES, LTD.**

1-1, Doshomachi 4-chome
Chuo-ku,
Osaka 541 (JP)

- (72) Inventor: Takatani, Muneo
6-1, Taniguchisono-machi,
Ukyo-ku
Kyoto 616 (JP)
Inventor: Kozai, Yoshio
9-5, Selfuso 1-chome
Toyonaka,
Osaka 564 (JP)
Inventor: Tomimatsu, Kiminori
E-104, 7 Nyoidani 3-chome
Minoo,
Osaka 562 (JP)
Inventor: Shibouta, Yumiko
601, 30-20, Deguchi-cho
Sulta,
Osaka 546 (JP)

- (74) Representative: Lederer, Franz, Dr. et al
Lederer, Keller & Riederer
Patentanwälte
Prinzregentenstrasse 16
D-80538 München (DE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 471 236 B1

Description

The present invention relates to imidazopyridine derivatives and their use. Particularly, it relates to imidazo[1,2-a]pyridine derivatives which are useful as medicines and a calmodulin inhibitor containing the same.

Recently, various cerebrovascular or cardiovascular ischemic diseases have been increased with increasing in population of people of advanced age. At present, as one of medicines for treating these diseases, a calcium channel blocker has been widely used clinically and, therefore, cerebrovascular disorders caused by hypertension are decreased. However, it is said that cardiac ischemic disorders are not decreased, and development of medicines having superior mechanism of activities has been desired.


On the other hand, it has been reported that chlorpromazine having an inhibitory activity to calmodulin which is an intracellular calcium-binding protein is effective for experimental ischemic disorders [G.E. Thomas, S. Levitsky and H. Feinberg, J. Med. Cell Cardiol., 15, 621 (1983); J.I. Dahlager and T. Bilde, Scand. J. Urol Nephrol., 10, 126 (1976); and K.R. Chien, J. Adams, R.G. Pfan and J.L. Farber, Am. J. Pathol., 88, 539 (1977)], and it is also said that calmodulin plays an important role in ischemic disorders [S.W. Schaffer, R.S. Roy and J.M. McCord, Eur. Heart J., 4 (Suppl. H), 81 (1983)]. However, phenothiadines such as chlorpromazine have a strong central depressant activity and, therefore, there is a drawback in the use thereof as a medicine for circulatory system. Therefore, development of a more superior calmodulin inhibitor has been desired.

There are lot of reports relating to imidazo[1,2-a]pyridine derivatives. However, there is few reports about pharmacological activities of compounds wherein a hydrocarbon group having a functional group is bound at the 5-position through S, S(O), S(O)₂, O or N. For example, EP-A-0 249 170 reports such compounds as starting materials for synthesis of cephem compounds. Japanese Patent Laid Open Publication Nos. 277393/1987 and 10792/1988 report them as cephem compounds. EP-A-6614 and DE2820938 report them as hypotensors. However, none of them discloses calmodulin inhibitory activity.

OBJECTS OF THE INVENTION

Under these circumstances, the present inventors have intensively studied about activities and synthesis of imidazo[1,2-a]pyridine derivatives wherein a hydrocarbon group having a functional group is bound at the 5-position through S, S(O), S(O)₂, O or N. As a result, certain derivatives having excellent calmodulin inhibitory activities have been found. Thus, the present invention has been completed.

According to the present invention, there is provided a calmodulin inhibitory composition comprising a compound of the formula (I):




(I)

wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is

(a) a group of the formula:



wherein l, m and n are integers of 0 to 5, respectively; and each of R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ is


EP 0 471 236 B1

independently (1) hydrogen, or (2) C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or R⁴ and R⁵ or R⁶ and R⁷ or R⁸ and R⁹ may bind to each other to form a ring, or R⁴ or R⁶ may bind to R⁸ or R⁹, respectively, to form a ring ,

or

(b) a group of the formula: -CH₂CH₂OCH₂CH₂- or


(c) a group of the formula:



wherein o and p are integers of 0 to 5 ;

B is

(a) a group of the formula:



wherein R¹⁰ is (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

which may have 1 to 4 substituents, or (3) a member selected from -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ and -CS-NR¹⁴R¹⁵; R¹¹ is -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ or -CS-NR¹⁴R¹⁵) or

(b) a group of the formula:




wherein R¹⁸ is (1) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl, phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents, or (2) -CO-NR¹⁴R¹⁵ or -CO-R¹⁹ ,

wherein

R¹², R¹⁴ and R¹⁵ are independently (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl, phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents;


R¹³, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are independently C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

R¹⁰ and R³ may bind together to form a ring of the formula:




wherein q is an integer of 2 or 3; A and R¹¹ are as defined above , or R¹⁰ may bind to R⁴, R⁶ or R⁸ to form a ring of the formula:


EP 0 471 236 B1



wherein q and r are an integer of 2 or 3, respectively; and R¹¹ is as defined above, or R¹⁰ may bind to R¹¹ to form a ring of the formula:



R¹⁴ and R¹⁵ together with the adjacent nitrogen atom may form 1-aziridinyl, 1-azetidiny, piperidino, perhydro-1-azepinyl, perhydro-1-azocynyl, morpholino, thiomorpholino, 1-piperazinyl, 3-thiazolidinyl, 1-indolyl, perhydro-1-indolyl, 2-isindolyl, perhydro-2-isindolyl, 1,2,3,4-tetrahydro-1-quinolyl, 1,2,3,4-tetrahydro-2-isoquinolyl, perhydro-1-quinolyl, perhydro-2-isoquinolyl, 3-azabicyclo[3.2.2]non-3-yl, 9-carbozoyl, 10-acridanyl,



10,11-dihydro-5H-5-dibenz[b,f]azepinyl, 5,6,11,12-tetrahydro-5-dibenz[b,f]azocinyl, 1,2,3,4-tetrahydro-9-carbazolyl, 10-phenoxadiny or 10-phenothiadiny;

EP 0 471 236 B1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxy-carbonyl or C₁₋₆ alkyl-carbonyl;

said substituent of C₁₋₃₀ alkyl or C₂₋₃₀ alkenyl is (1) C₃₋₈ cycloalkyl, (2) phenyl optionally substituted with 1 to 4 substituents selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, nitro and halogen, (3) naphthyl, (4) halogen, (5) cyano, (6) oxo or (7) C₁₋₆ alkoxy;

said substituent of C₃₋₈ cycloalkyl or saturated bi- or tricyclic hydrocarbon is C₁₋₆ alkyl, halogeno C₁₋₆ alkyl, hydroxy C₁₋₆ alkyl, acyloxy C₁₋₆ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy, halogeno C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl-C₁₋₆ alkoxy, C₁₋₆ alkenyloxy, aralkyloxy, C₁₋₆ alkoxy-C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl, carboxy, carbamoyl, N,N-di C₁₋₆ alkyl-carbamoyl, N-C₁₋₆ alkyl-carbamoyl, halogen, cyano, nitro, hydroxy, acyloxy, amino, C₁₋₆ alkylsulfonylamino, acylamino, C₁₋₆ alkoxy-carbonylamino, acyl, mercapto, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl or oxo;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxy-carbonyl, carbamoyl or C₁₋₆ alkyl-carbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy-carbonyl, carbamoyl or C₁₋₆ alkyl-carbamoyl;

and R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;

a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy-carbonyl group or a C₁₋₆-alkyl-carbamoyl group, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

In the formula (I), X is S, S(O), S(O)₂, O or NR³ wherein R³ is a hydrogen or as defined above.

Preferably, X is S or O.

As the C₁₋₆ alkyl group in each substituent in the formula (I), for example, there is a straight or branched alkyl group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like. As the alkenyl group having 2 to 6 carbon atoms there is a group such as vinyl, allyl, 2-butenyl, 3-butenyl and the like. The C₁₋₆ alkyl group may have 1 to 4 substituents such as halogen, nitro, amino, lower alkylamino, cyclic amino, lower alkoxy, aryloxy, carbamoyl, cyano, hydroxy, carboxy, lower alkoxy-carbonyl, lower alkoxy-carbamoyl and the like. Examples of halogen include fluorine, bromine, chlorine and iodine.

Examples of the lower alkylamino group as the above substituent include a N-monoalkylamino group of which alkyl moiety has 1 to 6 carbon atoms such as methylamino, ethylamino, propylamino, butylamino and the like, and a N,N-dialkylamino group of which alkyl moiety has 1 to 6 carbon atoms such as dimethylamino, diethylamino, dibutylamino, methylethylamino and the like.

Examples of the cyclic amino group as the above substituent include a 4 to 7 membered cyclic amino group such as N-pyrrolidinyl, piperidino, piperazinyl, morpholino, homopiperazino and the like.

Examples of the lower alkoxy group as the above substituent include a straight or branched alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy and the like.

Examples of the aryloxy group as the above substituent include a C₆₋₁₀ aryloxy group such as phenoxy, 1-naphthoxy, 2-naphthoxy group and the like.

Examples of the lower alkoxy-carbonyl group as the above substituent include an alkoxy-carbonyl group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and the like.

Examples of the lower alkyl-carbamoyl group as the above substituent include a N-monoalkyl-carbamoyl group of which alkyl moiety has 1 to 6 carbon atoms such as methyl-carbamoyl, ethyl-carbamoyl, propyl-carbamoyl, butyl-carbamoyl and the like, and a N,N-dialkyl-carbamoyl group of which alkyl moiety has 1 to 6 carbon atoms such as dimethyl-carbamoyl, diethyl-carbamoyl, dibutyl-carbamoyl, methylethyl-carbamoyl and the like.

As the C₁₋₃₀ alkyl group in the formula (I), for example, there are a straight or branched alkyl group having 1 to 30, preferably 1 to 10 carbon atoms such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosanyl, heneicosanyl, docosanyl, tricosanyl, tetracosanyl, pentacosanyl, hexacosanyl, heptacosanyl, octacosanyl, nonacosanyl, triacontanyl, farnesyl, dihydrophytyl and the like. As cycloalkyl group having 3 to 8 carbon atoms there is a group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. As saturated bicyclic hydrocarbon group formed by binding 5 to 8 membered rings

EP 0 471 236 B1

to each other there is a group such as norbornyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.0]octyl, perhydropentalenyl, perhydroindenyl, perhydroazulenyl, perhydrocyclopentacyclooctenyl, perhydronaphthyl, perhydrobenzocycloheptenyl, perhydrobenzocyclooctenyl, perhydroheptalenyl, perhydrocycloheptacyclooctenyl and the like; and as saturated tricyclic hydrocarbon group formed by binding 5 to 8 membered rings

to each other there is a group such as adamantylperhydroindacenyl (as, s), perhydroacenaphthylenyl, perhydrophenanthryl, perhydroanthryl and the like.

Examples of the alkenyl group having 2 to 30 carbon atoms are groups such as vinyl, allyl, 9-octadecenyl and the like.

The above alkyl group having 1 to 30 carbon atoms and alkenyl group having 2 to 30 carbon atoms may be substituted with about 1 to 4, preferably 1 or 2 substituents such as cycloalkyl group having 3 to 8 carbon atoms (e.g., cyclopropyl, etc.), phenyl, naphthyl, halogen (e.g., Br, Cl, etc.), cyano, oxo, lower alkoxy group having 1 to 6 carbon atoms and the like. The phenyl group as the substituent for the alkyl and alkenyl group may be substituted with 1 to 4 substituents such as lower alkyl group having 1 to 6 carbon atoms, lower alkoxy group having 1 to 6 carbon atoms, hydroxy, nitro, halogen and the like.

The C₃₋₈ cycloalkyl group and the saturated bi- or tricyclic hydrocarbon group formed by binding 5 to 8 membered rings to each other may be substituted with 1 to 4, preferably 1 or 2 substituents such as lower alkyl group, halogeno lower alkyl group, hydroxy lower alkyl group, acyloxy lower alkyl group, lower alkoxy-lower alkyl group, lower alkoxy group, halogeno lower alkoxy group, lower alkoxy-carbonyl-lower alkoxy group, lower alkenyloxy group, aralkyloxy group, lower alkoxy-lower alkoxy group, lower alkoxy-carbonyl group, carboxy group, carbamoyl group, N,N-di lower alkylcarbamoyl group, N-lower alkylcarbamoyl group, halogen, cyano, nitro, hydroxy, acyloxy group, amino group, lower alkylsulfonylamino group, acylamino group, lower alkoxy-carbonylamino group, acyl group, mercapto, lower alkylthio group, lower alkylsulfinyl group, lower alkylsulfonyl group, oxo and the like. When they are substituted with 2 or more substituents, the substituents may be the same or different.

Examples of the lower alkyl group as the above substituent include an alkyl group having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.

As the halogeno lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms which is substituted with 1 to 3 halogen atoms such as trifluoromethyl, fluoromethyl, chloroethyl, fluoroethyl and the like.

As the hydroxy lower alkyl group, for example, there is a hydroxyalkyl group having 1 to 6 carbon atoms such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and the like.

As the acyloxy lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms which is substituted with a lower alkanoyloxy or benzoyloxy group having 2 to 6 carbon atoms such as acetoxyethyl, benzoyloxyethyl and the like.

As the lower alkoxy-lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms which is substituted with an alkoxy group having 1 to 6 carbon atoms such as methoxyethyl, ethoxyethyl, propoxyethyl, butoxyethyl, methoxypropyl, methoxybutyl, ethoxypropyl, ethoxybutyl and the like.

As the lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.

As the halogeno lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms which is substituted with 1 to 3 halogen atoms such as chloroethoxy, fluoroethoxy, difluoroethoxy, trifluoroethoxy, chloropropoxy, chlorobutoxy and the like.

As the lower alkoxy-carbonyl-lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms which is substituted with an alkoxy-carbonyl group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonylmethoxy, ethoxycarbonylmethoxy, butoxycarbonylmethoxy, methoxycarbonylpropoxy, ethoxycarbonylethoxy and the like.

As the lower alkenyloxy group, for example, there is an alkenyloxy group having 2 to 6 carbon atoms such as vinyloxy, allyloxy, butenyloxy and the like.

As the aralkyloxy group, for example, there is a phenyl lower alkyloxy group of which lower alkyl moiety has 1 to 6 carbon atoms such as benzyloxy, phenethyloxy, 3-phenylpropyloxy, α -methylphenethyloxy, α -methylbenzyloxy, α -ethylbenzyloxy, β -ethylphenethyloxy, β -methylphenethyloxy and the like.

As the lower alkoxy-lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms which is substituted with an alkoxy group having 1 to 6 carbon atoms such as ethoxymethoxy, methoxyethoxy, butoxyethoxy, ethoxypropoxy and the like.

As the lower alkoxy-carbonyl, for example, there is an alkoxy-carbonyl group having 1 to 6 carbon atoms of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and the like.

EP 0 471 236 B1

As the N,N-di lower alkylcarbamoyle group, for example, there is a N,N-dialkylcarbamoyle group of which alkyl moiety has 1 to 6 carbon atoms such as N,N-dimethylcarbamoyle, N,N-diethylcarbamoyle, N,N-dipropylcarbamoyle, N,N-dibutylcarbamoyle, N-ethyl-N-methylcarbamoyle and the like and a N,N-di lower alkylcarbamoyle group of which alkyl moieties bound together to form 5 or 6 membered ring structure (e.g. N-pyrrolidinylcarbonyl, piperidinocarbonyl, etc.).

As the N-lower alkylcarbamoyle group, for example, there is a N-alkylcarbamoyle group of which alkyl moiety has 1 to 6 carbon atoms such as N-methylcarbamoyle, N-ethylcarbamoyle, N-propylcarbamoyle, N-butylcarbamoyle and the like.

Examples of halogen include chloro, fluoro, bromo, and iodo.

As the acyloxy group, for example, there is an alkanoyloxy group having 2 to 6 carbon atoms such as acetoxy, propanoyloxy, butyloxy, pivaloyloxy and the like, and benzyloxy group.

As the lower alkylsulfonylamino group, for example, there is an alkylsulfonylamino group having 1 to 6 carbon atoms such as methanesulfonylamino, ethanesulfonylamino and the like.

As the acylamino group, for example, there is an alkanoylamino having 2 to 6 carbon atoms such as acetamide, propanoylamino, butylamino, pivaloylamino and the like, and benzamide group.

As the lower alkoxy-carbonylamino group, for example, there is an alkoxy-carbonylamino group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxy-carbonylamino, ethoxy-carbonylamino, propoxy-carbonylamino, butoxy-carbonylamino and the like.

As the acyl group, for example, there is an alkanoyl group having 2 to 6 carbon atoms such as acetyl, propanoyl, butyl, pivaloyl and the like, and benzoyl group.

As the lower alkylthio group, for example, there is an alkylthio group having 1 to 6 carbon atoms such as methylthio, ethylthio, propylthio, butylthio and the like.

As the lower alkylsulfinyl group, for example, there is an alkylsulfinyl group having 1 to 6 carbon atoms such as methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl and the like.

As the lower alkylsulfonyl group, for example, there is an alkylsulfonyl having 1 to 6 carbon atoms such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl and the like.

As the phenyl-C₁₋₆ alkyl group in the formula (I), for example, there is a group such as benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl and the like. As the naphthyl-C₁₋₆ alkyl there is a group such as (1-naphthyl)methyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl and the like.

The phenyl moiety of the phenyl-C₁₋₆ alkyl group and the naphthyl moiety of the naphthyl-C₁₋₆ alkyl group may be substituted with 1 to 4 substituents such as halogen, lower alkyl group, lower alkoxy group, nitro, cyano, hydroxy, lower alkoxy-carbonyl group, carbamoyle group, lower alkylcarbamoyle group and the like.

Examples of halogen include fluoro, bromo, chloro and iodo. As the lower alkyl group, for example, there is the same lower alkyl group as that in the above formula (I).

As the lower alkoxy group, for example, there is a straight or branched alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy and the like.

As the lower alkoxy-carbonyl group, for example, there is an alkoxy-carbonyl group having 1 to 6 carbon atoms such as methoxy-carbonyl, ethoxy-carbonyl, propoxy-carbonyl, butoxy-carbonyl and the like.

As the lower alkylcarbamoyle group, for example, there is a N-alkylcarbamoyle group of which alkyl moiety has 1 to 6 carbon atoms such as methylcarbamoyle, ethylcarbamoyle, propylcarbamoyle, butylcarbamoyle and the like, and a N,N-dialkylcarbamoyle group of which alkyl moiety has 1 to 6 carbon atoms such as dimethylcarbamoyle, diethylcarbamoyle, dibutylcarbamoyle, methylethylcarbamoyle and the like.

The phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl in formula (I) may be substituted with 1 to 4, preferably 1 or 2 substituents such as halogen, lower alkyl group, lower alkoxy group, nitro, cyano, oxo, hydroxy, amino, lower alkoxy-carbonyl group, carbamoyle, lower alkylcarbamoyle group and the like.

Examples of halogen include fluoro, bromo, chloro and iodo.

As the lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms, or the lower alkyl group may have an unsaturated bond.

As the lower alkyl group having an unsaturated bond, for example, there is a lower alkenyl group having 2 to 6 carbon atoms.

As the alkyl group having 1 to 6 carbon atoms and the lower alkenyl group having 2 to 6 carbon atoms, for example, there is the same group as the lower alkyl group in the above formula (I).

Examples of the lower alkoxy group include an alkoxy group having 1 to 6 carbon atoms, examples of the lower alkoxy-carbonyl group include an alkoxy-carbonyl group of which alkoxy moiety has 1 to 6 carbon atoms, and examples of the lower alkylcarbamoyle group include a N-alkylcarbamoyle group of which alkyl moiety has 1 to 6 carbon atoms and a N,N-dialkylcarbamoyle group of which alkyl moiety has about 1 to 6

EP 0 471 236 B1


carbon atoms. Examples of these groups include the same groups as the lower alkoxy, lower alkoxycarbonyl and lower alkylcarbamoyl substituents of the phenyl moiety in the above phenyl-C₁₋₆ alkyl group.

As the aryl group containing oxo, for example, there are benzoquinolyl, naphthoquinolyl, anthraquinolyl and the like.

5 Examples of halogen in R¹ and R² include fluoro, bromo, chloro and iodo.


As the C₁₋₆-alkoxycarbonyl group and the C₁₋₆-alkylcarbamoyl group in R¹ and R², for example, there is the same groups as the lower alkoxycarbonyl and lower alkylcarbamoyl substituents on the phenyl moiety of the above phenyl-C₁₋₆ alkyl group.

10 Examples of the group wherein R¹⁰ and R³ are bound together to form a ring include that a group represented by the formula:




wherein q is 2 or 3, and A and R¹¹ are as defined above.

20 Examples of the group wherein R¹⁰ is bound with R⁴, R⁶ or R⁸ to form a ring include a group represented by the formula:




wherein q and r are 2 or 3, respectively; and R¹¹ is as defined above.

Examples of the group wherein -NR¹⁰R¹¹ forms a ring in B include a group represented by the formula:



EP 0 471 236 B1



15 and the like.

The above hetero ring may be substituted with 1 to 4, preferably 1 or 2 substituents such as lower alkyl group, halogeno lower alkyl group, hydroxy lower alkyl group, acyloxy lower alkyl group, lower alkoxy-lower alkyl group, lower alkoxy group, halogeno lower alkoxy group, lower alkoxy-carbonyl-lower alkoxy group, lower alkenyloxy group, aralkyloxy group, lower alkoxy-lower alkoxy group, lower alkoxy-carbonyl group, 20 carboxy group, carbamoyl group, N,N-di lower alkylcarbamoyl group, N-lower alkylcarbamoyl group, halogen, cyano, nitro, hydroxy, acyloxy group, amino, lower alkylsulfonylamino group, acylamino group, lower alkoxy-carbonylamino group, acyl group, mercapto group, lower alkylthio group, lower alkylsulfinyl group, lower alkylsulfonyl group, oxo and the like. When they are substituted with 2 or more substituents, the substituents may be the same or different.

25 Examples of the lower alkyl group as the above substituent include an alkyl group having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like.

As the halogeno lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms which is substituted with 1 to 3 halogens such as trifluoromethyl, fluoromethyl, chloromethyl, chloroethyl, fluoroethyl and the like.

30 As the hydroxy lower alkyl group, for example, there is a hydroxyalkyl group having 1 to 6 carbon atoms such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and the like.

As the acyloxy lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms which is substituted with a lower alkanoyl having 2 to 6 carbon atoms or benzoyloxyethyl such as acetoxyethyl, benzoyloxyethyl and the like.

35 As the lower alkoxy-lower alkyl group, for example, there is an alkyl group having 1 to 6 carbon atoms which is substituted with an alkoxy group having 1 to 6 carbon atoms such as methoxyethyl, ethoxyethyl, propoxyethyl, butoxyethyl, methoxypropyl, methoxybutyl, ethoxypropyl, ethoxybutyl and the like.

As the lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy and the like.

40 As the halogeno lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms which is substituted with 1 to 3 halogen atoms such as chloroethoxy, fluoroethoxy, difluoroethoxy, trifluoroethoxy, chloropropoxy, chlorobutoxy and the like.

As the lower alkoxy-carbonyl lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms of which alkoxy moiety is substituted with an alkoxy-carbonyl group having 1 to 6 carbon atoms such as methoxycarbonylmethoxy, ethoxycarbonylmethoxy, butoxycarbonylmethoxy, methoxycarbonylpropoxy, ethoxycarbonylethoxy and the like.

As the lower alkenyloxy group, for example, there is an alkenyloxy group having 2 to 6 carbon atoms such as vinyloxy, allyloxy, butenyloxy and the like.

50 As the aralkyloxy group, for example, there is a phenyl lower alkyloxy group of which lower alkyl moiety has 1 to 6 carbon atoms such as benzyloxy, phenethyloxy, 3-phenylpropyloxy, α -methylphenethyloxy, α -methylbenzyloxy, α -ethylbenzyloxy, β -ethylphenethyloxy, β -methylphenethyloxy and the like.

As the lower alkoxy-lower alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms which is substituted with an alkoxy group having 1 to 6 carbon atoms such as ethoxymethoxy, methoxyethoxy, butoxyethoxy, ethoxypropoxy and the like.

55 As the lower alkoxy-carbonyl, for example, there is an alkoxy-carbonyl group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and the like.

EP 0 471 236 B1

As the N,N-di lower alkylcarbamoyl group, for example, there is a N,N-dialkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon atoms such as N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-dibutylcarbamoyl, N-ethyl-N-methylcarbamoyl and the like and a N,N-di lower alkylcarbamoyl group of which alkyl moieties are bound together to form a 5 or 6 membered ring (e.g. N-pyrrolidinylcarbonyl, piperidinocarbonyl, etc.).

As the N-lower alkylcarbamoyl group, for example, there is a N-alkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon atoms such as N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-butylcarbamoyl and the like.

Examples of halogen include chloro, fluoro, bromo and iodo.

As the acyloxy group, for example, there is an alkanoyloxy group having 2 to 6 carbon atoms such as acetoxy, propanoyloxy, butyloxy, pivaloyloxy and the like, and benzoyloxy group.

As the lower alkylsulfonylamino group, for example, there is an alkylsulfonylamino group having 1 to 6 carbon atoms such as methanesulfonylamino, ethanesulfonylamino and the like.

As the acylamino group, for example, there is an alkanoylamino group having 1 to 6 carbon atoms such as acetamide, propanoylamino, butylamino, pivaloylamino and the like and benzamide group.

As the lower alkoxycarbonylamino group, for example, there is an alkoxycarbonylamino group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino and the like.

As the acyl group, for example, there is an alkanoyl group having 2 to 6 carbon atoms such as acetyl, propanoyl, butyl, pivaloyl and the like and benzoyl group.

As the lower alkylthio group, for example, there is an alkylthio group having 1 to 6 carbon atoms such as methylthio, ethylthio, propylthio, butylthio and the like.

As the lower alkylsulfinyl group, for example, there is an alkylsulfinyl group having 1 to 6 carbon atoms such as methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl and the like.

As the lower alkylsulfonyl group, for example, there is an alkylsulfonyl group having 1 to 6 carbon atoms such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl and the like.

As the optionally protected amino group of R¹ and R², for example, there are amino group, acylamino group and trimethylamino group, and examples of the acyl group include the same groups as those of R¹¹.

As the ring formed by connecting R⁴ with R⁵, or R⁶ with R⁷, or R⁸ with R⁹, for example, there are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.


As the ring formed by connecting R⁴ or R⁵ with R⁸ or R⁹, respectively, for example, there are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

The compound of the formula (I) forms a salt, for example, an acid addition salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or the like, or an organic acid such as acetic acid, oxalic acid, methanesulfonic acid, maleic acid, fumaric acid, citric acid, tartaric acid, lactic acid or the like.

Examples of a solvent of the solvate include alcohols such as methanol, ethanol, propanol, isopropanol and the like; ketones such as acetone and the like; ethers such as tetrahydrofuran, dioxane and the like.

The compound of the formula (I) may contain an assymmetric carbon in the molecule. When two kinds of stereoisomers of R-configuration and S-configuration are present, not only the separated isomers, but also a mixture thereof are included in the scope of the present invention.

Among the compounds represented by the formula (I), the compounds of the formula (I'):




(I')

wherein X, A, R¹ and R² are as defined above and B¹ is an amino group acylated by an acyl group derived from carboxylic acid having 2 or more carbon atoms, sulfonic acid, carbamic acid or thiocarbamic acid; the compounds of the formula (I'):

EP 0 471 236 B1


5



(I'')

10 wherein X, A, R¹ and R² are as defined above and B² is a group of the formula:


15



20

wherein all the symbols are as defined above;
and the compounds of the formula (I'''):

25



(I''')

35 wherein X, A, R¹ and R² are as defined above and B³ is -O-CO-NR¹⁵R¹⁶ or -O-CO-R¹⁹, wherein R¹⁵, R¹⁶ and R¹⁹ are as defined above;
and acid addition salts and solvates of these compounds have not been described heretofore in the prior art. Therefore, the present invention also provides these novel compounds.

40 As the amino group acylated by an acyl group derived from carboxylic acid having 2 or more carbon atoms, sulfonic acid, carbamic acid or thiocarbamic acid, there is, for example, a group of the formula: -NR¹⁰R¹¹ as defined in claim 5.

B³ is preferably a group of the formula: -O-CO-NHR¹⁵ (wherein R¹⁵ is as defined above).

45 Among the compounds of the formula (I), those wherein X is S or O, B is (1) an amino group acylated by an acyl group derived from a sulfonic acid, a carbamic acid or thiocarbamic acid, (2) a hydroxyl group acylated with an acyl group derived from a carboxylic acid or a carbamic acid, or (3) a ring formed by connecting the nitrogen atom of the acylated amino group of B with a carbon atom of A or R³. As the group B, an amino group acylated by an acyl group derived from a sulfonic acid is particularly preferred.


The starting materials or intermediates used for the production of the end products represented by the formula (I) are easily produced by the known processes or the *per se* known processes.

50 Imidazo[1,2-a]pyridine derivatives (I) and the salts thereof of the present invention can be synthesized for example, as follows:

55

EP 0 471 236 B1

(A) When X is S, O or NR³ in the formula (I), a compound of the formula (II):



10

wherein E is halogen such as chloro, bromo or iodo and the other substituents are as defined above, or a salt thereof reacts with a compound of the formula (III):

H-X¹-A-B (III)


15

wherein X¹ is S, O or NR³ and the other symbols are as defined above, to give the compound (I).

(B) When X is S or O in the formula (I), a compound of the formula (IV):

20

25



wherein X² is S or O and the other symbols are as defined above, or a salt thereof reacts with a compound of the formula:

30

E¹-A-B (V)

wherein E¹ is a leaving group such as halogen (i.e. chloro, bromo, iodo, etc.), toluenesulfonyl group or methanesulfonyl group and the other symbols are as defined above, to give the compound (I).

35

(C) When B is -NR¹⁰-CO-NR¹⁴R¹⁵, -NR¹⁰-CS-NR¹⁴R¹⁵ or -O-CO-NR¹⁴R¹⁵ in the formula (I), a compound of the formula (VI):

40

45



wherein B¹ is -O- or -NR¹⁰- and the other symbols are as defined above, or a salt thereof reacts with a compound of the formula:

50

Q¹-NR¹⁴R¹⁵ (VII)


wherein Q¹ is PhO-CO-, G-CO- or G-CS- (wherein Ph is a phenyl group and G is halogen such as chloro, etc.) and the other symbols are as defined above, or a salt thereof, to give the compound (I).

55

(D) When B is -NR¹⁰-CO-NR¹⁴R¹⁵, -NR¹⁰-CS-NR¹⁴R¹⁵ or -O-CO-NR¹⁴R¹⁵ in the formula (I), a compound of the formula (VIII):

EP 0 471 236 B1


5



(VIII)

10

wherein Q^2 is $OCN-$, $SCN-$, $PhO-CO-O-$, $G-CO-NR^{10}-$ or $G-CO-O-$ and the other symbols are as defined above, or a salt thereof reacts with a compound of the formula (IX):




15

wherein all the symbols are as defined above, or a salt thereof, to give the compound (I).

(E) When X is $S(O)$ or $S(O)_2$ in the formula (I), a compound of the formula (Ia):

20



(Ia)


25

wherein all the symbols are as defined above, or a salt thereof reacts with an oxidizing agent, to give the compound (I).

30

(F) When R^2 is halogen such as chloro, bromo, iodo and the like in the formula (I), a compound of the formula (Ib):

35



(Ib)

40

wherein all the symbols are as defined above, or a salt thereof reacts with a halogenating agent, to give the compound (I).


45

(G) When R^2 is nitro in the formula (I), a compound of the formula (Ib), or a salt thereof is nitrated to obtain the compound (I).

(H) When R^2 is a nitroso group in the formula (I), a compound of the formula (Ib) or a salt thereof is nitrosated to give the compound (I).

(I) When R^2 is CH_2R^{2a} (wherein R^{2a} is a lower dialkylamino group or a cyclic amino group) in the formula (I), the compound (I) is prepared by, for example, the following reaction:

50




55

EP 0 471 236 B1


(J) a compound of the formula (X):

5



(X)


10 wherein all the symbols are as defined above, or a salt thereof reacts with a compound of the formula (XI):



15 wherein the symbols are as defined above, to give the compound (I).

(K) When R^{11} is COR^{16} in the formula (I), a compound of the formula (XII):


20



(XII)

25


wherein the symbols are as defined above, or a salt thereof reacts with a compound of the formula (XIII):



30 wherein G^1 is halogen such as chloro, etc. or $\text{R}^{16}(\text{O})_q\text{-CO-O-}$ (wherein q is 0 or 1) and the other symbols are as defined above, to give the compound (I).

(L) The compound (XII) or a salt thereof is reacted with a compound of the formula (XIV):

35



wherein G^2 is halogen such as chloro, etc. or $\text{R}^{17}\text{SO}_2\text{O-}$ and the other symbols are as defined above, to give the compound (I).

40 (M) When R^2 is an amino group in the formula (I), reduction of a compound of the formula (I) wherein R^2 is nitro or nitroso, or a salt thereof gives the compound (I) wherein R^2 is an amino group. In the case of a protected amino group, the amino group is further acylated or tritylated.

In the above processes A to M, a compound which can form a salt may be used in the salt form, and examples of such a salt include those as described in the above compound (I). In the following explanation 45 of the processes A to M, a salt of each compound may be included.

The reaction of the compound (II) with the compound (III) in the process A can be conducted at -10°C to $+200^\circ\text{C}$ in a solvent in the presence of a basic compound such as sodium hydroxide, potassium hydroxide, sodium hydride, potassium carbonate or the like by using 1 equivalent to extremely excessive amount (1 to 10 equivalents) of the compound (III) per 1 equivalent of the compound (II). Examples of the 50 solvent to be used include water; lower alcohols such as methanol, ethanol, propanol and the like; ketones such as acetone, methyl ethyl ketone and the like; ethers such as tetrahydrofuran and the like; and non-aprotic polar solvents such as N,N-dimethylformamide, diethylsulfoxide and the like. The reaction time is normally 1 hour to 2 days, preferably 1 to 8 hours.

The reaction of the compound (IV) with the compound (V) in the process B is conducted under 55 conditions similar to those of the reaction of the compound (II) with the compound (III) in the process A.

The reaction of the compound (VI) with the compound (VII) in the process C is conducted at -10°C to $+150^\circ\text{C}$ in the absence or presence of a solvent (e.g. ether, toluene, benzene, chloroform, dichloromethane, dioxane, tetrahydrofuran, dimethylformamide, etc.). In order to promote the reaction, a tertiary

EP 0 471 236 B1

amine (e.g. triethylamine, pyridine, diethylaminopyridine, N-methylpiperidine, etc.) can be added. The compound (VII) is used in an amount of 1 to 10 equivalents per 1 equivalent of the compound (VI).

The reaction of the compound (VIII) with the compound (IX) in the process D is conducted under conditions similar to those of the reaction of the compound (VI) with the compound (VIII) in the process C. Further, when Q² is -NCO-, boron trifluoride-ethyl ether (BF₃·Et₂O) can be added. The reaction time is normally 0.5 to 24 hours, preferably 0.5 to 6 hours.

The oxidation of the compound (Ia) in the process E can be conducted at -30 to +100°C in the presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of an oxidizing agent per 1 equivalent of the compound (Ib). Examples of the solvent to be used include water, methanol, ethanol, dichloromethane, chloroform and the like. Examples of the oxidizing agent include m-chloroperbenzoic acid, sodium metaperiodate, hydrogen peroxide and the like. The reaction time is normally 0.5 hours to 2 days, preferably 0.5 to 12 hours.

The reaction of the compound (Ib) with a halogenating agent in the process F can be conducted at -20 to +150°C in the absence or presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of the halogenating agent per 1 equivalent of the compound (Ib). Examples of the solvent to be used include halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane, carbon tetrachloride and the like; acetic acid; propionic acid; and the like. Examples of the halogenating agent include a halogen molecule such as chlorine, bromine and the like; N-halogenosuccinimide such as N-chlorosuccinimide, N-bromosuccinimide and the like. Further, a radical reaction initiator such as benzoyl peroxide or the like can be added in the above reaction. The reaction time is normally 0.5 to 2 hours, preferably 1 to 12 hours.

The nitration of the compound (Ib) in the process (G) can be conducted at -20 to +100°C in the absence or presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of a nitrating agent per 1 equivalent of the compound (Ib). Examples of the solvent to be used include acetic acid, acetic anhydride, sulfuric acid and the like. Examples of the nitrating agent include fuming nitric acid, conc. nitric acid, a mixed acid (a mixture of sulfuric acid, fuming nitric acid, phosphoric acid or acetic anhydride and nitric acid) and the like. The reaction time is normally 0.5 to 24 hours, preferably 0.5 to 6 hours.

The nitrosation of the compound (Ib) in the process H can be conducted at -20 to +100°C in the absence or presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of a nitrosating agent per 1 equivalent of the compound (Ib). Examples of the solvent to be used include water; lower fatty acids such as acetic acid, propionic acid and the like; ethers such as tetrahydrofuran, dioxane and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. Examples of the nitrosating agent include potassium nitrite, sodium nitrite and the like. The reaction is conducted in the presence of an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid or the like. The reaction time is normally 0.5 to 24 hours, preferably 0.5 to 6 hours.

Mannich reaction of the compound (Ib) with a lower dialkylamine or a cyclic amine and formalin in the process I can be conducted at -20 to +100°C in the presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of a Mannich reagent per 1 equivalent of the compound (Ib). Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol, isopropanol and the like; lower fatty acids such as acetic acid, propionic acid and the like. The reaction time is normally 30 minutes to 1 day, preferably 1 to 12 hours.

The reaction of the compound (X) with the compound (XI) in the process J can be conducted at 0 to +200°C in the absence or presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of the compound (XI) per 1 equivalent of the compound (X). Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol and the like; ethers such as tetrahydrofuran, dimethoxyethane, dioxane and the like; nitriles such as acetonitrile, propionitrile and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. Further, in the above reaction, an inorganic base such as potassium carbonate, sodium bicarbonate or the like, or an organic base such as triethylamine, pyridine, dimethylanilin or the like can be added as an acid-trapping agent. The reaction time is normally 10 minutes to 7 days, preferably 1 hour to 2 days.

The reaction of the compound (XII) with the compound (XIII) in the process K can be conducted at -30 to +200°C in a solvent in the absence or presence of an inorganic base such as potassium carbonate, sodium bicarbonate or the like or an organic base such as triethylamine, pyridine, dimethylanilin, 1,4-diazabicyclo[2.2.2]octane (DABCO) or the like by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of the compound (XIII) per 1 equivalent of the compound (XII). Examples of the solvent to be used include halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and the like; ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and the like; esters such as methyl


EP 0 471 236 B1

acetate, ethyl acetate and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. The reaction time is normally 10 minutes to 24 hours, preferably 0.5 to 6 hours.

The reaction of the compound (XII) with the compound (XIV) in the process L is conducted under conditions similar to those of the reaction of the compound (XII) with the compound (XIII) in the process K.


5 The reduction of the compound (I) wherein R² is nitro group or nitroso group in the process M can be conducted at -20 to +200°C in the presence of a solvent by using 1 equivalent to extremely excess amount (1 to 10 equivalents) of a reducing agent per 1 equivalent of the compound (I). Examples of the solvent to be used include water, methanol, ethanol, propanol, isopropanol, acetic acid and the like. Examples of the reducing agent include a mixture of iron and hydrochloric acid or a mixture of zinc and
10 acetic acid. Further, the reaction can be conducted at -20 to +20°C in the presence of a solvent under normal hydrogen pressure by using a hydrogenating catalyst such as palladium black, palladium carbon, raney nickel or the like. Examples of the solvent to be used include water, methanol, ethanol, propanol, isopropanol, acetic acid and the like. The reaction time is normally 10 minutes to 24 hours, preferably 0.5 to 6 hours. When the protected amino group is -NH-CO-NR¹⁴R¹⁵ or -NH-CS-NR¹⁴R¹⁵, it can be obtained by
15 reacting the compound of the formula (I) wherein R² is an amino group with the compound (VII). This reaction is conducted under conditions similar to those of the reaction of the compound (VI) with the compound (VII) in the process C. When the protected amino group is tritylamino group, it can be obtained by reacting the compound of the formula (I) wherein R² is amino group with trityl chloride. This reaction is a known reaction and it can be conducted according to known conditions.

20 The compound (II) can be obtained, for example, by the following process.



30 The reaction of the compound (XV) with the compound (XI) is conducted under conditions similar to those of the reaction of the compound (X) with the compound (XI).

The compound (IV) can be obtained, for example, by the following process.




40 wherein Y is NaS-, KS-, NaO- or KO-.

The reaction of the compound (II) with the compound (XVI) can be conducted at 0 to +250°C in the presence of a solvent by using 1 equivalent to extremely excess amount of the compound (XVI) per 1 equivalent of the compound (II). Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol and the like; ethers such as tetrahydrofuran, dimethoxyethane, dioxane and the
45 like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like.

The compound (VI) can be obtained, for example, by the following processes.


(i) When X is S or O,



55 wherein the symbols are as defined above;



EP 0 471 236 B1

(ii) When X is S, O or NR³,



wherein the symbols are as defined above;



(iii) When X is S or O and B¹ is NR¹⁰,



wherein T is an amino protecting group such as benzyloxycarbonyl, tert-butoxycarbonyl, trifluoroacetyl, trityl, benzyl or the like, and B¹T is phthalimide, the other symbols are as defined above;



(iv) When X is S(O) or S(O)₂ and B¹ is NR¹⁰, the compound (XX) is treated with an oxidizing agent, and then any protective group is removed;

(v) When X is S or O and B¹ is NR¹⁰,



wherein the symbols are as defined above;

(vi) When X is S, O or NR³ and B¹ is NR¹⁰,



EP 0 471 236 B1

wherein the symbols are as defined above.

The reaction of the compound (IV) with the compound (XVII) in the process (i) is conducted under conditions similar to those of the reaction of the compound (IV) with the compound (V) in the process B.

The reaction of the compound (II) with the compound (XVIII) in the process (ii) is conducted under conditions similar to those of the reaction of the compound (II) with the compound (III) in the process A.

The reaction of the compound (IV) with the compound (XIX) in the process (iii) is conducted under conditions similar to those of the reaction of the compound (IV) with the compound (V) in the process B.

The reaction of the compound (XX) with the oxidizing agent in the process (iv) is conducted under conditions similar to those of the reaction of the compound (Ia) with an oxidizing agent.

The reaction of the compound (IV) with the compound (XXI) in the process (v) is conducted under conditions similar to those of the reaction of the compound (IV) with the compound (V) in the process B.


The reaction of the compound (II) with the compound (XXIII) in the process (vi) is conducted under conditions similar to those of the reaction of the compound (II) with the compound (III) in the process A.

The conversion of the hydroxyl group of the compound (XXII) in the processes (v) and (vi) into E¹ is conducted by, when E¹ is halogen, reacting the compound (XXII) with a halogenating agent such as a phosphorous halide (e.g., phosphorous trichloride, phosphorous oxychloride, phosphorous pentachloride, phosphorous tribromide, etc.), red phosphorous and halogen, or thionyl chloride and the like. When E¹ is toluenesulfonyl group or methanesulfonyloxy group, it can be obtained by the reaction of the compound (XXII) with toluenesulfonyl chloride or methanesulfonyl chloride. The reaction with R¹⁰NH which follows the above reaction is conducted at 0 to 200 °C in the absence of any solvent or in a suitable solvent.

All of those reactions are known and they can be conducted according to known conditions.


The compound (VIII) can be obtained, for example, by the following processes.

(i) When Q² is OCN-,




wherein the symbols are as defined above;

(ii) When Q² is OCN-,




wherein the symbols are as defined above;

(iii) When Q² is SCN-,




EP 0 471 236 B1

(iv) When Q² is SCN-,




wherein Y¹ is Na or K;


10 (v) When Q² is PhO-CO-O,



20 (vi) When Q² is G-CO-NR¹⁰,



30 (vii) When Q² is G-CO-O-,



40 Namely,

(i) the compound (XXIV) is reacted with phosgene, and then the reaction product is heated for dehydrochlorination.

(ii) The compound (XXV) is reacted with silver cyanate.

45 (iii) The compound (XXIV) is reacted with CS₂ and further with chlorocarbonate, and then the reaction product is heated.

(iv) The compound (XXV) is reacted with the compound (XXVI).

(v) The compound (XXII) is reacted with phenyl chlorocarbonate.

(vi) The compound (XII) is reacted with phosgene.

50 (vii) The compound (XXII) is reacted with phosgene.

All the reactions are known and they can be conducted according to known conditions.

All the reactions for removing the above protecting groups are known and they can be conducted according to known conditions.

For example, benzyloxycarbonyl group or benzyl group as the amino protecting group can be removed
55 by a catalytic reduction (reaction temperature: room temperature to +100 °C) in a solvent (e.g., alcohol, acetic acid, water, tetrahydrofuran and a mixed solvent thereof, etc.) in the presence of a catalyst (e.g., palladium on carbon, platinum oxide, etc.).

EP 0 471 236 B1

In the case of trityl group or tert-butoxycarbonyl group, it can be removed at 0 to +150 °C in a solvent (e.g., water, alcohol, tetrahydrofuran, dioxane, etc.) in the presence of an acid (e.g., mineral acids such as hydrochloric acid, phosphoric acid, sulfuric acid and the like; organic acids such as toluenesulfonic acid, methanesulfonic acid, acetic acid and the like). Trifluoroacetyl group can be readily removed by treating
 5 with an alkali (e.g., sodium hydroxide, sodium bicarbonate solution, etc.)

Phthalamide group can be removed by reacting with hydrazine hydrate in a solvent (e.g., methanol, ethanol, etc.).

The starting compounds can be removed from the desired product (I) obtained by the above processes or a salt thereof by the following conventional separation means. Or, a reaction mixture per se may be used
 10 as a starting material for the next step without purification.

The isolation and purification of the compound (I) or a salt thereof from the reaction mixture is conducted according to conventional separation means (e.g., extraction, concentration, filtration, recrystallization, column chromatography, thin layer chromatography, etc.).

The compounds (I) of the present invention or salts thereof have calmodulin inhibitory activity and are
 15 useful as safe medicines for various diseases of mammal (e.g., human, dog, cat, etc.) such as hypertension, ischemic diseases (e.g., angina, cardiac infarction, arrhythmia, renal failure, etc.), arteriosclerosis, vascular jerk after subarachnoid hemorrhage and inflammatory diseases (e.g., nephritis, asthma, hepatitis, etc.) and the like.

When the compound (I) of the present invention or a salt thereof is used as the above medicines, it can
 20 be admixed with a pharmaceutically acceptable carrier, excipient, diluent and administered orally or parenterally in a dosage form such as powder, granules, tablets, capsules, injection and the like. A dosage varies depending upon a particular administration route, conditions to be treated, age and weight of the patient and the like. For example, when it is orally administered to an adult patient, the dosage may be 0.2 to 50 mg/kg/day, preferably 0.5 to 30 mg/kg/day, more preferably 1 to 20 mg/kg/day and it can be
 25 administered once to several times in a day.

As described hereinabove, the compounds (I) of the present invention and salts thereof have excellent calmodulin inhibitory activities and are useful as hypotensors and medicines for treating ischemic diseases, antiarteriosclerotic agents, medicines for treating vascular jerk after subarachnoid hemorrhage, anti-inflam-
 30 matory agents and the like in human and mammal.

The following Reference Examples, Examples, Preparations and Experiments further illustrate the present invention in detail but are not to be construed to limit the scope thereof. In Examples, room temperature means 15 to 30 °C.

Reference Example 1

(1) Synthesis of 2-ethoxycarbonyl-5-chloroimidazo[1,2-a] pyridine

A solution of 2-amino-6-chloropyridine (6.43 g, 50 mmoles) and ethyl bromopyruvate (9.75 g, 50 mmoles) in ethanol (150 ml) was heated at reflux for 4 hours. After the solvent was removed, chloroform
 40 was added to the residue, which was washed in turn with saturated sodium bicarbonate and saturated saline, and then dried over anhydrous magnesium sulfate. After the solvent was concentrated, n-hexane was added to the mixture. Then, the crystals precipitated were filtered off and washed with n-hexane to obtain 7.60 g of the desired product (67.6%, pale yellow crystals).

Melting point: 143-145 °C

Elemental analysis for C ₁₀ H ₉ N ₂ O ₂ Cl,			
Calcd.	C, 53.47;	H, 4.04;	N, 12.47
Found	C, 53.45;	H, 3.99;	N, 12.59

NMR (90MHz, CDCl₃) δ: 1.42 (3H, t, J = 7Hz), 4.46 (2H, q, J = 7Hz), 6.95 (1H, dd, J = 7, 1Hz), 7.24 (1H, dd, J = 7Hz), 7.67 (1H, d, J = 9Hz), 8.36 (1H, s)

According to the same manner as that described in Reference Example 1 (1), the following compounds
 55 were obtained.

EP 0 471 236 B1

(2) 5-Chloro-2-methylimidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 2.47 (3H, s), 6.79 (1H, d, J=7Hz), 7.08 (1H, dd, J=9, 7Hz), 7.47 (1H, d, J=9Hz), 7.51 (1H, s)

(3) 3-Ethoxycarbonyl-5-chloro-2-methylimidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 1.40 (3H, t, J=7Hz), 2.60 (3H, s), 4.43 (2H, q, J=7Hz), 6.94 (1H, dd, J=1Hz), 7.26 (1H, dd, J=9, 7Hz), 7.54 (1H, dd, J=9, 1Hz)

(4) 2-Ethoxycarbonylmethyl-5-chloroimidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 1.28 (3H, t, J=7Hz), 3.87 (2H, s), 4.21 (2H, q, J=7Hz), 6.83 (1H, dd, J=7, 1Hz), 7.12 (1H, dd, J=9, 7Hz), 7.52 (1H, dd, J=9, 1Hz), 7.78 (1H, s)

Reference Example 2

(1) Synthesis of 5-[2-(amino)ethylthio]-2-methylimidazo[1,2-a]pyridine

To a suspension of cysteamine hydrochloride (2.95 g, 26 mmoles) in ethanol (100 ml) was added 60% sodium hydride (oily; 2.08 g, 26 mmoles) with stirring under ice-cooling and the mixture was stirred for 5 minutes. 5-chloro-2-methylimidazo[1,2-a]pyridine (3.33 g, 20 mmoles) was added to the mixture, followed by heating at reflux for 3 hours. After the solvent was distilled off, chloroform was added to the residue which was washed with 1N-NaOH and dried over anhydrous potassium carbonate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate/ethanol/triethylamine = 6:2:1) to obtain 2.2 g of the desired product (53.6%, brown oily product).

NMR (90MHz, CDCl₃) δ : 2.25 (2H, br), 2.50 (3H, s), 2.77-3.22 (4H, m), 6.88 (1H, dd, J=7, 1Hz), 7.06 (1H, dd, J=9, 7Hz), 7.46 (1H, d, J=9Hz), 7.62 (1H, s)

According to the same manner as that described in Reference Example 2 (1), the following compounds were obtained.

(2) 5-[2-(Amino)ethylthio]-2-ethoxycarbonylimidazo[1,2-a]pyridine

Elemental analysis for C₁₂H₁₅N₃O₂S•0.3H₂O,

Calcd.	C, 53.24;	H, 5.81;	N, 15.52
Found	C, 53.43;	H, 5.61;	N, 15.54

NMR (90MHz, CDCl₃) δ : 1.44 (3H, t, J=7Hz), 1.52 (2H, br), 2.83-3.19 (4H, m), 4.46 (2H, q, J=7Hz), 7.00 (1H, dd, J=7, 1Hz), 7.20 (1H, dd, J=9, 7Hz), 7.64 (1H, d, J=9Hz), 8.49 (1H, s)

(3) 5-[2-(Amino)ethylthio]-3-ethoxycarbonyl-2-methylimidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 1.40 (3H, t, J=7Hz), 1.47 (2H, br), 2.61 (3H, s), 2.81 (2H, m), 3.04 (2H, m), 4.43 (2H, q, J=7Hz), 7.02 (1H, dd, J=7, 1Hz), 7.30 (1H, dd, J=9, 7Hz), 7.48 (1H, dd, J=9, 1Hz)

(4) 5-[2-(Amino)ethylthio]-2-ethoxycarbonylmethylimidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 1.29 (3H, t, J=7Hz), 1.60 (2H, s), 2.80-3.20 (4H, m), 3.90 (2H, s), 4.21 (2H, q, J=7Hz), 6.90 (1H, dd, J=7, 1Hz), 7.11 (1H, dd, J=9, 1Hz), 7.51 (1H, d, J=9Hz), 7.89 (1H, s)

(5) 5-[(4-Piperidyl)thio]imidazo[1,2-a]pyridine

NMR (200MHz, CDCl₃) δ : 1.62 (2H, m), 1.93 (2H, m), 2.07 (1H, br), 2.64 (2H, m), 3.12 (2H, m), 3.33 (1H, m), 7.02 (1H, d, J=7Hz), 7.15 (1H, dd, J=9, 7Hz), 7.62 (1H, d, J=9Hz), 7.69 (1H, s), 7.96 (1H, s)

EP 0 471 236 B1

Reference Example 3

(1) Synthesis of 5-[4-(amino)butoxy]imidazo[1,2-a]pyridine

5 To a suspension of 60% sodium hydride (oily; 1.32 g, 33 mmol) in DMF (60 ml) was added a solution of 5-chloroimidazo[1,2-a]pyridine (4.59 g, 30.1 mmol) and 4-aminobutanol (2.68 g, 30.1 mmol) in DMF (60 ml) at room temperature with stirring and the mixture was stirred at the same temperature for 5 hours. Tert-butyl dicarbonate (9.83 g, 45 mmol) was added to the reaction solution, which was stirred at room temperature for 13 hours. After the solvent was distilled off, water was added to the residue, which was
10 extracted with ether twice, washed with water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off. The residue was dissolved in methanol (20 ml), followed by the addition of conc. hydrochloric acid (20 ml) and stirring at room temperature for 1 hour. After the solvent was distilled off, chloroform was added to the residue, which was washed with 3N NaOH. After drying over anhydrous potassium carbonate, the solvent was distilled off. The residue was purified by column chromatography
15 (eluent: methanol/chloroform = 1:5) to obtain 2.53 g of the desired product (40.9%, light brown oily product).

NMR (200MHz, CDCl₃) δ : 1.71 (2H, m), 1.96 (2H, br), 1.97 (2H, m), 2.83 (2H, m), 4.27 (2H, m), 6.03 (1H, d, J=7.2Hz), 7.17 (1H, dd, J=9, 7.2Hz), 7.27 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.66 (1H, s)

20 According to the same manner as that described in Reference Example 3 (1), the following compounds were obtained.

(2) 5-[5-(Amino)pentoxy]imidazo[1,2-a]pyridine

NMR (200MHz, CDCl₃) δ : 1.58 (4H, m), 1.66 (2H, br), 1.96 (2H, m), 2.77 (2H, m), 4.25 (2H, t, J=6, 4Hz), 6.02 (1H, d, J=7Hz), 7.16 (1H, dd, J=9, 7Hz), 7.27 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.66 (1H, s)

(3) 5-[6-(Amino)hexyloxy]imidazo[1,2-a]pyridine

30 NMR (200MHz, CDCl₃) δ : 1.34-1.70 (8H, s), 1.93 (2H, m), 2.73 (2H, m), 4.23 (2H, t, J=6, 4Hz), 6.02 (1H, dd, J=7, 1Hz), 7.16 (1H, dd, J=9, 7Hz), 7.26 (1H, m), 7.59 (1H, d, J=1.2Hz), 7.65 (1H, m)

(4) 5-[2-[1-(Amino)propoxy]]imidazo[1,2-a]pyridine

35 NMR (200MHz, CDCl₃) δ : 1.44 (3H, d, J=6.2Hz), 1.75 (2H, br), 2.96-3.15 (2H, m), 4.63 (1H, m), 6.10 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.27 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.66 (1H, m)

(5) 5-[2-(Amino)-1-(phenyl)ethoxy]imidazo[1,2-a]pyridine

40 NMR (200MHz, CDCl₃) δ : 1.75 (2H, br), 3.19 (1H, dd, J=14, 4.2Hz), 3.35 (1H, dd, J=14, 7.4Hz), 5.38 (1H, dd, J=7.4, 4.2Hz), 5.89 (1H, d, J=7Hz), 7.01 (1H, dd, J=9, 7Hz), 7.22 (1H, d, J=9Hz), 7.37 (5H, m), 7.64 (1H, d, J=1.2Hz), 7.82 (1H, s)

(6) 5-[(4-Piperidinyl)oxy]imidazo[1,2-a]pyridine

45 NMR (200MHz, CDCl₃) δ : 1.76 (1H, br), 1.87 (2H, m), 2.12 (2H, m), 2.82 (2H, m), 3.18 (2H, m), 4.67 (1H, m), 6.06 (1H, d, J=7.2Hz), 7.17 (1H, dd, J=9, 7.2Hz), 7.27 (1H, d, J=9Hz), 7.60 (1H, d, J=1Hz), 7.69 (1H, s)

50 Reference Example 4

Synthesis of 5-[2-(phenoxycarbonyloxy)ethylthio]imidazo[1,2-a]pyridine

55 To a solution of 5-[2-(hydroxy)ethylthio]imidazo[1,2-a]pyridine (5.83 g, 30 mmol) and pyridine (4.36 ml, 60 mmol) in methylene chloride (120 ml) was added phenyl chloroformate (7.53 ml, 60 mmol) with stirring under ice-cooling and the mixture was stirred under ice-cooling for 30 minutes. The reaction solution was washed in turn with an aqueous 5% sodium bicarbonate solution and saturated saline and dried over anhydrous magnesium sulfate, and then the solvent was distilled off. The residue was purified by column

EP 0 471 236 B1

chromatography (eluent: ethyl acetate) to obtain 8.61 g of the desired product (91.3%, oily product).

NMR (200MHz, CDCl₃) δ: 3.30 (2H, t, J=6.6Hz), 4.42 (2H, t, J=6.6Hz), 7.06-7.45 (8H, m), 7.69 (1H, d, J=1.4Hz), 7.73 (1H, d, J=1.4Hz), 7.92 (1H, m)

5 Reference Example 5

Synthesis of 5-[2-(methylsulfonyloxy)ethylthio]imidazo[1,2-a]pyridine

To a solution of 5-[2-(hydroxy)ethylthio]imidazo[1,2-a]pyridine (9.71 g, 50 mmoles) and triethylamine (10.5 ml, 75.3 mmoles) in methylene chloride (300 ml) was added methanesulfonyl chloride (4.26 ml, 55 mmoles) with stirring under ice-cooling and the mixture was stirred under ice-cooling for 2 hours. The reaction solution was washed in turn with an aqueous saturated sodium bicarbonate solution and saturated saline and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off to obtain 13.6 g of the desired product (quantitative, brown oily product).

15 NMR (200MHz, CDCl₃) δ: 2.97 (3H, s), 3.28 (2H, t, J=6.4Hz), 4.35 (2H, t, J=6.4Hz), 7.08 (1H, dd, J=7, 1.2Hz), 7.18 (1H, dd, J=8.8, 7Hz), 7.64 (1H, m), 7.73 (1H, d, J=1.4Hz), 7.91 (1H, m)

Reference Example 6

20 (1) Synthesis of 5-[2-(methylamino)ethylthio]imidazo[1,2-a]pyridine

A solution of 5-[2-(methylsulfonyloxy)ethylthio]imidazo[1,2-a]pyridine (2.18 g, 8 mmoles), triethylamine (2.24 ml, 16 mmoles) and a 40% methylamine-methanol solution (20 ml) in chloroform (20 ml) was heated at reflux for 3 hours. The reaction solution was washed with an aqueous 3N-sodium hydroxide solution and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: methanol/chloroform = 1:10) to obtain 781 mg of the desired product (47.1%, light brown oily product).

25 NMR (200MHz, CDCl₃) δ: 2.31 (1H, br), 2.88 (2H, t, J=6.4Hz), 3.16 (2H, t, J=6.4Hz), 6.94 (1H, dd, J=7, 1Hz), 7.15 (1H, dd, J=9, 7Hz), 7.58 (1H, dd, J=9, 1Hz), 7.69 (1, d, J=1.2Hz), 7.86 (1H, s)

30 IR (KBr) cm⁻¹: 3290, 3105, 2930, 2850, 2790, 1655, 1615, 1530, 1490

According to the same manner as that described in Reference Example 6 (1), the following compounds were obtained.

35 (2) 5-[2-(Ethylamino)ethylthio]imidazo[1,2-a]pyridine

NMR (200MHz, CDCl₃) δ: 1.11 (3H, t, J=7Hz), 1.88 (1H, br), 2.70 (2H, m), 2.90 (2H, t, J=6.2Hz), 3.15 (2H, t, J=6.2Hz), 6.94 (1H, dd, J=7, 1Hz), 7.16 (1H, dd, J=9, 7Hz), 7.59 (1H, dd, J=9, 1Hz), 7.70 (1H, d, J=1.2Hz), 7.87 (1H, s)

40 IR (KBr) cm⁻¹: 3280, 3105, 2965, 2930, 2890, 2820, 1655, 1620, 1530, 1490

Reference Example 7

(1) Synthesis of 5-[3-(amino)propoxy]imidazo[1,2-a]pyridine

45 To a solution of 5-[3-(tert-butoxycarbonylamino)propoxy]imidazo[1,2-a]pyridine in methanol (10 ml) was added concentrated hydrochloric acid (5 ml) and the mixture was stirred at room temperature for 1 hour. After the solvent was distilled off, chloroform (30 ml) and 3N-NaOH (10 ml) were added to the residue which was extracted with chloroform and dried over anhydrous potassium carbonate. Then, the solvent was distilled off to obtain 687 mg of the desired product (78.7%, pale yellow oily product).

50 NMR (200MHz, CDCl₃) δ: 1.51 (2H, br), 2.07 (2H, m), 3.00 (2H, t, J=6.8Hz), 4.35 (2H, t, J=6.2Hz), 6.06 (2H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.28 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.65 (1H, s)

According to the same manner as that described in Reference Example 7 (1), the following compounds were obtained.

55 (2) 5-[2-(Amino)ethoxy]imidazo[1,2-a]pyridine

NMR (200MHz, CDCl₃) δ: 1.66 (2H, br), 3.25 (2H, t, J=5.2Hz), 4.28 (2H, t, J=5.2Hz), 6.06 (2H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.29 (1H, d, J=9Hz), 7.61 (1H, d, J=1Hz), 7.68 (1H, s)

EP 0 471 236 B1

(3) 5-[2-(Amino)ethylamino]imidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 1.70 (2H, br), 3.07 (2H, m), 3.29 (2H, m), 5.17 (1H, br), 5.88 (1H, dd, J=6, 2.5Hz), 7.02-7.30 (2H, m), 7.48 (1H, s), 7.61 (1H, s)

(4) 5-[3-(Amino)propylamino]imidazo[1,2-a]pyridine

NMR (90MHz, CDCl₃) δ : 1.57 (2H, br), 1.87 (2H, m), 3.01 (2H, m), 3.39 (2H, m), 5.78 (1H, dd, J=7, 1.5Hz), 6.78 (1H, br), 6.96-7.28 (2H, m), 7.38 (1H, s), 7.59 (1H, s)

Reference Example 8

Synthesis of 5-[3-(amino)propylamino]imidazo[1,2-a]pyridine•dihydrochloride

To a suspension of 5-[3-(tert-butoxycarbonylamino)propylamino]imidazo[1,2-a]pyridine (1.742 g, 6 mmol) in methylene chloride (40 ml) was added hydrogen chloride-methanol (6 ml) and the mixture was stirred at room temperature for 20 hours. After the solvent was distilled off, ethanol (15 ml) and ether (30 ml) were added to the residue. Then, the crystals precipitated were filtered off and washed in turn with ether and a small amount of ethanol to obtain 1.311 g of the desired product (83.0%, pale yellow crystals).

Elemental analysis for C ₁₀ H ₁₄ N ₄ O•2HCl•0.2H ₂ O,			
Calcd.	C, 45.02;	H, 6.20;	N, 21.00
Found	C, 45.15;	H, 6.25;	N, 21.17

NMR (90MHz, DMSO-d₆) δ : 2.02 (2H, m), 2.95 (2H, m), 3.52 (2H, m), 6.53 (1H, d, J=8Hz), 7.08 (1H, d, J=8.5Hz), 7.79 (1H, dd, J=8.5, 8Hz), 8.12 (1H, d, J=2Hz), 8.27 (3H, br), 8.53 (1H, br), 8.78 (1H, d, J=2Hz)

Reference Example 9

Synthesis of 5-[3-(amino)propylthio]imidazo[1,2-a]pyridine

To a mixed solution of 10% potassium hydroxide (69.3 g, 105 mmol) and dimethylsulfoxide (50 ml) was added S-[3-(amino)propyl]isothiourea•dihydrobromide (8.85 g, 39 mmol) and the mixture was stirred at room temperature for 1.5 hours. To the reaction solution was added 5-chloroimidazo[1,2-a]pyridine (3.05 g, 20 mmol), followed by stirring at room temperature for 1.5 hours and additional stirring at 65 °C for 20 hours. Water was added to the reaction solution, which was extracted with chloroform, washed several times with 1N-sodium chloride and dried over anhydrous magnesium sulfate. After the solvent was distilled off to obtain 2.66 g of the desired product (64.3%, pale yellow oily product).

NMR (200MHz, CDCl₃) δ : 1.29 (2H, br), 1.80 (2H, m), 2.85 (2H, t, J=6.8Hz), 3.08 (2H, t, J=7.2Hz), 6.91 (1H, dd, J=7, 1Hz), 7.16 (1H, dd, J=9, 7Hz), 7.58 (1H, d, J=9, 1Hz), 7.71 (1H, d, J=1.2Hz), 7.85 (1H, d, J=1.2Hz)

Reference Example 10

According to the same manner as that described in Reference Example 8, the following compounds were obtained.

(1) 5-[2-(Amino)ethylsulfonyl]imidazo[1,2-a]pyridine•dihydrochloride

Melting point: 210-220 °C (dec.)

Elemental analysis for C ₉ H ₁₁ N ₃ O ₂ S•2HCl•0.5H ₂ O,			
Calcd.	C, 35.19;	H, 4.59;	N, 13.68
Found	C, 35.18;	H, 4.49;	N, 13.98

(2) 5-[2-(Amino)ethylsulfinyl]imidazo[1,2-a]pyridine•dihydrochloride

Melting point: 195-205 °C (dec.)

EP 0 471 236 B1

Elemental analysis for $C_9H_{11}N_3OS \cdot 2HCl \cdot 0.3H_2O$			
Calcd.	C, 37.59;	H, 4.77;	N, 14.61
Found	C, 37.76;	H, 4.77;	N, 14.60

(3) 5-[2-(Amino)ethoxy]imidazo[1,2-a]pyridine • dihydrochloride
Melting point: 209-220 °C (dec.)

Elemental analysis for $C_9H_{11}N_3O \cdot 2HCl \cdot H_2O$			
Calcd.	C, 40.31;	H, 5.64;	N, 15.67
Found	C, 40.20;	H, 5.65;	N, 15.58

(4) 5-[4-(Piperidyl)thio]imidazo[1,2-a]pyridine • dihydrochloride
Melting point: 204-218 °C (dec.)

Elemental analysis for $C_{12}H_{15}N_3S \cdot 2HCl$			
Calcd.	C, 47.06;	H, 5.59;	N, 13.72
Found	C, 47.00;	H, 5.63;	N, 13.56

Reference Example 11

Synthesis of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine

After a suspension of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine • dihydrochloride (13.31 g, 50 mmol) in chloroform (200 ml) was washed with 3N-sodium hydroxide (50 ml), the aqueous layer was extracted with chloroform, combined the chloroform layer was dried over anhydrous magnesium sulfate. After the solvent was distilled off to obtain 9.63 g of the desired product (99.7%, pale yellow oily product).

NMR (200MHz, $CDCl_3$) δ : 1.67 (2H, br), 2.95 (2H, m), 3.08 (2H, m), 6.95 (1H, d, J = 7Hz), 7.15 (1H, dd, J = 9.2, 7Hz), 7.59 (1H, d, J = 9.2Hz), 7.71 (1H, s), 7.88 (1H, s)

Reference Example 12

Synthesis of 5-[3-(chloro)propylthio]imidazo[1,2-a]pyridine

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (5.02 g, 33.4 mmol) and 1-bromo-3-chloropropane (5.26 g, 33.4 mmol) in ethanol (100 ml) was added triethylamine (4.66 ml, 33.4 mmol) and the mixture was stirred at room temperature for 17 hours. After the solvent was distilled off, chloroform was added to the residue, which was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 5.46 g of the desired product (72.0%, light brown oily product).

NMR (200MHz, $CDCl_3$) δ : 2.09 (2H, m), 3.17 (2H, t, J = 7Hz), 3.68 (2H, t, J = 6Hz), 6.94 (1H, dd, J = 7.2, 1Hz), 7.16 (1H, dd, J = 9.2, 7.2Hz), 7.60 (1H, m), 7.72 (1H, d, J = 1.2Hz), 7.86 (1H, m)

Example 1

Synthesis of 5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 1)

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (9.63 g, 49.8 mmol) and triethylamine (7.64 ml) in methylene chloride (150 ml) was added methanesulfonyl chloride (3.85 ml, 49.7 mmol) with stirring under ice-cooling and was stirred under ice-cooling for 1 hour. The reaction solution was poured into water and stirred. Then, the crystals precipitated were filtered off, washed with water and dried to obtain 10.53 g of the desired product (77.9%, colorless crystals).

Melting point: 130-131 °C

EP 0 471 236 B1

Elemental analysis (%) for C ₁₀ H ₁₃ N ₃ O ₂ S ₂ .			
Calcd.	C, 44.26;	H, 4.83;	N, 15.48
Found	C, 44.05;	H, 4.82;	N, 15.31

NMR (90MHz, DMSO-d₆) δ : 2.96 (3H, s), 3.22 (4H, s), 7.10 (1H, dd, J=7, 1.5Hz), 7.26 (1H, dd, J=9, 7Hz), 7.31 (1H, br), 7.56 (1H, d, J=9Hz), 7.68 (1H, d, J=1Hz), 7.97 (1H, s)
 IR (KBr) cm⁻¹: 3450, 3140, 2930, 1620, 1490, 1315, 1155

Example 2

Synthesis of 5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine • hydrochloride (Compound 2)

A suspension of 5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (543 g, 2 mmoles) in methanol (20 ml) was treated with hydrogen chloride-methanol. After the solvent was distilled off, the residue was crystallized from chloroform ether. Then, the crystals thus obtained were washed with ether and dried to obtain 550 mg of the desired product (89.3%, colorless crystals).

Melting point: 154-160 °C

Example 3

(1) Synthesis of 5-[2-(ethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 3)

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (1.93 g, 10 mmoles) and triethylamine (1.53 ml, 11 mmoles) in methylene chloride (100 ml) was added ethanesulfonyl chloride (0.95 ml, 10 mmoles) at room temperature with stirring and the mixture was stirred at room temperature for 1 hour. The reaction mixture was washed in turn with an aqueous saturated sodium bicarbonate solution and water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off. The residue was purified by column chromatography (eluent: ethanol/ethyl acetate = 1:5) to obtain 2.23 g of the desired product (78.2%, colorless crystals).

Elemental analysis for C ₁₁ H ₁₅ N ₃ O ₂ S ₂ • 0.1H ₂ O,			
Calcd.	C, 46.01;	H, 5.34;	N, 14.63
Found	C, 45.74;	H, 5.26;	N, 14.36

NMR (90MHz, DMSO-d₆) δ : 1.16 (3H, t, J=7Hz), 2.99 (2H, q, J=7Hz), 3.21 (4H, m), 7.11 (1H, dd, J=7, 1.5Hz), 7.28 (1H, dd, J=8.5, 7Hz), 7.33 (1H, br), 7.59 (1H, d, J=8.5Hz), 7.71 (1H, s), 7.99 (1H, s)

According to the same manner as that described in Example 3 (1), the following compounds were obtained.

(2) 5-[2-(Propylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 4)

Elemental analysis for C ₁₂ H ₁₇ N ₃ O ₂ S • 0.2H ₂ O,			
Calcd.	C, 47.57;	H, 5.79;	N, 13.87
Found	C, 47.62;	H, 5.74;	N, 14.03

NMR (200MHz, CDCl₃) δ : 1.04 (3H, t, J=7.4Hz), 1.83 (2H, m), 2.98 (2H, m), 3.19 (2H, m), 3.33 (2H, m), 4.93 (1H, br), 7.02 (1H, dd, J=7, 1.2Hz), 7.17 (1H, dd, J=9, 7Hz), 7.63 (1H, m), 7.70 (1H, d, J=1.4Hz), 7.85 (1H, m)

(3) 5-[2-(Isopropylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 5)

NMR (200Hz, CDCl₃) δ : 1.36 (6H, d, J=6.8Hz), 3.16 (1H, heptet, J=6.8Hz), 3.19 (2H, t, J=6.4Hz), 3.36 (2H, m), 4.80 (1H, br), 7.02 (1H, dd, J=7, 1.2Hz), 7.17 (1H, dd, J=9, 7Hz), 7.62 (1H, d, J=9Hz), 7.70 (1H,

EP 0 471 236 B1

s), 7.86 (1H, m)

(4) 5-[2-(Butylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 6)

5

Elemental analysis for C ₁₃ H ₁₉ N ₃ O ₂ S ₂			
Calcd.	C, 49.82;	H, 6.11;	N, 13.41
Found	C, 49.76;	H, 6.15;	N, 13.40

10

NMR (200Hz, CDCl₃) δ : 0.93 (3H, t, J=7.2Hz), 1.43 (2H, m), 1.76 (2H, m), 3.00 (2H, m), 3.19 (2H, m), 3.33 (2H, m), 5.06 (1H, br), 7.01 (1H, dd, J=7, 1.2Hz), 7.16 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9Hz), 7.69 (1H, d, J=1.2Hz), 7.84 (1H, m)

15

(5) 5-[2-(Octylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 7)

NMR (90Hz, CDCl₃) δ : 0.73-2.00 (15H, m), 2.88-3.52 (6H, m), 6.24 (1H, br), 7.00 (1H, dd, J=7, 1.5Hz), 7.13 (1H, dd, J=9, 7Hz), 7.58 (1H, d, J=9Hz), 7.63 (1H, s), 7.81 (1H, s)

20

(6) 5-[2-[3-(Chloro)propylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 8)

25

Elemental analysis for C ₁₂ H ₁₆ N ₃ O ₂ S ₂ Cl			
Calcd.	C, 43.17;	H, 4.83;	N, 12.59
Found	C, 43.41;	H, 4.83;	N, 12.47

NMR (90Hz, CDCl₃-DMSO-d₆) δ : 2.22 (2H, m), 2.97-3.46 (6H, m), 3.66 (2H, t, J=6.5Hz), 7.07 (1H, dd, J=7.5, 2Hz), 7.19 (1H, dd, J=9, 7.5Hz), 7.26 (1H, br), 7.59 (1H, m), 7.69 (1H, s), 7.90 (1H, s)

30

(7) 5-[2-(Hexadecylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 9)

NMR (200Hz, CDCl₃) δ : 0.88 (3H, t, J=6.8), 1.25 (26H, m), 1.78 (2H, m), 3.00 (2H, m), 3.18 (2H, m), 3.33 (2H, m), 4.73 (1H, br), 7.02 (1H, dd, J=7.1Hz), 7.17 (1H, dd, J=9, 7Hz), 7.64 (1H, d, J=9Hz), 7.72 (1H, d, J=1.2Hz), 7.87 (1H, s)

35

Example 4

(1) Synthesis of 3-chloro-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 10) and 3-chloro-5-[2-(methylsulfonylamino)ethylthio]-2-succinimide-imidazo[1,2-a]pyridine (Compound 11)

To a suspension of 5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (534 mg, 2 mmoles) in chloroform (60 ml) was added N-chlorosuccinimide (267 mg, 2 mmoles) at room temperature with stirring and the mixture was stirred at room temperature for 24 hours. The reaction mixture was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off. The residue was purified by column chromatography (eluent: ethanol/ethyl acetate = 1:10) to obtain 245 mg of the desired product (Compound 10, 40.0%, gray crystals) as Fraction 1.

50

Elemental analysis for C ₁₀ H ₁₂ N ₃ O ₂ S ₂ Cl			
Calcd.	C, 39.28;	H, 3.96;	N, 13.74
Found	C, 39.47;	H, 4.00;	N, 13.61

55

NMR (90MHz, DMSO-d₆) δ : 2.90 (3H, s), 3.22 (4H, m), 7.06 (1H, dd, J=7, 1.5Hz), 7.23 (1H, dd, J=9, 7Hz), 7.53 (1H, dd, J=9, 1.5Hz), 7.66 (1H, s)

As Fraction 2, 96 mg of the desired product (Compound 11, 11.9%, colorless crystals) was obtained.

NMR (90MHz, DMSO-d₆) δ : 2.94 (3H, s), 2.97 (4H, s), 3.23 (4H, m), 7.19 (1H, dd, J=7, 2Hz), 7.40 (1H,

EP 0 471 236 B1

dd, J=9, 7Hz), 7.59 (1H, dd, J=9, 1.5Hz)

According to the same manner as that described in Example 4 (1), the following compounds were obtained.

5 (2) 3-Bromo-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 12)

10

Elemental analysis for C ₁₀ H ₁₂ N ₃ O ₂ S ₂ Br,			
Calcd.	C, 34.29;	H, 3.45;	N, 12.00
Found	C, 34.26;	H, 3.45;	N, 11.94

15

NMR (90MHz, DMSO-d₆) δ: 2.90 (3H, s), 3.19 (4H, m), 7.07 (1H, dd, J=7, 1.5Hz), 7.23 (1H, dd, J=9, 7Hz), 7.56 (1H, dd, J=9, 1.5Hz), 7.66 (1H, s)

(3) 3-Iodo-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 13)

20

NMR (90MHz, DMSO-d₆) δ: 2.98 (3H, s), 3.17 (4H, m), 7.07 (1H, dd, J=7, 1.5Hz), 7.24 (1H, dd, J=9, 7Hz), 7.60 (1H, dd, J=9, 1.5 Hz), 7.68 (1H, s)

Example 5

Synthesis of 5-[2-(methylsulfonylamino)ethylthio]-3-morpholinomethylimidazo[1,2-a]pyridine (Compound 14)

25

30

To a solution of 37% formalin (178 mg, 2.2 mmoles) in acetic acid (2 ml) was added morpholin (192 μl, 2.2 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 30 minutes. 5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (543 mg, 2 mmoles) was added to the reaction mixture, followed by stirring at 60 °C for 2 hours. After the solvent was distilled off, the residue was dissolved in chloroform (50 ml) and washed with 1N NaOH (10 ml). Then, the aqueous layer was extracted with chloroform (30 ml x 3) and the combined chloroform layer was dried over anhydrous magnesium sulfate, and then the solvent was distilled off. The residue was purified by column chromatography (eluent: ethanol/ethyl acetate = 1:10 → 1:5) to obtain 530 mg of the desired product (71.5%, colorless solid).

35

NMR (90MHz, CDCl₃) δ: 2.94 (4H, m), 2.67 (3H, s), 3.27 (4H, m), 3.67 (4H, m), 4.08 (2H, s), 6.62 (1H, br), 6.94 (2H, m), 7.50 (1H, s), 7.57 (1H, dd, J=8.5, 2Hz)

Example 6

40

According to the same manner as that described in Example 4 (1), the following compounds were obtained.

5-[2-(Methylsulfonylamino)ethylthio]-3-morpholinomethylimidazo[1,2-a]pyridine dihydrochloride (Compound 15)

45

NMR (200MHz, DMSO-d₆) δ: 2.92 (3H, s), 3.15-4.20 (14H, m), 5.08 (1H, br), 7.44 (1H, m), 7.69 (1H, dd, J=7, 1.4Hz), 7.83 (1H, dd, J=8.7, 7Hz), 7.94 (1H, dd, J=8.8, 1.4Hz), 8.40 (1H, s)

Example 7

50

According to the same manner as that described in Examples 2 and 5, the following compounds were obtained.

55

EP 0 471 236 B1

3-Dimethylaminomethyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine • dihydrochloride. (Compound 16)

5

Elemental analysis for C ₁₃ H ₂₀ N ₄ O ₂ S ₂ • 2HCl,			
Calcd.	C, 38.05;	H, 5.65;	N, 13.65
Found	C, 38.33;	H, 5.65;	N, 13.61

10

NMR (90MHz, DMSO-d₆-D₂O) δ: 2.95 (9H, s), 3.30 (4H, m), 5.08 (2H, s), 7.68-8.06 (3H, m), 8.43 (1H, s)

Example 8

15

According to the same manner as that described in Example 3, the following compounds were obtained.

(1) 2-Methyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 17)

20

Melting point: 179-181 °C

25

Elemental analysis for C ₁₁ H ₁₅ N ₃ O ₂ S ₂ ,			
Calcd.	C, 46.29;	H, 5.30;	N, 14.72
Found	C, 46.03;	H, 5.27;	N, 14.39

(2) 2-Ethoxycarbonylmethyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 18)

30

NMR (90MHz, CDCl₃) δ: 1.29 (3H, t, J = 7Hz), 2.95 (3H, s), 3.05-3.48 (4H, m), 3.88 (2H, s, J = 7Hz), 5.61 (1H, br), 6.97 (1H, dd, J = 7, 1.5Hz), 7.12 (1H, dd, J = 9, 7Hz), 7.53 (1H, d, J = 9Hz), 7.86 (1H, s)

35

(3) 3-Ethoxycarbonyl-2-methyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 19)

NMR (90MHz, CDCl₃) δ: 1.40 (3H, t, J = 7Hz), 2.60 (3H, s), 2.85 (3H, s), 3.21 (4H, m), 4.43 (2H, q, J = 7Hz), 5.20 (1H, br), 7.07 (1H, dd, J = 7, 1.5Hz), 7.33 (1H, dd, J = 9, 7Hz), 7.51 (1H, dd, J = 9, 1.5Hz)

40

(4) 2-Ethoxycarbonyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 20)

NMR (90MHz, DMSO-d₆) δ: 1.34 (3H, t, J = 7Hz), 2.92 (3H, s), 3.26 (4H, m), 4.30 (2H, q, J = 7Hz), 7.23 (1H, dd, J = 7, 1Hz), 7.30 (1H, br), 7.39 (1H, dd, J = 9, 7Hz), 7.64 (1H, d, J = 9Hz), 8.43 (1H, s)

Example 9

45

Synthesis of 2-carboxymethyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 21)

To a solution of 2-ethoxycarbonyl-5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (1.65 g, 4.62 mmoles) in methanol (5 ml) was added 1N NaOH (6.93 ml, 6.93 mmoles) and the mixture was stirred at room temperature for 2.5 hours. After the reaction mixture was washed with methylene chloride, 1N HCl (17.39 ml, 17.39 mmoles) was added thereto and the solvent was distilled off. Water was added to the residue and the resulting solid was washed with water and dried to obtain 777 mg of the desired product (51.1%, colorless solid).

55

EP 0 471 236 B1

Elemental analysis for C ₁₂ H ₁₅ N ₃ O ₄ S ₂			
Calcd.	C, 43.76;	H, 4.59;	N, 12.76
Found	C, 43.68;	H, 4.60;	N, 12.64

NMR (200MHz, DMSO-d₆) δ: 2.92 (3H, s), 3.24 (4H, s), 3.75 (2H, s), 7.09 (1H, dd, J=7.2, 1Hz), 7.27 (1H, dd, J=9, 7.2Hz), 7.36 (1H, br), 7.48 (1H, d, J=9Hz), 7.86 (1H, s)

Example 10

According to the same manner as that described in Examples 2 and 3 (1), the following compounds were obtained.

(1) 5-[2-(N-Methyl-N-methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 22)

NMR (200Hz, CDCl₃) δ: 2.82 (3H, s), 2.89 (3H, s), 3.22 (2H, m), 3.40 (2H, m), 7.03 (1H, dd, J=7, 1Hz), 7.19 (1H, dd, J=9, 7Hz), 7.62 (1H, d, J=9Hz), 7.72 (1H, d, J=1.2Hz), 7.86 (1H, s)

(2) 5-[2-(N-methyl-N-methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine • hydrochloride (Compound 23)

Melting point: 152-154 °C

(3) 5-[2-(methylsulfonylamino)ethylsulfinyl]imidazo[1,2-a]pyridine (Compound 24)

Elemental analysis for C ₁₀ H ₁₃ N ₃ O ₃ S ₂ • 2H ₂ O,			
Calcd.	C, 41.28;	H, 4.64;	N, 14.44
Found	C, 41.48;	H, 4.57;	N, 14.66

NMR (200Hz, CDCl₃-DMSO-d₆) δ: 2.98 (3H, s), 3.16-3.33 (1H, m), 3.39-3.76 (3H, m), 7.33-7.47 (3H, m), 7.33-7.84 (2H, m), 8.03 (1H, m)

(4) 5-[2-(Methylsulfonylamino)ethylsulfonyl]imidazo[1,2-a]pyridine (Compound 25)

Elemental analysis for C ₁₀ H ₁₃ N ₃ O ₄ S ₂ ,			
Calcd.	C, 39.59;	H, 4.32;	N, 13.85
Found	C, 39.31;	H, 4.33;	N, 13.78

NMR (200Hz, CDCl₃-DMSO-d₆) δ: 2.88 (3H, s), 3.45-3.66 (4H, m), 7.40 (1H, d, J=9, 7Hz), 7.71 (1H, dd, J=7, 1.2Hz), 7.85 (1H, d, J=1.2Hz), 7.96 (1H, d, J=9Hz), 8.30 (1H, s)

(5) 5-[2-(Trifluoromethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 26)

NMR (90Hz, DMSO-d₆) δ: 3.12-3.52 (4H, m), 7.13 (1H, dd, J=7, 1.5Hz), 7.28 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9Hz), 7.71 (1H, d, J=1.5Hz), 8.02 (1H, s)

EP 0 471 236 B1

(6) 5-[3-(Methylsulfonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 27)

5

Elemental analysis for $C_{11}H_{15}N_3O_2S_2$,			
Calcd.	C, 46.29;	H, 5.30;	N, 14.72
Found	C, 46.35;	H, 5.34;	N, 14.71

10 NMR (90Hz, $CDCl_3$) δ : 1.90 (2H, m), 2.93 (2H, s), 3.07 (2H, m), 3.27 (2H, m), 5.54 (1H, br), 6.90 (1H, dd, J = 7, 1Hz), 7.11 (1H, dd, J = 9, 7Hz), 7.57 (1H, d, J = 9Hz), 7.65 (1H, d, J = 1.5Hz), 7.82 (1H, s)

(7) 5-[3-(Trifluoromethylsulfonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 28)

15

Elemental analysis for $C_{11}H_{12}N_3O_2S_2F_3$,			
Calcd.	C, 38.93;	H, 3.56;	N, 12.38
Found	C, 38.91;	H, 3.64;	N, 12.27

20

NMR (200Hz, $CDCl_3$ -DMSO- d_6) δ : 1.91 (2H, m), 3.09 (2H, t, J = 7.2Hz), 3.36 (2H, t, J = 6.2Hz), 6.97 (1H, dd, J = 7, 1Hz), 7.19 (1H, dd, J = 9, 7Hz), 7.58 (1H, dd, J = 9, 1Hz), 7.70 (1H, d, J = 1.2Hz), 7.88 (1H, s)

(8) 5-[1-(Methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine•hydrochloride (Compound 29)

25

Melting point: 191-200 °C

NMR (200Hz, $CDCl_3$) of the free compound δ : 1.70-2.13 (4H, m), 2.79 (3H s), 2.90 (2H, m), 3.35 (1H, m), 3.69 (2H, m), 7.05 (1H, dd, J = 7, 1.2Hz), 7.17 (1H, dd, J = 8.8, 7Hz), 7.67 (1H, d, J = 8.8Hz), 7.71 (1H, d, J = 1.2Hz), 7.96 (1H, s)

30

(9) 5-[2-(Phenylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 30)

35

Elemental analysis for $C_{15}H_{15}N_3O_2S_2$,			
Calcd.	C, 54.03;	H, 4.53;	N, 12.60
Found	C, 53.88;	H, 4.53;	N, 12.43

40 NMR (200Hz, $CDCl_3$) δ : 3.01-3.23 (4H, m), 5.05 (1H, br), 6.84 (1H, d, J = 7Hz), 7.08 (1H, dd, J = 9, 7Hz), 7.41-7.63 (4H, m), 7.68 (1H, d, J = 1.4Hz), 7.75-7.83 (3H, m)

(10) 5-[2-[4-(Methyl)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 31)

45

Elemental analysis for $C_{16}H_{17}N_3O_2S_2 \cdot 0.5H_2O$,			
Calcd.	C, 53.91;	H, 5.09;	N, 11.79
Found	C, 54.13;	H, 4.94;	N, 11.57

50

NMR (90Hz, $CDCl_3$ -DMSO- d_6) δ : 2.39 (3H, s), 3.16 (4H, m), 6.90-7.33 (3H, m), 7.47-7.90 (7H, m)

55

EP 0 471 236 B1

(11) 5-[2-[4-(Acetamido)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 32)

Elemental analysis for $C_{17}H_{18}N_4O_3S_2 \cdot 1H_2O$,			
Calcd.	C, 49.98;	H, 4.93;	N, 13.72
Found	C, 50.16;	H, 4.60;	N, 13.60

NMR (200Hz, DMSO- d_6) δ : 2.09 (3H, s), 2.98 (2H, m), 3.13 (2H, m), 6.99 (1H, dd, J = 1Hz), 7.23 (1H, dd, J = 9, 7Hz), 7.52-7.77 (6H, m), 7.83 (1H, br), 7.90 (1H, m)

(12) 5-[2-[4-(Acetamido)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine • hydrochloride (Compound 33)

Melting point: 126-130 °C

(13) 5-[2-[4-(Chloro)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 34)

Elemental analysis for $C_{15}H_{14}N_3O_2S_2Cl \cdot 0.5H_2O$,			
Calcd.	C, 47.80;	H, 4.01;	N, 11.15
Found	C, 48.03;	H, 3.63;	N, 11.18

NMR (200Hz, CDCl₃-DMSO- d_6) δ : 3.68 (4H, m), 6.98 (1H, d, J = 7Hz), 7.18 (1H, dd, J = 9, 7Hz), 7.44 (2H, m), 7.56 (1H, d, J = 9Hz), 7.67 (1H, d, J = 1.2Hz), 7.74 (2H, m), 7.83 (1H, s), 7.87 (1H, br)

(14) 5-[2-[4-(Fluoro)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 35)

Elemental analysis for $C_{15}H_{14}N_3O_2S_2F$			
Calcd.	C, 51.27;	H, 4.02;	N, 11.96
Found	C, 51.16;	H, 4.05;	N, 12.05

NMR (200Hz, CDCl₃-DMSO- d_6) δ : 3.08 (4H, m), 6.95 (1H, dd, J = 7, 1Hz), 7.07-7.20 (3H, m), 7.48 (1H, br), 7.58 (1H, d, J = 9Hz), 7.68 (1H, d, J = 1.2Hz), 7.77-7.86 (3H, m)

(15) 5-[2-[4-(Methoxy)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 36)

Elemental analysis for $C_{16}H_{17}N_3O_3S_2 \cdot 0.3H_2O$,			
Calcd.	C, 52.10;	H, 4.81;	N, 11.39
Found	C, 52.25;	H, 4.73;	N, 11.47

NMR (200Hz, CDCl₃-DMSO- d_6) δ : 3.07 (4H, m), 3.86 (3H, s), 6.86-6.97 (3H, m), 7.15 (1H, dd, J = 9, 7Hz), 7.20 (1H, br), 7.57 (1H, d, J = 9Hz), 7.64-7.76 (3H, m), 7.81 (1H, s)

EP 0 471 236 B1

(16) 5-[2-[2,4,5-(Trichloro)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 37)

5

Elemental analysis for $C_{15}H_{12}N_3O_2S_2Cl_3 \cdot 0.5H_2O$,			
Calcd.	C, 40.42;	H, 2.94;	N, 9.43
Found	C, 40.65;	H, 2.74;	N, 9.50

10 NMR (200Hz, $CDCl_3$ -DMSO- d_6) δ : 3.07-3.25 (4H, m), 6.95 (1H, dd, J=7, 1Hz), 7.16 (1H, dd, J=9, 7Hz), 7.57 (1H, d, J=9Hz), 7.59 (1H, s), 8.07 (1H, s)

(17) 5-[2-[2,4,6-(Trimethyl)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 38)

15

Elemental analysis for $C_{18}H_{21}N_3O_2S_2$,			
Calcd.	C, 57.57;	H, 5.65;	N, 11.19
Found	C, 57.32;	H, 5.65;	N, 11.09

20

NMR (200Hz, $CDCl_3$) δ : 2.30 (3H, s), 2.58 (6H, s), 2.98-3.20 (4H, m), 5.00 (1H, br), 6.81 (1H, d, J=7Hz), 6.92 (2H, s), 7.08 (1H, dd, J=9, 7Hz), 7.60 (1H, d, J=9Hz), 7.68 (1H, s), 7.77 (1H, s)

(18) 5-[2-[2,4,6-(Triisopropyl)phenylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 39)

25

Elemental analysis for $C_{24}H_{33}N_3O_2S_2$,			
Calcd.	C, 62.71;	H, 7.24;	N, 9.14
Found	C, 62.65;	H, 7.15;	N, 9.07

30

NMR (200Hz, $CDCl_3$) δ : 1.24 (12H, d, J=6.8Hz), 1.26 (6H, d, J=7Hz), 2.94 (1H, heptet, J=7Hz), 3.06-3.25 (4H, m), 4.10 (2H, heptet, J=6.8Hz), 4.90 (1H, br), 6.83 (1H, dd, J=7, 1Hz), 7.08 (1H, dd, J=9, 7Hz), 7.59 (1H, d, J=9Hz), 7.68 (1H, d, J=1.2Hz), 7.80 (1H, m)

35

(19) 5-[2-[(2-Thienyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 40)

40

Elemental analysis for $C_{13}H_{13}N_3O_2S_3$,			
Calcd.	C, 46.00;	H, 3.86;	N, 12.38
Found	C, 45.71;	H, 3.88;	N, 12.30

45

NMR (200Hz, DMSO- d_6) δ : 3.03-3.20 (4H, m), 7.04 (1H, dd, J=7, 1Hz), 7.12 (1H, m), 7.26 (1H, dd, J=9, 7Hz), 7.50-7.61 (2H, m), 7.69 (1H, d, J=1.4Hz), 7.89 (1H, m), 7.93 (1H, m), 8.16 (1H, br)

(20) 5-[2-[(2-Thienyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 41)

50

Melting point: 140-143 °C

55

Elemental analysis for $C_{13}H_{13}N_3O_2S_3 \cdot HCl$,			
Calcd.	C, 41.54;	H, 3.75;	N, 11.18
Found	C, 41.25;	H, 3.80;	N, 11.05

EP 0 471 236 B1

(21) 5-[2-[(1-Naphthyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 42)

5

Elemental analysis for $C_{19}H_{17}N_3O_2S_2$			
Calcd.	C, 59.51;	H, 4.47;	N, 10.96
Found	C, 59.73;	H, 4.61;	N, 10.77

10 NMR (200Hz, $CDCl_3$) δ : 2.97 (2H, m), 3.07 (2H, m), 5.55 (1H, br), 6.56 (1H, dd, $J=7, 1$ Hz), 6.92 (1H, dd, $J=9, 7$ Hz), 7.44-7.72 (6H, m), 7.96 (1H, m), 8.06 (1H, d, $J=8.2$ Hz), 8.20 (1H, dd, $J=7.4, 1.2$ Hz), 8.64 (1H, m)

(22) 5-[2-[(1-Naphthyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 43)

15

Melting point: 179-185 °C

(23) 5-[2-[(2-Naphthyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 44)

20

Melting point: 179-185 °C

25

Elemental analysis for $C_{19}H_{17}N_3O_2S_2 \cdot 0.2H_2O$			
Calcd.	C, 58.95;	H, 4.53;	N, 10.86
Found	C, 59.15;	H, 4.78;	N, 10.55

NMR (200Hz, $CDCl_3$) δ : 3.07 (2H, m), 3.20 (2H, m), 5.31 (1H, br), 6.74 (1H, dd, $J=7, 1$ Hz), 6.89 (1H, dd, $J=9, 7$ Hz), 7.51 (1H, d, $J=9$ Hz), 7.58-7.85 (5H, m), 7.88-7.97 (3H, m), 8.39 (1H, d, $J=1.6$ Hz)

30 (24) 5-[2-[(2-Naphthyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine • hydrochloride (Compound 45)

Melting point: 170-175 °C

(25) 5-[2-[(8-Quinolyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 46)

35

40

Elemental analysis for $C_{18}H_{16}N_4O_2S_2$			
Calcd.	C, 56.23;	H, 4.19;	N, 14.57
Found	C, 56.39;	H, 4.23;	N, 14.69

45 NMR (200Hz, $CDCl_3$) δ : 3.00-3.22 (4H, m), 6.65 (1H, dd, $J=7, 1$ Hz), 6.81 (1H, br), 6.97 (1H, dd, $J=9, 7$ Hz), 7.47-7.74 (5H, m), 8.06 (1H, dd, $J=8.4, 1.4$ Hz), 8.26 (1H, dd, $J=8.4, 1.8$ Hz), 8.40 (1H, dd, $J=7.2, 1.4$ Hz), 8.95 (1H, dd, $J=4.2, 1.8$ Hz)

(26) 5-[2-[(8-Quinolyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine • hydrochloride (Compound 47)

Melting point: 190-196 °C

50

(27) 5-[2-[5-(Dimethylamino)-(1-naphthyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 48)

55

NMR (200Hz, $CDCl_3$) δ : 2.90 (6H, s), 2.93-3.12 (4H, m), 5.46 (1H, br), 6.56 (1H, dd, $J=7, 1$ Hz), 6.92 (1H, dd, $J=9, 7$ Hz), 7.19 (1H, d, $J=7.6$ Hz), 7.43-7.63 (4H, m), 7.67 (1H, s), 8.18 (1H, dd, $J=7.4, 1.2$ Hz), 8.27 (1H, d, $J=8.6$ Hz), 8.53 (1H, d, $J=8.6$ Hz)

EP 0 471 236 B1

(28) 5-[2-[(E)-Styrylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 49)

Elemental analysis for $C_{17}H_{17}N_3O_2S_2$			
Calcd.	C, 56.80;	H, 4.77;	N, 11.69
Found	C, 56.95;	H, 4.84;	N, 11.62

NMR (200Hz, $CDCl_3$) δ : 3.14-3.34 (4H, m), 4.95 (1H, br), 6.70 (1H, d, $J=15.4$ Hz), 6.98 (1H, dd, $J=7$, 1Hz), 7.09 (1H, dd, $J=9$, 7Hz), 7.43 (5H, m), 7.46 (1H, d, $J=15.4$ Hz), 7.59 (1H, d, $J=9$ Hz), 7.68 (1H, d, $J=1.4$ Hz), 7.84 (1H, s)

(29) 5-[2-[N,N-di-(E)-Styrylsulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 50)

Elemental analysis for $C_{25}H_{23}N_3O_4S_2$			
Calcd.	C, 57.12;	H, 4.41;	N, 7.99
Found	C, 57.07;	H, 4.48;	N, 7.81

NMR (200Hz, $CDCl_3$) δ : 3.33 (2H, m), 3.91 (2H, m), 7.05 (1H, dd, $J=7$, 1Hz), 7.12 (2H, d, $J=15.4$ Hz), 7.18 (1H, dd, $J=8.8$, 7Hz), 7.38-7.56 (12H, m), 7.61 (1H, d, $J=8.8$ Hz), 7.66 (1H, d, $J=1.2$ Hz), 7.77 (1H, s)

(30) 5-[2-[2-(Acetylamino)-4-(methyl)-(5-thiazolyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 51)

NMR (200Hz, $DMSO-d_6$) δ : 2.17 (3H, s), 2.38 (3H, s), 3.07-3.49 (4H, m), 7.02 (1H, d, $J=7.2$ Hz), 7.23 (1H, dd, $J=8.8$, 7.2Hz), 7.54 (1H, d, $J=8.8$ Hz), 7.67 (1H, s), 7.90 (1H, s), 8.20 (1H, br)

(31) 5-[3-(1-Naphthylsulfonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 52) Melting point: 140-141 °C

Elemental analysis for $C_{20}H_{19}N_3O_2S_2$			
Calcd.	C, 60.43;	H, 4.82;	N, 10.57
Found	C, 60.58;	H, 4.85;	N, 10.60

(32) 5-[2-[N-Methyl-N-(1-naphthylsulfonylamino)]ethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 53)

Melting point: 161-164 °C

Elemental analysis for $C_{20}H_{19}N_3O_2S_2 \cdot HCl$			
Calcd.	C, 55.35;	H, 4.65;	N, 9.68
Found	C, 55.31;	H, 4.69;	N, 9.55

NMR (200Hz, $CDCl_3$) of the free compound: δ : 2.90 (3H, s), 3.12 (2H, m), 3.42 (2H, m), 6.92 (1H, dd, $J=7$, 1Hz), 7.14 (1H, dd, $J=9$, 7Hz), 7.45 (1H, dd, $J=8.4$, 7.4Hz), 7.53-7.71 (5H, m), 7.90 (1H, m), 8.02 (1H, d, $J=8.4$ Hz), 8.09 (1H, dd, $J=7.4$, 1.2Hz), 8.60 (1H, m)

EP 0 471 236 B1

(33) 5-[2-[N-Ethyl-N-(1-naphthylsulfonylamino)]ethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 54)

Melting point: 178-185 °C

Elemental analysis for $C_{21}H_{21}N_3O_2S_2 \cdot HCl$,			
Calcd.	C, 56.30;	H, 4.95;	N, 9.38
Found	C, 56.27;	H, 4.97;	N, 9.29

NMR (200Hz, $CDCl_3$) of the free compound δ : 1.06 (3H, t, $J=7.2$ Hz), 3.06 (2H, m), 3.30-3.50 (4H, m), 6.90 (1H, d, $J=7.2$ Hz), 7.15 (1H, dd, $J=9, 7.2$ Hz), 7.41 (1H, m), 7.53-7.71 (5H, m), 7.86-8.10 (3H, m), 8.54 (1H, m)

(34) 5-[2-[N-(2-Hydroxyethyl)-N-(1-naphthylsulfonylamino)]ethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 55)

Melting point: 172-176 °C

Elemental analysis for $C_{21}H_{21}N_3O_3S_2 \cdot HCl$,			
Calcd.	C, 54.36;	H, 4.78;	N, 9.06
Found	C, 54.74;	H, 4.85;	N, 8.88

NMR (200Hz, $CDCl_3$) of the free compound δ : 2.10 (1H, br), 3.18 (2H, m), 3.41-3.62 (4H, m), 3.74 (2H, t, $J=5.2$ Hz), 6.90 (1H, dd, $J=7, 1$ Hz), 7.12 (1H, dd, $J=9, 7$ Hz), 7.42 (1H, m), 7.85-8.10 (3H, m), 7.85-8.10 (3H, m), 8.56 (1H, m)

(35) 2-Methyl-5-[2-(1-naphthylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 56)

Elemental analysis for $C_{20}H_{19}N_3O_2S_2$,			
Calcd.	C, 60.43;	H, 4.82;	N, 10.57
Found	C, 60.24;	H, 4.84;	N, 10.52

NMR (200Hz, $CDCl_3$) δ : 2.44 (3H, s), 2.89-3.11 (4H, m), 5.30 (1H, br), 6.47 (1H, dd, $J=7, 1.2$ Hz), 6.85 (1H, dd, $J=9, 7$ Hz), 7.36-7.53 (3H, m), 7.96 (1H, dd, $J=6.8, 1.8$ Hz), 8.06 (1H, d, $J=8.2$ Hz), 8.19 (1H, dd, $J=7.4, 1.2$ Hz), 8.63 (1H, d, $J=8.4$ Hz)

(36) 3-Ethoxycarbonyl-2-methyl-5-[2-[1-(naphthyl)sulfonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 57)

Elemental analysis for $C_{23}H_{23}N_3O_4S_2 \cdot 0.5H_2O$,			
Calcd.	C, 57.72;	H, 5.05;	N, 8.78
Found	C, 57.85;	H, 5.02;	N, 8.63

NMR (200Hz, $CDCl_3$) δ : 1.41 (3H, t, $J=7.2$ Hz), 2.61 (3H, s), 2.95-3.05 (4H, m), 4.42 (2H, q, $J=7.2$ Hz), 5.29 (1H, br), 6.82 (1H, dd, $J=7.2, 1$ Hz), 7.22 (1H, dd, $J=9, 7.2$ Hz), 7.42-7.66 (4H, m), 7.91 (1H, m), 8.04 (1H, d, $J=8$ Hz), 8.16 (1H, dd, $J=7.4, 1.4$ Hz), 8.54 (1H, m)

EP 0 471 236 B1

(37) 2-Ethoxycarbonyl-5-[2-(1-naphthylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 58)

5

Elemental analysis for C ₂₂ H ₂₁ N ₃ O ₄ S ₂ ,			
Calcd.	C, 58.00;	H, 4.65;	N, 9.22
Found	C, 57.79;	H, 4.63;	N, 9.24

10 NMR (200Hz, CDCl₃) δ: 1.45 (3H, t, J=7.2Hz), 2.98 (2H, m), 3.12 (2H, m), 4.47 (2H, q, J=7, 2Hz), 5.26 (1H, br), 6.65 (1H, dd, J=7, 1Hz), 7.03 (1H, dd, J=9, 7Hz), 7.44-7.73 (4H, m), 7.95 (1H, dd, J=7.8, 1.6Hz), 8.05 (1H, d, J=8.2Hz), 8.19 (1H, dd, J=7.2, 1.2Hz), 8.24 (1H, s), 8.62 (1H, m)

Example 11

15

According to the same manner as that described in Example 4 (1), the following compound was obtained.

3-Bromo-5-[2-(1-(naphthyl)sulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 59)

20

Elemental analysis for C ₁₉ H ₁₅ N ₃ O ₂ S ₂ Br,			
Calcd.	C, 49.35;	H, 3.49;	N, 9.09
Found	C, 49.39;	H, 3.47;	N, 8.98

25

NMR (200Hz, CDCl₃) δ: 2.91 (2H, m), 3.10 (2H, m), 5.32 (1H, br), 6.51 (1H, dd, J=7, 1Hz), 6.83 (1H, dd, J=9, 7Hz), 7.43-7.73 (5H, m), 7.94 (1H, dd, J=7.8, 1.6Hz), 8.04 (1H, d, J=8.2Hz), 8.19 (1H, dd, J=7.4, 1.2Hz), 8.64 (1H, d, J=8.2Hz)

30

Example 12

According to the same manner as that described in Example 3 (1), the following compounds were obtained.

35

(1) 5-[2-(Methylsulfonylamino)ethylamino]imidazo[1,2-a]pyridine (Compound 60)

NMR (90Hz, CDCl₃-DMSO-d₆) δ: 2.90 (3H, s), 3.44 (4H, m), 6.16 (1H, d, J=7.5Hz), 6.99 (1H, d, J=9Hz), 7.28 (2H, br), 7.43 (1H, dd, J=9, 7.5Hz), 7.66 (1H, d, J=1.5Hz), 8.23 (1H, s)

40

(2) 5-[3-(Methylsulfonylamino)propylamino]imidazo[1,2-a]pyridine (Compound 61)

NMR (90Hz, CDCl₃-DMSO-d₆) δ: 1.97 (2H, m), 2.90 (3H, s), 3.17 (2H, m), 3.46 (2H, m), 6.19 (1H, d, J=8Hz), 6.91-7.20 (2H, m), 7.37-7.63 (2H, m), 7.71 (1H, d, J=2Hz), 8.36 (1H, d, J=2Hz)

45

(3) 5-[2-(Methylsulfonylamino)ethyloxy]imidazo[1,2-a]pyridine (Compound 62)

50

Elemental analysis for C ₁₀ H ₁₃ N ₃ O ₃ S,			
Calcd.	C, 47.05;	H, 5.13;	N, 16.46
Found	C, 46.95;	H, 5.17;	N, 16.38

55 NMR (200MHz, DMSO-d₆) δ: 2.98 (3H, s), 3.49 (2H, m), 4.35 (2H, t, J=5.2Hz), 6.34 (1H, dd, J=6, 1.6Hz), 7.16-7.32 (2H, m), 7.50 (1H, br), 7.57 (1H, d, J=1.2Hz), 7.91 (1H, s)

EP 0 471 236 B1

(4) 5-[2-(Trifluoromethylsulfonylamino)ethoxy]imidazo[1,2-a]pyridine (Compound 63)

NMR (200MHz, DMSO-d₆) δ: 3.71 (2H, m), 4.38 (2H, t, J=5Hz), 6.38 (1H, dd, J=6.5, 1.6Hz), 7.19-7.34 (2H, m), 7.60 (1H, s), 7.87 (1H, s)

(5) 5-[3-(methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine (Compound 64)

NMR (200Hz, CDCl₃-DMSO-d₆) δ: 2.20 (2H, m), 2.93 (3H, s), 3.35 (2H, m), 4.39 (2H, t, J=6.2Hz), 6.11 (1H, dd, J=6.8, 1.6Hz), 6.91 (1H, br), 7.14-7.29 (2H, m), 7.57 (1H, d, J=1.4Hz), 7.67 (1H, m)

(6) 5-[3-(Trifluoromethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine (Compound 65)

NMR (200Hz, DMSO-d₆) δ: 2.05 (2H, m), 2.91 (3H, s), 3.21 (2H, m), 4.38 (2H, t, J=6Hz), 6.35 (1H, dd, J=7, 1.2Hz), 7.10-7.32 (3H, m), 7.56 (1H, d, J=1.4Hz), 7.78 (1H, s)

(7) 5-[4-(methylsulfonylamino)butyloxy]imidazo[1,2-a]pyridine (Compound 66)

Elemental analysis for C ₁₂ H ₁₇ N ₃ O ₃ S			
Calcd.	C, 50.87;	H, 6.05;	N, 14.83
Found	C, 50.60;	H, 6.11;	N, 14.78

NMR (200Hz, CDCl₃) δ: 1.87 (2H, m), 2.04 (2H, m), 2.99 (3H, s), 3.28 (2H, m), 4.29 (2H, t, J=6.2Hz), 4.58 (1H, br), 6.04 (1H, d, J=7.2Hz), 7.17 (1H, dd, J=9, 7.2Hz), 7.29 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.63 (1H, m)

(8) 5-[4-(Trifluoromethylsulfonylamino)butyloxy]imidazo[1,2-a]pyridine (Compound 67)

Elemental analysis for C ₁₂ H ₁₄ N ₃ O ₃ SF ₃			
Calcd.	C, 42.73;	H, 4.18;	N, 12.56
Found	C, 42.53;	H, 4.27;	N, 12.25

NMR (200Hz, CDCl₃-DMSO-d₆) δ: 1.87 (2H, m), 2.03 (2H, m), 3.30 (2H, m), 4.30 (2H, t, J=6Hz), 6.08 (1H, dd, J=6.4, 1.4Hz), 7.14-7.28 (2H, m), 7.57 (1H, s), 7.68 (1H, s)

(9) 5-[5-(Methylsulfonylamino)pentyloxy]imidazo[1,2-a]pyridine (Compound 68)

Elemental analysis for C ₁₃ H ₁₉ N ₃ O ₃ S			
Calcd.	C, 52.51;	H, 6.44;	N, 14.13
Found	C, 52.22;	H, 6.53;	N, 13.83

NMR (200Hz, CDCl₃) δ: 1.54-1.80 (4H, m), 1.97 (2H, m), 3.20 (2H, m), 4.25 (2H, t, J=6.2Hz), 4.59 (1H, br), 6.02 (1H, dd, J=7.2, 1Hz), 7.17 (1H, dd, J=9, 7Hz), 7.28 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.63 (1H, m)

EP 0 471 236 B1

(10) 5-[5-(Trifluoromethylsulfonylamino)pentyloxy]imidazo[1,2-a]pyridine (Compound 69)

5

Elemental analysis for $C_{13}H_{16}N_3O_3SF_3$			
Calcd.	C, 44.44;	H, 4.59;	N, 11.96
Found	C, 44.47;	H, 4.63;	N, 11.71

10 NMR (200Hz, $CDCl_3$) δ : 1.63-2.02 (6H, m), 3.42 (2H, m), 4.18 (2H, t, J=6Hz), 5.94 (1H, d, J=7Hz), 7.12 (1H, dd, J=9, 7Hz), 7.23 (1H, d, J=9Hz), 7.30 (1H, d, J=1Hz), 7.41 (1H, d, J=1Hz)

(11) 5-[6-(Methylsulfonylamino)hexyloxy]imidazo[1,2-a]pyridine (Compound 70)

15

Elemental analysis for $C_{14}H_{21}N_3O_3S \cdot 0.2H_2O$			
Calcd.	C, 53.38;	H, 6.85;	N, 13.34
Found	C, 53.67;	H, 7.04;	N, 13.28

20

NMR (200Hz, $CDCl_3$) δ : 1.40-1.73 (6H, m), 1.91 (2H, m), 3.17 (2H, m), 4.24 (2H, t, J=6.2Hz), 4.61 (1H, br), 6.02 (1H, dd, J=7, 1Hz), 7.17 (1H, dd, J=9, 7Hz), 7.28 (1H, d, J=9Hz), 7.59 (1H, d, J=1.4Hz), 7.65 (1H, m)

25 (12) 5-[6-(Trifluoromethylsulfonylamino)hexyloxy]imidazo[1,2-a]pyridine (Compound 71)

NMR (200Hz, $CDCl_3$) δ : 1.32-2.03 (8H, m), 3.37 (2H, t, 6.6Hz), 4.17 (2H, t, J=6.2Hz), 5.97 (1H, d, J=7Hz), 7.16 (1H, dd, J=9, 7Hz), 7.21 (1H, br), 7.25 (1H, d, J=9Hz), 7.51 (1H, d, J=1.1Hz), 7.54 (1H, s)

30 (13) 5-[2-(Methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine (Compound 72)

Melting point: 171-172 °C

(14) 5-[1-(Methylsulfonylamino)-(2-propyloxy)]imidazo[1,2-a]pyridine (Compound 73)

35

Elemental analysis for $C_{11}H_{15}N_3O_3S$			
Calcd.	C, 49.06;	H, 5.61;	N, 15.60
Found	C, 48.81;	H, 5.63;	N, 15.59

40

NMR (200Hz, $CDCl_3$) δ : 1.47 (3H, d, J=6.2 Hz), 3.01 (3H, s), 3.50 (2H, m), 4.84 (1H, m), 6.10 (1H, d, J=7.4Hz), 6.38 (1H, br), 7.09 (1H, dd, J=9, 7.4Hz), 7.21 (1H, d, J=9Hz), 7.41 (1H, d, J=1.4Hz)

45

(15) 5-[2-(Methylsulfonylamino)-1-(phenyl)ethyloxy]imidazo[1,2-a]pyridine (Compound 74)

NMR (200Hz, $CDCl_3$) δ : 2.94 (3H, s), 3.61-3.83 (2H, m), 5.33 (1H, br), 5.58 (1H, dd, J=7, 4.6Hz), 5.91 (1H, d, J=7.4Hz), 7.00 (1H, dd, J=9, 7.4Hz), 7.24 (1H, d, J=9Hz), 7.40 (5H, m), 7.60 (1H, d, J=1.4Hz), 7.73 (1H, s)

50

(16) 5-[[1-(Phenyl)-2-(trifluoromethylsulfonylamino)]ethyloxy]imidazo[1,2-a]pyridine (Compound 75)

NMR (200Hz, $CDCl_3$ -DMSO- d_6) δ : 3.49 (2H, m), 5.06 (1H, dd, J=8, 4Hz), 5.98 (1H, d, J=8.8Hz), 5.98 (1H, br), 7.04 (1H, d, J=8.8Hz), 7.20-7.52 (6H, m), 7.60 (1H, s), 7.81 (1H, s)

55

EP 0 471 236 B1

(17) 5-[1-(Methylsulfonyl)-4-piperidyloxy]imidazo[1,2-a]pyridine (Compound 76)

NMR (200Hz, CDCl₃) δ: 2.19 (4H, m), 2.86 (3H, s), 3.44 (4H, m), 4.84 (1H, quint, J = 4.4Hz), 6.08 (1H, d, J = 7Hz), 7.18 (1H, dd, J = 9, 7Hz), 7.31 (1H, d, J = 9Hz), 7.63 (1H, d, J = 1.4Hz), 7.65 (1H, s)

(18) 5-[1-(Trifluoromethylsulfonyl)-4-piperidyloxy]imidazo[1,2-a]pyridine (Compound 77)

NMR (200Hz, CDCl₃) δ: 2.18 (4H, m), 3.71 (4H, s), 4.99 (1H, m), 6.08 (1H, d, J = 7Hz), 7.19 (1H, dd, J = 9, 7Hz), 7.33 (1H, d, J = 9Hz), 7.64 (1H, s), 7.65 (1H, s)

(19) 5-[2-(1-(Naphthyl)sulfonylamino)ethyloxy]imidazo[1,2-a]pyridine (Compound 78)

Elemental analysis for C ₁₉ H ₁₇ N ₃ O ₃ S,			
Calcd.	C, 62.11;	H, 4.66;	N, 11.44
Found	C, 62.04;	H, 4.57;	N, 11.41

NMR (200Hz, DMSO-d₆) δ: 3.38 (2H, m), 4.11 (2H, t, J = 5.2Hz), 6.06 (1H, m), 7.08-7.20 (2H, m), 7.46-7.65 (5H, m), 8.00 (1H, m), 8.16 (1H, s), 8.20 (1H, s), 8.47 (1H, br), 8.64 (1H, m)

(20) 5-[3-(1-(Naphthyl)sulfonylamino)propyloxy]imidazo[1,2-a]pyridine (Compound 79)

Elemental analysis for C ₂₀ H ₁₉ N ₃ O ₃ S,			
Calcd.	C, 62.97;	H, 5.02;	N, 11.02
Found	C, 62.82;	H, 4.98;	N, 11.14

NMR (200Hz, CDCl₃-DMSO-d₆) δ: 1.98 (2H, m), 3.19 (2H, m), 3.98 (2H, t, J = 6Hz), 5.59 (1H, d, J = 7.2Hz), 6.99-7.35 (4H, m), 7.43-7.63 (3H, m), 7.67-7.80 (3H, m), 8.14 (1H, d, J = 7.4Hz), 8.68 (1H, d, J = 8.2Hz)

(21) 5-[6-(1-(Naphthyl)sulfonylamino)hexyloxy]imidazo[1,2-a]pyridine (Compound 80)

Elemental analysis for C ₂₃ H ₂₅ N ₃ O ₃ S•0.3H ₂ O,			
Calcd.	C, 64.40;	H, 6.02;	N, 9.80
Found	C, 64.66;	H, 6.07;	N, 9.68

NMR (200Hz, CDCl₃) δ: 1.10-1.83 (8H, m), 2.94 (2H, m), 4.12 (2H, t, J = 6.4Hz), 4.76 (1H, t, J = 6.6Hz), 5.98 (1H, d, J = 7Hz), 7.16 (1H, dd, J = 9, 7Hz), 7.28 (1H, d, J = 9Hz), 7.50-7.72 (5H, m), 7.94 (1H, d, J = 7.6Hz), 8.07 (1H, d, J = 8.4Hz), 8.28 (1H, dd, J = 7.4, 1.2Hz), 8.66 (1H, d, J = 8.8Hz)

(22) 5-[2-(1-(Naphthyl)sulfonylamino)propyloxy]imidazo[1,2-a]pyridine (Compound 81)

Melting point: 188-190 °C

(23) 5-[(1-(1-(Naphthyl)sulfonyl))-(4-piperidyl)oxy]imidazo[1,2-a]pyridine (Compound 82)

NMR (200Hz, CDCl₃) δ: 1.94-2.23 (4H, m), 3.29-3.53 (4H, m), 4.70 (1H, m), 5.98 (1H, d, J = 7Hz), 7.12 (1H, dd, J = 9, 7Hz), 7.25 (1H, d, J = 9Hz), 7.39 (1H, s), 7.53 (1H, s), 7.53-7.73 (3H, m), 7.98 (1H, dd, J = 7.2, 2.2Hz), 8.13 (1H, d, J = 8.4Hz), 8.27 (1H, dd, J = 7.4, 1.2Hz), 8.75 (1H, dd, J = 7.8, 2.2Hz)

EP 0 471 236 B1

Example 13

(1) Synthesis of 5-[2-(acetylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 83)

- 5 To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine dihydrochloride (2.66 g, 10 mmoles) and triethylamine (4.32 ml, 31 mmoles) in N,N-dimethylformamide (24 ml) was added acetyl chloride (0.71 ml, 10 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 4 hours. The reaction mixture was poured into water and extracted with chloroform. The chloroform layer was washed with saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethanol/ethyl acetate = 1:3) to obtain 1.57 g of the desired product (66.8%, colorless crystals).

15

Elemental analysis for $C_{11}H_{13}N_3OS \cdot 0.3H_2O$			
Calcd.	C, 54.89;	H, 5.69;	N, 17.46
Found	C, 55.29;	H, 5.52;	N, 17.42

20

NMR (90MHz, $CDCl_3$) δ : 1.93 (3H, s), 3.13 (2H, m), 3.46 (2H, m), 6.98 (1H, dd, J = 7, 1.5Hz), 7.07 (1H, br), 7.13 (1H, dd, J = 8.5, 7Hz), 7.51 (1H, d, J = 8.5Hz), 7.65 (1H, s), 7.81 (1H, s)

According to the same manner as that described in Examples 2 and 13 (1), the following compounds were obtained.

(2) 5-[2-(Trifluoroacetyl amino)ethylthio]imidazo[1,2-a]pyridine (Compound 84)

25

NMR (90MHz, $DMSO-d_6$) δ : 3.17-3.60 (4H, m), 7.12 (1H, dd, J = 7, 1.5Hz), 7.27 (1H, dd, J = 9, 7Hz), 7.58 (1H, d, J = 9Hz), 7.67 (1H, d, J = 1.5Hz), 7.96 (1H, s), 9.60 (1H, br)

(3) 5-[2-(Decanoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 85)

30

NMR (90MHz, $CDCl_3$) δ : 1.70-1.78 (17H, m), 2.15 (2H, m), 3.15 (2H, m), 3.49 (2H, m), 6.53 (1H, br), 7.00 (dd, J = 7, 1.5Hz), 7.15 (1H, d, J = 9, 7Hz), 7.23 (1H, d, J = 9Hz), 7.67 (1H, s), 7.84 (1H, s)

(4) 5-[2-(Aminoacetyl amino)ethylthio]imidazo[1,2-a]pyridine dihydrochloride (compound 86)

35

NMR (200MHz, $DMSO-d_6$) δ : 3.32-3.53 (4H, m), 3.55 (2H, s), 7.69 (1H, dd, J = 6, 2.6Hz), 7.86-7.99 (2H, m), 8.22 (1H, d, J = 2.2Hz), 8.26 (1H, d, J = 2.2Hz), 8.79 (1H, br)

(5) 5-[2-(Benzoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 87)

40

NMR (90MHz, $CDCl_3$) δ : 3.27 (2H, m), 3.70 (2H, m), 6.74 (1H, br), 6.97-7.23 (2H, m), 7.30-7.95 (8H, m)

(6) 5-[2-[3(2H)-Pyridazinone-6-carbonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 88)

45

NMR (90MHz, $DMSO-d_6$) δ : 3.15-3.67 (4H, m), 6.93 (1H, d, J = 10Hz), 7.10-7.62 (3H, m), 7.66 (1H, s), 7.80 (1H, d, J = 10Hz), 7.92 (1H, s), 8.64 (1H, br)

(7) 5-[2-[(2-Thenoylamino)]ethylthio]imidazo[1,2-a]pyridine (Compound 89)

50

NMR (200MHz, $CDCl_3$) δ : 3.27 (2H, t, J = 6.4Hz), 3.68 (2H, m), 6.57 (1H, br), 7.02-7.20 (3H, m), 7.41-7.69 (3H, m), 7.69 (1H, d, J = 1.2Hz), 7.85 (1H, s)

(8) 5-[2-(1-Naphthoyl)aminoethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 90)

55

NMR (200MHz, $DMSO-d_6$) δ : 3.50-3.75 (4H, m), 7.51-7.67 (4H, m), 7.75-8.07 (5H, m), 8.22 (1H, m), 8.32 (1H, d, J = 2.2Hz), 8.41 (1H, d, J = 2.2Hz), 8.85 (1H, br)

NMR (200MHz, $CDCl_3$) of the free amine δ : 3.30 (2H, t, J = 6.4Hz), 3.74 (2H, m), 6.68 (1H, br), 7.01-7.16 (2H, m), 7.36-7.58 (5H, m), 7.64 (1H, d, J = 1.2Hz), 7.80-7.94 (3H, m), 8.29 (1H, m)

EP 0 471 236 B1

(9) 5-[2-(2-Naphthoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 91)

NMR (200MHz, CDCl₃) δ : 3.34 (2H, t, J=6.4Hz), 3.78 (2H, m), 6.72 (1H, br), 7.06-7.20 (2H, m), 7.51-7.94 (9H, m), 8.20 (1H, s)

(10) 5-[2-(Nicotinoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 92)

NMR (200MHz, CDCl₃) δ : 3.30 (2H, t, J=6.4Hz), 3.74 (2H, m), 6.85 (1H, br), 7.05 (1H, dd, J=7, 1.2Hz), 7.16 (1H, dd, J=9, 7Hz), 7.39 (1H, m), 7.55 (1H, d, J=9Hz), 7.68 (1H, d, J=1.4Hz), 7.85 (1H, s), 8.05 (1H, m), 8.74 (1H, dd, J=4.8, 1.8Hz), 8.95 (1H, d, J=7.2Hz)

(11) 5-[2-(Isonicotinoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 93)

NMR (200MHz, CDCl₃-DMSO-d₆) δ : 3.29 (2H, m), 3.68 (2H, m), 7.11 (1H, dd, J=7, 1.4Hz), 7.19 (1H, dd, J=8.8, 7.2Hz), 7.57 (1H, d, J=8.8Hz), 7.68 (2H, m), 7.88 (1H, m), 8.23 (1H, br), 8.72 (2H, m)

(12) 5-[2-[3,4-(Dimethoxy)phenylacetyl]amino]ethylthio]imidazo[1,2-a]pyridine•hydrochloride (Compound 94)

Melting point: 150-165 °C

NMR (200MHz, CDCl₃) of the free amine δ : 3.11 (2H, t, J=6.6Hz), 3.43 (2H, m), 3.49 (2H, s), 3.85 (3H, s), 3.87 (3H, s), 6.02 (1H, br), 6.69-6.95 (4H, m), 7.12 (1H, dd, J=9, 7Hz), 7.56 (1H, d, J=9Hz), 7.66 (1H, s), 7.74 (1H, s)

(13) 5-[2-[3-(3-Pyridyl)acryloyl]amino]ethylthio]imidazo[1,2-a]pyridine•dihydrochloride (Compound 95)

NMR (200MHz, D₂O) δ : 3.41 (2H, m), 3.61 (2H, m), 6.60 (1H, d, J=16Hz), 7.36 (1H, d, J=16Hz), 7.58-8.05 (5H, m), 8.22 (1H, d, J=2.6Hz), 8.59-8.72 (2H, m), 8.66 (1H, m)

(14) 5-[3-(Benzoylamino)propylamino]imidazo[1,2-a]pyridine (Compound 96)

NMR (90MHz, CDCl₃-DMSO-d₆) δ : 1.99 (2H, m), 3.27-3.70 (4H, m), 5.86 (1H, d, J=7Hz), 6.25 (1H, br), 6.98 (1H, d, J=9Hz), 7.17 (1H, dd, J=9, 7Hz), 7.33-8.17 (8H, m)

(15) 5-[3-(Decanoylamino)propylamino]imidazo[1,2-a]pyridine (Compound 97)

NMR (90MHz, CDCl₃) δ : 0.73-2.00 (19H, m), 2.22 (2H, m), 3.22-3.53 (4H, m), 5.77-6.03 (2H, m), 6.21 (1H, br), 6.95-7.22 (2H, m), 7.62 (1H, s), 7.71 (1H, s)

Example 14

(1) Synthesis of 5-[2-[2-(carboxy)benzoylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 98)

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (1.12 g, 5.8 mmoles) in chloroform (58 ml) was added phthalic anhydride (1.12 g, 7.56 mmoles) and the mixture was stirred at room temperature for 14 hours and then heated at reflux for 5 hours. The reaction mixture was cooled by standing. The crystals precipitated were filtered off, washed with chloroform and dried to obtain 1.68 g of the desired product (84.8%, colorless crystals).

NMR (90MHz, DMSO-d₆) δ : 3.17-3.63 (4H, m), 7.15-7.91 (8H, m), 7.98 (1H, s), 8.21 (1H, br)

Example 15

(1) Synthesis of 5-[2-(phthalimide)ethylthio]imidazo[1,2-a]pyridine (Compound 99)

To 5-[2-[2-(carboxy)benzoylamino]ethylthio]imidazo[1,2-a]pyridine dihydrochloride (638 mg, 2 mmoles) was added hydrogen chloride-methanol solution (40 ml) and the mixture was heated at reflux for 24 hours. After the solvent was distilled off, the residue was dissolved in chloroform, washed with an aqueous saturated sodium bicarbonate solution and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 530 mg of

EP 0 471 236 B1

the desired product (81.9%, yellow crystals).

NMR (90MHz, CDCl₃) δ : 3.31 (2H, t, J = 7Hz), 3.95 (2H, t, J = 7Hz), 7.05-7.19 (2H, m), 7.42-7.92 (7H, m)

Example 16

5

(1) Synthesis of 5-[2-(methylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 100)

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (1.93 g, 10 mmoles) in methylene chloride (30 ml) was added methyl isocyanate (0.59 ml, 10 mmoles) under ice-cooling with stirring and the mixture
10 was stirred under ice-cooling for 1 hour. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethanol/ethyl acetate = 1:5) to obtain 2.15 g of the desired product (86.0%, pale yellow crystals).

NMR (90MHz, CDCl₃) δ : 2.74 (3H, d, J = 5.5Hz), 3.14 (2H, m), 3.43 (2H, m), 5.28 (1H, br), 5.76 (1H, br), 6.96 (1H, dd, J = 7, 1Hz), 7.12 (1H, dd, J = 9, 7Hz), 7.51 (1H, d, J = 9Hz), 7.65 (1H, s), 7.79 (1H, s)

15 According to the same manner as that described in Example 16 (1), the following compounds were obtained.

(2) 5-[2-(Ethylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 101)

20 NMR (200MHz, CDCl₃) δ : 1.11 (3H, t, J = 7.2Hz), 3.16 (4H, m), 3.44 (2H, m), 4.72 (1H, br), 5.16 (1H, br), 6.97 (1H, dd, J = 7, 1Hz), 7.14 (1H, dd, J = 9, 7Hz), 7.53 (1H, d, J = 9Hz), 7.66 (1H, d, J = 1.2Hz), 7.78 (1H, s)

(3) 5-[2-(Propylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 102)

25

NMR (200MHz, CDCl₃) δ : 0.90 (3H, t, J = 7.4Hz), 1.49 (2H, m), 3.03-3.22 (4H, m), 3.45 (2H, m), 4.68 (1H, br), 5.07 (1H, br), 6.98 (1H, dd, J = 7, 1Hz), 7.15 (1H, d, J = 9, 7Hz), 7.54 (1H, d, J = 9Hz), 7.67 (1H, d, J = 1.2Hz), 7.80 (1H, s)

30 (4) 5-[2-(Isopropylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 103)

NMR (200MHz, CDCl₃) δ : 1.22 (6H, t, J = 6.6Hz), 3.17 (2H, t, J = 6.4Hz), 3.44 (2H, m), 3.84 (1H, heptet, J = 6.4Hz), 4.44 (1H, br), 4.96 (1H, br), 6.98 (1H, d, J = 7Hz), 7.15 (1H, dd, J = 9, 7Hz), 7.55 (1H, d, J = 9Hz), 7.68 (1H, d, J = 1.2Hz), 7.80 (1H, s)

35

(5) 5-[2-(Butylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 104)

NMR (200MHz, CDCl₃) δ : 0.89 (3H, t, J = 7Hz), 1.20-1.52 (4H, m), 3.07-3.20 (4H, m), 3.43 (2H, m), 5.23 (1H, br), 5.68 (1H, br), 6.95 (1H, dd, J = 7, 1Hz), 7.12 (1H, dd, J = 9, 7Hz), 7.49 (1H, d, J = 9Hz), 7.63 (1H, d, J = 1.2Hz), 7.75 (1H, s)

40

(6) 5-[2-(Cyclohexylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 105)

NMR (200MHz, CDCl₃) δ : 0.95-1.97 (10H, m), 3.17 (2H, t, J = 6.4Hz), 3.35-3.55 (3H, m), 4.48 (1H, br),
45 4.93 (1H, br), 6.99 (1H, d, J = 7.2Hz), 7.16 (1H, dd, J = 9, 7.2Hz), 7.55 (1H, d, J = 9Hz), 7.68 (1H, s), 7.80 (1H, s)

(7) 5-[2-(Phenylcarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 106)

50 NMR (200MHz, CDCl₃-DMSO-d₆) δ : 3.19 (2H, m), 3.46 (2H, m), 6.25 (1H, br), 6.83-7.63 (8H, m), 7.69 (1H, s), 7.88 (1H, s), 8.14 (1H, br)

Example 17

55 (1) Synthesis of 5-[2-(methylthiocarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 107)

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (2.96 g, 15.3 mmoles) in methylene chloride (50 ml) was added methyl isocyanate (1.12 ml, 15.3 mmoles) under ice-cooling with stirring and the

EP 0 471 236 B1

mixture was stirred at room temperature for 3 hours. After the solvent was concentrated, ether was added. Then, the crystals precipitated were filtered off and washed with ether to obtain 2.76 g of the desired product (67.6%, colorless crystals).

5

Elemental analysis for C ₁₁ H ₁₄ N ₄ S ₂ ,			
Calcd.	C, 49.60;	H, 5.30;	N, 21.03
Found	C, 49.63;	H, 5.34;	N, 21.03

10

NMR (200MHz, CDCl₃-DMSO-d₆) δ:2.95 (3H, d, J = 5Hz), 3.30 (2H, m), 3.80 (2H, m), 7.00-7.65 (5H, m), 7.67 (1H, d, J = 1Hz), 7.87 (1H, s)

According to the same manner as that described in Example 17 (1), the following compounds were obtained.

15

(2) 5-[2-(Phenylthiocarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 108)

NMR (200MHz, CDCl₃) δ:3.31 (2H, m), 3.86 (2H, m), 6.44 (1H, br), 6.96 (1H, dd, J = 7, 1.5Hz), 7.03-7.64 (7H, m), 7.67 (1H, dd, J = 7, 1.5Hz), 7.77 (1H, s), 8.05 (1H, br)

20

(3) 5-[2-[4-(Methoxy)phenylthiocarbamoylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 109)

NMR (200MHz, CDCl₃-DMSO-d₆) δ:3.32 (2H, m), 3.79 (2H, m), 3.82 (2H, m), 6.78-7.58 (1H, d, J = 7, 2Hz), 7.64 (1H, d, J = 2Hz), 7.85 (1H, d, J = 2Hz), 9.21 (1H, br)

25

(4) 5-[2-[4-(Methyl)phenylthiocarbamoylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 110)

NMR (200MHz, CDCl₃-DMSO-d₆) δ:2.34 (3H, s), 3.32 (2H, m), 3.86 (2H, m), 7.05-7.33 (7H, m), 7.55 (1H, d, J = 9Hz), 7.68 (1H, s), 7.85 (1H, s), 8.98 (1H, br)

30

(5) 5-[2-[4-(Chloro)phenylthiocarbamoylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 111)

NMR (200MHz, CDCl₃-DMSO-d₆) δ:3.34 (2H, m), 3.86 (2H, m), 7.05-7.75 (9H, m), 7.88 (1H, s), 9.36 (1H, br)

35

(6) 5-[2-[(1-Naphthyl)thiocarbamoylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 112)

NMR (200MHz, CDCl₃-DMSO-d₆) δ:3.32 (2H, m), 3.80 (2H, m), 7.07-7.23 (2H, m), 7.37-8.08 (11H, m), 9.65 (1H, br)

40

(7) 2-Ethoxycarbonylmethyl-5-[2-(phenylthiocarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 113)

NMR (200MHz, CDCl₃) δ:1.30 (3H, t, J = 7Hz), 3.23 (2H, t, J = 6.4Hz), 3.85 (2H, m), 3.88 (2H, s), 4.22 (2H, q, J = 7Hz), 6.31 (1H, br), 6.94 (1H, dd, J = 7, 1Hz), 7.11 (1H, dd, J = 9, 7Hz), 7.13-7.53 (6H, m), 7.69 (1H, br), 7.79 (1H, s)

45

(8) 2-Ethoxycarbonyl-5-[2-(phenylthiocarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 114)

NMR (200MHz, CDCl₃) δ:1.46 (3H, t, J = 7.2Hz), 3.38 (2H, t, J = 6.6Hz), 3.94 (2H, m), 4.71 (2H, q, J = 7.2Hz), 6.62 (1H, br), 7.07 (1H, dd, J = 7, 1.2Hz), 7.16-7.54 (7H, m), 7.91 (1H, br), 8.83 (1H, s)

50

(9) 2-Methyl-5-[2-(phenylthiocarbamoylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 1115)

NMR (200MHz, CDCl₃) δ:2.47 (3H, s), 3.31 (2H, t, J = 6.4Hz), 3.85 (2H, m), 6.38 (1H, br), 6.88 (1H, dd, J = 7, 1Hz), 7.07 (1H, dd, J = 9, 7Hz), 7.15-7.52 (7H, m), 7.82 (1H, br)

55

EP 0 471 236 B1

(10) 3-Ethoxycarbonyl-2-methyl-5-[2-(phenylthiocarbamoylamino)ethylthio]imidazo[1,2-a]pyridine. (Compound 116)

NMR (200MHz, CDCl_3) δ : 1.37 (3H, t, $J = 7\text{Hz}$), 2.58 (3H, s), 3.33 (2H, t, $J = 6\text{Hz}$), 3.76 (2H, m), 4.35 (2H, q, $J = 7\text{Hz}$), 3.76 (2H, m), 4.35 (2H, q, $J = 7\text{Hz}$), 6.47 (1H, br), 6.99-7.57 (8H, m), 7.76 (1H, br)

(11) 5-[3-(Phenylthiocarbamoylamino)propylthio]imidazo[1,2-a]pyridine (Compound 117)

NMR (200MHz, CDCl_3) δ : 1.96 (2H, m), 3.01 (2H, t, $J = 7\text{Hz}$), 3.79 (2H, m), 6.13 (1H, br), 6.87 (1H, d, $J = 7\text{Hz}$), 7.00-7.70 (8H, m), 7.88 (1H, s), 7.85 (1H, br)

Example 18

(1) Synthesis of 5-[2-(methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine (Compound 118)

To a solution of 5-[2-(hydroxy)ethylthio]imidazo[1,2-a]pyridine (971 mg, 5 mmoles) and triethylamine (0.91 ml, 6.53 mmoles) in methylene chloride (40 ml) was added methyl isocyanate (0.65 ml, 11 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 12 hours. The reaction mixture was washed with saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: methanol/chloroform = 1:20) to obtain 1.07 g of the desired product (85.2%, colorless crystals).

NMR (200MHz, CDCl_3) δ : 2.74 (3H, d, $J = 4.8\text{Hz}$), 3.21 (2H, t, $J = 6.2\text{Hz}$), 4.27 (2H, t, $J = 6.2\text{Hz}$), 4.56 (1H, br), 7.05 (1H, dd, $J = 9, 7\text{Hz}$), 7.21 (1H, dd, $J = 9, 7\text{Hz}$), 7.61 (1H, d, $J = 9\text{Hz}$), 7.71 (1H, s), 7.89 (1H, s)

According to the same manner as that described in Example 18 (1), the following compounds were obtained.

(2) 5-[2-(Butylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine (Compound 119)

NMR (200MHz, CDCl_3) δ : 0.92 (3H, t, $J = 7\text{Hz}$), 1.21-1.55 (4H, m), 3.03-3.30 (4H, m), 4.26 (2H, t, $J = 6.4\text{Hz}$), 4.55 (1H, br), 7.05 (1H, d, $J = 7\text{Hz}$), 7.17 (1H, dd, $J = 9, 7\text{Hz}$), 7.62 (1H, d, $J = 9\text{Hz}$), 7.72 (1H, s), 7.89 (1H, s)

(3) 5-[2-(Phenylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine (Compound 120)

NMR (200MHz, $\text{DMSO}-d_6$) δ : 3.45 (2H, t, $J = 6.2\text{Hz}$), 4.32 (2H, t, $J = 6.2\text{Hz}$), 7.00 (1H, m), 7.16 (1H, dd, $J = 7, 1\text{Hz}$), 7.22-7.34 (3H, m), 7.42-7.50 (2H, m), 7.57 (1H, d, $J = 9\text{Hz}$), 7.70 (1H, d, $J = 9\text{Hz}$), 7.70 (1H, d, $J = 1.2\text{Hz}$), 7.99 (1H, s), 9.74 (1H, br)

(4) 5-[2-[(1-Naphthyl)carbamoyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 121)

NMR (200MHz, CDCl_3 - $\text{DMSO}-d_6$) δ : 3.30 (2H, t, $J = 6.4\text{Hz}$), 4.41 (2H, t, $J = 6.4\text{Hz}$), 7.05-7.21 (2H, m), 7.41-7.75 (7H, m), 7.82-8.02 (3H, m), 8.11 (1H, br)

(5) 5-[2-(Benzylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine (Compound 122)

NMR (200MHz, CDCl_3) δ : 3.21 (2H, t, $J = 6.4\text{Hz}$), 4.24-4.37 (4H, m), 4.99 (1H, br), 7.24 (1H, d, $J = 7\text{Hz}$), 7.13 (1H, dd, $J = 9, 7\text{Hz}$), 7.24 (1H, d, $J = 7\text{Hz}$), 7.20-7.39 (5H, m), 7.58 (1H, dd, $J = 9, 0.8\text{Hz}$), 7.68 (1H, d, $J = 1.2\text{Hz}$), 7.87 (1H, s)

Example 19

(1) Synthesis of 5-[2-[3-(hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 123)

To 5-[2-(phenoxy-carbonyloxy)ethylthio]imidazo[1,2-a]pyridine (1.10 g, 3.50 mmoles) was added 3-aminopropanol (0.27 ml, 3.52 mmoles) and the mixture was stirred at 120°C for 1.5 hours. The reaction mixture was cooled by standing and chloroform was added thereto, which was washed with water and dried over anhydrous magnesium sulfate, and then the solvent was distilled off. Then, the residue was purified by column chromatography (eluent: methanol/chloroform = 1:20) to obtain 575 mg of the desired product

EP 0 471 236 B1

(55.6%, colorless crystals).

5

Elemental analysis for $C_{13}H_{17}N_3O_3S \cdot 0.2H_2O$,			
Calcd.	C, 52.23;	H, 5.87;	N, 14.06
Found	C, 52.46;	H, 5.78;	N, 14.26

10

NMR (200MHz, $CDCl_3$) δ : 1.66 (2H, m), 2.82 (1H, br), 3.15-3.32 (4H, m), 3.66 (2H, t, $J = 5.6$ Hz), 4.27 (2H, t, $J = 6.2$ Hz), 4.81 (1H, br), 7.07 (1H, dd, $J = 7, 1.2$ Hz), 7.18 (1H, dd, $J = 9, 7$ Hz), 7.61 (1H, d, $J = 9$ Hz), 7.70 (1H, d, $J = 1.4$ Hz), 7.90 (1H, s)

According to the same manner as that described in Example 19 (1), the following compounds were obtained.

15

(2) 5-[2-[6-(Hydroxy)hexylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 124)

20

Elemental analysis for $C_{16}H_{23}N_3O_3S \cdot 0.2H_2O$,			
Calcd.	C, 56.35;	H, 6.92;	N, 12.32
Found	C, 56.63;	H, 6.89;	N, 12.43

25

NMR (200MHz, $CDCl_3$) δ : 1.22-1.65 (8H, m), 2.16 (1H, br), 3.10 (2H, m), 3.21 (2H, t, $J = 6.2$ Hz), 3.64 (2H, t, $J = 6.2$ Hz), 4.26 (2H, t, $J = 6.2$ Hz), 4.48 (1H, br), 7.05 (1H, dd, $J = 7, 1.2$ Hz), 7.17 (1H, dd, $J = 8.8, 7$ Hz), 7.60 (1H, m), 7.70 (1H, d, $J = 1.4$ Hz), 7.89 (1H, m)

(3) 5-[2-[3-(Morpholino)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 125)

30

NMR (200MHz, $CDCl_3$) δ : 1.66 (2H, m), 2.35-2.48 (6H, m), 3.16-3.30 (4H, m), 3.65-3.75 (4H, m), 4.26 (2H, t, $J = 6.4$ Hz), 5.77 (1H, br), 7.05 (1H, dd, $J = 7, 1$ Hz), 7.17 (1H, dd, $J = 9, 7$ Hz), 7.61 (1H, d, $J = 9$ Hz), 7.72 (1H, d, $J = 1.2$ Hz), 7.89 (1H, s)

(4) 5-[2-[3-(1-Imidazolyl)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 126)

35

NMR (200MHz, $CDCl_3$) δ : 1.96 (2H, q, $J = 6.8$ Hz), 3.06-3.27 (4H, m), 3.97 (2H, t, $J = 6.8$ Hz), 4.27 (2H, t, $J = 6.2$ Hz), 5.06 (1H, br), 6.93 (1H, s), 7.05 (1H, d, $J = 7$ Hz), 7.07 (1H, s), 7.17 (1H, m), 7.48 (1H, s), 7.61 (1H, dd, $J = 9, 0.8$ Hz), 7.71 (1H, s), 7.89 (1H, s)

(5) 5-[2-[(4-Pyridyl)methylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 127)

40

NMR (200MHz, $CDCl_3$) δ : 3.23 (2H, t, $J = 6.2$ Hz), 4.25-4.40 (4H, m), 5.36 (1H, br), 7.05 (1H, d, $J = 7$ Hz), 7.10-7.20 (2H, m), 7.60 (1H, d, $J = 9$ Hz), 7.70 (1H, d, $J = 1$ Hz), 7.90 (1H, s), 7.90 (1H, s), 8.56 (2H, m)

Example 20

45

(1) Synthesis of 5-[2-(methoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 128)

50

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (1.93 g, 10 mmoles) and triethylamine (1.53 ml, 11 mmoles) in methylene chloride (30 ml) was added methyl chloroformate (0.77 ml, 10 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was washed in turn with an aqueous sodium bicarbonate solution and water, dried over anhydrous magnesium sulfate, and then the solvent was distilled off. The residue was purified by column chromatography (eluent: ethanol/ethyl acetate = 1:10) to obtain 1.68 g of the desired product (66.9%, colorless crystals).

55

Melting point: 198.0-200.0 °C

EP 0 471 236 B1

Elemental analysis for $C_{11}H_{13}N_3O_2S$,			
Calcd.	C, 52.57;	H, 5.21;	N, 16.72
Found	C, 52.68;	H, 5.22;	N, 16.60

5

NMR (200MHz, $CDCl_3$) δ : 3.12 (2H, m), 3.40 (2H, m), 3.68 (3H, s), 5.10 (1H, br), 7.00 (1H, d, $J=7$ Hz), 7.16 (1H, dd, $J=9, 7$ Hz), 7.61 (1H, d, $J=9$ Hz), 7.72 (1H, s), 7.87 (1H, s)

According to the same manner as that described in Examples 2 and 20 (1), the following compounds were obtained.

10

(2) 5-[2-(Ethoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 129)

Melting point: 68-70 °C

15

Elemental analysis for $C_{12}H_{15}N_3O_2S$,			
Calcd.	C, 54.32;	H, 5.70;	N, 15.84
Found	C, 54.43;	H, 5.75;	N, 15.83

20

(3) 5-[2-(Propyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 130)

Melting point: 62-64 °C

25

Elemental analysis for $C_{13}H_{17}N_3O_2S$,			
Calcd.	C, 55.89;	H, 6.13;	N, 15.04
Found	C, 55.87;	H, 6.09;	N, 14.96

30

NMR (200MHz, $CDCl_3$) δ : 0.92 (3H, t, $J=7.4$ Hz), 1.62 (2H, m), 3.14 (2H, t, $J=6.6$ Hz), 3.42 (1H, m), 4.01 (1H, t, $J=6.6$ Hz), 5.07 (1H, br), 7.02 (1H, d, $J=7$ Hz), 7.17 (1H, dd, $J=9, 7$ Hz), 7.60 (1H, d, $J=9$ Hz), 7.71 (1H, d, $J=1.2$ Hz), 7.86 (1H, s)

IR (KBr) cm^{-1} : 3210, 3025, 2965, 1695, 1620, 1545, 1490, 1275

35

(4) 5-[2-(Butyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 131)

Melting point: 75-76 °C

40

Elemental analysis for $C_{14}H_{19}N_3O_2S$,			
Calcd.	C, 57.31;	H, 6.53;	N, 14.32
Found	C, 57.32;	H, 6.55;	N, 14.23

45

NMR (200MHz, $CDCl_3$) δ : 0.93 (3H, t, $J=7$ Hz), 1.35 (2H, m), 1.58 (2H, m), 3.14 (2H, t, $J=6.4$ Hz), 3.41 (2H, m), 4.05 (2H, t, $J=6.6$ Hz), 5.04 (1H, br), 7.16 (1H, dd, $J=9, 7$ Hz), 7.60 (1H, d, $J=9$ Hz), 7.71 (1H, d, $J=1.2$ Hz), 7.85 (1H, s)

IR (KBr) cm^{-1} : 3490, 3210, 2970, 1695, 1615, 1500, 1285

50

55

EP 0 471 236 B1

(5) 5-[2-(Isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 132)

Melting point: 80.0-81.0 °C

5

Elemental analysis for C ₁₃ H ₁₇ N ₃ O ₂ S,			
Calcd.	C, 55.89;	H, 6.13;	N, 15.04
Found	C, 55.85;	H, 6.14;	N, 14.96

10

NMR (200MHz, CDCl₃) δ: 1.22 (6H, t, J=6.2Hz), 3.14 (2H, t, J=6.4Hz), 3.41 (2H, m), 4.94 (1H, br), 7.02 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9Hz), 7.71 (1H, d, J=1.4Hz), 7.86 (1H, s)
IR (KBr) cm⁻¹: 3220, 3025, 2970, 1705, 1630, 1545, 1300, 1240

15

(6) 5-[2-(Isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine • hydrochloride (Compound 133)

Melting point: 145-150 °C

20

(7) 5-[2-(Isobutyloxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 134)

Melting point: 75-76 °C

25

Elemental analysis for C ₁₄ H ₁₉ N ₃ O ₂ S,			
Calcd.	C, 57.31;	H, 6.53;	N, 14.32
Found	C, 57.29;	H, 6.53;	N, 14.41

30

NMR (200MHz, CDCl₃) δ: 0.91 (6H, d, J=6.8Hz), 1.89 (1H, m), 3.14 (2H, t, J=6.4Hz), 3.42 (2H, m), 3.84 (2H, d, J=6.6Hz), 5.15 (1H, br), 7.01 (1H, d, J=7Hz), 7.16 (1H, dd, J=9, 7Hz), 7.59 (1H, d, J=9Hz), 7.70 (1H, d, J=1.2Hz), 7.85 (1H, s)

35

(8) 5-[2-(Allyloxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 135)

Melting point: 72.5-73.5 °C

40

Elemental analysis for C ₁₃ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 56.30;	H, 5.45;	N, 15.15
Found	C, 56.34;	H, 5.44;	N, 15.04

45

NMR (200MHz, CDCl₃) δ: 3.15 (2H, t, J=6.4Hz), 3.43 (2H, m), 4.56 (2H, m), 5.07 (1H, br), 5.18-5.36 (2H, m), 5.90 (1H, m), 7.02 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9Hz), 7.72 (1H, d, J=1.4Hz), 7.86 (1H, m)
IR (KBr) cm⁻¹: 3205, 3020, 1700, 1625, 1570, 1490, 1270

50

(9) 5-[2-[2,2,2-(Trichloro)ethoxycarbonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 136)

Melting point: 113-114.0 °C

55

Elemental analysis for C ₁₂ H ₁₂ N ₃ O ₂ SCl ₃ ,			
Calcd.	C, 39.10;	H, 3.28;	N, 11.40
Found	C, 39.23;	H, 3.27;	N, 11.25

NMR (200MHz, CDCl₃) δ: 3.17 (2H, t, J=6.4Hz), 3.48 (2H, m), 4.73 (2H, s), 5.52 (1H, br), 7.03 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.62 (1H, d, J=9Hz), 7.71 (1H, d, J=1.2Hz), 7.87 (1H, m)
IR (KBr) cm⁻¹: 3195, 2975, 1725, 1615, 1545, 1485, 1260, 1210

EP 0 471 236 B1

(10) 5-[2-(Benzyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 137)

Melting point: 52-53 °C

5

Elemental analysis for C ₁₇ H ₁₇ N ₃ O ₂ S,			
Calcd.	C, 62.36;	H, 5.23;	N, 12.83
Found	C, 62.34;	H, 5.22;	N, 12.75

10

NMR (200MHz, CDCl₃) δ: 3.14 (2H, t, J = 6.4Hz), 3.43 (2H, m), 5.09 (2H, s), 5.17 (1H, br), 6.99 (1H, d, J = 6.8Hz), 7.13 (1H, dd, J = 9.2, 6.8Hz), 7.35 (5H, s), 7.59 (1H, d, J = 9.2Hz), 7.69 (1H, s), 7.84 (1H, s)

(11) 5-[2-[(9-Fluorenyl)methyloxycarbonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 138)

15

Melting point: 105.0-108.0 °C

20

Elemental analysis for C ₂₅ H ₂₁ N ₃ O ₂ S•0.4H ₂ O,			
Calcd.	C, 69.07;	H, 5.05;	N, 9.67
Found	C, 69.14;	H, 5.23;	N, 9.96

NMR (200MHz, CDCl₃) δ: 3.13 (2H, t, J = 6Hz), 3.42 (2H, m), 4.21 (1H, t, J = 6.6Hz), 4.43 (2H, d, J = 6.6Hz), 5.17 (1H, br), 7.01 (1H, d, J = 7.4Hz), 7.15 (1H, dd, J = 8.6, 7.4Hz), 7.29-7.46 (4H, m), 7.53-7.65 (3H, m), 7.60-7.87 (4H, m)

25

IR (KBr) cm⁻¹: 3205, 3020, 1710, 1625, 1550, 1485, 1450, 1270

(12) 5-[2-(Phenoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 139)

30

Melting point: 96.0-97.0 °C

35

Elemental for C ₁₆ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 61.32;	H, 4.82;	N, 13.41
Found	C, 61.35;	H, 4.86;	N, 13.30

IR (KBr) cm⁻¹: 3200, 3005, 1725, 1615, 1555, 1485, 1270, 1210

40

(13) 5-[2-(N-Methyl-N-isopropylloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 140)

NMR (200MHz, CDCl₃) δ: 1.02-1.35 (6H, m), 2.91 (3H, s), 3.05-3.26 (2H, m), 3.38-3.60 (2H, m), 4.89 (1H, m), 7.01 (1H, br), 7.18 (1H, dd, J = 9, 7Hz), 7.60 (1H, d, J = 9Hz), 7.71 (1H, s), 7.84 (1H, s)

IR (KBr) cm⁻¹: 3220, 3025, 2970, 1705, 1630, 1545

45

(14) 5-[2-(N-Ethyl-N-isopropylloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 141)

NMR (200MHz, CDCl₃) δ: 0.95-1.35 (9H, m), 3.02-3.68 (6H, m), 4.90 (1H, m), 7.04 (1H, m), 7.19 (1H, dd, J = 9, 7Hz), 7.60 (1H, d, J = 9Hz), 7.72 (1H, s), 7.83 (1H, s)

50

IR (KBr) cm⁻¹: 3220, 3025, 2970, 1705, 1630, 1545

Example 21

(1) According to the same manner as that described in Example 4 (1), the following compounds were obtained.

55

EP 0 471 236 B1

3-Bromo-5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 142)

Melting point: 103.0-104.0 °C

5

Elemental analysis for C ₁₃ H ₁₆ N ₃ O ₂ SBr,			
Calcd.	C, 43.58;	H, 4.50;	N, 11.73
Found	C, 43.60;	H, 4.53;	N, 11.74

10

NMR (200MHz, CDCl₃) δ: 1.22 (6H, d, J = 6.2Hz), 3.11 (2H, t, J = 6.6Hz), 3.42 (2H, m), 4.90 (1H, heptet, J = 6.2Hz), 4.96 (1H, br), 7.00 (1H, dd, J = 7, 1.2Hz), 7.14 (1H, dd, J = 8.8, 7Hz), 7.57 (1H, dd, J = 8.8, 1.2Hz), 7.59 (1H, s)

15

(2) 3-Chloro-5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 143)

Melting point: 113.0-114.0 °C

20

Elemental for C ₁₃ H ₁₆ N ₃ O ₂ SCl•0.2H ₂ O,			
Calcd.	C, 49.19;	H, 5.21;	N, 13.24
Found	C, 49.38;	H, 5.26;	N, 13.22

NMR (200MHz, CDCl₃) δ: 1.22 (6H, d, J = 6.4Hz), 3.12 (2H, t, J = 6.4Hz), 3.43 (2H, m), 4.90 (1H, heptet, J = 6.4Hz), 4.96 (1H, br), 6.99 (1H, dd, J = 7.2, 1.2Hz), 7.10 (1H, dd, J = 8.8, 7.2Hz), 7.53 (1H, dd, J = 8.8, 1.2Hz), 7.54 (1H, s)

Example 22

30

According to the same manner as that described in Example 5, the following compound was obtained.

5-[2-(Isopropoxyloxycarbonylamino)ethylthio]-3-(morpholinomethyl)imidazo[1,2-a]pyridine (Compound 144)

NMR (200MHz, CDCl₃) δ: 0.96 (6H, d, J = 6.2Hz), 2.56 (4H, m), 3.26 (2H, m), 3.36 (2H, m), 3.65 (4H, m), 4.10 (2H, s), 4.59 (1H, heptet, J = 6.2Hz), 6.85 (1H, br), 7.01 (1H, d, J = 5Hz), 7.13 (1H, dd, J = 8.6, 6.6Hz), 7.51 (1H, s), 7.53 (1H, d, J = 8.6Hz)

Example 23

40

(1) According to the same manner as that described in Example 20 (1), the following compounds were obtained.

5-[3-(Methoxycarbonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 145)

45

Melting point: 69.0-70.0 °C

50

Elemental analysis for C ₁₂ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 54.32;	H, 5.70;	N, 15.84
Found	C, 54.48;	H, 5.74;	N, 15.72

NMR (200MHz, CDCl₃) δ: 1.85 (2H, m), 3.02 (2H, t, J = 7Hz), 3.32 (2H, m), 3.67 (3H, s), 4.85 (1H, br), 6.91 (1H, dd, J = 7, 1.2Hz), 7.15 (1H, dd, J = 9, 7Hz), 7.58 (1H, d, J = 9Hz), 7.70 (1H, d, J = 1.2Hz), 7.84 (1H, s)

55

EP 0 471 236 B1

(2) 5-[3-(Isopropoxyloxycarbonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 146)

NMR (200MHz, CDCl₃) δ : 1.22 (6H, d, J=6.2Hz), 1.85 (2H, m), 3.03 (2H, m), 3.31 (2H, m), 4.82 (1H, br), 4.90 (1H, heptet, J=6.2Hz), 6.90 (1H, dd, J=7, 1Hz), 7.15 (1H, dd, J=9, 7Hz), 7.57 (1H, m), 7.69 (1H, d, J=1.4Hz), 7.84 (1H, m)
IR (KBr) cm⁻¹: 3210, 3025, 2965, 1695, 1620, 1545, 1490, 1275

(3) 5-[1-(tert-Butoxycarbonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (Compound 147)

NMR (200MHz, CDCl₃) δ : 1.45 (9H, s), 1.50-1.98 (4H, m), 2.90 (2H, m), 3.36 (1H, m), 3.98 (2H, m), 7.03 (1H, dd, J=7, 1.2Hz), 7.15 (1H, dd, J=9, 7Hz), 7.64 (1H, m), 7.70 (1H, d, J=1.2Hz), 7.96 (1H, m)

(4) 5-[1-(Isopropoxyloxycarbonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (Compound 148)

NMR (200MHz, CDCl₃) δ : 1.23 (6H, d, J=6.2Hz), 1.50-1.98 (4H, m), 2.94 (2H, m), 3.37 (1H, m), 4.03 (2H, m), 4.91 (1H, heptet, J=6.2Hz), 7.03 (1H, dd, J=7, 1.2Hz), 7.16 (1H, dd, J=9, 7Hz), 7.65 (1H, d, J=9Hz), 7.71 (1H, d, J=1.2Hz), 7.97 (1H, s)

Example 24

(1) Synthesis of 5-[2-(tert-butoxycarbonylamino)ethoxy]imidazo[1,2-a]pyridine (Compound 149)

To a suspension of 60% sodium hydride (oily; 4.8 g, 0.12 mmoles) in DMF (150 ml) was added a solution of 5-chloroimidazo[1,2-a]pyridine (15.26 g, 0.1 moles) and 2-aminoethanol (6.72 g, 0.11 mole) in DMF (120 ml) with stirring at room temperature and the mixture was stirred at the same temperature for 33 hours. To the reaction mixture was added di-tert-butyl dicarbonate (32.74 g, 0.15 moles), followed by stirring at room temperature for 13 hours. After the solvent was distilled off, water (800 ml) was added to the residue, which was extracted twice with ether. The extract was washed with water, dried over anhydrous magnesium sulfate and concentrated, and then ether was added. The crystals precipitated were filtered off and washed with ether to obtain 10.77 g of the desired product (38.8%, colorless crystals). As second crystals, 1.31 g of the desired product was obtained (4.7%, colorless crystals).

NMR (200MHz, CDCl₃) δ : 1.46 (9H, s), 3.68 (2H, s), 4.31 (2H, t, J=5.2Hz), 5.00 (1H, br), 6.06 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.30 (1H, d, J=9Hz), 7.60 (1H, d, J=1.2Hz), 7.66 (1H, s)

According to the same manner as that described in Example 24 (1), the following compound was obtained.

(2) 5-[3-(tert-Butoxycarbonylamino)propoxy]imidazo[1,2-a]pyridine (compound 150)

NMR (200MHz, CDCl₃) δ : 1.44 (9H, s), 2.14 (2H, q, J=6.2Hz), 3.40 (2H, m), 4.31 (2H, t, J=6.2Hz), 4.83 (1H, br), 6.04 (1H, d, J=7.2Hz), 7.16 (1H, dd, J=9, 7.2Hz), 7.28 (1H, d, J=9Hz), 7.59 (1H, d, J=1.2Hz), 7.66 (1H, s)

Example 25

(1) Synthesis of 5-[2-(tert-butoxycarbonylamino)ethylsulfonyl]imidazo[1,2-a]pyridine (Compound 151) and 5-[2-(tert-butoxycarbonylamino)ethylsulfinyl]imidazo[1,2-a]pyridine (Compound 152)

To a solution of 5-[2-(tert-butoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (2.93 g, 10 mmoles) in chloroform (50 ml) was added 85% m-chloroperbenzoic acid (5.08 g, 25 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 4 hours. Then, chloroform (50 ml) was added to the mixture, which was washed in turn with an aqueous sodium bicarbonate solution and saturated saline, dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was purified by column chromatography (eluent: ethyl acetate) to obtain 560 mg of 5-[2-(tert-butoxycarbonylamino)ethylsulfonyl]imidazo[1,2-a]pyridine (Compound 151; 17.2%, colorless crystals) as Fraction 1.

EP 0 471 236 B1

Elemental analysis for $C_{14}H_{19}N_3O_2S \cdot 0.3H_2O$			
Calcd.	C, 50.83;	H, 5.97;	N, 12.70
Found	C, 50.97;	H, 5.91;	N, 12.80

NMR (200MHz, $CDCl_3$) δ : 1.37 (9H, s), 3.42-3.63 (4H, m), 5.03 (1H, br), 7.36 (1H, dd, $J=9.7$ Hz), 7.68 (1H, dd, $J=7, 1.5$ Hz), 7.85 (1H, d, $J=1.5$ Hz), 7.96 (1H, d, $J=9$ Hz), 8.25 (1H, m)

As Fraction 2, 5-[2-(tert-butoxycarbonylamino)ethylsulfinyl]imidazo[1,2-a]pyridine (Compound 152; 27.5%, colorless crystals) was obtained.

Elemental analysis for $C_{14}H_{19}N_3O_4S \cdot 0.4H_2O$			
Calcd.	C, 53.11;	H, 6.30;	N, 13.27
Found	C, 53.27;	H, 6.18;	N, 13.36

NMR (200MHz, $CDCl_3$) δ : 1.43 (9H, s), 3.14-3.75 (4H, m), 5.07 (1H, br), 7.30-7.41 (2H, m), 7.73-7.87 (3H, m)

Example 26

Synthesis of 5-(phthalimidomethylthio)imidazo[1,2-a]pyridine (Compound 153)

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (3.00 g, 20 mmoles) and N-bromomethylphthalimide (5.28 g, 22 mmoles) in ethanol (200 ml) was added triethylamine (4.2 ml, 30 mmoles) and the mixture was stirred at room temperature for 1 hour. After the solvent was distilled off, chloroform was added to the residue, which was washed with water, dried over anhydrous magnesium sulfate and the solvent was distilled off. Then, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 4.29 g of the desired product (69.4%, pale yellow crystals).

NMR (200MHz, $CDCl_3$) δ : 5.10 (2H, s), 7.02-7.13 (2H, m), 7.61-7.84 (6H, m), 7.99 (1H, m)

Example 27

Synthesis of 5-[2-(phthalimido)ethylthio]imidazo[1,2-a]pyridine (Compound 99)

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (3.00g, 20 mmoles) and N-[2-(bromo)ethyl]phthalimide (5.59 g, 22 mmoles) in ethanol (200 ml) was added triethylamine (4.2 ml, 30 mmoles) and the mixture was stirred at room temperature for 3 hours and heated at reflux for 4 hours. After the solvent was distilled off, chloroform was added to the residue, which was washed with water, dried over anhydrous magnesium sulfate and the solvent was distilled off. Then, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 3.95 g of the desired product (61.1%, yellow crystals).

NMR (200MHz, $CDCl_3$) δ : 3.33 (2H, t, $J=6.6$ Hz), 3.97 (2H, t, $J=6.6$ Hz), 7.11-7.21 (2H, m), 7.55 (1H, m), 7.67-7.87 (6H, m)

Example 28

Synthesis of 5-[3-(phthalimido)propylthio]imidazo[1,2-a]pyridine (Compound 154)

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (3.00g, 20 mmoles) and N-[3-(bromo)propyl]phthalimide (5.90 g, 22 mmoles) in ethanol (200 ml) was added triethylamine (4.2 ml, 30 mmoles) and the mixture was stirred at room temperature for 1 hour and heated at reflux for 1 hour. After the solvent was distilled off, chloroform was added to the residue, which was washed with water, dried over anhydrous magnesium sulfate and the solvent was distilled off. Then, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 4.79 g of the desired product (71.1%, colorless crystals).

NMR (200MHz, $CDCl_3$) δ : 2.02 (2H, m), 3.02 (2H, t, $J=7.2$ Hz), 3.85 (2H, t, $J=6.8$ Hz), 6.98 (1H, dd, $J=7, 1$ Hz), 7.16 (1H, dd, $J=9, 7$ Hz), 7.58 (1H, m), 7.67-7.88 (6H, m)

EP 0 471 236 B1

Example 29

Synthesis of 5-[4-(phthalimido)butylthio]imidazo[1,2-a]pyridine (Compound 155)

5 To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (3.00g, 20 mmoles) and N-[4-(bromo)butyl]-phthalimide (6.21 g, 22 mmoles) in ethanol (200 ml) was added triethylamine (4.2 ml, 30 mmoles) and the mixture was stirred at room temperature for 1 hour and heated at reflux for 45 minutes. After the solvent was distilled off, chloroform was added to the residue, which was washed with saturated saline, dried over anhydrous magnesium sulfate and the solvent was distilled off. Then, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 4.50 g of the desired product (64.1%, pale yellow crystals).

10 NMR (200MHz, CDCl₃) δ: 1.62-1.95 (4H, m), 3.04 (2H, t, J = 7Hz), 3.71 (2H, t, J = 6.8Hz), 6.89 (1H, dd, J = 7, 1Hz), 7.10 (1H, dd, J = 9, 7Hz), 7.54 (1H, d, J = 9Hz), 7.65-7.86 (6H, m)

Example 30

15 Synthesis of 5-[6-(phthalimido)hexylthio]imidazo[1,2-a]pyridine (Compound 156)

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (1.50g, 10 mmoles) and N-[6-(bromo)hexyl]-phthalimide (3.10 g, 10 mmoles) in ethanol (100 ml) was added triethylamine (2.1 ml, 15 mmoles) and the mixture was stirred at room temperature for 12 hours. After the solvent was distilled off, chloroform was added to the residue, which was washed with water, dried over anhydrous magnesium sulfate and the solvent was distilled off. Then the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 2.86 g of the desired product (75.5%, light tan solid).

25 NMR (200MHz, CDCl₃) δ: 1.24-1.77 (8H, m), 2.99 (2H, t, J = 7.2Hz), 3.68 (2H, t, J = 7.2Hz), 6.87 (1H, dd, J = 7, 1Hz), 7.15 (1H, dd, J = 9, 7Hz), 7.56 (1H, d, J = 9Hz), 7.65-7.88 (6H, m)

Example 31

Synthesis of 5-[2-[2-(phthalimido)ethoxy]ethylthio]imidazo[1,2-a]pyridine (Compound 157)

30 To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (3.00g, 20 mmoles) and N-[2-[2-(bromo)ethoxy]ethyl]phthalimide (5.96 g, 20 mmoles) in ethanol (200 ml) was added triethylamine (4.2 ml, 30 mmoles) and the mixture was stirred at room temperature for 12 hours and heated at reflux for 3 hours. After the solvent was distilled off, chloroform was added to the residue, which was washed with water, dried over anhydrous magnesium sulfate and the solvent was distilled off. Then, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 4.00 g of the desired product (54.5%, light tan solid).

35 NMR (200MHz, CDCl₃) δ: 3.12 (2H, t, J = 6.4Hz), 3.64-3.77 (4H, m), 3.89 (2H, t, J = 5.4Hz), 6.91 (1H, dd, J = 7.1Hz), 7.20 (1H, dd, J = 9, 7Hz), 7.56 (1H, d, J = 9Hz), 7.63-7.88 (6H, m)

Example 32

According to the same manner as that described in Example 31, the following compounds were obtained.

45 (1) 5-[3-[[2-(Anilino)ethyl]-N-(acetyl)amino]propylthio]imidazo[1,2-a]pyridine (Compound 158)

NMR (200MHz, CDCl₃) δ: 1.89 (2H, m), 2.05 and 2.09 (each 1.5H, s), 2.97 (2H, m), 3.25-3.60 (6H, m), 6.53-6.63 (2H, m), 6.63-6.80 (1H, m), 6.89 (1H, m), 7.07-7.25 (3H, m), 7.59 (1H, m), 7.70 (1H, m), 7.83 (1H, s)

50 (2) 5-[3-[[2-[N-(acetyl)anilino]ethyl]-N-(acetyl)amino]propylthio]imidazo[1,2-a]pyridine (Compound 159)

NMR (200MHz, CDCl₃) δ: 1.70-2.07 (8H, m), 2.88-3.06 (2H, m), 3.32-3.58 (4H, m), 3.70-3.85 (2H, m), 6.88-7.00 (1H, m), 7.08-7.26 (3H, m), 7.32-7.50 (3H, m), 7.57-7.68 (1H, m), 7.68-7.74 (1H, m), 7.80-7.88 (1H, m)

EP 0 471 236 B1

(3) 5-[3-[[2-(anilino)ethyl]-N-(tert-butoxycarbonyl)amino]propylthio]imidazo[1,2-a]pyridine (Compound 160)

NMR (200MHz, CDCl₃) δ: 1.45 (9H, s), 1.87 (2H, m), 2.96 (2H, t, J=7.2Hz), 3.27 (2H, m), 3.34 (2H, m), 6.52-6.62 (2H, m), 6.69 (1H, dd, J=9, 7.4Hz), 6.85 (1H, d, J=7.4Hz), 7.07-7.22 (3H, m), 7.56 (1H, m), 7.69 (1H, d, J=1.4Hz), 7.81 (1H, s)

(4) 5-[3-[[2-[N-(acetyl)anilino]ethyl]-N-(tert-butoxycarbonyl)amino]propylthio]imidazo[1,2-a]pyridine (Compound 161)

NMR (200MHz, CDCl₃) δ: 1.13-1.48 (9H, m), 1.72-1.98 (5H, m), 2.97 (2H, t, J=7.2Hz), 3.38 (4H, m), 3.75 (2H, m), 6.94 (1H, d, J=7Hz), 7.08-7.47 (6H, m), 7.61 (1H, d, J=9Hz), 7.70 (1H, d, J=1.2Hz), 7.85 (1H, m)

Example 33

Synthesis of 5-[2-[2-(hydroxy)benzoylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 162)

To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (3.87 g, 20 mmoles) and triethylamine (5.58 ml, 40 mmoles) in methylene chloride (200 ml) was added o-acetylsalicyloyl chloride (4.77 g, 24 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 30 minutes. After the solvent was distilled off, ethanol (60 ml) and 1N NaOH (40 ml) were added to the residue, followed by stirring for 1 hour. 1N HCl (40 ml) was added and ethanol was distilled off, and then the residue was extracted with chloroform and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate/ethanol = 10:1) to obtain 3.51 g of the desired product (56.0%, colorless solid).

Melting point: 156-157 °C

Elemental analysis for C ₁₆ H ₁₅ N ₃ O ₂ S			
Calcd.	C, 61.32;	H, 4.82;	N, 13.41
Found	C, 61.44;	H, 5.04;	N, 13.45

NMR (200Hz, DMSO-d₆) δ: 3.34 (2H, m), 3.58 (2H, m), 6.83-6.93 (2H, m), 7.18 (1H, dd, J=7, 1.2Hz), 7.27 (1H, dd, J=8.6, 7.0Hz), 7.39 (1H, m), 7.54 (1H, m), 7.68 (1H, d, J=1.2Hz), 7.77 (1H, m), 7.95 (1H, d, J=1.2Hz), 9.04 (1H, br)

Example 34

Synthesis of 5-[2-[2H-1,3-benzoxazine-2-thion-4(3H)-on-3-yl]ethylthio]imidazo[1,2-a]pyridine (Compound 163)

To a suspension of 5-[2-[2-(hydroxy)benzoylamino]ethylthio]imidazo[1,2-a]pyridine (627 mg, 2.00 mmoles) in dry tetrahydrofuran (30 ml) was added 1,1'-thiocarbonyldiimidazole (713 mg, 4.00 mmoles) and the mixture was stirred at room temperature for 46 hours. After the solvent was distilled off, chloroform was added to the residue, which was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 600 mg of the desired product. The product was recrystallized from methylene chloride-ethyl acetate to obtain 448 mg of the desired product (63.0%, light red powder).

NMR (200MHz, CDCl₃) δ: 3.45 (2H, m), 4.73 (2H, m), 7.15-7.47 (4H, m), 7.60 (1H, m), 7.71 (1H, d, J=1.4Hz), 7.75 (1H, m), 7.85 (1H, m), 8.04 (1H, m)

Example 35

Synthesis of 5-[2-[2H-1,3-benzoxazine-2,4(3H)-dion-3-yl]ethylthio]imidazo[1,2-a]pyridine (Compound 164)

To a solution of 5-[2-[2-(hydroxy)benzoylamino]ethylthio]imidazo[1,2-a]pyridine (627 mg, 2.00 mmoles) in dry tetrahydrofuran (30 ml) was added 1,1'-carbonyldiimidazole (649 mg, 4.00 mmoles) and the mixture was stirred at room temperature for 15 hours. After the solvent was distilled off, chloroform was added to

EP 0 471 236 B1

the residue, which was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 528 mg of the desired product (77.8%, colorless crystals).

NMR (200MHz, CDCl₃) δ : 3.38 (2H, m), 4.34 (2H, m), 7.13-7.33 (3H, m), 7.39 (1H, m), 7.57 (1H, m),
5 7.67-7.78 (2H, m), 7.83 (1H, s), 8.05 (1H, dd, J = 7.8, 1.8Hz)

Example 36

Synthesis of 5-[1-(trifluoromethanesulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (Compound 165)

10

To a solution of 5-(4-piperidylthio)imidazo[1,2-a]pyridine dihydrochloride (919 mg, 3 mmoles) and triethylamine (1.39 ml, 9.89 mmoles) in methylene chloride (40 ml) was added trifluoromethanesulfonic anhydride (0.61 ml, 3.63 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 1 hour. The residue was washed with saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate/n-hexane = 1:1) to obtain 0.66 g of the desired product (60.2%, colorless solid).

15

Melting point: 102-103 °C

20

NMR (200MHz, CDCl₃) δ : 1.68-1.90 (2H, m), 1.97-2.13 (2H, m), 3.22 (2H, m), 3.41 (1H, m), 3.89 (2H, m), 7.05 (1H, dd, J = 7, 1.2Hz), 7.17 (1H, dd, J = 8.8, 7Hz), 7.68 (1H, m), 7.72 (1H, d, J = 1.2Hz), 7.95 (1H, m)

Example 37

Synthesis of 5-[4-(methanesulfonamido)butylthio]imidazo[1,2-a]pyridine (Compound 166)

25

To a solution of 5-[4-(amino)butylthio]imidazo[1,2-a]pyridine (440 mg, 1.99 mmoles) and triethylamine (0.42 ml, 3.01 mmoles) in methylene chloride (20 ml) was added methanesulfonyl chloride (0.19 ml, 2.45 mmoles) under ice-cooling with stirring and the mixture was stirred under ice-cooling for 1 hour. The reaction mixture was washed in turn with an aqueous saturated sodium bicarbonate solution and saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 302 mg of the desired product (50.8%, light red brown solid).

30

NMR (200MHz, CDCl₃) δ : 1.74 (4H, m), 2.94 (3H, s), 3.02 (2H, m), 3.15 (2H, m), 4.53 (1H, br), 6.92 (1H, dd, J = 7.1Hz), 7.16 (1H, dd, J = 9, 7Hz), 7.59 (1H, m), 7.70 (1H, d, J = 1.2Hz), 7.84 (1H, m)

35

Example 38

Synthesis of 5-[4-(trifluoromethanesulfonamido)butylthio]imidazo[1,2-a]pyridine (Compound 167)

40

To a solution of 5-[4-(amino)butylthio]imidazo[1,2-a]pyridine (460 mg, 2.08 mmoles) and triethylamine (0.44 ml, 3.16 mmoles) in methylene chloride (20 ml) was added trifluoromethanesulfonic anhydride (0.38 ml, 2.26 mmoles) under ice-cooling with stirring and the mixture was stirred under ice-cooling for 30 minutes. The reaction mixture was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 277 mg of the desired product (37.7%, colorless crystals).

45

NMR (200MHz, CDCl₃) δ : 1.74 (4H, m), 3.04 (2H, m), 3.22 (2H, m), 6.94 (1H, dd, J = 7, 1Hz), 7.19 (1H, dd, J = 9, 7Hz), 7.56 (1H, d, J = 9Hz), 7.69 (1H, d, J = 1.2Hz), 7.86 (1H, m), 8.71 (1H, br)

Example 39

50

Synthesis of 5-[4-(1-naphthalenesulfonylamino)butylthio]imidazo[1,2-a]pyridine (Compound 168)

To a solution of 5-[4-(amino)butylthio]imidazo[1,2-a]pyridine (300 mg, 1.36 mmoles) and triethylamine (0.29 ml, 2.08 mmoles) in methylene chloride (15 ml) was added 1-naphthalenesulfonyl chloride (307 mg, 1.35 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 1 hour. The reaction mixture was washed in turn with an aqueous sodium bicarbonate solution and water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 296 mg of the desired product (53.0%, colorless solid).

55

EP 0 471 236 B1

NMR (200MHz, CDCl₃) δ : 1.55 (4H, m), 2.81 (2H, m), 2.92 (2H, m), 4.83 (1H, br), 6.78 (1H, dd, J=7, 1Hz), 7.11 (1H, dd, J=9, 7Hz), 7.45-7.75 (6H, m), 7.93 (1H, m), 8.05 (1H, d, J=8.4Hz), 8.25 (1H, dd, J=7.2, 1.2Hz), 8.62 (1H, m)

5 Example 40

Synthesis of 5-[4-(isopropoxyloxycarbonylamino)butylthio]imidazo[1,2-a]pyridine (Compound 169)

To a solution of 5-[4-(amino)butylthio]imidazo[1,2-a]pyridine (370 mg, 1.67 mmoles) and triethylamine
10 (0.35 ml, 2.51 mmoles) in methylene chloride (20 ml) was added isopropyl chloroformate (0.25 g, 2.04 mmoles) under ice-cooling with stirring and the mixture was stirred under ice-cooling for 1 hour. The reaction mixture was washed in turn with an aqueous sodium bicarbonate solution and saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 215 mg of the desired product (41.8%, light tan
15 oily product).

NMR (200MHz, CDCl₃) δ : 1.22 (6H, d, J=6.2Hz), 1.54-1.72 (4H, m), 3.02 (2H, m), 3.18 (2H, m), 4.66 (1H, br), 4.90 (1H, hept, J=6.2Hz), 6.90 (1H, dd, J=7, 1Hz), 7.15 (1H, dd, J=9, 7Hz), 7.58 (1H, d, J=9Hz), 7.84 (1H, m)

20 Example 41

Synthesis of 5-[3-(benzenesulfonamido)propyloxy]imidazo[1,2-a]pyridine (Compound 170)

To a suspension of 5-[3-(amino)propyloxy]imidazo[1,2-a]pyridine dihydrochloride (2.64 g, 10 mmoles)
25 and triethylamine (4.88 ml, 35 mmoles) in methylene chloride (100 ml)-acetonitrile (30 ml) was added benzenesulfonyl chloride (1.53 ml, 12 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 1 hour. The reaction mixture was washed in turn with an aqueous sodium bicarbonate solution and saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the crude product thus obtained was recrystallized from methylene-ethanol to obtain 1.97 g of the
30 desired product (59.5%, light brown crystals).

Melting point: 155-156 °C

NMR (200MHz, CDCl₃) δ : 2.14 (2H, m), 3.26 (2H, m), 4.27 (2H, t, J=5.8Hz), 5.93 (1H, dd, J=7, 1.2Hz), 6.08 (1H, br), 7.11 (1H, dd, J=9, 7Hz), 7.17 (1H, m), 7.33 (1H, m), 7.37-7.56 (4H, m), 7.84-7.92 (2H, m)

35 Example 42

Synthesis of 5-[2-[2-(methanesulfonamido)ethyloxy]ethylthio]imidazo[1,2-a]pyridine (Compound 171)

To a suspension of 5-[2-[2-(phthalimido)ethyloxy]ethylthio]imidazo[1,2-a]pyridine (1.10 g, 3 mmoles) in
40 ethanol (15 ml) was added hydrazine monohydrate (0.44 ml, 9.1 mmoles) and the mixture was heated at reflux for 1 hour. After the mixture was cooled by standing, methylene chloride (30 ml) was added and an insoluble product was filtered off, and then the solvent was distilled off from the filtrate. Methylene chloride (30 ml) and triethylamine (0.84 ml, 6 mmoles) were added to the residue, to which was further added methanesulfonic anhydride (679 mg, 3.9 mmoles) under ice-cooling with stirring and the mixture was stirred
45 at room temperature for 1 hour. Then, it was washed with saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate/ethanol = 10:1) to obtain 0.82 g of the desired product (86.9%, pale yellow oily product).

NMR (200MHz, CDCl₃) δ : 2.96 (3H, s), 3.16 (2H, t, J=6Hz), 3.22 (2H, m), 3.54 (2H, t, J=5Hz), 3.68 (2H,
50 t, J=6Hz), 5.12 (1H, br), 6.99 (1H, dd, J=7, 6Hz), 7.16 (1H, dd, J=9, 7Hz), 7.61 (1H, m), 7.70 (1H, d, J=1.2Hz), 7.88 (1H, m)

55

EP 0 471 236 B1

Example 43

Synthesis of 5-[3-[1,2-benzisothiazole-3(2H)-on-1,1-dioxido-2-yl]propylthio]imidazo[1,2-a]pyridine (Compound 172)

5 To a solution of 5-[3-(chloro)propylthio]imidazo[1,2-a]pyridine (1.17 g, 5.16 mmol) and saccharin (1.50 g, 8.19 mmol) in DMF (30 ml) was added 1,8-diazabicyclo[5.4.0]-7-undecene (0.78 ml, 5.22 mmol) and the mixture was stirred at 80 °C for 24 hours. The reaction mixture was poured into an aqueous sodium bicarbonate solution, which was extracted with ethyl acetate. The extract was washed with water and dried
10 over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 658 mg of the desired product (34.1%, colorless crystals).

Melting point: 99-100 °C

NMR (200MHz, CDCl₃) δ: 2.17 (2H, m), 3.09 (2H, t, J = 7Hz), 3.95 (2H, t, J = 6.8Hz), 7.00 (1H, dd, J = 7, 1Hz), 7.16 (1H, dd, J = 8.8, 7Hz), 7.60 (1H, m), 7.69 (1H, d, J = 1.2Hz), 7.80-7.97 (4H, m), 8.06 (1H, m)

Example 44

Synthesis of 5-[3-(methanesulfonamido)benzyl]imidazo[1,2-a]pyridine (Compound 173)

20 To a solution of 3-aminobenzyl alcohol (1.23 g, 10 mmol) and triethylamine (3.07 ml, 22 mmol) in methylene chloride (50 ml) was added methanesulfonyl (1.55 ml, 20 mmol) under ice-cooling with stirring and the mixture was stirred at room temperature for 1 hour. Then, 5-mercaptoimidazo[1,2-a]pyridine (1.50 g, 10 mmol) and triethylamine (1.40 ml, 10 mmol) were added, followed by stirring for 5 hours. The mixture was washed in turn with an aqueous saturated solid bicarbonate solution and saturated saline and
25 dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 0.88 g of the desired product (26.4%, light brown product).

NMR (200MHz, CDCl₃) δ: 2.91 (3H, s), 4.13 (2H, s), 6.52 (1H, m), 6.81 (1H, m), 6.92-7.28 (4H, m), 7.58 (1H, m), 7.66 (1H, m), 7.86 (1H, m)

Example 45

Synthesis of 5-[3-(acetyloxy)propylthio]imidazo[1,2-a]pyridine (Compound 174)

35 To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (2.00 g, 9.60 mmol) and triethylamine (1.60 ml, 11.5 mmol) in methylene chloride (50 ml) was added acetic anhydride (1.10 ml, 11.6 mmol) with stirring at room temperature and the mixture was further stirred at room temperature for 7.5 hours. The reaction mixture was washed with an aqueous 1N sodium hydroxide solution and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: hexane/acetone (1:1)] to
40 obtain 2.40 g of the desired product (100%, brown oily product).

NMR (200MHz, CDCl₃) δ : 1.98 (2H, quint, J = 6.6Hz), 2.04 (3H, s), 3.06 (2H, t, J = 7.0Hz), 4.19 (2H, t, J = 6.2Hz), 6.94 (1H, d, J = 6.8Hz), 7.17 (1H, dd, J = 8.8, 6.8Hz), 7.62 (1H, d, J = 8.8Hz), 7.71 (1H, s), 7.85 (1H, s)

IR (Neat) cm⁻¹: 1740, 1488, 1240

Example 46

Synthesis of 5-[3-(acetyloxy)propylthio]imidazo[1,2-a]pyridine (Compound 174)

50 To a solution of 3-bromo-1-propanol (0.50 g, 3.60 mmol) and triethylamine (0.60 ml, 0.40 mmol) in methylene chloride (15 ml) was added acetic anhydride (0.40 ml, 4.24 mmol) with stirring at room temperature and the mixture was further stirred at room temperature overnight. The reaction mixture was washed with an aqueous 1N sodium hydroxide solution and dried. After the solvent was distilled off, ethanol (10 ml) and triethylamine (1.00 ml, 7.17 mmol) was added to the residue. To the mixture was added 5-
55 mercaptopyridine (0.49 g, 3.26 mmol) with stirring at room temperature and the mixture was stirred at room temperature for 5 minutes. The solvent was distilled off and the residue was purified by column chromatography [eluent: hexane/acetone (1:1)] to obtain 0.54 g of the desired product (66.3%, brown oily product).

EP 0 471 236 B1

NMR (200MHz, CDCl₃) δ : 1.98 (2H, quint, J=6.6Hz), 2.04 (3H, s), 3.06 (2H, t, J=7.0Hz), 4.19 (2H, t, J=6.2Hz), 6.94 (1H, d, J=6.8Hz), 7.17 (1H, dd, J=8.8, 6.8Hz), 7.62 (1H, d, J=8.8Hz), 7.71 (1H, s), 7.85 (1H, s)

IR (Neat) cm⁻¹: 1740, 1488, 1240

5

Example 47

Synthesis of 5-[3-(benzoyloxy)propylthio]imidazo[1,2-a]pyridine (Compound 175)

10 To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (1.00 g, 4.80 mmoles) and triethylamine (0.80 ml, 5.74 mmoles) in methylene chloride (25 ml) was added benzoyl chloride (1.10 ml, 11.6 mmoles) with stirring at room temperature and the mixture was further stirred at room temperature for 30 minutes. The reaction mixture was washed with an aqueous 1N sodium hydroxide solution and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: hexane/acetone (1:1)]
15 to obtain 1.32 g of the desired product (88.1%, white solid).

Melting point: 60-61 °C

20

Elemental analysis for C ₁₇ H ₁₆ N ₂ O ₂ S,			
Calcd.	C, 65.36;	H, 5.16;	N, 8.97
Found	C, 65.52;	H, 5.17;	N, 8.84

25 NMR (200MHz, CDCl₃) δ : 2.13 (2H, quint, J=6.6Hz), 3.16 (2H, t, J=7.2Hz), 4.46 (2H, t, J=6.2Hz), 6.96 (1H, d, J=7.0Hz), 7.15 (1H, dd, J=9.2, 7.0Hz), 7.38-7.64 (4H, m), 7.69 (1H, s), 7.86 (1H, s), 7.99 (2H, dd, J=7.2, 1.6Hz)

IR (Neat) cm⁻¹: 1713, 1487, 1280

Example 48

30 Synthesis of 5-[3-[2-(phenyl)ethylcarbonyloxy]propylthio]imidazo[1,2-a]pyridine (Compound 176)

To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (1.00 g, 4.80 mmoles) and triethylamine (0.80 ml, 5.74 mmoles) in methylene chloride (25 ml) was added 3-phenylpropionyl chloride (1.01 g, 5.99 mmoles) with stirring at room temperature and the mixture was further stirred at room temperature for 2
35 hours. The reaction mixture was washed with an aqueous 1N sodium hydroxide solution and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: hexane/acetone (1:1)] to obtain 1.37 g of the desired product (84.2%, yellow oily product).

40

Elemental analysis for C ₁₉ H ₂₀ N ₂ O ₂ S,			
Calcd.	C, 67.03;	H, 5.92;	N, 8.23
Found	C, 66.86;	H, 6.01;	N, 7.81

45 NMR (200MHz, CDCl₃) δ : 1.92 (2H, quint, J=6.6Hz), 2.63 (2H, t, J=7.7Hz), 2.94 (4H, t, J=7.2Hz), 4.19 (2H, t, J=6.2Hz), 6.91 (1H, d, J=7.2Hz), 7.10-7.35 (6H, m), 7.61 (1H, d, J=9.0Hz), 7.72 (1H, s), 7.84 (1H, s)

IR (Neat) cm⁻¹: 1730, 1487, 1288

Example 49

Synthesis of 5-[3-(acetyloxy)propylsulfinyl]imidazo[1,2-a]pyridine (Compound 177) and 5-[3-(acetyloxy)propylsulfonyl]imidazo[1,2-a]pyridine (Compound 178)

55 To a solution of 5-[3-(acetyloxy)propylthio]imidazo[1,2-a]pyridine (1.00 g, 3.99 mmoles) in chloroform (25 ml) was added m-chloroperbenzoic acid (1.47 g, 5.96 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 1.5 hours. The reaction mixture was washed in turn with an aqueous 20% sodium bisulfite solution and an aqueous saturated sodium bicarbonate solution and dried.

EP 0 471 236 B1

After the solvent was distilled off, the residue was purified by column chromatography [eluent: hexane/acetone (1:1)] to obtain 0.19 g of 5-[3-(acetyloxy)propylsulfinyl]imidazo[1,2-a]pyridine (Compound 177) (34.6%, yellow oily product) and 0.19 g of 5-[3-(acetyloxy)propylsulfonyl]imidazo[1,2-a]pyridine (Compound 178) (16.5%, yellow oily product).

5

5-[3-(acetyloxy)propylsulfinyl]imidazo[1,2-a]pyridine (Compound 177)

NMR (200MHz, CDCl₃) δ : 1.90-2.30 (2H, m), 2.02 (3H, s), 3.05-3.30 (2H, m), 4.10-4.30 (2H, m), 7.31-7.38 (2H, m), 7.47-7.87 (2H, m), 7.92 (1H, s)

10 IR (Neat) cm⁻¹: 1740, 1240, 1063, 1033

5-[3-(acetyloxy)propylsulfonyl]imidazo[1,2-a]pyridine (Compound 178)

NMR (200MHz, CDCl₃) δ : 1.98 (3H, s), 2.03-2.20 (2H, m), 3.30-3.40 (2H, m), 4.13 (2H, t, J=6.2Hz), 7.36 (1H, dd, J=9.0, 7.2Hz), 7.68 (1H, dd J=7.2, 1.2Hz), 7.86 (1H, s), 7.96 (1H, d, J=9.0Hz), 8.28 (1H, s)

15 IR (Neat) cm⁻¹: 1740, 1325, 1240, 1130

Example 50

20 Synthesis of 5-[3-(methoxy)propylthio]imidazo[1,2-a]pyridine(Compound 179)

To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (803 mg, 3.86 mmoles) in tetrahydrofuran (30 ml) was added 60% sodium hydride in oil (0.19 g, 4.6 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 30 minutes. To the reaction mixture was added methyl iodide (0.36 ml, 5.8 mmoles), followed by stirring at room temperature overnight. The reaction mixture was poured into water, which was extracted with methylene chloride (30 ml x 3). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 308 mg of the desired product (35.9%, light brown oily product).

30 NMR (200MHz, CDCl₃) δ : 1.92 (2H, tt, J=6.0, 7.2Hz), 3.10 (2H, t, J=7.3Hz), 3.32 (3H, s), 3.48 (2H, t, J=5.8Hz), 6.91 (1H, dd, J=1.2, 7.0Hz), 7.15 (1H, dd, J=7.2, 9.0Hz), 7.57 (1H, td, J=1.0, 9.0Hz), 7.70 (1H, d, J=1.2Hz), 7.84 (1H, t, J=0.8Hz)

Example 51

35

Synthesis of 5-[3-(phenoxy)propylthio]imidazo[1,2-a]pyridine (Compound 180)

(1) Synthesis of 5-[3-(methanesulfonyloxy)propylthio]imidazo[1,2-a]pyridine

40 To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (1.030 g, 4.95 mmoles) and triethylamine (1.03 ml, 7.4 mmoles) in methylene chloride (30 ml) was added methanesulfonyl chloride (0.46 ml, 5.9 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 10 minutes. The reaction mixture was washed with water and the aqueous layer was extracted with methylene chloride (30 ml x 3). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off to obtain crude 5-[3-(methanesulfonyloxy)propylthio]imidazo[1,2-a]pyridine as a yellow oily product.

45

(2) Synthesis of 5-[3-(phenoxy)propylthio]imidazo[1,2-a]pyridine (Compound 180)

50 To a solution of phenol (0.70 g, 7.4 mmoles) in tetrahydrofuran (20 ml) was added 60% sodium hydride in oil (0.30 ml, 7.4 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 30 minutes. To the reaction mixture was added a solution of crude 5-[3-(methanesulfonyloxy)propylthio]imidazo[1,2-a]pyridine obtained in the above (1) in tetrahydrofuran (10 ml), followed by heating under reflux overnight. The reaction mixture was poured into water, which was extracted with methylene chloride (30 ml x 4). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 1.220 g of the desired product (86.8%, light brown oily product).

55

NMR (200MHz, CDCl₃) δ : 2.13 (2H, tt, J=5.9, 7.1Hz), 3.22 (2H, t, J=7.2Hz), 4.09 (2H, t, J=5.8Hz),

EP 0 471 236 B1

6.85-7.00 (4H, m), 7.13 (1H, dd, J=7.0, 9.0Hz), 7.25-7.33 (2H, m), 7.57 (1H, td, J=0.8, 9.0Hz), 7.71 (1H, d, J=1.4Hz), 7.85 (1H, s)

Example 52

5

Synthesis of 5-[3-[2-(phenoxy)ethoxy]propylthio]imidazo[1,2-a]pyridine (Compound 181)

(1) Synthesis of 1-methanesulfonyloxy-2-(phenoxy)ethane

10 To a solution of 2-(phenoxy)ethanol (1.35 g, 9.78 mmoles) and triethylamine (2.04 ml, 14.7 mmoles) in methylene chloride (30 ml) was added methanesulfonyl chloride (0.91 ml, 12 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 10 minutes. The reaction solution was washed with water and the aqueous layer was extracted with methylene chloride (30 ml x 3). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled
15 off, the residue was subjected to column chromatography [eluent: hexane/methyl (1:1)] to obtain crude 1-methanesulfonyloxy-2-(phenoxy)ethane as a pale yellow oily product.

(2) Synthesis of 5-[3-[2-(phenoxy)ethoxy]propylthio]imidazo[1,2-a]pyridine (Compound 181)

20 To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (1.018 g, 4.89 mmoles) in tetrahydrofuran (20 ml) was added 60% sodium hydride in oil (0.30 ml, 7.4 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 30 minutes. To the reaction mixture was added a solution of crude 1-methanesulfonyloxy-2-(phenoxy)ethane obtained in the above (1) in tetrahydrofuran (10 ml), followed by heating under reflux for 4.5 hours. The reaction solution was poured
25 into water, which was extracted with methylene chloride (30 ml x 4). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 0.870 g of the desired product (54.2%, light brown oily product).

30 NMR (200MHz, CDCl₃) δ : 1.96 (2H, tt, J=6.1, 7.1Hz), 3.13 (2H, t, J=7.2Hz), 3.66 (2H, t, J=5.9Hz), 3.78 (2H, dd, J=3.3, 6.1Hz), 4.11 (2H, dd, J=3.9, 5.5Hz), 6.88-7.00 (4H, m), 7.13 (1H, dd, J=7.0, 9.0Hz), 7.24-7.32 (2H, m), 7.56 (1H, td, J=0.9, 9.0Hz), 7.69 (1H, d, J=1.2Hz), 7.83 (1H, t, J=0.8Hz)

Example 53

35 Synthesis of 5-[3-[3-(phenyl)propyloxy]propylthio]imidazo[1,2-a]pyridine (Compound 182)

To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (1.070 g, 5.137 mmoles) in tetrahydrofuran (30 ml) was added 60% sodium hydride in oil (0.25 g, 6.2 mmoles) with stirring under ice-cooling and the mixture was stirred under ice-cooling for 30 minutes. To the reaction mixture was added
40 methyl iodide (1.53 g, 7.71 mmoles), followed by stirring at room temperature overnight. The reaction mixture was poured into water, which was extracted with methylene chloride (30 ml x 3). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 0.987 g of the desired compound (58.9%, light brown oily product).

45 NMR (200MHz, CDCl₃) δ : 1.81-1.99 (4H, m), 2.68 (2H, t, J=7.6Hz), 3.12 (2H, t, J=7.2Hz), 3.41 (2H, t, J=6.4Hz), 3.51 (2H, t, J=5.8Hz), 6.91 (1H, dd, J=1.1, 7.1Hz), 7.10-7.32 (6H, m), 7.56 (1H, td, J=1.0, 9.0Hz), 7.69 (1H, d, J=1.4Hz), 7.84 (1H, t, J=1.0Hz)

Example 54

50

Synthesis of 5-[3-[2-(anilino)ethoxy]propylthio]imidazo[1,2-a]pyridine (Compound 183)

(1) Synthesis of 5-[3-(methanesulfonyloxy)propylthio]imidazo[1,2-a]pyridine

55 To a solution of 5-[3-(hydroxy)propylthio]imidazo[1,2-a]pyridine (2.003 g, 9.62 mmoles) and triethylamine (2.01 ml, 14.4 mmoles) in methylene chloride (30 ml) was added methanesulfonyl chloride (0.89 ml, 12 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 10 minutes. The reaction mixture was washed with water and the aqueous layer was extracted with

EP 0 471 236 B1

methylene chloride (30 ml x 3). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off to obtain crude 5-[3-(methanesulfonyloxy)propylthio]imidazo[1,2-a]pyridine as a yellow oily product.

5 (2) Synthesis of 5-[3-[2-(anilino)ethoxy]propylthio]imidazo[1,2-a]pyridine (Compound 183)

To a solution of 2-anilinoethanol (1.98 g, 14.4 mmoles) in tetrahydrofuran (20 ml) was added 60% sodium hydride in oil (1.15 ml, 28.9 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 30 minutes. To the reaction mixture was added a solution of crude 5-[3-(methanesulfonyloxy)propylthio]imidazo[1,2-a]pyridine obtained in the above (1) in tetrahydrofuran (10 ml), followed by heating under reflux for 1 hour. The reaction mixture was poured into water which was extracted with methylene chloride (30 ml x 4). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 0.951 g of the desired product (30.2%, light green crystals).

NMR (200MHz, CDCl₃) δ : 1.94 (2H, tt, J=5.9, 7.1Hz), 3.10 (2H, t, J=7.2Hz), 3.28 (2H, t, J=5.2Hz), 3.57 (2H, t, J=6.0Hz), 3.62 (2H, t, J=5.1Hz), 3.98 (1H, br, s), 6.63 (2H, d, J=7.3Hz), 6.72 (1H, t, J=7.3Hz), 6.89 (1H, dd, J=1.0, 7.4Hz), 7.10-7.22 (3H, m), 7.57 (1H, d, J=9.0Hz), 7.70 (1H, d, J=1.4Hz), 7.83 (1H, s)

20 Example 55

Synthesis of 5-[3-[2-(N-methanesulfonylanilino)ethoxy]propylthio]imidazo[1,2-a]pyridine (Compound 184)

To a solution of 5-[3-[2-(phenylamino)ethoxy]propylthio]imidazo[1,2-a]pyridine (1.034 g, 3.158 mmoles) and triethylamine (0.88 ml, 6.3 mmoles) in methylene chloride (30 ml) was added methanesulfonyl chloride (0.37 ml, 4.7 mmoles) with stirring under ice-cooling and the mixture was further stirred under ice-cooling for 10 minutes. The reaction mixture was washed with water and the aqueous layer was extracted with methylene chloride (30 ml x 3). The methylene chloride layers were combined and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 16 mg of the desired product (brown oily product)

NMR (200MHz, CDCl₃) δ : 1.86 (2H, tt, J=5.9, 7.2Hz), 2.92 (3H, s), 3.03 (2H, t, J=7.2Hz), 3.50 (2H, t, J=5.3Hz), 3.50 (2H, t, J=5.8Hz), 3.84 (2H, t, J=5.7Hz), 6.89 (1H, dd, J=1.0, 7.0Hz), 7.15 (1H, dd, J=7.0, 9.0Hz), 7.31-7.40 (5H, m), 7.57 (1H, d, J=9.0Hz), 7.70 (1H, d, J=1.0Hz), 7.82 (1H, s)

35 Example 56

Synthesis of 5-[1-(2-thienylcarbonyl)-4-piperidyloxy]imidazo[1,2-a]pyridine (Compound 185)

To a suspension of 60% sodium hydride in oil (0.40 g, 10 mmoles) in dimethylformamide (30 ml) was added 1-(2-thienylcarbonyl)-4-hydroxypiperidine (2.11 g, 10 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 30 minutes. To this reaction mixture was added 5-chloroimidazo[1,2-a]pyridine (1.53 g, 10 mmoles) with stirring under ice-cooling, followed by stirring at room temperature for 7 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate and dried. After the solvent was distilled off, the residue was purified with column chromatography [eluent: ethyl acetate/hexane (1:1) \rightarrow ethyl acetate/hexane (2:1) \rightarrow ethyl acetate/ethanol (50:1)] to obtain 0.15 g of the desired product (4.6%, pale yellow oily product).

NMR (200MHz, CDCl₃) δ : 2.03-2.16 (4H, m), 3.85-3.96 (4H, m), 4.84-4.93 (1H, m), 6.09 (1H, d, J=7.0Hz), 7.06 (1H, dd, J=3.6, 5.0Hz), 7.12-7.35 (3H, m), 7.47 (1H, dd J=1.2, 5.0Hz), 7.62 (1H, d, J=1.2Hz), 7.67 (1H, d, J=0.8Hz)

50

Example 57

Synthesis of 5-[2-(N-benzylmethylsulfonylamino)ethoxy]imidazo[1,2-a]pyridine (Compound 186)

55 (1) Synthesis of 2-(N-benzylmethylsulfonylamino)1-ethanol

To a solution of N-benzylamino ethanol (7.10 ml, 50 mmoles) and triethylamine (7.67 ml, 55 mmoles) in dichloromethane (100 ml) was added methylsulfonyl chloride (4.26 ml, 55 mmoles) with stirring under ice-

EP 0 471 236 B1

cooling and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was washed in turn with an aqueous saturated sodium bicarbonate solution and water and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/hexane (1:1) → ethyl acetate/hexane (2:1) → ethyl acetate] to obtain 1.99 g of the desired product (17.4%, pale yellow oily product).

NMR (200MHz, CDCl_3) δ : 1.89 (1H, bs), 2.94 (3H, s), 3.37 (2H, t, $J=5.0\text{Hz}$), 3.65 (2H, t, $J=5.0\text{Hz}$), 4.47 (2H, s), 7.35-7.39 (5H, m)

IR (Neat) cm^{-1} : 3520, 3030, 2930, 1600, 1595, 1455, 1320, 1140

10 (2) Synthesis of 5-[2-(N-benzylmethylsulfonylamino)ethoxy]imidazo[1,2-a]pyridine (Compound 186)

To a suspension of 60% sodium hydride in oil (0.20 g, 5 mmoles) in dimethylformamide (20 ml) was added 2-(N-benzylmethylsulfonylamino)-1-ethanol (1.14 g, 5 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 30 minutes. To this reaction mixture was added 5-chloroimidazo[1,2-a]pyridine (0.763 g, 5 mmoles) with stirring under ice-cooling, followed by stirring at 80 °C for 16 hours. After cooling, water was added to the reaction mixture, which was extracted with ethyl acetate and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/hexane (1:1) → ethyl acetate/hexane (2:1)] to obtain 0.68 g of the desired product (39.4%, pale yellow oily product).

20 NMR (200MHz, CDCl_3) δ : 2.94 (3H, s), 3.72 (2H, t, $J=6.0\text{Hz}$), 4.23 (2H, t, $J=5.8\text{Hz}$), 4.52 (2H, s), 5.87 (1H, d, $J=6.8\text{Hz}$), 7.11 (1H, d, $J=7.2, 9.0\text{Hz}$), 7.25-7.40 (6H, m), 7.58 (2H, s)

IR (Neat) cm^{-1} : 3150, 3030, 2930, 1640, 1540

Example 58

25

Synthesis of 5-[3-(methylsulfonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 27)

(1) Synthesis of 3-methylsulfonylamino-1-methylsulfonyloxypropane

30 To a solution of 3-amino-1-propanol (11.47 ml, 150 mmoles) and triethylamine (46 ml, 330 mmoles) in dichloromethane (250 ml) was added methylsulfonyl chloride (25.5 ml, 330 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was washed in turn with an aqueous sodium bicarbonate and water and dried. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 24.22 g of the desired product (69.8%, white crystals).

Melting point: 53.5-55.5 °C

NMR (200MHz, CDCl_3) δ : 2.02 (2H, quint, $J=6.4\text{Hz}$), 2.98 (3H, s), 3.05 (3H, s), 3.31 (2H, q, $J=6.4\text{Hz}$), 4.37 (2H, t, $J=5.8\text{Hz}$), 4.68 (1H, bs)

40 (2) Synthesis of 5-[3-(methylsulfonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 27)

To a solution of 5-mercaptoimidazo[1,2-a]pyridine (1.50 g, 10 mmoles) and 4M sodium methylate (2.93 ml, 12 mmoles) in ethanol (50 ml) was added 3-methylsulfonylamino-1-methylsulfonyloxypropane (2.77 g, 12 mmoles) at room temperature and the mixture was heated under reflux for 16 hours. After cooling, the solvent was distilled off. The residue was dissolved in chloroform, washed with an aqueous saturated sodium bicarbonate solution and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/ethanol (50:1)] to obtain 1.34 g of the desired product (47.5%, pale yellow crystals).

Melting point: 114-116 °C

50 NMR (200MHz, CDCl_3) δ : 1.92 (2H, quint, $J=6.8\text{Hz}$), 2.95 (3H, s), 3.09 (2H, t, $J=7.0\text{Hz}$), 3.30 (2H, q, $J=6.6\text{Hz}$), 4.82 (1H, bs), 6.94 (1H, d, $J=7.0\text{Hz}$), 7.15 (1H, dd, $J=7.0, 9.0\text{Hz}$), 7.60 (1H, d, $J=9.0\text{Hz}$), 7.69 (1H, s), 7.84 (1H, s)

IR (KBr) cm^{-1} : 3440, 3080, 2850, 1615, 1485, 1315, 1140

55

EP 0 471 236 B1

Example 59

Synthesis of 5-[1-(methylsulfonyl)-4-piperidylsulfinyl]imidazo[1,2-a]pyridine (Compound 187) and 5-[1-(methylsulfonyl)-4-piperidylsulfonyl]imidazo[1,2-a]pyridine (Compound 188)

5 To a solution of 5-[1-(methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (0.934 ml, 3.0 mmoles) in chloroform (30 ml) was added m-chloroperbenzoic acid (0.914 g, 4.5 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 2 hours. To this reaction mixture was added m-chloroperbenzoic acid (0.609 g, 3.0 mmoles) with stirring under ice-cooling and the mixture was stirred at
10 room temperature for 1 hour. The reaction mixture was washed with an aqueous 1N sodium hydroxide solution and dried. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/ethanol (25:1 → 10:1)] to obtain 0.272 g of the sulfone compound (24.2%, white crystals) as Fraction 1 and 0.273 g of the sulfoxide compound (26.5%, white crystals) as Fraction 2.

15 5-[1-(methylsulfonyl)-4-piperidylsulfonyl]imidazo[1,2-a]pyridine (Compound 188)

Melting point: 224-226 °C

NMR (200MHz, CDCl₃) δ : 1.96-2.12 (4H, m), 2.68-2.82 (1H, m), 2.79 (3H, s), 3.22 (1H, m), 3.85-3.97 (2H, m), 7.36 (1H, dd, J = 7.2, 8.8Hz), 7.64 (1H, d, J = 7.2Hz), 7.86 (1H, bs), 7.98 (1H, d, J = 9.0Hz), 8.34 (1H, bs)
20

5-[1-(methylsulfonyl)-4-piperidylsulfinyl]imidazo[1,2-a]pyridine (Compound 189)

Melting point: 205 °C (decomp.)

25 NMR (200MHz, CDCl₃) δ : 1.69-2.08 (4H, m), 2.66-2.85 (1H, m), 2.79 (3H, s), 3.29 (1H, m), 3.82-3.79 (2H, m), 7.25-7.38 (2H, m), 7.81-7.86 (2H, m), 8.09 (1H, bs)

Example 60

30 Synthesis of 5-[2-[3-(hydroxy)isoindolin-1-one-2-yl]ethylthio]imidazo[1,2-a]pyridine (Compound 189)

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (159 mg, 1 mmole) and 2-[2-(bromo)ethyl]-3-hydroxyindolin-1-one (256 mg, 1 mmole) in ethanol (15 ml) was added trimethylamine (0.21 ml, 1.5 mmoles) and the mixture was stirred at room temperature for 12 hours and heated under reflux for 2
35 hours. After the solvent was distilled off, chloroform was added to the residue, which was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/ethanol (10:1)] to obtain 11.9 g of the desired product (36.6%, pale yellow solid).

40 NMR (200MHz, CDCl₃-DMSO-d₆) δ : 3.38 (2H, m), 3.88 (2H, m), 5.82 (1H, m), 6.47 (1H, m), 7.14-7.67 (2H, m), 7.44-7.67 (5H, m), 7.76 (1H, m), 7.85 (1H, m)

Example 61

Synthesis of 5-[2-(isoindolin-1-one-2-yl)ethylthio]imidazo[1,2-a]pyridine (Compound 190)

45 To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (150 mg, 1 mmole) and 2-[2-(bromo)ethyl]-isoindolin-1-one (240 mg, 1 mmole) in ethanol (15 ml) was added triethylamine (0.21 ml, 1.5 mmoles) and the mixture was stirred at room temperature for 12 hours and heated at reflux for 2 hours. After the solvent was distilled off, chloroform was added to the residue which was washed with water and dried over
50 anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/ethanol (15:1)] to obtain 238 mg of the desired product (77.0%, light brown solid).

NMR (200MHz, CDCl₃) δ : 3.32 (2H, t, J = 6.8Hz), 3.89 (2H, t, J = 6.8Hz), 4.39 (2H, s), 7.05-7.18 (2H, m), 7.37-7.60 (4H, m), 7.70 (1H, d, J = 1.2Hz), 7.82-7.88 (2H, m)
55

EP 0 471 236 B1

Example 62

Synthesis of 5-[2-(phenylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 191)

5 To a suspension of 5-[2-(phenylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine (600 mg, 1.8 mmoles) in chloroform (50 ml) was added m-chloroperbenzoic acid (913 mg, 4.5 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 22 hours. The reaction mixture was washed in turn with an aqueous 1N sodium hydroxide solution and saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/ethanol(10:1)] to obtain 200 mg of the desired product (31.8%, light brown solid).

10 NMR (200MHz, CDCl₃) δ : 3.16 (1H, m), 3.35-3.65 (3H, m), 5.96 (1H, br), 7.28-7.36 (2H, m), 7.48-7.67 (3H, m), 7.75-7.90 (5H, m)

Example 63

15 Synthesis of 5-[2-(tert-butoxycarbonylamino)ethylthio]-3-nitroimidazo[1,2-a]pyridine (Compound 192)

To a solution of cysteamine (2.95 g, 38.2 mmoles) in DMF (50 ml) was added 60% sodium hydride in oil (1.53 g, 38.2 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 10 minutes. To the mixture was added 5-chloro-3-nitroimidazo[1,2-a]pyridine (5.81 g, 29.4 mmoles), followed by stirring under ice-cooling for 30 minutes and further stirring at room temperature for 30 minutes. Di-tert-butyl dicarbonate (9.62 g, 44 mmoles) was added, followed by stirring at room temperature for 4 hours. The reaction mixture was poured into water, which was extracted with ethyl acetate, washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 2.06 g of the desired product (20.7%, tan solid).

25 NMR (200MHz, CDCl₃) δ : 1.41 (9H, s), 3.17-3.41 (4H, m), 5.00 (1H, br), 7.36 (1H, dd, J=6.2, 2.6Hz), 7.59-7.71 (2H, m), 8.54 (1H, s)

Example 64

Synthesis of 5-[2-(methylsulfonylamino)ethylthio]-3-nitroimidazo[1,2-a]pyridine (Compound 193)

(1) Synthesis of 5-[2-(amino)ethylthio]-3-nitroimidazo[1,2-a]pyridine•dihydrochloride

35 To a suspension of 5-[2-(tert-butoxycarbonylamino)ethylthio]-3-nitroimidazo[1,2-a]pyridine (364 mg, 1.08 mmoles) in methanol (3 ml) was added conc. hydrochloric acid (2 ml) and the mixture was stirred at room temperature for 1 hour. Then, the solvent was distilled off to obtain 340 mg of the desired product (quantitative, brown solid).

40 (2) Synthesis of 5-[2-(methylsulfonylamino)ethylthio]-3-nitroimidazo[1,2-a]pyridine (Compound 193)

To a solution of 5-[2-(amino)ethylthio]-3-nitroimidazo[1,2-a]pyridine•dihydrochloride (221 mg, 0.71 mmole) and triethylamine (0.33 ml, 2.37 mmoles) in methylene chloride (30 ml) was added methanesulfonyl chloride (0.08 ml, 1.03 mmoles) with stirring under ice-cooling and the mixture was further stirred at the same temperature for 10 minutes. After washing with water, the reaction mixture was dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 108 mg of the desired product (48.0%, orange solid).

50 NMR (200MHz, CDCl₃) δ : 2.84 (3H, s), 3.09 (3H, s), 3.33 (2H, m), 7.24 (1H, br), 7.65 (1H, m), 7.77-7.90 (2H, m), 8.78 (1H, s)

Example 65

Synthesis of 5-[1-(methylsulfonyl)-4-piperidyloxy]-3-nitroimidazo[1,2-a]pyridine (Compound 194)

55 To a solution of 4-hydroxy-1-methylsulfonylpiperidine (2.15 g, 12 mmoles) in dimethylformamide (3 ml) was added 60% sodium hydride in oil (0.48 g, 12 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 5-chloro-3-nitroimidazo-

EP 0 471 236 B1

[1,2-a]pyridine (1.976 g, 10 mmoles) with stirring under ice-cooling and the mixture was stirred at the same temperature for 30 minutes. The reaction mixture was poured into water, which was extracted with ethyl acetate. The precipitate was filtered off, washed with water and dried to obtain 1.862 g of the desired product (54.7%, yellow solid). The organic layer was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the crude crystals thus obtained were recrystallized from methylene-n-hexane to obtain 460 mg of the desired product (460 mg, tan solid).

NMR (200MHz, CDCl₃) δ : 2.02-2.23 (3H, s), 2.90 (3H, s), 3.29 (2H, m), 3.66 (2H, m), 4.95 (1H, m), 6.44 (1H, d, J = 7.6Hz), 7.43 (1H, d, J = 8.8Hz), 7.58 (1H, dd, J = 8.8, 7.6Hz), 8.40 (1H, s)

10 Example 66

Synthesis of 3-amino-5-[1-(methylsulfonyl)-4-piperidyloxy]imidazo[1,2-a]pyridine (Compound 195)

To a solution of 5-[1-(methylsulfonyl)-4-piperidyloxy]-3-nitroimidazo[1,2-a]pyridine (70 mg, 0.226 mmole) in methylene chloride (10 ml) was added 10% palladium-carbon (50 ml) and the mixture was stirred in hydrogen atmosphere at room temperature for 1.5 hours. After the reaction mixture was treated with Cellite, the solvent was distilled off. To the residue was added chloroform, which was washed in turn with an aqueous saturated sodium bicarbonate solution and water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: chloroform/methanol (15:1)] to obtain 93 mg of the desired product (30.0%, brown oily product).

NMR (200MHz, CDCl₃) δ : 2.17 (4H, m), 2.84 (3H, s), 3.28-3.53 (4H, m), 4.70 (1H, m), 5.87 (1H, dd, J = 7.2Hz), 6.87 (1H, dd, J = 9, 7.2Hz), 7.07 (1H, d, J = 9Hz), 7.27 (1H, s)

25 Example 67

Synthesis of 2-isobutylcarbamoyl-5-[2-(methylsulfonylamino)ethylthio][1,2-a]pyridine (Compound 196)

A mixture of 2-ethoxycarbonyl-5-[2-(methylsulfonylamino)ethylthio][1,2-a]pyridine (148 mg, 0.431 mmole), isobutylamine (0.86 ml, 8.65 mmoles) and ethanol (10 ml) was heated under reflux for 18 hours. To the mixture was further added isobutylamine (1.72 ml, 17.3 mmoles) and the mixture was heated under reflux for 17 hours. To the mixture was further added isobutylamine (1.72 ml, 17.3 mmoles) and the mixture was heated under reflux for 8 hours. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 139 mg of the desired product (86.9%, pale yellow solid).

NMR (200MHz, CDCl₃) δ : 1.00 (6H, d, J = 6.6Hz), 1.93 (1H, nonet, J = 6.6Hz), 2.98 (3H, s), 3.15-3.43 (6H, m), 5.51 (1H, brt, J = 6Hz), 7.10 (1H, dd, J = 7, 1.2Hz), 7.24 (1H, dd, J = 9, 7Hz), 7.49 (1H, br), 7.55 (1H, m), 8.47 (1H, s)

35 Example 68

40 According to the same manner as that described in Example 31, the following compound was obtained.

5-[3-[N-(methylsulfonyl)-3-(phenyl)propylamino]propylthio]imidazo[1,2-a]pyridine (Compound 197)

NMR (200MHz, CDCl₃) δ : 1.80-2.00 (4H, t), 2.62 (2H, t, J = 7.6Hz), 2.80 (3H, s), 3.02 (2H, t, J = 7Hz), 3.17 (2H, m), 3.28 (2H, m), 6.91 (1H, dd, J = 7, 1Hz), 7.07-7.34 (6H, m), 7.59 (1H, d, J = 9Hz), 7.85 (1H, m)

45 Example 69

Synthesis of 5-[1-(methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (free compound of Compound 29)

50 (1) Synthesis of 1-methylsulfonyl-4-methylsulfonyloxypiperidine

To a solution of 4-hydroxypiperidine (5.10 g, 50 mmoles) and triethylamine (20.9 ml, 150 mmoles) in methylene chloride (150 ml) was added methanesulfonyl chloride (8.54 ml, 110 mmoles) with stirring under ice-cooling and the mixture was stirred at room temperature for 1 hour. The reaction mixture was washed in turn with an aqueous saturated sodium bicarbonate solution and saturated saline and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was solidified with ethyl acetate-n-hexane to obtain 11.45 g of the desired product (88.3%, pale yellow solid).

EP 0 471 236 B1

NMR (200MHz, CDCl₃) δ : 2.07 (4H, s), 2.81 (3H, s), 3.36 (4H, m), 4.93 (1H, m)

(2) Synthesis of 5-[1-(methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (free compound of Compound 29)

5

To a suspension of 5-mercaptoimidazo[1,2-a]pyridine (1.50 g, 10 mmoles) in ethanol (100 ml) was added a solution of 4.1 M sodium methylate (2.44 ml, 10 mmoles) in methanol and the mixture was stirred at room temperature for 10 minutes. To the reaction mixture was added 1-methylsulfonyl-4-methylsulfonyloxypiperidine (2.83 g, 11 mmoles) at room temperature and the mixture was heated under reflux for 14 hours. After the solvent was distilled off, the residue was dissolved in chloroform, which was washed in turn with an aqueous 1N sodium hydroxide solution and water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethyl acetate/ethanol (10:1)] to obtain 1.27 g of the desired product (40.8%, light brown solid).

10
15 NMR (200MHz, CDCl₃) δ : 1.70-2.13 (4H, m), 2.79 (3H, s), 2.90 (2H, m), 3.35 (1H, m), 3.69 (2H, m), 7.05 (1H, dd, J=7, 1.2Hz), 7.17 (1H, dd, J=8.8, 7Hz), 7.67 (1H, d, J=8.8Hz), 7.71 (1H, d, J=1.2Hz), 7.96 (1H, s)

Preparation 1

20

25

(1) Compound 1	100 g
(2) Lactose	50 g
(3) Corn starch	15 g
(4) Carboxymethylcellulose calcium	44 g
(5) Magnesium stearate	1 g
1,000 Tablets	210 g

30 All the components (1), (2) and (3) and 30 g of the component (4) were kneaded with water, dried under vacuum and granulated. The granulated powder was mixed with 14 g of the component (4) and 1 g of the component (5) and the mixture was charged in a tableting machine to obtain 1,000 tablets containing 100 mg of the component (1) per one tablet.

Preparation 2

35

40

(1) Compound 1	10 g
(2) Lactose	4.5 g
(3) Corn starch	4.5 g
(4) Magnesium stearate	1 g
100 Capsules	20 g

45 All the components were thoroughly admixed and filled into a suitable gellatin capsule to obtain 100 capsules containing 100 mg of the component (1) per one capsule.

50

55

EP 0 471 236 B1

Preparation 3

5	(1) Compound 2	10 g
	(2) Sodium chloride	1.8 g
	(3) Distilled water for injection	suitable amount
10	Total amount	200 ml

The component (3) was added to all the components (1) and (2) to dissolve them and the total amount of the solution was adjusted to 200 ml. Then, the solution was sterilized and filled into ampoules of suitable size to obtain 100 ampoules containing 100 mg of the component (1) per one ampoule.

Experiment 1Calmodulin inhibitory activity

(Experimental method)

To a reaction system (0.45 ml) composed of 50 mM Tris-HCl buffer (pH 7.4), 5 mM $MgCl_2$, 10 μM $CaCl_2$ and calmodulin [2 units; manufactured by Sigma Co., p-0270] or 3mM EGTA, cyclic nucleotide phosphodiesterase [0.01 unit; manufactured by Sigma Co., p-0520], and 1 μM cGMP ($[^3H]$ cGMP, containing 3nCi) was added the compound of the present invention obtained in the above Example (1% DMSO solution, 50 μl) and the reaction was carried out at 37°C for 15 minutes. Then, the reaction was terminated by boiling the tubes for 2 minutes. The $[^3H]5'$ -GMP products was converted to $[^3H]$ guanosine by additional incubation at 37°C for 10 minutes with 50 μg of snake venom (*C. atrox*), as 5'-nucleotidase. Following the addition of carrier guanosine, into the reaction tubes Dowex 1 x 8 resin was added, and the tubes were centrifuged for 1 minute. Radioactivity in the 250 μl of supernatant was counted. The determination of the inhibition was according to the following formula.

% Inhibition = $100 - (\text{count in the presence of a medicine} - \text{count in the presence of EGTA}) / (\text{count in the absence of a medicine} - \text{count in the presence of EGTA}) \times 100$

The results are shown in Table 1.

EP 0 471 236 B1

Table 1 (Calmodulin inhibitory activity)

Compound No.	Inhibitory activity ($\text{Z}, 10^{-5}\text{M}$)	Compound No.	Inhibitory activity ($\text{Z}, 10^{-5}\text{M}$)
1	94	48	50
5	50	50	65
9	100	51	83
14	85	56	62
16	66	62	79
26	100	69	57
27	51	64	82
28	72	67	72
30	64	69	57
32	62	74	50
34	53	75	55
37	58	77	80
42	100	78	56
44	65	79	50

EP 0 471 236 B1

Table 1 (continued)

Compound No.	Inhibitory activity (%, 10 ⁻⁵ M)	Compound No.	Inhibitory activity (%, 10 ⁻⁵ M)
83	76	128	50
84	69	130	50
87	51	132	50
89	54	135	60
101	56	136	52
102	52	144	60
103	52	145	63
105	67	158	81
109	50	165	65
115	53	168	56
118	74	169	58
127	57		

As shown in Table 1, the compounds of the present invention have excellent calmodulin inhibitory activity.

Experiment 2

Hypotensive activity in spontaneous hypertensive rat (SHR)

(Experimental method)

SHR male rats of twenty weeks old were used. They were warmed in an incubator at 37°C for 5 minutes and the measurement was conducted according to Plethysmograph method. Medicines (the compounds in the above Examples) were suspended in gum arabic-water and were orally administered in an amount of 2.5 ml/kg. Blood pressure was measured before administration of medicines, at 1 hour and at 5 hours after administration, and the change of the value from that before administration was determined, respectively.

The results are shown in Table 2.

EP 0 471 236 B1

Table 2

5	Hypotensive activity			
	Compound No.	Dose (mg/kg)	Change of blood pressure (mmHg)	
			1 hour	5 hours
	1	100	-11.2	-11.5
	28	100	-13.5	-43.0
10	64	100	-31.0	-27.0
	67	100	-15.0	-22.0
	69	100	-7.0	-32.0

As shown in Table 2, the compounds of the present invention have excellent hypotensive activity.

Experiment 3

Effect on incidence of arrhythmia caused by ischemia and following reperfusion in rat heart

(Experimental method)

Male Sprague Dawley rats (Japan Clea) of 9 to 10 weeks old were anesthetized with 50 mg/kg (i.p.) of sodium pentobarbital. The heart was exposed by a left thoractomy under artificial ventilation with room air and silk suture was placed under the main left coronary artery (LAD) to ligate for 5 minutes. Then, the ligature was released again for reperfusion. The incidence of ventricular tachycardia (VT), ventricular fibrillation (VF) and cardiac arrest (CA) caused until 10 minutes after reperfusion were noted. Medicines (compounds obtained in the above Examples) were orally administered (5 ml/kg) at 1 hour before tightening the ligature. The effect of medicines were estimated in comparison with the frequency of a group received a vehicle according to X²-test.

The results are shown in Table 3 below.

Table 3

35	Effect on incidence of arrhythmia caused by ischemia and following reperfusion in rat heart				
	Compound No.	Dose (mg/kg)	VT	VF	CA
			(Frequency)		
	1	10	2/4	2/4	1/4
40	1	30	1/4	1/4	0/4
	14	10	1/3	0/3	0/3
	26	10	2/3	1/3	1/3
	32	30	1/3	1/3	1/3
	64	30	1/3	1/3	1/3
45	118	30	1/3	1/3	0/3
	127	30	1/3	1/3	0/3
	vehicle	-	7/7	7/7	2/7

As shown in Table 3, the compounds of the present invention decrease the frequency of arrhythmia induced by 5 minutes of occlusion followed by reperfusion.

EP 0 471 236 B1

Experiment 4

Effect on acute renal failure caused by ischemia and following reperfusion in rat kidneys.

5 (Experimental method)

SD rats (male) of 6 to 7 weeks old were anesthetized with pentobarbital sodium (50 mg/kg, i.p.) and bilateral renal arteries were ligated. After 45 minutes, a clip was removed to reperfuse. After 20 hours, blood was collected from abdominal aorta under anesthesia with pentobarbital sodium and blood urea nitrogen (BUN) was measured. Medicines (compounds obtained in the above Examples) were administered (5 ml/kg) 1 hour before occlusion of renal artery.

The results are shown in Table 4.

Table 4

15

20

Effect on acute renal failure caused by ischemic renal/reperfusion in rat		
Compound No.	Dose (mg/kg)	Blood urea nitrogen (mg/dl)
1	10	83.3 \pm 20.4
1	30	71.1 \pm 11.4
1	50	65.6 \pm 5.1
vehicle	-	118.2 \pm 5.0

25 As shown in Table 4, the compounds of the present invention depress the increase in BUN in ischemic renal/reperfusion of rats.

Another aspect of the present invention to provide novel angiogenesis inhibitors.

It is well known that angiogenesis occurs in normal physiologic conditions of human or mammal such as embryogenesis and ovulation or placentation caused by female sexual cycle, wound healing, restoration process of inflammation, and in various morbidity wherein blood capillaries rapidly form and increase to cause serious damage to tissue and the like shown as follows. As the diseases caused by such a pathologic increase of blood capillaries, for example, there have been known diabetic retinopathy, retrolental fibroplasia, angiogenesis accompanying keratoplasty, glaucoma, ophthalmic tumor and trachoma and the like in the ophthalmologic field; psoriasis, suppurative granuloma and the like in the dermatologic field; angioma, fibrous angioma and the like in the pediatric field; hypergenetic cicatrix, granulation and the like in the surgical field; arthritis rheumatica, edematous sclerosis and the like in the medical field; atherosclerosis and the like in cardiac diseases; various tumors and the like.

Particularly, a lot of people become blindness by abnormal increase of angiogenesis in diabetic retinopathy and trachoma. Further, a lot of people suffer from breakage of cartilage by abnormal angiogenesis in a joint due to arthritis rheumatica. Accordingly, it is requested to develop a compound useful as a medicine for treatment or prevention of diseases accompanying such an abnormal increase of angiogenesis. Furthermore, it is considered that rapid growth and extension of a tumor is caused by vascularization induced by an angiogenesis factor which is produced by tumor cells. Therefore, it is expected that an angiogenesis inhibitor becomes a new medicine for treatment of various tumors and studies on angiogenesis inhibitors have been started [J. Folkman, Advance in Cancer Research, 43, 175 (1985), edited by George Klein and Sidney Weinhouse].

It has already been known that angiogenesis is inhibited by using heparin or heparin fragment in combination with a so-called "angiostatic steroid" (angiogenesis inhibiting steroid) such as cortison and the like [J. Folkman et al., Science, 221, 719 (1983); J. Folkman et al., Annals of Surgery, 206, 374 (1981)].

Further, it has been recognized that angiogenesis inhibitory activity is synergistically exhibited by using sulfated α , β , and γ -cyclodextrin, particularly, β -cyclodextrin tetradeasulfate or heparin in combination with an angiostatic steroid as described above, fumagillin, a collagen synthesis inhibitor or the like [D. Ingber and J. Folkman, Laboratory Investigation, 59, 44 (1988)].

On the other hand, U.S. Patent No. 4,599,331 discloses that angiogenesis inhibitory activity is observed by using a steroid (etianic acid derivative) alone. However, this steroid has also strong adrenocorticosteroid hormone activity and, therefore, there is a large difficulty to use it as a medicine.

There has been a lot of reports concerning imidazo[1,2-a]pyridine derivatives. However, there are few reports of a pharmacological activity concerning a compound wherein an alkylthio group having a functional


EP 0 471 236 B1

group is bound at 5-position thereof. Particularly, regarding such a compound having a carbamate ester as the functional group, only 5-(2-tert-butoxycarbonylaminoethylthio)imidazo[1,2-a]pyridine and 5-[2-(N-chloroacetylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine are reported as a starting material of synthesis of cephem compounds having excellent antibacterial activity in European Patent Application P87108189.9.

5 However, there is no description about a pharmacological activity thereof.


Under these circumstances, the present inventors have synthesized various imidazo[1,2-a]pyridine derivatives having a substituent at 5-position and intensively studied their pharmacological activities. As a result, it has been found that some of them have excellent angiogenesis inhibitory activities.

Thus, the present invention also provides a novel angiogenesis inhibitory composition comprising a
10 compound of the formula (1):



wherein A' is

(a) a group of the formula:




wherein x, y and z are integers of 0 to 5, respectively; R^e, R^f, R^g, R^h, Rⁱ and R^j are (1) hydrogen, or (2) optionally substituted C₁₋₆ alkyl, C₂₋₆ alkenyl, or (3) phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl, C₆₋₁₄ aryl, or an aromatic monocyclic or bicyclic heterocyclic group containing 1 to 4 heteroatoms selected from sulfur, oxygen and nitrogen, which may have 1 to 4 substituents;

or R^e and R^f or R^g and R^h or Rⁱ and R^j may bind together to form a C₃₋₈ cycloalkane ring, or R^e or R^g may bind together with R^f or R^j to form a C₃₋₈ cycloalkane ring,

(b) a group of the formula -CH₂CH₂OCH₂CH₂- or

(c) a group of the formula:




wherein a and b are integers of 0 to 5, respectively and the like.

R^a and R^b are the same or different and are a hydrogen,

a C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or C₆₋₁₄ aryl group, which may have 1 to 4 substituents; a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxycarbonyl group or a C₁₋₆-alkylcarbamoyl group; R^c is a hydrogen or R^c and R^d is C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or C₆₋₁₄ aryl, which may have 1 to 5 substituents;

R^c and R^e or R^f, or R^c and R^g or R^h, or R^c and Rⁱ or R^j may bind together to form

EP 0 471 236 B1



wherein Q and R are interger of 2 or 3, respectively.

Examples of the C₁₋₆ alkyl group represented by R^a, Rⁱ, R^o, R^h, Rⁱ and R^l include a straight or
 15 branched alkyl group having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like. Examples of the C₂₋₆ alkenyl group represented by R^a, Rⁱ, R^o, R^h, Rⁱ and R^l include an alkenyl group having 2 to 6 carbon atoms such as vinyl, allyl, 2-butenyl, 3-butenyl and the like. The C₁₋₆ alkyl and C₂₋₆ alkenyl group may have 1 to 5 substituents and examples thereof include halogen, nitro, amino, lower alkylamino, cyclic amino, lower alkoxy, aryloxy, carbamoyl,
 20 cyano, hydroxy, carboxy, lower alkoxycarbonyl, lower alkylcarbamoyl and the like. Examples of halogen include fluoro, bromo, chloro and iodo.

Examples of the lower alkylamino group as the above substituent include a N-monoalkylamino group of which alkyl moiety has 1 to 6 carbon atoms such as methylamino, ethylamino, propylamino, butylamino and the like, and a N,N-dialkylamino group of which alkyl moiety has 1 to 6 carbon atoms such as
 25 dimethylamino, diethylamino, dibutylamino, methylethylamino and the like.

Examples of the cyclic amino group as the above substituent include a 4 to 7 membered cyclic amino group such as N-pyrrolidino, piperazino, piperadiny, morpholino, homopiperazino and the like.

Examples of the lower alkoxy group as the above substituent include a straight or branched alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy and the like.
 30 Examples of the aryloxy group as the above substituent include a C₆₋₁₀ aryloxy group such as phenoxy, 1-naphthoxy, 2-naphthoxy and the like. Examples of the lower alkoxycarbonyl group as the above substituent include an alkoxycarbonyl group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl propoxycarbonyl, butoxycarbonyl and the like. Examples of the lower alkylcarbamoyl group as the above substituent include a N-monoalkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon
 35 atoms such as methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl and the like and a N,N-dialkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon atoms such as dimethylcarbamoyl, diethylcarbamoyl, dibutylcarbamoyl, methylethylcarbamoyl and the like.

As the phenyl-C₁₋₆ alkyl and naphthyl-C₁₋₆ alkyl group represented by R^a, Rⁱ, R^o, R^h, Rⁱ and R^l, for example, there is benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl and the like; and (1-naphthyl)methyl, 2-(1-naphthyl)ethyl, 2-(2-naphthyl)ethyl and the like. The phenyl moiety of the phenyl-C₁₋₆ alkyl group and the naphthyl part of the naphthyl-C₁₋₆ alkyl group may be substituted with 1 to 4 substituents such as halogen, lower alkyl, lower alkoxy, nitro, cyano, hydroxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl and the like. Examples of halogen include fluoro, bromo, chloro and iodo. Examples of the lower alkyl group and the lower alkenyl group include those similar to the lower alkyl group or a lower alkenyl
 45 group represented by R^a, Rⁱ, R^o, R^h, Rⁱ and R^l. As the lower alkoxy group, for example, there is a straight or branched alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy and the like. As the lower alkoxycarbonyl group, for example, there are an alkoxycarbonyl group of which alkoxy moiety has 1 to 6 carbon atoms such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and the like. As the lower alkylcarbamoyl group, for example, there are a N-alkylcarbamoyl
 50 group of which alkyl moiety has 1 to 6 carbon atoms such as methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl and the like, and a N,N-dialkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon atoms such as dimethylcarbamoyl, diethylcarbamoyl, dibutylcarbamoyl, methylethylcarbamoyl and the like.

As the C₆₋₁₄ aryl group represented by R^a, Rⁱ, R^o, R^h, Rⁱ and R^l, for example, there are an aromatic monocyclic, bicyclic or tricyclic hydrocarbon group such as phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl and the like, and examples of the aromatic monocyclic group or bicyclic heterocyclic group containing 1 to 4 hetero atoms selected from sulfur, oxygen, nitrogen there are groups such as thienyl, furyl, benzothienyl, benzofranyl and the like. The C₆₋₁₄ aryl group and the aromatic monocyclic or bicyclic

EP 0 471 236 B1

heterocyclic group may be substituted with 1 to 4, preferably 1 or 2 substituents such as halogen, lower alkyl, lower alkoxy, nitro, cyano, oxo, hydroxy, amino, lower alkoxy carbonyl, carbamoyl, lower alkylcarbamoyl and the like. Examples of halogen in the above substituents include fluoro, bromo, chloro and iodo. As the lower alkyl group, for example, there is the alkyl group having 1 to 6 carbon atoms as described above and, as the lower alkenyl group, for example, there is a lower alkenyl group having 2 to 6 carbon atoms as described above. As the alkoxy group, for example, there is an alkoxy group having 1 to 6 carbon atoms and, as the lower alkoxy carbonyl group, for example, there is an alkoxy carbonyl group of which alkoxy moiety has 1 to 6 carbon atoms. As the lower alkylcarbamoyl group, for example, there is a N-monoalkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon atoms and a N,N-dialkylcarbamoyl group of which alkyl moiety has 1 to 6 carbon atoms. Examples of these groups include groups similar to the lower alkoxy group, the lower alkoxy carbonyl group and the lower alkylcarbamoyl group as the substituents of the phenyl moiety in the above aralkyl group. As the aryl group having oxo group, for example, there is benzoquinolyl, naphthoquinolyl, anthraquinolyl and the like.

As the C₃₋₈ cycloalkane ring formed by binding R^a and R^f, R^a and R^h, or Rⁱ and R^l, for example, there is cyclopropane, cyclobutane, cyclohexane and the like. As the C₃₋₈ cycloalkane ring formed by binding R^a or R^g with R^h or Rⁱ, for example, there is cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and the like.

The C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl, or C₂₋₁₄ aryl groups in R^a and R^b are optionally substituted with the substituents in the above group represented by A'. Further, examples of halogen include fluoro, chloro, bromo and iodo. As the optionally protected amino group, for example, there are an amino group, an acylamino group and the like. As the acyl group of the above acylamino group, there is a group represented by -COR^d or -CO₂R^d, for example, a lower alkylcarbonyl group (e.g. C₁₋₆ alkylcarbonyl group such as acetyl, etc.), aralkylcarbonyl group (e.g. C₇₋₁₀ aralkylcarbonyl group such as benzylcarbonyl, etc.), arylcarbonyl group (i.e. C₆₋₁₀ arylcarbonyl group such as benzoyl, etc.), a lower alkoxy carbonyl group (e.g. C₁₋₄ alkoxy carbonyl group such as methoxycarbonyl, etc.), aralkyloxy carbonyl group (e.g. C₇₋₁₀ aralkyloxy carbonyl group such as benzyloxy carbonyl, etc.), aryloxy carbonyl group (e.g. C₆₋₁₀ aryloxy carbonyl group such as phenoxycarbonyl, etc.) and the like.


As the C₁₋₆ alkoxy carbonyl group and the C₁₋₆ alkylcarbamoyl group in R^a and R^b, for example, there is a group similar to a lower alkoxy carbonyl group and a lower alkylcarbamoyl group as the substituent of the phenyl moiety in the aralkyl group represented by R^a, R^f, R^g, R^h, Rⁱ and R^l.

As the optionally substituted C₁₋₆ alkyl group, the C₂₋₆ alkenyl group, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl and C₆₋₁₄ aryl group of R^c and R^d, for example, there is a group similar to those described with respect to the group represented by A'. As the C₃₋₈ cycloalkyl group, for example, there is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. As the substituent of the C₃₋₈ cycloalkyl group, for example, there are those similar to the substituent of the optionally substituted C₁₋₆ alkyl group as described in A' and the number thereof is 1 to 5.

The compound of the formula (1) can form, for example, an acid addition salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or the like and an organic acid such as acetic acid, oxalic acid, methanesulfonic acid, maleic acid, fumaric acid, citric acid, tartaric acid, lactic acid or the like.

The compound (1) or a salt thereof may be a solvate and examples of a solvent of the solvate include alcohols such as methanol, ethanol, propanol, isopropanol and the like; ketones such as acetone and the like; ethers such as tetrahydrofuran, dioxane and the like.

As the preferred embodiment of the compound of the above formula (1) or a salt thereof, for example, there is a compound represented by the formula:



wherein R^a is a hydrogen or a lower alkyl group; R^b is a hydrogen or an optionally substituted lower alkyl group; and R^d is an optionally substituted lower alkyl group, a cycloalkyl group or a lower alkenyl group, or

EP 0 471 236 B1


a salt thereof.

In the formula (1'), examples of the lower alkyl group represented by R^a , the optionally substituted lower alkyl group represented by R^b , and lower alkyl group and lower alkenyl group represented R^d include those described with respect to the groups represented by R^a , R^1 , R^2 , R^h , R^i and R^j . Examples of the optionally substituted lower alkyl group represented by R^d include those described in the above R^d . R^d is preferably C_{1-6} alkyl or C_{1-6} alkenyl.

The compound (1) may contain an assymetric carbon in the molecule. When stereoisomers of R-and S-configurations are present, not only these isomers, but also a mixture thereof are included in the scope of the present invention.


Imidazo[1,2-a]pyridine derivatives (1) of the present invention or a salt thereof can be synthesized, for example, according to the following method.

(A) A compound of the formula:



(2)

wherein X' is a halogen such as chloro, bromo, iodo or the like and R^a and R^b are as defined above is reacted with a compound of the formula:



(3)


wherein A' , R^c and R^d are as defined above, or a salt thereof.

(B) A compound of the formula:



(4)

wherein R^a and R^b are as defined above or a salt thereof is reacted with a compound of the formula:




(5)


wherein A' , R^c and R^d are as defined above, X^1 is a leaving group such as halogen (e.g. chloro, bromo, iodo, etc.), an arylsulfonyloxy group such as toluenesulfonyloxy group or an alkylsulfonyloxy group such as methanesulfonyloxy group, or a salt thereof.

EP 0 471 236 B1

(C) A compound of the formula:




wherein A', R^a, R^b and R^c are as defined above, or a salt thereof is reacted with a compound of the formula:



wherein R^d and X' are as defined above.

(D) A compound of the formula:




30

wherein A', R^a, R^b and R^d are as defined above, or a salt thereof is reacted with a compound of the formula:



wherein X' is as defined above and R^c is an optionally substituted hydrocarbon group.

(E) A compound of the formula:



wherein A', R^a and R^b are as defined above is reacted with a compound of the formula:




wherein R^d is as defined above.

55

EP 0 471 236 B1

(F) A compound of the formula:




wherein X^2 is a leaving group such as halogen (e.g. chloro, etc.), phenoxy group, imidazolyl and the like and A' , R^a , R^b and R^c are as defined above, or a salt thereof is reacted with a compound of the formula:




wherein R^d is as defined above.

(G) A compound of the formula;



30


wherein A' , R^a , R^c and R^d are as defined above, or a salt thereof is reacted with a halogenating agent to obtain a compound of the formula:



wherein A' , R^a , R^c and R^d are as defined above and X' is halogen, or a salt thereof.

45


(H) A compound of the formula (1a) or a salt thereof is nitrosated to obtain a compound of the formula:



wherein A' , R^a , R^c and R^d are as defined above, or a salt.


EP 0 471 236 B1

(I) A compound of the formula (1a) is nitrosated to obtain a compound of the formula:




wherein A', R^a, R^c and R^d are as defined above, or a salt thereof.

(J) A compound of the formula (1c) or (1d), or a salt thereof is reduced to obtain a compound of the formula:




wherein A', R^a, R^c and R^d are as defined above, or a salt thereof, or the compound (1e) or a salt thereof is further reacted with a compound (7) or a compound X'COR^d (wherein X' and R^d are as defined above) to obtain a compound of the formula:



wherein R^k is -CO₂R^d or -COR^d and A, R^a, R^c and R^d are as defined above, or a salt thereof.

(K) According to the following scheme, the compound (1g) or a salt thereof is obtained.



wherein R^{2a} is a lower dialkylamino group or a cyclic amino group and A', R^a, R^c and R^d are as defined above.

EP 0 471 236 B1

The reaction of the compound (2) or a salt thereof with the compound (3) in the process A can be conducted at -10°C to $+200^{\circ}\text{C}$ in a solvent in the presence of a basic compound such as sodium hydroxide, potassium hydroxide, sodium hydride, potassium carbonate and the like by using 1 equivalent to excess amount (but not interfering with the reaction) of the compound (3) per 1 equivalent of the compound (2) or a salt thereof. Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol and the like; ketones such as acetone, methyl ethyl ketone and the like; ethers such as tetrahydrofuran and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. The reaction time is normally 1 hour to 2 days, preferably 1 to 8 hours.

The reaction of the compound (4) or a salt thereof with the compound (5) in the process B is conducted under conditions similar to those of the reaction of the compound (2) with the compound (3) in the process A.

The reaction of the compound (6) or a salt thereof with the compound (7) in the process C is conducted in a solvent at -30°C to $+200^{\circ}\text{C}$ in the presence of an inorganic base such as potassium carbonate, sodium bicarbonate or the like or an organic base such as triethylamine, pyridine, dimethylaniline, 1,4-azabicyclo[2.2.2]octane (DABCO) or the like by using 1 equivalent to extremely excess amount of the compound (7) based on the compound (6) or a salt thereof. Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol and the like; ketones such as acetone, methyl ethyl ketone and the like; ethers such as tetrahydrofuran and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. The reaction time is normally 10 minutes to 24 hours, preferably 30 minutes to 6 hours.

The reaction of the compound (8) or a salt thereof with the compound (9) in the process D can be conducted in a solvent at -30 to $+20^{\circ}\text{C}$ in the presence of a base such as potassium hydride, sodium hydride, sodium amide and the like by using 1 equivalent to extremely excess amount of the compound (9) based on the compound (8) or a salt thereof. Examples of the solvent to be used include ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. The reaction time is normally 30 minutes to 24 hours, preferably 30 minutes to 6 hours.

The reaction of the compound (10) with the compound (11) in the process E can be conducted at -10 to $+150^{\circ}\text{C}$ in the absence or presence of a solvent by using 1 equivalent to extremely excess amount of the compound (11) based on the compound (10). Examples of the solvent to be used include ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and the like; halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. In order to promote the reaction, a tertiary amine such as triethylamine, pyridine, dimethylaminopyridine, N-methylpiperidine or the like, or boron trifluoride ether ($\text{BF}_3 \cdot \text{Et}_2\text{O}$) can be added. The reaction time is normally 30 minutes to 24 hours, preferably 30 minutes to 6 hours.

The reaction of the compound (12) or a salt thereof with the compound (11) in the process F can be conducted at -30°C to $+200^{\circ}\text{C}$ in the absence or presence of a solvent by using 1 equivalent to extremely excess amount of the compound (11) based on the compound (12) or a salt thereof. Examples of the solvent to be used include ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane and the like; halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. In order to promote the reaction, a tertiary amines such as triethylamine, pyridine, dimethylaminopyridine, N-methylpiperidine or the like may be added. The reaction time is normally 30 minutes to 24 hours, preferably 30 minutes to 6 hours.

The reaction of the compound (1a) or a salt thereof with the halogenating agent in the process G can be conducted at -20 to $+150^{\circ}\text{C}$ in the absence or presence of a solvent by using 1 equivalent to extremely excess amount of the halogenating agent based on the compound (1a) or a salt thereof. Examples of the solvent to be used include halogenated hydrocarbons such as methylene chloride, chloroform, dichloroethane, carbon tetrachloride and the like, acetic acid, propionic acid and the like. Examples of the hydrogenating agent include halogen molecules such as chlorine, bromine and the like; and N-halogenated succinimides such as N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide and the like. Further, upon reaction, a radical reaction initiator such as benzoyl peroxide or the like may be added. The reaction time is normally 30 minutes to 12 hours, preferably 1 to 12 hours.

The nitration of the compound (1a) or a salt thereof in the process H can be conducted at -20 to $+100^{\circ}\text{C}$ in the absence or presence of a solvent by using 1 equivalent to extremely excess amount of a nitrating agent based on the compound (1a) or a salt thereof. Examples of the solvent to be used include acetic acid, acetic anhydride, sulfuric acid and the like. As the nitrating agent, for example, there is fuming nitric acid, conc. nitric acid, mixed acid (nitric acid with sulfuric acid, phosphoric acid or acetic anhydride) and the like. The reaction time is normally 30 minutes to 1 day, preferably 30 minutes to 6 hours.

EP 0 471 236 B1

The nitrosation of the compound (1a) or a salt thereof in the process I can be conducted at -20 to +100°C in the absence or presence of a solvent by using 1 equivalent to extremely excess amount of a nitrosating agent based on the compound (1a) or a salt thereof. Examples of the solvent to be used include water; lower fatty acids such as acetic acid, propionic acid and the like; ethers such as tetrahydrofuran, dioxane and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. As the nitrosating agent, for example, there are potassium nitrite, sodium nitrite and the like. The above reaction is conducted in the presence of an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid or the like. The reaction time is normally 30 minutes to 1 day, preferably 30 minutes to 6 hours.


The reduction of the compound (1c) or (1d) or a salt thereof in the process J can be conducted at -20 to +200°C in the presence of a solvent by using 1 equivalent to extremely excess amount of a reducing agent based on the compound (1c) or (1d). Examples of the solvent to be used include water, methanol, ethanol, propanol, acetic acid and the like. As the reducing agent, for example, there is a mixture of iron and hydrochloric acid, zinc and acetic acid and the like. Further, the reaction can also be conducted at -20 to +200°C in the presence of a solvent under atmospheric pressure of hydrogen by using a hydrogenation catalyst such as palladium black, palladium on carbon, raney-nickel or the like. The reaction time is normally 30 minutes to 2 days, preferably 1 to 12 hours.

Further, the reaction of the compound (1e) or a salt thereof with the compound (7), or the reaction of the compound (1e) or a salt thereof with X'COR⁴ is conducted under conditions similar to those of the reaction of the compound (6) or a salt thereof with the compound (7) in the process C.

The Mannich reaction of the compound (1a) or a salt thereof with a lower dialkylamine and formalin, or cyclic amine and formal in the process K can be conducted at -20 to +10°C in the presence of a solvent by using 1 equivalent to extremely excess amount of a Mannich reagent based on the compound (1a) or a salt thereof. Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol, isopropanol and the like; lower fatty acids such as acetic acid, propionic acid and the like. The reaction time is normally 30 minutes to 1 day, preferably 1 to 12 hours.

In the above processes A to K, the compound which forms a salt may be used in the form of a salt and examples of such a salt include those described in the salt of the compound (1).

In the starting material used in the processes A to K, for example, the compound (2) can be obtained by the following process.




The reaction of the compound (13) with the compound (14) can be conducted at 0 to +200°C in the absence or presence of a solvent by using 1 equivalent to extremely excess amount of the compound (14) based on the compound (13). Examples of the solvent to be used include water; lower alcohols such as methanol, ethanol, propanol and the like; ethers such as tetrahydrofuran, dimethoxyethane, dioxane and the like; nitriles such as acetonitrile, propionitrile and the like; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide and the like. Further, on the above reaction, an inorganic base such as potassium carbonate, sodium bicarbonate or the like, or an organic base such as triethylamine, pyridine, dimethylaniline or the like may be added as an acid-trapping agent. The reaction time is normally 10 minutes to 7 days, preferably 1 hour to 2 days.

EP 0 471 236 B1


The compound (4) can be obtained, for example, by the following processes.

(i)




wherein Y is sodium or potassium and R^a and R^b are as defined above.


(ii)



(iii)



removal of
protecting group



wherein T is a protecting group such as p-methoxybenzyl, benzyl or the like and R^a and R^b are as defined above.

45 The reaction of the compound (2) with YSH is conducted under conditions similar to those of the reaction of the compound (2) with the compound (3).

The reaction of the compound (15) with the compound (14) is conducted under conditions similar to those of the above reaction of the compound (13) with the compound (14).

The reaction of the compound (16) with the the compound (14) is conducted under conditions similar to those of the reaction of the compound (13) with the compound (14).


50

55

EP 0 471 236 B1


The compound (6) can be obtained, for example, by the following processes.

(i)




wherein A', R^a, R^b, R^c and R^d are as defined above.

(ii)




removal of
protecting group




wherein T¹ is an amino protecting group such as benzyloxycarbonyl, tert-butoxycarbonyl, trifluoroacetyl, trityl, benzyl or the like; and A', R^a, R^b and R^c are as defined above.

(iii)



removal of
protecting group





55

EP 0 471 236 B1


wherein A', T' and R^c are as defined above, but further including that -NT'R^c is phthalimide.

(iv)




wherein A', R^a, R^b, R^c, R^d and X¹ are as defined above.

(v)



wherein X¹ and R^c are as defined above.

(vi)



wherein A', R^c and T' are as defined above, but further including that -NT'R^c is phthalimide.

The reaction of the compound (2) with the compound (18), the reaction of the compound (2) with the compound (19), the reaction of the compound (4) with the compound (21), the reaction of the compound (2) with the compound (22) and the reaction of the compound (4) with the compound (25) are conducted under conditions similar to those of the reaction of the compound (2) with the compound (3) in the above process A.

When X¹ is halogen, the conversion of the hydroxyl group of the compound (22) into X¹ is conducted by treating the compound (23) with phosphorous halide such as phosphorous trichloride, phosphorous

EP 0 471 236 B1

oxychloride, phosphorous pentachloride, phosphorous tribromide and the like; a halogenating agent such as red phosphorous and halogen, thionyl chloride and the like. When X' is toluenesulfonyloxy group or methanesulfonyloxy group, it can be obtained by treating the compound (23) with toluenesulfonyl chloride or methanesulfonyl chloride. The subsequent reaction with the compound (24) is conducted at 0 to 200°C in the absence or presence of a suitable solvent. All of these reactions are known and they can be conducted according to known conditions.

The reaction of the compound (26) with the compound (14) is conducted under conditions similar to those of the above reaction of the compound (13) with the compound (14).


The compound (10) is obtained, for example, by the following processes.

(i) The compound (27) is reacted with phosgene and the reaction mixture is heated to conduct dehydrochlorination.

(ii) The compound (28) is reacted with silver cyanate.


All of these reactions are also known and they can be conducted according to known conditions.

(i)



wherein A', R^a and R^b are as defined above.

(ii)



wherein A', R^a and R^b are as defined above.

The compound (12) can be obtained, for example, by the following processes.

(i) When X² is Cl, the compound (6) is reacted with phosgene.

(ii) When X² is phenoxy, the compound (6) is reacted with phenyl chlorocarbonate.

(iii) When X² is imidazolyl, the compound (6) is reacted with carbonyldiimidazole.

All of these reactions are known and they can be conducted according to known conditions.

All of the reactions for removing the above protecting group are known and they can be conducted according to known conditions. For example, p-methoxybenzyl group as a protecting group of a mercapto group can be removed by treating with mercuric acetate in trifluoroacetic acid and treating with hydrogen sulfide or 2-mercaptoethanol. Benzyl group can be removed by sodium metal in liquid ammonia.

For example, benzyloxycarbonyl group and benzyl group as protecting groups of amino group can be removed by conducting catalytic reduction (reaction temperature: 0 to 100°C) in a solvent (e.g., alcohols, acetic acid, water, tetrahydrofuran, a mixed solvent thereof, etc.) in the presence of a catalyst (e.g., palladium on carbon, platinum oxide, etc.).

In the case of trityl group and tert-butoxycarbonyl group, they can be removed at 0 to 150°C in a solvent (e.g., water, alcohols, tetrahydrofuran, dioxane, etc.) in the presence of an acid (e.g., mineral acids such as hydrochloric acid, phosphoric acid, sulfuric acid, etc.; organic acids such as toluenesulfonic acid, methanesulfonic acid, acetic acid, etc.). Trifluoroacetyl group can be readily removed by treating with an

EP 0 471 236 B1

alkali (e.g., sodium hydroxide, sodium bicarbonate solution, etc.)

Phthalimide group can be removed by treating with hydrazine hydrate in a solvent (e.g. methanol, ethanol, etc.).

The compounds (2), (4), (6), (10) and (12) can be isolated by the following conventional separation methods, but they may also be used in the form of a reaction mixture as a starting material for producing the desired compound (1) or a salt thereof. Further, among the above compounds, the compounds (3), (5), (7), (13), (14), (18), (19), (21), (22), (24) and (25) can be produced, for example, according to the processes described in Shinzikken Kagaku Koza, Vol.14, "Synthesis and Reaction of Organic compounds I-V", Japan Chemical Society, published by Maruzen K.K., Tokyo; Shinzikken Kagaku Koza, Vol.15, "Oxidation and Reduction I-V", Japan Chemical Society, published by Maruzen K.K., Tokyo; "Organic Syntheses", John Wiley and Sons, Inc., New York; "Theilheimer's Synthetic Methods of Organic Chemistry", Basel, New York, Karger and the like or modification thereof.

The isolation and purification of the compound (1) or a salt thereof from a reaction mixture is conducted according to conventional separation means (e.g. extraction, concentration, filtration, recrystallization, column chromatography, thin layer chromatography, etc.).

The compounds (1) or a salt thereof of the present invention have angiogenesis inhibitory activity and are useful as angiogenesis inhibitors, for example, antineoplastic agents, antiinflammatory agents, anti-rheumatoid arthritis agents, anti-diabetic retinopathy agents and the like.

The compound (1) or a salt thereof has low toxicity, and therefore, it can be orally or parenterally administered to mammal (e.g., human, rabbit, dog, cat, rat, mouse, guinea pig, etc.) as it is as a powder or a pharmaceutical composition in a suitable dosage form. The dosage varies depending upon a particular administration route, conditions to be treated, age, weight of the patient or the like. When the compound (1) or a salt thereof is used as an antineoplastic agent, such an agent can be obtained by admixing the compound (1) or a salt thereof with a pharmaceutically acceptable carrier. The compound (1) or a salt thereof can also be used by formulating it into a suitable dosage form such as instillations, injections, capsules, tablets, suppositories, solutions, emulsions, suspensions and other suitable dosage forms.

When a dosage form for parenterally administration, for example, injection is produced, isotonicities (e.g., glucose, D-sorbitol, D-mannitol, sodium chloride, etc.), preservatives (e.g., benzyl alcohol, chlorobutanol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, etc.), anticoagulants (e.g., dextran sulfuric acid, heparin, etc.) and buffer agents (e.g., phosphoric acid buffer, sodium acetate buffer, etc.) may be used. Further, a dosage form for oral administration can be used as capsules wherein the compound (1) or a salt thereof is admixed with lactose and the like, or used as sugar-coated tablets produced by a conventional method.

For example, in the case of administering the compound (1) or a salt thereof parenterally by injection to the diseased part (s.c., i.v. or i.m.), the dosage may be about 0.05 to 50 mg/kg/day, preferably about 0.2 to 20 mg/kg/day, more preferably about 0.5 to 10 mg/kg/day. In the case of oral administration, the dosage may be about 0.1 to 500 mg/kg/day, preferably about 1 to 100 mg/kg/day, more preferably 5 to 50 mg/kg/day. Further, the compound (1) or a salt thereof can be used for topical application. For example, by washing a diseased part of the body such as head, breast, abdomen, limb and the like with a solution wherein the compound (1) or a salt thereof is dissolved in an isotonic solution in a concentration of about 0.01 to 2 w/v %, or by applying an ointment containing the compound (1) or a salt thereof in an amount of about 0.1 to 50 mg/g to the above diseased part, the compound (1) or a salt thereof can be used for preventing and treating tumor of these parts.

As described hereinabove, an angiogenesis inhibitory composition comprising the compound (1) and a salt thereof of the present invention have excellent activity and, in view of this activity, they are useful as medicines for prevention and treatment of tumor, rheumatoid arthritis and the like of human and mammal.

The following Reference Examples, Examples, Preparations and Experiments further illustrate this aspect of the present invention in detail but are not to be construed to limit the scope thereof. In the Reference Examples, Examples and Preparations, "room temperature" is 15 to 25 °C.

Reference Example 1'

(1) Synthesis of 5-[2-(methylsulfonyloxy)ethylthio]imidazo[1,2-a] pyridine

To a solution of 5-(2-hydroxy)ethylthioimidazo[1,2-a]pyridine (9.71 g, 50 mmoles) and triethylamine (10.5 ml, 75.3 mmoles) in methylene chloride (300 ml) was added methanesulfonyl chloride (4.26 ml, 55 mmoles) under ice-cooling with stirring and the mixture was stirred under ice-cooling for 2 hours. The reaction mixture was washed in turn with aqueous saturated sodium bicarbonate and saturated saline and

EP 0 471 236 B1

dried over anhydrous magnesium sulfate. Then, the solvent was distilled off to obtain 13.6 g of the desired product (quantitative, brown oily product).

NMR (200MHz, CDCl₃) δ : 2.97 (3H, s), 3.28 (2H, t, J=6.4Hz), 4.35 (2H, t, J=6.4Hz), 7.08 (1H, dd, J=7, 1.2Hz), 7.18 (1H, dd, J=8.8, 7Hz), 7.64 (1H, m), 7.73 (1H, d, J=1.4Hz), 7.91 (1H, m)

5

Reference Example 2'

(1) Synthesis of 5-[2-(methylamino)ethylthio]imidazo[1,2-a]pyridine

10 A solution of 5-[2-(methylsulfonyloxy)ethylthio]imidazo[1,2-a]pyridine (2.18 g, 8 mmoles), triethylamine (2.24 ml, 16 mmoles) and a 40% methylamine-methanol solution (20 ml) in chloroform (20 ml) was heated at reflux for 3 hours. The reaction mixture was washed with 3N NaOH and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: methanol/chloroform (1:10)] to obtain 781 mg of the desired product (47.1%, light brown oily product).

15 NMR (200MHz, CDCl₃) δ : 2.31 (1H, br), 2.88 (2H, t, J=6.4Hz), 3.16 (2H, t, J=6.4Hz), 6.94 (1H, dd, J=7, 1Hz), 7.15 (1H, dd, J=9, 7Hz), 7.58 (1H, dd, J=9, 1Hz), 7.69 (1H, d, J=1.2Hz)

IR (KBr) cm⁻¹: 3290, 3105, 2930, 2850, 2790, 1655, 1615, 1530, 1490

According to the same manner as that described in Reference Example 2' (1), the following compound was obtained.

20

(2) 5-[2-(Ethylamino)ethylthio]imidazo[1,2-a]pyridine

NMR (200MHz, CDCl₃) δ : 1.11 (3H, t, J=7Hz), 1.88 (1H, br), 2.70 (2H, m), 2.90 (2H, t, J=6.2Hz), 3.15 (2H, t, J=6.2Hz), 6.94 (1H, dd, J=7, 1Hz), 7.16 (1H, dd, J=9, 7Hz), 7.59 (1H, dd, J=9, 1Hz), 7.70 (1H, d, J=1.2Hz), 7.87 (1H, s)

25

IR (KBr) cm⁻¹: 3280, 3105, 2965, 2930, 2890, 2820, 1655, 1620, 1530, 1490

Reference Example 3'

30 (1) Synthesis of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine

After a suspension of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine dihydrochloride (13.31 g, 50 mmoles) in chloroform (200 ml) was washed with 3N sodium hydroxide (50 ml), the aqueous layer was extracted with chloroform, the combined chloroform layer was dried over anhydrous magnesium sulfate. Then, the solvent was distilled off to obtain 9.63 g of the desired product (99.7%, pale yellow oily product).

35

NMR (200MHz, CDCl₃) δ : 1.67 (2H, br), 2.95 (2H, m), 3.08 (2H, m), 6.95 (1H, d, J=7Hz), 7.15 (1H, dd, J=9.2, 7Hz), 7.59 (1H, d, J=9.2Hz), 7.71 (1H, s), 7.88 (1H, s)

Reference Example 4'

40

Synthesis of 5-[3-(amino)propylthio]imidazo[1,2-a]pyridine

To a mixed solution of 10% (w/w) potassium hydroxide (69.3 g, 105 mmoles) and dimethylsulfoxide (50 ml) was added S-(3-aminopropyl)isothioureia dihydrobromide (8.85 g, 39 mmoles) and the mixture was stirred at room temperature for 1.5 hours. To the reaction mixture was added 5-chloroimidazo[1,2-a]pyridine (3.05 g, 20 mmoles), followed by stirring at room temperature and additionally at 65 °C for 20 hours. Water was added to the reaction mixture, which was extracted with chloroform, washed with 1N sodium hydroxide several times and dried over anhydrous magnesium sulfate. Then, the solvent was distilled off to obtain 2.66 g of the desired product (64.3%, pale yellow oily product).

45

50 NMR (200MHz, CDCl₃) δ : 1.29 (2H, br), 1.80 (2H, m), 2.85 (2H, t, J=6.8Hz), 3.08 (2H, t, J=7.2Hz), 6.91 (1H, dd, J=7, 1Hz), 7.16 (1H, dd, J=9, 7Hz), 7.58 (1H, d, J=9, 1Hz), 7.71 (1H, d, J=1.2Hz), 7.85 (1H, d, J=1.2Hz)

55

EP 0 471 236 B1

Example 1'

(1) Synthesis of 5-[2-(methoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 1')

5 To a solution of 5-[2-(amino)ethylthio]imidazo[1,2-a]pyridine (1.93 g, 10 mmoles) and triethylamine (1.53 ml, 11 mmoles) in methylene chloride (30 ml) was added methyl chloroformate (0.77 ml, 10 mmoles) under ice-cooling with stirring and the mixture was stirred at room temperature for 20 minutes. The reaction mixture was washed in turn with aqueous sodium bicarbonate and water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography
 10 [eluent: ethano/ethylacetate (1:10)] to obtain 1.68 g of the desired product (66.9%, colorless crystals).

Melting point: 198-200.0 °C

15

Elemental analysis for C ₁₁ H ₁₃ N ₃ O ₂ S,			
Calcd.	C, 52.57;	H, 5.21;	N, 16.72
Found	C, 52.68;	H, 5.22;	N, 16.60

20

NMR (200MHz, CDCl₃) δ: 3.12 (2H, m), 3.40 (2H, m), 3.68 (3H, s), 5.10 (1H, br), 7.00 (1H, d, J=7Hz), 7.16 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9Hz), 7.72 (1H, s), 7.87 (1H, s)

According to the same manner as that described in Example 1' (1), the following compounds were obtained.

(2) 5-[2-(Ethoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 2')

25

Melting point: 68-70 °C

30

Elemental analysis for C ₁₂ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 54.32;	H, 5.70;	N, 15.84
Found	C, 54.33;	H, 5.75;	N, 15.83

35

(3) 5-[2-(Propyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 3')

Melting point: 62-64 °C

40

Elemental analysis for C ₁₃ H ₁₇ N ₃ O ₂ S,			
Calcd.	C, 55.89;	H, 6.13;	N, 15.04
Found	C, 55.87;	H, 6.09;	N, 14.96

45

NMR (200MHz, CDCl₃) δ: 0.92 (3H, t, J=7.4Hz), 1.62 (2H, m), 3.14 (2H, t, J=6.6Hz), 3.42 (1H, m), 4.01 (1H, t, J=6.6Hz), 5.07 (1H, br), 7.02 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.60 (1H, d, J=9Hz), 7.71 (1H, d, J=1.2Hz), 7.86 (1H, s)

IR (KBr) cm⁻¹: 3210, 3025, 2965, 1695, 1620, 1545, 1490, 1275

50

55

EP 0 471 236 B1

(4) 5-[2-(Butyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 4')

Melting point: 75-76 °C

5

Elemental analysis for C ₁₄ H ₁₉ N ₃ O ₂ S,			
Calcd.	C, 57.31;	H, 6.53;	N, 14.32
Found	C, 57.32;	H, 6.55;	N, 14.23

10

NMR (200MHz, CDCl₃) δ: 0.93 (3H, t, J=7Hz), 1.35 (2H, m), 1.58 (2H, m), 3.14 (2H, t, J=6.4Hz), 3.41 (2H, m), 4.05 (2H, t, J=6.6Hz), 5.04 (1H, br), 7.16 (1H, dd, J=9, 7Hz), 7.60 (1H, d, J=9Hz), 7.71 (1H, d, 1.2Hz), 7.85 (1H, s)

IR (KBr) cm⁻¹: 3490, 3210, 2970, 1695, 1615, 1500, 1285

15

(5) 5-[2-(Isopropoxyxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 5')

Melting point: 80.0-81.0 °C

20

Elemental analysis for C ₁₃ H ₁₇ N ₃ O ₂ S,			
Calcd.	C, 55.89;	H, 6.13;	N, 15.04
Found	C, 55.85;	H, 6.14;	N, 14.96

25

NMR (200Hz, CDCl₃) δ: 1.22 (6H, d, J=6.2Hz), 3.14 (2H, t, J=6.4Hz), 3.41 (2H, m), 4.94 (1H, br), 7.02 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9, 7Hz), 7.71 (1H, d, J=1.4Hz), 7.86 (1H, s)

IR (KBr) cm⁻¹: 3220, 3025, 2970, 1705, 1630, 1545, 1300, 1240

30

(6) 5-[2-(Isobutyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 6')

Melting point: 75-76 °C

35

Elemental analysis for C ₁₄ H ₁₉ N ₃ O ₂ S,			
Calcd.	C, 57.31;	H, 6.53;	N, 14.32
Found	C, 57.29;	H, 6.53;	N, 14.41

40

NMR (200Hz, CDCl₃) δ: 0.91 (6H, d, J=6.8Hz), 1.89 (1H, m), 3.14 (2H, t, J=6.4Hz), 3.42 (2H, m), 3.84 (2H, t, J=6.6Hz), 5.15 (1H, br), 7.01 (1H, dd, J=7Hz), 7.16 (1H, dd, J=9, 7Hz), 7.59 (1H, d, J=9Hz), 7.70 (1H, d, J=1.2Hz), 7.85 (1H, s)

(7) 5-[2-(Allyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 7')

45

Melting point: 72.5-73.5 °C

50

Elemental analysis for C ₁₃ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 56.30;	H, 5.45;	N, 15.15
Found	C, 56.34;	H, 5.44;	N, 15.04

NMR (200Hz, CDCl₃) δ: 3.15 (2H, t, J=6.4Hz), 3.43 (2H, m), 4.56 (2H, m), 5.07 (1H, br), 5.18-5.36 (2H, m), 5.90 (1H, m), 7.02 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.61 (1H, d, J=9Hz), 7.72 (1H, d, J=1.4Hz), 7.86 (1H, m)

55

IR (KBr) cm⁻¹: 3205, 3020, 1700, 1625, 1570, 1490, 1270

EP 0 471 236 B1

(8) 5-[2-[2,2,2-(Trichloro)ethoxycarbonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 8')

Melting point: 113.0-114.0 °C

5

Elemental analysis for C ₁₂ H ₁₂ N ₃ O ₂ SCl ₃ ,			
Calcd.	C, 39.10;	H, 3.28;	N, 11.4
Found	C, 39.23;	H, 3.27;	N, 11.25

10

NMR (200MHz, CDCl₃) δ: 3.17 (2H, t, J=6.4Hz), 3.48 (2H, m), 4.73 (2H, s), 5.52 (1H, br), 7.03 (1H, d, J=7Hz), 7.17 (1H, dd, J=9, 7Hz), 7.62 (1H, d, J=9Hz), 7.71 (1H, d, J=1.2Hz), 7.87 (1H, m)
IR (KBr) cm⁻¹: 3195, 2975, 1725, 1615, 1545, 1485, 1260, 1210

15

(9) 5-[2-(Benzyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 9')

Melting point: 52.0-53.0 °C

20

Elemental analysis for C ₁₇ H ₁₇ N ₃ O ₂ S,			
Calcd.	C, 62.36;	H, 5.23;	N, 12.83
Found	C, 62.34;	H, 5.22;	N, 12.75

25

NMR (200MHz, CDCl₃) δ: 3.14 (2H, t, J=6.4Hz), 3.43 (2H, m), 5.09 (2H, s), 5.17 (1H, br), 6.99 (1H, d, J=6.8Hz), 7.13 (1H, dd, J=9.2, 6.8Hz), 7.35 (5H, s), 7.59 (1H, d, J=9.2Hz), 7.69 (1H, s), 7.84 (1H, s)

(10) 5-[2-[(9-Fluorenyl)methyloxycarbonylamino]ethylthio]imidazo[1,2-a]pyridine (Compound 10')

Melting point: 105.0-108.0 °C

30

Elemental analysis for C ₂₄ H ₂₁ N ₃ O ₂ S•0.4H ₂ O,			
Calcd.	C, 69.07;	H, 5.05;	N, 9.67
Found	C, 69.14;	H, 5.23;	N, 9.96

35

NMR (200MHz, CDCl₃) δ: 3.13 (2H, t, J=6Hz), 3.42 (2H, m), 4.21 (1H, t, J=6.6Hz), 4.43 (2H, d, J=6.6Hz), 5.17 (1H, br), 7.01 (1H, d, J=7.4Hz), 7.15 (1H, dd, J=8.6, 7.4Hz), 7.29-7.46 (4H, m), 7.53-7.65 (3H, m), 7.60-7.87 (4H, m)

40

IR (KBr) cm⁻¹: 3205, 3020, 1710, 1625, 1550, 1485, 1450, 1270

(11) 5-[2-(Phenoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 11')

Melting point: 96.0-97.0 °C

45

Elemental analysis for C ₁₆ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 61.32;	H, 4.82;	N, 13.41
Found	C, 61.35;	H, 4.86;	N, 13.30

50

IR (KBr) cm⁻¹: 3200, 3005, 1725, 1615, 1555, 1485, 1270, 1210

(12) 5-[2-(N-Methyl-N-isopropylloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 12')

55

NMR (200MHz, CDCl₃) δ: 1.02-1.35 (6H, m), 2.91 (3H, s), 3.05-3.26 (2H, m), 3.38-3.60 (2H, m), 4.89 (1H, m), 7.01 (1H, br), 7.18 (1H, dd, J=9, 7Hz), 7.60 (1H, d, J=9Hz), 7.71 (1H, s), 7.84 (1H, s)
IR (KBr) cm⁻¹: 3220, 3025, 2970, 1705, 1630, 1545

EP 0 471 236 B1

(13) 5-[2-(N-Ethyl-N-isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 13')

NMR (200MHz, CDCl₃) δ: 0.95-1.35 (9H, m), 3.02-3.68 (6H, m), 4.90 (1H, m), 7.04 (1H, m), 7.19 (1H, dd, J=9, 7Hz), 7.60 (1H, d, J=9Hz), 7.72 (1H, s), 7.83 (1H, s)

IR (KBr) cm⁻¹: 3220, 3025, 2970, 1705, 1630, 1545

(14) 5-[3-(Methoxycarbonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 14')

Melting point: 69.0-70.0 °C

Elemental analysis for C ₁₂ H ₁₅ N ₃ O ₂ S,			
Calcd.	C, 54.32;	H, 5.70;	N, 15.84
Found	C, 54.48;	H, 5.74;	N, 15.72

NMR (200MHz, CDCl₃) δ: 1.85 (2H, m), 3.02 (2H, t, J=7Hz), 3.32 (2H, m), 3.67 (3H, s), 4.85 (1H, br), 6.91 (1H, dd, J=7, 1.2Hz), 7.15 (1H, dd, J=9, 7Hz), 7.58 (1H, d, J=9Hz), 7.70 (1H, d, J=1.2Hz), 7.84 (1H, s)

(15) 5-[3-(isopropoxyloxycarbonylamino)propylthio]imidazo[1,2-a]pyridine (Compound 15')

NMR (200MHz, CDCl₃) δ: 1.22 (6H, d, J=6.2Hz), 1.85 (2H, m), 3.03 (2H, m), 3.31 (2H, m), 4.82 (1H, br), 4.90 (1H, heptet, J=6.2Hz), 6.90 (1H, dd, J=7, 1Hz), 7.15 (1H, dd, J=9, 7Hz), 7.57 (1H, m), 7.69 (1H, d, J=1.4Hz), 7.84 (1H, m)

IR (KBr) cm⁻¹: 3210, 3025, 2965, 1695, 1620, 1545, 1490, 1275

(16) 5-[1-(tert-Butoxycarbonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (Compound 16')

NMR (200MHz, CDCl₃) δ: 1.45 (9H, s), 1.50-1.98 (4H, m), 2.90 (2H, m), 3.36 (1H, m), 3.98 (2H, m), 7.03 (1H, dd, J=7, 1.2Hz), 7.15 (1H, dd, J=9, 7Hz), 7.64 (1H, m), 7.70 (1H, d, J=1.2Hz), 7.96 (1H, m)

(17) 5-[1-(isopropoxyloxycarbonyl)-4-piperidylthio]imidazo[1,2-a]pyridine (Compound 17')

NMR (200MHz, CDCl₃) δ: 1.23 (6H, d, J=6.2Hz), 1.50-1.98 (4H, m), 2.94 (2H, m), 3.37 (1H, m), 4.03 (2H, m), 4.91 (1H, heptet, J=6.2Hz), 7.03 (1H, dd, J=7, 1.2Hz), 7.16 (1H, dd, J=9, 7Hz), 7.65 (1H, d, J=9Hz), 7.71 (1H, d, J=1.2Hz), 7.97 (1H, s)

Example 2'

(1) Synthesis of 3-bromo-5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 18')

To a solution of 5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (279 mg, 1 mmole) in chloroform (5 ml) was added N-bromosuccinimide (187 ml, 1.05 mmoles) and the mixture was stirred at room temperature for 1 hour. The reaction solution was washed with water and dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 296 mg of the desired product (82.7%, colorless solid).

Melting point: 103.0-104.0 °C

Elemental analysis for C ₁₃ H ₁₆ N ₃ O ₂ SBr,			
Calcd.	C, 43.58;	H, 4.50;	N, 11.73
Found	C, 43.60;	H, 4.53;	N, 11.74

NMR (200MHz, CDCl₃) δ: 1.22 (6H, d, J=6.2Hz), 3.11 (2H, t, J=6.6Hz), 3.42 (2H, m), 4.90 (1H, heptet, J=6.2Hz), 4.96 (1H, br), 7.00 (1H, dd, J=7, 1.2Hz), 7.14 (1H, dd, J=8.8, 7Hz), 7.57 (1H, dd, J=8.8, 1.2Hz), 7.59 (1H, s)

According to the same manner as that described in Example 2' (1), the following compound was

EP 0 471 236 B1

obtained.

(2) 3-Chloro-5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (Compound 19')

5 Melting point: 113.0-114.0 °C

10

Elemental analysis for C ₁₃ H ₁₆ N ₃ O ₂ SCl•0.2H ₂ O,			
Calcd.	C, 49.19;	H, 5.21;	N, 13.24
Found	C, 49.38;	H, 5.26;	N, 13.22

15

NMR (200MHz, CDCl₃) δ: 1.22 (6H, d, J=6.4Hz), 3.12 (2H, t, J=6.4Hz), 3.43 (2H, m), 4.90 (1H, heptet, J=6.4Hz), 4.96 (1H, br), 6.99 (1H, dd, J=7.2, 1.2Hz), 7.10 (1H, dd, J=8.8, 7.2Hz), 7.53 (1H, dd, J=8.8, 1.2Hz), 7.54 (1H, s)

Example 3'

20

(1) Synthesis of 5-[2-(isopropoxyloxycarbonylamino)ethylthio]-3-morpholinomethylimidazo[1,2-a]pyridine (Compound 20')

25

To a solution of an aqueous 37% formalin solution (210 mg, 2.59 mmoles) in acetic acid (2 ml) was added morpholine (226 μl, 2.59 mmoles) under ice-cooling and the mixture was stirred at room temperature for 45 minutes. 5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (651 mg, 2.33 mmoles) was added, followed by stirring at 60 °C for 2 hours. After the solvent was distilled off, the residue was diluted with chloroform, washed in turn with aqueous 1N NaOH and saturated saline, and then dried over anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography [eluent: ethanol/ethyl acetate = 1:10] to obtain 442 mg of the desired product (50.1%, light brown solid).

30

NMR (200MHz, CDCl₃) δ: 0.96 (6H, d, J=6.2Hz), 2.56 (4H, m), 3.26 (2H, m), 3.36 (2H, m), 3.69 (4H, m), 4.10 (2H, s), 4.59 (1H, heptet, J=6.2Hz), 6.85 (1H, br), 7.01 (1H, d, J=5Hz), 7.13 (1H, dd, J=8.6, 6.6Hz), 7.51 (1H, s), 7.53 (1H, d, J=8.6Hz)

Example 4'

35

Synthesis of 5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine hydrochloride (Compound 21')

40

A solution of 5-[2-(isopropoxyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine (279 mg, 1 mmoles) in methanol (10 ml) was treated with hydrogen chloride-methanol. After the solvent was distilled off, the residue was crystallized from isopropanol-ethyl acetate-methanol. The crystals thus obtained were washed with water and dried to obtain 290 mg of the desired product (92.1%, colorless crystals).

Melting point: 145-150 °C

45

Elemental analysis for C ₁₃ H ₁₇ N ₃ O ₂ S•HCl,			
Calcd.	C, 49.44;	H, 5.74;	N, 13.30
Found	C, 49.51;	H, 5.64;	N, 13.14

50

Example 5'

Synthesis of 5-[4-(isopropoxyloxycarbonylamino)butylthio]imidazo[1,2-a]pyridine (Compound 22')

55

To 5-(4-amino)butylthioimidazo[1,2-a]pyridine (370 mg, 1.67 mmoles) and triethylamine (0.35 ml, 2.51 mmoles) in methylene chloride (20 ml) was added isopropyl chloroformate (0.25 g, 2.04 mmoles) under ice-cooling with stirring and the mixture was stirred under ice-cooling for 1 hour. The reaction mixture was washed in turn with aqueous saturated sodium bicarbonate and saturated saline, and then dried over

EP 0 471 236 B1

anhydrous magnesium sulfate. After the solvent was distilled off, the residue was purified by column chromatography (eluent: ethyl acetate) to obtain 215 mg of the desired product (41.8%, light tan oily product).

NMR (200MHz, CDCl₃) δ : 1.22 (6H, d, J=6.2Hz), 1.54-1.72 (4H, m), 3.02 (2H, m), 3.18 (2H, m), 4.66 (1H, br), 4.90 (1H, heptet, J=6.2Hz), 6.90 (1H, dd, J=7, 1Hz), 7.15 (1H, dd, J=9, 7Hz), 7.58 (1H, d, J=9Hz), 7.70 (1H, m), 7.84 (1H, m)

Preparation 1'

10

15

(1) Compound 5'	50 g
(2) Lactose	100 g
(3) Corn starch	15 g
(4) Carboxymethylcellulose calcium	44 g
(5) Magnesium stearate	1 g
1000 Tablet	210 g

All the components (1), (2) and (3) and 30 g of the component (4) were kneaded with water, dried under vacuum and granulated. This granulated powder was mixed with 14 g of the component (4) and 1 g of the component (5) and the mixture was charged in a tableting machine to produce 1000 tablets containing 50 mg of the component (1) per one tablet.

Preparation 2'

25

An ointment was prepared by uniformly kneading the following components.

30

Compound 5'	0.5 g
Liquid paraffin	1 g
White petrolatum	suitable amount
Total amount	100 g

35 Preparation 3'

40

(1) Compound 5'	1 g
(2) Cacao fat	19 g

All the components (1) and (2) were kneaded on a water bath at about 60°C. Then, the mix was charged in a suppository mold and cooled to produce 10 suppositories, each containing 2 g of the mixture.

45 Preparation 4'

50

(1) Compound 5'	10 g
(2) Lactose	4.5 g
(3) Corn starch	4.5 g
(4) Magnesium stearate	1 g
1000 capsules	20 g

All the components were thoroughly admixed and the mixture was filled in a suitable gelatin capsule to produce 100 capsules containing 100 mg of the component (1) per one capsule.

EP 0 471 236 B1

Preparation 5'

An injection preparation filled in an ampoule was prepared by admixing and dissolving the following components.

	per one ampoule
Compound 21'	50 mg
Sodium chloride	18 mg
Distilled water for injection	suitable amount
Total amount	2 ml

Experiment 1'

Effect of the desired compound on growth of endothelial cells

This experiment was conducted by using endothelial cells (HUVE cells) obtained from human umbilical vein. 2×10^3 HUVE cells were suspended in a complete medium prepared by adding 2.5% FBS (fetal bovine serum) to GIT medium (manufactured by Nihon Seiyaku K.K.). Then, the suspension was distributed in a 96-well microtiter plate, which was cultivated at 37°C in an atmosphere of 5% carbon dioxide-7% oxygen-88 % nitrogen. After 24 hours, human recombinant basic FGF (endothelial cell growth factor) was added thereto in the final concentration of 2 ng/ml and a test compound was further added, followed by cultivation for 3 days. After cultivation, growth rate of HUVE cells was measured by MTT method [Cancer Treatment Reports, Vol. 71, page 1141-1149, 1987].

The test compounds inhibited growth of human umbilical endothelial cells.

IC₅₀ value (the concentration of the test compound inhibiting growth of endothelial cells by 50%) of the test compound was determined from a graph of growth curve of HUVE cells. The results are shown in Table 1'.

Table 1'

Test compound	IC ₅₀ (μM)
1'	18
2'	7
3'	27
5'	4
7'	29
8'	12
10'	43
18'	20
19'	6
21'	5

As shown in Table 1', the compounds of the present invention have excellent inhibitory activity of endothelial cells growth.

Experiment 2'

Effect of the desired compound on growth of bovine artery endothelial cells

This experiment was conducted by using endothelial cells (BAE cells) derived from bovine aorta. 5×10^3 BAE cells were suspended in a complete medium prepared by adding 5% FBS (fetal bovine serum) to Dulbecco's modified Eagle's minimum essential medium (D-MEM medium). Then, the suspension was distributed in a 96-well microtiter plate, which was cultivated at 37°C in an atmosphere of 5% carbon dioxide-95% air. After 24 hours, human recombinant basic FGF (endothelial cell growth factor) was added

EP 0 471 236 B1

thereto in the final concentration of 2 ng/ml and a test compound was further added, followed by cultivation for 3 days. After cultivation, growth rate of BAE cells was measured by MTT method [Cancer Treatment Reports, Vol. 71, page 1141-1149, 1987].

The test compounds inhibited growth of bovine artery endothelial cells.

- 5 IC₅₀ value (the concentration of the test compound inhibiting growth of endothelial cells by 50%) of Compound 1' was 48 μM.

Experiment 3'

- 10 Effect of the desired compound on growth of human umbilical vein endothelial cells by phorbol ester

This experiment was conducted by using endothelial cells (HUVE cells) obtained from human umbilical vein. 2 x 10³ HUVE cells were suspended in a complete medium prepared by adding 2.5% FBS (fetal bovine serum) to GIT medium (manufactured by Nihon Seiyaku K.K.). Then, the suspension was distributed
15 in a 96-well microtiter plate, which was cultivated at 37°C in an atmosphere of 5% carbon dioxide-7% oxygen-88% nitrogen. After 24 hours, 12-O-tetradecanoylphorbol 13-acetate (TPA) was added thereto in the final concentration of 1 nM and a test compound was added, followed by cultivation for 3 days. After cultivation, growth rate of HUVE cells was measured by MTT method [Cancer Treatment Reports, Vol. 71, page 1141-1149, 1987].

- 20 The test compounds inhibited growth of human umbilical endothelial cells by phorbol ester.

IC₅₀ value (the concentration of the test compound inhibiting growth of endothelial cells by 50%) of Compound 1 was 15 μM.

Experiment 4'

- 25 Effect of the desired compound on inhibition of increase in intracellular calcium concentration by phorbol ester

Bovine aorta endothelial cells (BAE cells) were cultivated on a cover glass loaded with 4 μM Flar 2
30 (manufactured by Dojin Kagaku Kenkyusho) and inserted into a quartz cuvette containing 2.5 ml of HEPES buffer (pH 7.5).

The quartz cuvette was fixed so that the cover glass was positioned on the diagonal side at angles of 45° to the incident direction of an excited light.

Fluormetry was conducted with a spectrophotofluorometer F-4000 (manufactured by Hitachi Seisakusho
35 K.K.). Excitation was obtained at 340 nm and 380 nm and fluorescence of 505 nm was recorded.

F_{max} was determined by Ionomycin (2 μM, manufactured by Carbiarochen Co.) which was a calcium ionophore and F_{min} was determined by EGTA (8 mM) which was a chelating agent of calcium ion.

Intracellular calcium ion concentration [Ca⁺⁺]_i was calculated by the following formula:

- 40
$$[Ca^{++}]_i = K_d \times (R - R_{min}) \times Sf_2 / (R_{max} - R) \times Sb_2$$

$$R = \{D(W_1) - AutoF_1\} / \{D(W_2) - AutoF_2\}$$

wherein D (W₁): a measured value of excited wavelength W₁; D (W₂): a measured value of excited wavelength W₂; AutoF₁: autofluorescence at W₁; AutoF₂: autofluorescence at W₂; R_{min}: R (Ca⁺⁺ = 0) =
45 $F_{min}(W_1)/F_{min}(W_2)$; R_{max}: R (saturated Ca⁺⁺ concentration) = $F_{max}(W_1)/F_{max}(W_2)$; Sf₂: fluorescence intensity in a free state at W₂; Sb₂: fluorescence intensity in Ca⁺⁺ bound state at W₂, which was obtained by correcting the formula of Zehn et al.:

- $$[Ca^{++}]_i = K_d \times (F - F_{min}) / (F_{max} - F)$$

50 by taking K_d as 224 nM.

The experiment was conducted by adding a test compound at various concentrations to a solution in a cuvette and incubated for 5 minutes. Then, 12-O-tetradecanoylphorbol 13-acetate (TPA) of 2 nM in the final concentration was added and change of fluorescence intensity was observed.

- 55 It was found that the test compounds inhibited increase in intracellular calcium concentration by phorbol ester (TPA).

Change of inhibitory activity due to change of the concentration of Compound 1' is shown in Table 2'.

EP 0 471 236 B1


Table 2'

Effect of Compound 1' on inhibition of increase in intracellular calcium concentration by phorbol ester	
Concentration of Compound (M)	Inhibitory activity (%)
8 x 10 ⁻⁶	100
8 x 10 ⁻⁷	88
8 x 10 ⁻⁸	81

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE


1. A calmodulin inhibitory composition comprising a compound of the formula (I):



wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is

(a) a group of the formula:




wherein l, m and n are integers of 0 to 5, respectively; and each of R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ is independently (1) hydrogen, or (2) C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or R⁴ and R⁵ or R⁶ and R⁷ or R⁸ and R⁹ may bind to each other to form a ring, or R⁴ or R⁵ may bind to R⁸ or R⁹, respectively, to form a ring,

or

(b) a group of the formula: -CH₂CH₂OCH₂CH₂- or


(c) a group of the formula:



wherein o and p are integers of 0 to 5 ;

B is

(a) a group of the formula:



wherein R¹⁰ is (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi-

EP 0 471 236 B1

or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or (3) a member selected from -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ and -CS-NR¹⁴R¹⁵; R¹¹ is -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ or -CS-NR¹⁴R¹⁵) or
 (b) a group of the formula:




wherein R¹⁸ is (1) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents, or (2) -CO-NR¹⁴R¹⁵ or -CO-R¹⁹,

wherein


R¹², R¹⁴ and R¹⁵ are independently (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents;

R¹³, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are independently C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

R¹⁰ and R³ may bind together to form a ring of the formula:




wherein q is an integer of 2 or 3; A and R¹¹ are as defined above, or R¹⁰ may bind to R⁴, R⁶ or R⁸ to form a ring of the formula:



wherein q and r are an integer of 2 or 3, respectively; and R¹¹ is as defined above, or R¹⁰ may bind to R¹¹ to form a ring of the formula:

EP 0 471 236 B1



30 R^{14} and R^{15} together with the adjacent nitrogen atom may form 1-aziridinyl, 1-azetidiny, piperidino, perhydro-1-azepinyl, perhydro-1-azocynyl, morpholino, thiomorpholino, 1-piperazinyl, 3-thiazolidinyl, 1-indolyl, perhydro-1-indolyl, 2-isindolyl, perhydro-2-isindolyl, 1,2,3,4-tetrahydro-1-quinolyl, 1,2,3,4-tetrahydro-2-isoquinolyl, perhydro-1-quinolyl, perhydro-2-isoquinolyl, 3-azabicyclo[3.2.2]non-3-yl, 9-carbozoyl, 10-acridanyl,



10,11-dihydro-5H-5-dibenz[b,f]azepinyl, 5,6,11,12-tetrahydro-5-dibenz[b,f]azocinyl, 1,2,3,4-tetrahydro-9-carbazolyl, 10-phenoxadiny or 10-phenothiadiny;

45 said substituent of C_{1-6} alkyl is halogen, nitro, amino, N-mono C_{1-6} alkylamino, N,N-di C_{1-6} alkylamino, 4 to 7 membered cyclic amino, C_{1-6} alkoxy, C_{6-10} aryloxy, carbamoyl, cyano, hydroxy, carboxy, C_{1-6} alkoxycarbonyl or C_{1-6} alkylcarbonyl;

50 said substituent of C_{1-30} alkyl or C_{2-30} alkenyl is (1) C_{3-8} cycloalkyl, (2) phenyl optionally substituted with 1 to 4 substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, nitro and halogen, (3) naphthyl, (4) halogen, (5) cyano, (6) oxo or (7) C_{1-6} alkoxy;

55 said substituent of C_{3-8} cycloalkyl or saturated bi- or tricyclic hydrocarbon is C_{1-6} alkyl, halogeno C_{1-6} alkyl, hydroxy C_{1-6} alkyl, acyloxy C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy, halogeno C_{1-6} alkoxy, C_{1-6} alkoxy-carbonyl- C_{1-6} alkoxy, C_{1-6} alkenyloxy, aralkyloxy, C_{1-6} alkoxy- C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, carboxy, carbamoyl, N,N-di C_{1-6} alkylcarbamoyl, N- C_{1-6} alkylcarbamoyl, halogen, cyano, nitro, hydroxy, acyloxy, amino, C_{1-6} alkylsulfonylamino, acylamino, C_{1-6} alkoxycarbonylamino, acyl, mercapto, C_{1-6} alkylthio, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl or oxo;

said substituent of phenyl- C_{1-6} alkyl or naphthyl- C_{1-6} alkyl is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, nitro, cyano, hydroxy, C_{1-6} alkoxycarbonyl, carbamoyl or C_{1-6} alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl


EP 0 471 236 B1

or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

and R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;


a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy carbonyl group or a C₁₋₆-alkylcarbamoyl group, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

2. A calmodulin inhibitory composition according to claim 1, wherein the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ of claim 1 or tritylamino.
3. Use of a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.
4. A compound of the formula (I'):




wherein X is S, S(O), S(O)₂, O or NR³ wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:



wherein all the symbols are as defined in claim 1, or -CH₂CH₂OCH₂CH₂- or a group of the formula:



wherein o and p are integers of 0 to 5 ;


B¹ is an amino group acylated by an acyl group derived from a carboxylic acid having 2 or more carbon atoms, a sulfonic acid, a carbamic acid or a thiocarbamic acid; and R¹ and R² are the same or different and are a hydrogen,

independently C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, a thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;

a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy carbonyl group or a C₁₋₆-alkylcarbamoyl group, or a salt or solvate thereof.

EP 0 471 236 B1

5. A compound according to claim 4, wherein
B¹ is a group of the formula:



5

wherein R¹⁰ is (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkanyl, phenyl C₁₋₆ alkyl, naphthyl C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

10

which may have 1 to 4 substituents, or (3) -CO-R¹², -SO₂R¹³, -CONR¹⁴R¹⁵ and -CS-NR¹⁴R¹⁵;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkyl carbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkyl carbamoyl; and

15

R¹¹ is -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ or -CS-NR¹⁴R¹⁵;

wherein R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are as defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl carbonyl; and

20

the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ or tritylamino.

6. A compound according to claim 4, wherein B¹ is -NH-SO₂R¹⁷, wherein R¹⁷ is as defined in claim 1.

25

7. A compound according to claim 4, wherein X is S or O, and B¹ is -NH-SO₂R¹⁷, wherein R¹⁷ is as defined in claim 1.

8. A compound according to claim 4 which is

30

5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[2-(trifluoromethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[3-(methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
5-[3-(trifluoromethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
5-[3-(methylsulfonylamino)propylthio]imidazo[1,2-a]pyridine, or
5-[3-(trifluoromethylsulfonylamino)propylthio]imidazo[1,2-a]pyridine.

35


9. A calmodulin inhibitory composition comprising a compound of the formula (I') as defined in claim 4 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

40

10. Use of a compound of the formula (I') as defined in claim 4 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.

11. A compound of the formula (I''):

45



50


(I'')

55


wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:


EP 0 471 236 B1



wherein all the symbols are defined in claim 1,
or a group of the formula: $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ or a group of the formula:



wherein o and p are integers of 0 to 5 ;
B² is a group of the formula:



wherein all the symbols are defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl carbonyl;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkyl carbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkyl carbamoyl;

and R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;

a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy carbonyl group or a C₁₋₆-alkyl carbamoyl group, or a salt or solvate thereof.

12. A compound according to claim 11, wherein
the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ or tritylamino.
13. A compound according to claim 11, wherein X is S or O.
14. A compound according to claim 11 which is
5-[1-(methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine,
5-[1-(trifluoromethyl)-4-piperidylthio]imidazo[1,2-a]pyridine.
15. A calmodulin inhibitory composition comprising a compound of the formula (I'') as defined in claim 11, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.


EP 0 471 236 B1

16. Use of a compound of the formula (I'') as defined in claim 11 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.

17. A compound of the formula (I'''):

5

10




(I''')

15

wherein X is S, S(O), S(O)₂ or NR³, wherein R³ is hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;
A is a group of the formula:


20



25

wherein all the symbols are defined in claim 1,
or a group of the formula: -CH₂CH₂OCH₂CH₂- or a group of the formula:

30



35

wherein o and p are integers of 0 to 5 ;

R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents; a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxycarbonyl group or a C₁₋₆-alkylcarbamoyl group; and

40

B³ is -O-CO-NR¹⁵R¹⁶ or -O-CO-R¹⁹,

wherein R¹⁵, R¹⁶ and R¹⁹ are defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbamoyl;

45

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

50


18. A compound according to claim 17, wherein the optionally protected amino group of R¹ and R² is amino, acylamino (wherein the acyl group is the same as that of R¹¹) or tritylamino.

55


19. A compound according to claim 17, wherein X is S or O and B³ is -O-CONHR¹⁶, wherein R¹⁶ is as defined in claim 1 .

EP 0 471 236 B1


20. A compound according to claim 17 which is
 5-[2-(methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine, or
 5-[2-[3-(hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine.
21. A calmodulin inhibitory composition comprising a compound of the formula (I''') as defined in claim 17,
 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier,
 diluent or excipient.
22. Use of a compound of the formula (I''') as defined in claim 17, or a pharmaceutically acceptable salt or
 solvate thereof in the preparation of a calmodulin inhibitory composition.
23. A process for producing a compound according to claim 4 or 11 or a salt or solvate thereof which
 comprises;
 reacting a compound of the formula:



- wherein all the symbols are as defined in claim 1 or 2 with a compound of the formula Q¹-NR¹⁴R¹⁵, G¹-
 CO(O)_q-R¹⁶ or G²-SO₂R¹⁷ wherein Q¹ is PhO-CO-, G-CO- or G-CS (wherein Ph is a phenyl group and
 G is a halogen), G¹ is a halogen or R¹⁶(O)_q-CO-O- (wherein q is 0 or 1), q is 0 or 1, G² is a halogen or
 R¹⁷SO₂O-, and the other symbols are defined in claim 1.
24. A process for producing a compound according to claim 4 or a salt or solvate thereof which comprises;
 reacting a compound of the formula:



wherein E is a halogen and the other symbols are as defined in claim 4, with a compound of the
 formula HX¹-A-B¹ wherein X¹ is S, O or NR³ and the other substituents are as defined in claim 4, or
 when, X is S or O, reacting a compound of the formula:



- wherein X² is S or O and the other symbols are as defined in claim 4 with a compound of the formula
 E¹-A-B¹ wherein E¹ is a leaving group, and the other symbols are as defined in claim 4, or
 when X is S(O) or S(O)₂, oxidizing a compound of the formula:

EP 0 471 236 B1

5




10

wherein all the symbols are as defined in claim 4.

25. A process for producing a compound according to claim 11 or a salt or solvate which comprises reacting a compound of the formula:

15




20

wherein E is a halogen and the other symbols are as defined in claim 11, with a compound of the formula HX^1-A-B^2 wherein X^1 is S, O or NR^3 and the other symbols are as defined in claim 11, or

25

when the nitrogen atom of the amino group of B^2 forms a ring with a carbon atom of A, reacting a compound of the formula:

30




35

wherein X^2 is S or O and the other symbols are as defined in claim 11 with a compound of the formula E^1-A-B^2 wherein E^1 is a leaving group, and the other symbols are as defined in claim 11 or

40

when X is $S(O)$ or $S(O)_2$, oxidizing a compound of the formula:

45



50


wherein all the symbols are as defined in claim 11.

26. A process for producing a compound according to claim 17 or a salt or solvate thereof which comprises reacting a compound of the formula:

55

EP 0 471 236 B1


5



10

wherein the symbols are as defined in claim 17 with a compound of the formula $Q^1-NR^{15}R^{16}$ or $G^1-CO-(O)_q-R^{19}$ wherein Q^1 , G^1 and q are defined in claim 23, and the other symbols are defined in claim 1, or reacting a compound of the formula:


15



20

wherein E is a halogen and the other symbols are as defined in claim 17, with a compound of the formula HX^1-A-B^3 wherein X^1 is S, O or NR^3 and the other symbols are as defined in claim 17, or reacting a compound of the formula:

25




30

35

wherein X^2 is S or O and the other symbols are as defined in claim 17 with a compound of the formula E^1-A-B^3 wherein E^1 is a leaving group, and the other symbols are defined in claim 17 or when X is S(O) or S(O)₂, oxidizing a compound of the formula:

40



45


wherein all the symbols are as defined in claim 17.

50

55

EP 0 471 236 B1

27. An angiogenesis inhibitory composition comprising a compound of the formula (1):



wherein A' is

(a) a group of the formula:



wherein x, y and z are integers of 0 to 5, respectively; each of R^e, R^f, R^g, R^h, Rⁱ and R^j is (1) a hydrogen, or (2) a C₁₋₆ alkyl, C₂₋₆ alkenyl, which may have 1 to 5 substituents, or (3) phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl, C₆₋₁₄ aryl, or an aromatic monocyclic or bicyclic heterocyclic group containing 1 to 4 hetero atoms selected from sulfur, oxygen and nitrogen, which may have 1 to 4 substituents, or R^e and R^f or R^g and R^h or Rⁱ and R^j may bind together to form C₃₋₈ cycloalkane ring, or R^e or R^g may bind together with R^f or R^j to form C₃₋₈ cycloalkane ring, or

(b) a group of the formula: -CH₂CH₂OCH₂CH₂- or

(c) the formula:




wherein a and b are integers of 0 to 5, respectively;

R^a and R^b are the same or different and are a hydrogen,

a C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or C₆₋₁₄ aryl group, which may have 1 to 4 substituents; a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxycarbonyl group or a C₁₋₆-alkylcarbamoyl group; R^c is a hydrogen or R^c and R^d is C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or C₆₋₁₄ aryl, which may have 1 to 5 substituents;

R^c and R^e or R^f, or R^c and R^g or R^h, or R^c and Rⁱ or R^j may bind together to form



wherein Q and R are interger of 2 or 3, respectively;

EP 0 471 236 B1


said substituent of C₁₋₆ alkyl, C₃₋₈ cycloalkyl or C₂₋₆ alkenyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, C₄₋₇ cyclic amino, C₁₋₆ alkoxy, phenoxy, 1-naphthoxy, 2-naphthoxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or heterocyclic group is halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

28. An angiogenesis inhibitory composition according to claim 27, wherein
the optionally protected amino group of R^a or R^b is amino or acylamino, wherein the acyl group is C₁₋₆ alkylcarbonyl, C₇₋₁₀ aralkylcarbonyl, C₆₋₁₀ arylcarbonyl, C₁₋₄ alkoxycarbonyl, C₇₋₁₀ aralkyloxycarbonyl or C₆₋₁₀ aryloxycarbonyl.
29. An angiogenesis inhibitory composition according to claim 27, wherein A' is ethylene, R^c is hydrogen and R^d is C₁₋₆ alkyl or C₂₋₆ alkenyl.
30. An angiogenesis inhibitory composition according to claim 27, wherein the compound is
5-[2-(isopropoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[2-(ethoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[2-(methoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[2-(propoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine, or
5-[2-(allyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridine.
31. Use of a compound of the formula (1) as defined in claim 27 or a pharmaceutically acceptable salt or solvate thereof in the preparation of an angiogenesis inhibitory composition.

Claims for the following Contracting State : ES


1. A process for the preparation of a calmodulin inhibitory composition which comprises mixing a compound of the formula (I):



(I)

wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;
A is

(a) a group of the formula:




wherein l, m and n are integers of 0 to 5, respectively; and each of R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ is independently (1) hydrogen, or (2) C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or R⁴ and R⁵ or R⁶ and R⁷ or R⁸ and R⁹ may bind to each other to form a ring, or R⁴ or R⁶ may bind to R⁸ or R⁹, respectively, to form a ring,

EP 0 471 236 B1

or

(b) a group of the formula: $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ or

(c) a group of the formula:



wherein o and p are integers of 0 to 5 ;

B is

(a) a group of the formula:



wherein R^{10} is (1) hydrogen, or (2) C_1 - $_{30}$ straight or branched alkyl, C_3 - $_{8}$ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C_2 - $_{30}$ alkenyl, phenyl- C_1 - $_{6}$ alkyl, naphthyl- C_1 - $_{6}$ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

which may have 1 to 4 substituents, or (3) a member selected from $-\text{CO}-\text{R}^{12}$, $-\text{SO}_2\text{R}^{13}$, $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ and $-\text{CS}-\text{NR}^{14}\text{R}^{15}$; R^{11} is $-\text{CO}-\text{R}^{16}$, $-\text{CO}-\text{OR}^{16}$, $-\text{SO}_2\text{R}^{17}$, $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ or $-\text{CS}-\text{NR}^{14}\text{R}^{15}$) or

(b) a group of the formula:




wherein R^{18} is (1) C_1 - $_{30}$ straight or branched alkyl, C_3 - $_{8}$ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C_2 - $_{30}$ alkenyl, phenyl- C_1 - $_{6}$ alkyl, naphthyl- C_1 - $_{6}$ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents, or (2) $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ or $-\text{CO}-\text{R}^{19}$,

wherein


R^{12} , R^{14} and R^{15} are independently (1) hydrogen, or (2) C_1 - $_{30}$ straight or branched alkyl, C_3 - $_{8}$ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C_2 - $_{30}$ alkenyl, phenyl- C_1 - $_{6}$ alkyl, naphthyl- C_1 - $_{6}$ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents;

R^{13} , R^{16} , R^{17} , R^{18} and R^{19} are independently C_1 - $_{30}$ straight or branched alkyl, C_3 - $_{8}$ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C_2 - $_{30}$ alkenyl, phenyl- C_1 - $_{6}$ alkyl, naphthyl- C_1 - $_{6}$ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

R^{10} and R^3 may bind together to form a ring of the formula:



wherein q is an integer of 2 or 3; A and R^{11} are as defined above , or R^{10} may bind to R^4 , R^6 or R^8 to form a ring of the formula:



EP 0 471 236 B1

wherein q and r are an integer of 2 or 3, respectively; and R¹¹ is as defined above, or R¹⁰ may bind to R¹¹ to form a ring of the formula:

5

10

15

20

25

30

R¹⁴ and R¹⁵ together with the adjacent nitrogen atom may form 1-aziridinyl, 1-azetidiny, piperidino, perhydro-1-azepinyl, perhydro-1-azocynyl, morpholino, thiomorpholino, 1-piperazinyl, 3-thiazolidinyl, 1-indolyl, perhydro-1-indolyl, 2-isoindolyl, perhydro-2-isoindolyl, 1,2,3,4-tetrahydro-1-quinolyl, 1,2,3,4-tetrahydro-2-isoquinolyl, perhydro-1-quinolyl, perhydro-2-isoquinolyl, 3-azabicyclo[3.2.2]non-3-yl, 9-carbazolyl, 10-acridanyl,

40

45

10,11-dihydro-5H-5-dibenz[b,f]azepinyl, 5,6,11,12-tetrahydro-5-dibenz[b,f]azocinyl, 1,2,3,4-tetrahydro-9-carbazolyl, 10-phenoxadiny or 10-phenothiadiny;

50

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbonyl;

said substituent of C₁₋₃₀ alkyl or C₂₋₃₀ alkenyl is (1) C₃₋₈ cycloalkyl, (2) phenyl optionally substituted with 1 to 4 substituents selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, nitro and halogen, (3) naphthyl, (4) halogen, (5) cyano, (6) oxo or (7) C₁₋₆ alkoxy;

55

said substituent of C₃₋₈ cycloalkyl or saturated bi- or tricyclhydrocarbon is C₁₋₆ alkyl, halogeno C₁₋₆ alkyl, hydroxy C₁₋₆ alkyl, acyloxy C₁₋₆ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkoxy, halogeno C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl-C₁₋₆ alkoxy, C₁₋₆ alkenyloxy, aralkyloxy, C₁₋₆ alkoxy-C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, carboxy, carbamoyl, N,N-di C₁₋₆ alkylcarbamoyl, N-C₁₋₆ alkylcarbamoyl, halo-

EP 0 471 236 B1

gen, cyano, nitro, hydroxy, acyloxy, amino, C₁₋₆ alkylsulfonylamino, acylamino, C₁₋₆ alkoxy-carbonylamino, acyl, mercapto, C₁₋₆ alkylthio, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl or oxo;


said substituent or phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxy-carbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy-carbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

and R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;


a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy-carbonyl group or a C₁₋₆-alkylcarbamoyl group, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

2. A process according to claim 1, wherein the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ of claim 1 or tritylamino.
3. Use of a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.
4. A process for producing a compound of the formula (I'):




wherein X is S, S(O), S(O)₂, O or NR³ wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:



wherein all the symbols are as defined in claim 1, or -CH₂CH₂OCH₂CH₂- or a group of the formula:



wherein o and p are integers of 0 to 5 ;


B¹ is an amino group acylated by an acyl group derived from a carboxylic acid having 2 or more carbon atoms, a sulfonic acid, a carbamic acid or a thiocarbamic acid; and R¹ and R² are the same or different and are a hydrogen,

independently C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;

a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy-car-


EP 0 471 236 B1

bonyl group or a C₁₋₆-alkylcarbamoyl group, or a salt or solvate thereof or a compound of the formula (I''):




wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:




wherein all the symbols are defined in claim 1,

or a group of the formula: -CH₂CH₂OCH₂CH₂- or a group of the formula:



wherein o and p are integers of 0 to 5 ;

B² is a group of the formula:



wherein all the symbols are defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl carbonyl;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkyl carbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkyl carbamoyl;

and R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;


a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-

EP 0 471 236 B1

alkoxycarbonyl group or a C₁₋₆-alkylcarbamoyl group, or a salt or solvate thereof which comprises;
reacting a compound of the formula:


5

10



wherein all the symbols are as defined in claim 1 or 2 with a compound of the formula Q¹-NR¹⁴R¹⁵, G¹-CO(O)_q-R¹⁶ or G²-SO₂R¹⁷ wherein Q¹ is PhO-CO-, G-CO- or G-CS (wherein Ph is a phenyl group and G is a halogen), G¹ is a halogen or R¹⁶(O)_q-CO-O- (wherein q is 0 or 1), q is 0 or 1, G² is a halogen or R¹⁷SO₂O-, and the other symbols are defined in claim 1.

5. A process according to claim 4, wherein
B¹ is a group of the formula:



wherein R¹⁰ is (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkanyl, phenyl C₁₋₆ alkyl, naphthyl C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or (3) -CO-R¹², -SO₂R¹³, -CONR¹⁴R¹⁵ and -CS-NR¹⁴R¹⁵;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl; and

R¹¹ is -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ or -CS-NR¹⁴R¹⁵;

wherein R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are as defined in claim 1


said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbonyl; and

the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ or tritylamino.

6. A process according to claim 4, wherein B¹ is -NH-SO₂R¹⁷, wherein R¹⁷ is as defined in claim 1.
7. A process according to claim 4, wherein X is S or O, and B¹ is -NH-SO₂R¹⁷, wherein R¹⁷ is as defined in claim 1.
8. A process according to claim 4 wherein
5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[2-(trifluoromethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[3-(methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
5-[3-(trifluoromethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
5-[3-(methylsulfonylamino)propylthio]imidazo[1,2-a]pyridine, or
5-[3-(trifluoromethylsulfonylamino)propylthio]imidazo[1,2-a]pyridine is produced.
9. Use of a compound of the formula (I') as defined in claim 4 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.

EP 0 471 236 B1


10. A process according to claim 4, wherein
the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is
the same as that of R¹¹ or tritylamino.
- 5 11. A process according to claim 4, wherein X is S or O.
12. A process according to claim 4 wherein
5-[1-(methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine,
5-[1-(trifluoromethyl)-4-piperidylthio]imidazo[1,2-a]pyridine is produced.
- 10 13. Use of a compound of the formula (I'') as defined in claim 4 or a pharmaceutically acceptable salt or
solvate thereof in the preparation of a calmodulin inhibitory composition.
14. A process for producing a compound of the formula (I'''):



(I''')


wherein X is S, S(O), S(O)₂ or NR³, wherein R³ is hydrogen or an optionally substituted C₁₋₆ alkyl,
phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:



wherein all the symbols are defined in claim 1,

or a group of the formula: -CH₂CH₂OCH₂CH₂- or a group of the formula:



wherein o and p are integers of 0 to 5;

R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl,
phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl,
furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents; a halogen, a nitro group, a
nitroso group, an optionally protected amino group, a C₁₋₆-alkoxycarbonyl group or a C₁₋₆-
alkylcarbamoyl group; and

B³ is -O-CO-NR¹⁵R¹⁶ or -O-CO-R¹⁹,

wherein R¹⁵, R¹⁶ and R¹⁹ are defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆
alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy,
carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbamoyl;


said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy,
nitro, cyano, hydroxy, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl


EP 0 471 236 B1

or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy-carbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;


with the proviso that the compound of formula I''' is not 5-[2-(N-chloroacetylcarbamoyloxy)-ethylthio] imidazo[1,2-a]pyridine or its salt or solvate, which comprises reacting a compound of the formula:




wherein the symbols are as defined in claim 17 with a compound of the formula Q¹-NR¹⁵R¹⁶ or G¹-CO-(O)_q-R¹⁹ wherein Q¹, G¹ and q are defined in claim 4, and the other symbols are defined in claim 1, or reacting a compound of the formula:



wherein E is a halogen and the other symbols are as defined above, with a compound of the formula HX¹-A-B³ wherein X¹ is S, O or NR³ and the other symbols are as defined in claim 17, or reacting a compound of the formula:



wherein X² is S or O and the other symbols are as defined above with a compound of the formula E¹-A-B³ wherein E¹ is a leaving group, and the other symbols are defined above or when X is S(O) or S(O)₂, oxidizing a compound of the formula:



wherein all the symbols are as defined above.

15. A process according to claim 14, wherein

the optionally protected amino group of R¹ and R² is amino, acylamino (wherein the acyl group is the same as that of R¹¹) or tritylamino.

EP 0 471 236 B1


16. A process according to claim 14, wherein X is S or O and B³ is -O-CONHR¹⁶, wherein R¹⁶ is as defined in claim 1.

17. A process according to claim 14 which is


- 5 5-[2-(methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine, or
 5-[2-[3-(hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine.

18. Use of a compound of the formula (I'') as defined in claim 14, or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.

19. A process for producing a compound according to claim 4 or a salt or solvate thereof which comprises; reacting a compound of the formula:



wherein E is a halogen and the other symbols are as defined in claim 4, with a compound of the formula HX¹-A-B¹ wherein X¹ is S, O or NR³ and the other substituents are as defined in claim 4, or when, X is S or O, reacting a compound of the formula:




35 wherein X² is S or O and the other symbols are as defined in claim 4 with a compound of the formula E¹-A-B¹ wherein E¹ is a leaving group, and the other symbols are as defined in claim 4, or when X is S(O) or S(O)₂, oxidizing a compound of the formula:




wherein all the symbols are as defined in claim 4.

20. A process for producing a compound according to claim 4 or a salt or solvate which comprises reacting a compound of the formula:

EP 0 471 236 B1



wherein E is a halogen and the other symbols are as defined in claim 11, with a compound of the formula HX^1-A-B^2 wherein X^1 is S, O or NR^3 and the other symbols are as defined in claim 11, or when the nitrogen atom of the amino group of B^2 forms a ring with a carbon atom of A, reacting a compound of the formula:




wherein X^2 is S or O and the other symbols are as defined in claim 11 with a compound of the formula E^1-A-B^2 wherein E^1 is a leaving group, and the other symbols are as defined in claim 11 or when X is S(O) or $S(O)_2$, oxidizing a compound of the formula:



wherein all the symbols are as defined in claim 4.

21. Use of a compound of the formula (1):




(1)

wherein A' is

EP 0 471 236 B1

(a) a group of the formula:




wherein x, y and z are integers of 0 to 5, respectively; each of R^e, R^f, R^g, R^h, Rⁱ and R^j is (1) a hydrogen, or (2) a C₁₋₆ alkyl, C₂₋₆ alkenyl, which may have 1 to 5 substituents, or (3) phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl, C₆₋₁₄ aryl, or an aromatic monocyclic or bicyclic heterocyclic group containing 1 to 4 hetero atoms selected from sulfur, oxygen and nitrogen, which may have 1 to 4 substituents, or R^e and R^f or R^g and R^h or Rⁱ and R^j may bind together to form C₃₋₈ cycloalkane ring, or R^e or R^g may bind together with Rⁱ or R^j to form C₃₋₈ cycloalkane ring, which may contain ethereal oxygen at any possible position

or

(b) a group of the formula: -CH₂CH₂OCH₂CH₂- or

(c) the formula:





wherein a and b are integers of 0 to 5, respectively;

R^a and R^b are the same or different and are a hydrogen,

a C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or C₆₋₁₄ aryl group, which may have 1 to 4 substituents; a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxycarbonyl group or a C₁₋₆-alkylcarbamoyl group; R^c is a hydrogen or R^c and R^d is C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or C₆₋₁₄ aryl, which may have 1 to 5 substituents;

R^c and R^e or R^f, or R^c and R^g or R^h, or R^c and Rⁱ or R^j may bind together to form



wherein Q and R are integer of 2 or 3, respectively;


said substituent of C₁₋₆ alkyl, C₃₋₈ cycloalkyl or C₂₋₆ alkenyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, C₄₋₇ cyclic amino, C₁₋₆ alkoxy, phenoxy, 1-naphthoxy, 2-naphthoxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or heterocyclic group is halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient in the preparation of an angiogenesis inhibitory composition.

EP 0 471 236 B1

Claims for the following Contracting State : GR


1. A process for the preparation of a calmodulin inhibitory composition which comprises mixing a compound of the formula (I):



15 wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is

(a) a group of the formula:




30 wherein l, m and n are integers or 0 to 5, respectively; and each of R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ is independently (1) hydrogen, or (2) C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or R⁴ and R⁵ or R⁶ and R⁷ or R⁸ and R⁹ may bind to each other to form a ring, or R⁴ or R⁶ may bind to R⁸ or R⁹, respectively, to form a ring ,

or

(b) a group of the formula: -CH₂CH₂OCH₂CH₂- or


35 (c) a group of the formula:



wherein o and p are integers of 0 to 5 ;

B is

(a) a group of the formula:



50 wherein R¹⁰ is (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or (3) a member selected from -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ and -CS-NR¹⁴R¹⁵; R¹¹ is -CO-R¹⁵, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ or -CS-NR¹⁴R¹⁵) or

(b) a group of the formula:



wherein R¹⁸ is (1) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic

EP 0 471 236 B1


hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents, or (2) -CO-NR¹⁴R¹⁵ or -CO-R¹⁹,

wherein


R¹², R¹⁴ and R¹⁵ are independently (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl, which may have 1 to 4 substituents;

R¹³, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are independently C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkenyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl

R¹⁰ and R³ may bind together to form a ring of the formula:




wherein q is an integer of 2 or 3; A and R¹¹ are as defined above, or R¹⁰ may bind to R⁴, R⁵ or R⁸ to form a ring of the formula:




wherein q and r are an integer of 2 or 3, respectively; and R¹¹ is as defined above, or R¹⁰ may bind to R¹¹ to form a ring of the formula:

EP 0 471 236 B1



30 R^{14} and R^{15} together with the adjacent nitrogen atom may form 1-aziridinyl, 1-azetidinyl, piperidino, perhydro-1-azepinyl, perhydro-1-azocynyl, morpholino, thiomorpholino, 1-piperazinyl, 3-thiazolidinyl, 1-indolyl, perhydro-1-indolyl, 2-isindolyl, perhydro-2-isindolyl, 1,2,3,4-tetrahydro-1-quinolyl, 1,2,3,4-tetrahydro-2-isoquinolyl, perhydro-1-quinolyl, perhydro-2-isoquinolyl, 3-azabicyclo[3.2.2]non-3-yl, 9-carbazolyl, 10-acridanyl,



45 10,11-dihydro-5H-5-dibenz[b,f]azepinyl, 5,6,11,12-tetrahydro-5-dibenz[b,f]azocinyl, 1,2,3,4-tetrahydro-9-carbazolyl, 10-phenoxadinyll or 10-phenothiadinyll;

said substituent of C_{1-6} alkyl is halogen, nitro, amino, N-mono C_{1-6} alkylamino, N,N-di C_{1-6} alkylamino, 4 to 7 membered cyclic amino, C_{1-6} alkoxy, C_{6-10} aryloxy, carbamoyl, cyano, hydroxy, carboxy, C_{1-6} alkoxy-carbonyl or C_{1-6} alkyl-carbonyl;

50 said substituent of C_{1-30} alkyl or C_{2-30} alkenyl is (1) C_{3-8} cycloalkyl, (2) phenyl optionally substituted with 1 to 4 substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, nitro and halogen, (3) naphthyl, (4) halogen, (5) cyano, (6) oxo or (7) C_{1-6} alkoxy;

said substituent of C_{3-8} cycloalkyl or saturated bi- or tricyclic hydrocarbon is C_{1-6} alkyl, halogeno C_{1-6} alkyl, hydroxy C_{1-6} alkyl, acyloxy C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkoxy, halogeno C_{1-6} alkoxy, C_{1-6} alkoxy-carbonyl- C_{1-6} alkoxy, C_{1-6} alkenyloxy, aralkyloxy, C_{1-6} alkoxy- C_{1-6} alkoxy, C_{1-6} alkoxy-carbonyl, carboxy, carbamoyl, N,N-di C_{1-6} alkyl-carbamoyl, N- C_{1-6} alkyl-carbamoyl, halogen, cyano, nitro, hydroxy, acyloxy, amino, C_{1-6} alkylsulfonamino, acylamino, C_{1-6} alkoxy-carbonylamino, acyl, mercapto, C_{1-6} alkylthio, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyl or oxo;

55 said substituent of phenyl- C_{1-6} alkyl or naphthyl- C_{1-6} alkyl is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, nitro, cyano, hydroxy, C_{1-6} alkoxy-carbonyl, carbamoyl or C_{1-6} alkyl-carbamoyl;


EP 0 471 236 B1

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxy carbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

and R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;


a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy carbonyl group or a C₁₋₆-alkylcarbamoyl group, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

2. A process according to claim 1, wherein the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ of claim 1 or tritylamino.
3. Use of a compound of the formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.
4. A compound of the formula (I'):




wherein X is S, S(O), S(O)₂, O or NR³ wherein R³ is a hydrogen or an optionally substituted C₁₋₆ alkyl phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:



wherein all the symbols are as defined in claim 1, or -CH₂CH₂OCH₂CH₂- or a group of the formula:



wherein o and p are integers of 0 to 5 ;

B¹ is an amino group acylated by an acyl group derived from a carboxylic acid having 2 or more carbon atoms, a sulfonic acid, a carbamic acid or a thiocarbamic acid; and R¹ and R² are the same or different and are a hydrogen,

independently C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;

a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxy carbonyl group or a C₁₋₆-alkylcarbamoyl group, or a salt or solvate thereof.

5. A compound according to claim 4, wherein B¹ is a group of the formula:

EP 0 471 236 B1

-NR¹⁰R¹¹

wherein R¹⁰ is (1) hydrogen, or (2) C₁₋₃₀ straight or branched alkyl, C₃₋₈ cycloalkyl, saturated bi- or tricyclic hydrocarbon group formed by fusing 5 to 8 membered rings, C₂₋₃₀ alkanyl, phenyl C₁₋₆ alkyl, naphthyl C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents, or (3) -CO-R¹², -SO₂R¹³, -CONR¹⁴R¹⁵ and -CS-NR¹⁴R¹⁵;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl; and

R¹¹ is -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ or -CS-NR¹⁴R¹⁵;

wherein R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ and R¹⁷ are as defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbonyl; and

the optionally protected amino group of R¹ and R² is amino, acylamino wherein the acyl group is the same as that of R¹¹ or tritylamino.

6. A compound according to claim 4, wherein B¹ is -NH-SO₂R¹⁷, wherein R¹⁷ is as defined in claim 1.


7. A compound according to claim 4, wherein X is S or O, and B¹ is -NH-SO₂R¹⁷, wherein R¹⁷ is as defined in claim 1.

8. A compound according to claim 4 which is

5-[2-(methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[2-(trifluoromethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridine,
5-[3-(methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
5-[3-(trifluoromethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
5-[3-(methylsulfonylamino)propylthio]imidazo[1,2-a]pyridine, or
5-[3-(trifluoromethylsulfonylamino)propylthio]imidazo[1,2-a]pyridine.

9. Use of a compound of the formula (I') as defined in claim 4 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.

10. A compound of the formula (I''):



(I'')

wherein X is S, S(O), S(O)₂, O or NR³, wherein R³ is hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:


EP 0 471 236 B1



wherein all the symbols are defined in claim 1,
 10 or a group of the formula: $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ or a group of the formula:



wherein o and p are integers of 0 to 5 ;
 20 B^2 is a group of the formula:



wherein all the symbols are defined in claim 1
 said substituent of C_{1-6} alkyl is halogen, nitro, amino, N-mono C_{1-6} alkylamino, N,N-di C_{1-6} alkylamino, 4 to 7 membered cyclic amino, C_{1-6} alkoxy, C_6-10 aryloxy, carbamoyl, cyano, hydroxy,
 35 carboxy, C_{1-6} alkoxycarbonyl or C_{1-6} alkylcarbonyl;
 said substituent of phenyl- C_{1-6} alkyl or naphthyl- C_{1-6} alkyl is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, nitro, cyano, hydroxy, C_{1-6} alkoxycarbonyl, carbamoyl or C_{1-6} alkylcarbamoyl;
 said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, nitro, cyano, oxo, hydroxy, amino, C_{1-6} alkoxycar-
 40 bonyl, carbamoyl or C_{1-6} alkylcarbamoyl;
 and R^1 and R^2 are the same or different and are a hydrogen, an optionally substituted C_{1-6} alkyl, phenyl- C_{1-6} alkyl, naphthyl- C_{1-6} alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents;
 a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C_{1-6} -alkoxycarbonyl group or a C_{1-6} -alkylcarbamoyl group, or a salt or solvate thereof.

11. A compound according to claim 10, wherein
 the optionally protected amino group of R^1 and R^2 is amino, acylamino wherein the acyl group is
 50 the same as that of R^{11} or tritylamino.


12. A compound according to claim 10, wherein X is S or O.

13. A compound according to claim 10 which is
 55 5-[1-(methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridine,
 5-[1-(trifluoromethyl)-4-piperidylthio]imidazo[1,2-a]pyridine.

14. Use of a compound of the formula (I'') as defined in claim 10 or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.


EP 0 471 236 B1

15. A compound of the formula (I'''):




wherein X is S, S(O), S(O)₂ or NR³, wherein R³ is hydrogen or an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl, which may have 1 to 4 substituents;

A is a group of the formula:



wherein all the symbols are defined in claim 1, or a group of the formula: -CH₂CH₂OCH₂CH₂- or a group of the formula:



wherein o and p are integers of 0 to 5 ;

R¹ and R² are the same or different and are a hydrogen, an optionally substituted C₁₋₆ alkyl, phenyl-C₁₋₆ alkyl, naphthyl-C₁₋₆ alkyl or phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl which may have 1 to 4 substituents; a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C₁₋₆-alkoxycarbonyl group or a C₁₋₆-alkylcarbamoyl group; and

B³ is -O-CO-NR¹⁵R¹⁶ or -O-CO-R¹⁹,

wherein R¹⁵, R¹⁶ and R¹⁹ are defined in claim 1

said substituent of C₁₋₆ alkyl is halogen, nitro, amino, N-mono C₁₋₆ alkylamino, N,N-di C₁₋₆ alkylamino, 4 to 7 membered cyclic amino, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, carbamoyl, cyano, hydroxy, carboxy, C₁₋₆ alkoxycarbonyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl-C₁₋₆ alkyl or naphthyl-C₁₋₆ alkyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, hydroxy, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

said substituent of phenyl, 1-naphthyl, 2-naphthyl, phenanthryl, anthryl, thienyl, furyl, benzothienyl or benzofuranyl is halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro, cyano, oxo, hydroxy, amino, C₁₋₆ alkoxycarbonyl, carbamoyl or C₁₋₆ alkylcarbamoyl;

45

16. A compound according to claim 15, wherein

the optionally protected amino group of R¹ and R² is amino, acylamino (wherein the acyl group is the same as that of R¹¹) or tritylamino.

50

17. A compound according to claim 15, wherein X is S or O and B³ is -O-CONHR¹⁶, wherein R¹⁶ is as defined in claim 1.

55 18. A compound according to claim 15 which is

5-[2-(methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridine, or

5-[2-[3-(hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridine.

EP 0 471 236 B1

19. Use of a compound of the formula (I'') as defined in claim 15, or a pharmaceutically acceptable salt or solvate thereof in the preparation of a calmodulin inhibitory composition.

20. A process for producing a compound according to claim 4 or 10 or a salt or solvate thereof which comprises;
 5 reacting a compound of the formula:



wherein all the symbols are as defined in claim 1 or 2 with a compound of the formula $Q^1-NR^{14}R^{15}$, $G^1-CO(O)_q-R^{16}$ or $G^2-SO_2R^{17}$ wherein Q^1 is $PhO-CO-$, $G-CO-$ or $G-CS$ (wherein Ph is a phenyl group and G is a halogen), G^1 is a halogen or $R^{16}(O)_q-CO-O-$ (wherein q is 0 or 1), q is 0 or 1, G^2 is a halogen or $R^{17}SO_2O-$, and the other symbols are defined in claim 1.

20

21. A process for producing a compound according to claim 4 or a salt or solvate thereof which comprises;
 25 reacting a compound of the formula:



wherein E is a halogen and the other symbols are as defined in claim 4, with a compound of the formula HX^1-A-B^1 wherein X^1 is S , O or NR^3 and the other substituents are as defined in claim 4, or
 35 when, X is S or O , reacting a compound of the formula:



wherein X^2 is S or O and the other symbols are as defined in claim 4 with a compound of the formula E^1-A-B^1 wherein E^1 is a leaving group, and the other symbols are as defined in claim 4, or
 50 when X is $S(O)$ or $S(O)_2$, oxidizing a compound of the formula:




EP 0 471 236 B1

wherein all the symbols are as defined in claim 4.

22. A process for producing a compound according to claim 10 or a salt or solvate which comprises reacting a compound of the formula:

5

10




15

wherein E is a halogen and the other symbols are as defined in claim 11, with a compound of the formula HX^1-A-B^2 wherein X^1 is S, O or NR^3 and the other symbols are as defined in claim 11, or

when the nitrogen atom of the amino group of B^2 forms a ring with a carbon atom of A, reacting a compound of the formula:

20

25



wherein X^2 is S or O and the other symbols are as defined in claim 11 with a compound of the formula E^1-A-B^2 wherein E^1 is a leaving group, and the other symbols are as defined in claim 11 or

30

when X is S(O) or S(O)₂, oxidizing a compound of the formula:

35




40

wherein all the symbols are as defined in claim 10.

23. A process for producing a compound according to claim 15 or a salt or solvate thereof which comprises reacting a compound of the formula:

45

50




55

wherein the symbols are as defined in claim 15 with a compound of the formula $Q^1-NR^{15}R^{16}$ or $G^1-CO-(O)_q-R^{19}$ wherein Q^1 , G^1 and q are defined in claim 20, and the other symbols are defined in claim 1, or reacting a compound of the formula:

EP 0 471 236 B1


5



10

wherein E is a halogen and the other symbols are as defined in claim 15, with a compound of the formula HX^1-A-B^3 wherein X^1 is S, O or NR^3 and the other symbols are as defined in claim 15, or reacting a compound of the formula:


15



20

wherein X^2 is S or O and the other symbols are as defined in claim 15 with a compound of the formula E^1-A-B^3 wherein E^1 is a leaving group, and the other symbols are defined in claim 15 or when X is $S(O)$ or $S(O)_2$, oxidizing a compound of the formula:

25




30

35 wherein all the symbols are as defined in claim 15.

24. Use of a compound of the formula (1)

40



45


(1)

wherein A' is

50

(a) a group of the formula:

55




EP 0 471 236 B1

wherein x, y and z are integers of 0 to 5, respectively; each of R^a , R^i , R^g , R^h , R^j and R^l is (1) a hydrogen, or (2) a C_{1-6} alkyl, C_{2-6} alkenyl, which may have 1 to 5 substituents, or (3) phenyl- C_{1-6} alkyl, naphthyl- C_{1-6} alkyl, C_{6-14} aryl, or an aromatic monocyclic or bicyclic heterocyclic group containing 1 to 4 hetero atoms selected from sulfur, oxygen and nitrogen, which may have 1 to 4 substituents, or R^a and R^i or R^g and R^h or R^j and R^l may bind together to form C_{3-8} cycloalkane ring, or R^a or R^g may bind together with R^i or R^l to form C_{3-8} cycloalkane ring, which may contain etheral oxygen at any possible position or

(b) a group of the formula: $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ or

(c) the formula:




wherein a and b are integers of 0 to 5, respectively;

R^a and R^b are the same or different and are a hydrogen,

a C_{1-6} alkyl, C_{2-6} alkenyl, phenyl- C_{1-6} alkyl, naphthyl- C_{1-6} alkyl or C_{6-14} aryl group, which may have 1 to 4 substituents; a halogen, a nitro group, a nitroso group, an optionally protected amino group, a C_{1-6} -alkoxycarbonyl group or a C_{1-6} -alkylcarbamoyl group; R^c is a hydrogen or R^c and R^d is C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{2-6} alkenyl, phenyl- C_{1-6} alkyl, naphthyl- C_{1-6} alkyl or C_{6-14} aryl, which may have 1 to 5 substituents;

R^c and R^e or R^f , or R^c and R^g or R^h , or R^c and R^i or R^j may bind together to form



wherein Q and R are interger of 2 or 3, respectively;

said substituent of C_{1-6} alkyl, C_{3-8} cycloalkyl or C_{2-6} alkenyl is halogen, nitro, amino, N-mono C_{1-6} alkylamino, N,N-di C_{1-6} alkylamino, C_{4-7} cyclic amino, C_{1-6} alkoxy, phenoxy, 1-naphthoxy, 2-naphthoxy, carbamoyl, cyano, hydroxy, carboxy, C_{1-6} alkoxycarbonyl or C_{1-6} alkylcarbamoyl;


said substituent of phenyl C_{1-6} alkyl, naphthyl- C_{1-6} alkyl or heterocyclic group is halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy, nitro, cyano, oxo, hydroxy, amino, C_{1-6} alkoxycarbonyl, carbamoyl or C_{1-6} alkylcarbamoyl or a pharmaceutically acceptable salt or solvate thereof in the preparation of an angiogenesis inhibitory composition.

EP 0 471 236 B1

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Calmodulin-Inhibitor-Zusammensetzung, umfassend eine Verbindung der Formel (I):




(I)

worin:

X S, S=O, SO₂, O oder NR³ ist, worin R³ ein Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A


(a) eine Gruppe der Formel:



worin l, m und n ganze Zahlen von 0 bis 5 sind und R⁴, R⁵, R⁶, R⁷, R⁸ und R⁹ unabhängig voneinander jeweils (1) Wasserstoff oder (2) C₁₋₆-Alkyl, C₂₋₆-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl ist, die 1 - 4 Substituenten tragen können, oder worin R⁴ und R⁵ oder R⁶ und R⁷ oder R⁸ und R⁹ miteinander zu einem Ring verbunden sein können, oder

(b) eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder


(c) eine Gruppe der Formel:



ist, worin o und p ganze Zahlen von 0 bis 5 sind;

B

(a) eine Gruppe der Formel:



worin R¹⁰ (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (3) ein Vertreter ausgewählt aus -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ und -CS-NR¹⁴R¹⁵ ist, und R¹¹ = -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ oder -CS-NR¹⁴R¹⁵ ist, oder

(b) eine Gruppe der Formel:




EP 0 471 236 B1

ist, worin R^{18} (1) geradkettiges oder verzweigtes C_{1-30} -Alkyl, C_{3-8} -Cycloalkyl, eine gesättigte durch Anellieren von 5-bis 8-gliedrigen Ringen gebildete bi- oder trizyklische Kohlenwasserstoffgruppe, C_{2-30} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (2) $-CO-NR^{14}R^{15}$ oder $-CO-R^{19}$ ist, worin:


R^{12} , R^{14} und R^{15} unabhängig voneinander (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C_{1-30} -Alkyl, C_{3-8} -Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C_{2-30} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, sind;

R^{13} , R^{16} , R^{17} , R^{18} und R^{19} unabhängig voneinander geradkettiges oder verzweigtes C_{1-30} -Alkyl, C_{3-8} -Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C_{2-30} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl sind,

R^{10} und R^3 miteinander zu einem Ring der Formel:




verbunden sein können, worin q eine ganze Zahl von 2 oder 3 ist, A und R^{11} wie zuvor definiert sind, oder R^{10} mit R^4 , R^5 oder R^8 zu einem Ring der Formel:




verbunden sein kann, worin q und r ganze Zahlen von 2 oder 3 sind und R^{11} wie zuvor definiert ist, oder R^{10} mit R^{11} zu einem Ring der Formel:


5




10



15




20



25

30

35



40

45

50

55

130

EP 0 471 236 B1

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist; und


R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind,

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, sowie einen pharmazeutisch annehmbaren Träger, Verdünner oder Exipienten.

2. Calmodulin-Inhibitor-Zusammensetzung nach Anspruch 1, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹ nach Anspruch 1 ist, oder Tritylamino ist.

3. Verwendung einer Verbindung der Formel (I), wie in Anspruch 1 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.

4. Verbindung der Formel (I'):




(I')


worin:

X S, S = O, SO₂, O oder NR³ ist, worin R³ ein Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A eine Gruppe der Formel:



worin alle Symbole wie in Anspruch 1 definiert sind, oder -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:



ist, worin o und p ganze Zahlen von 0 bis 5 sind;


B¹ eine Aminogruppe ist, die mit einer Acylgruppe acyliert ist, die von einer Carbonsäure mit 2 oder mehr Kohlenstoffatomen, einer Sulfonsäure, einer Carbaminsäure oder einer Thiocarbaminsäure stammt; und

R¹ und R² gleich oder unterschiedlich und Wasserstoff, unabhängig voneinander C₁₋₆-Alkyl,

EP 0 471 236 B1

Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind,
 5 oder ein Salz oder Solvat davon.

5. Verbindung nach Anspruch 4, worin:
 B¹ eine Gruppe der Formel:



ist, worin R¹⁰ (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten
 15 tragen können, oder (3) -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ und -CS-NR¹⁴R¹⁵ ist;

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist; und
 20 worin R¹¹ -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ oder -CS-NR¹⁴R¹⁵ ist;


worin R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ und R¹⁷ wie in Anspruch 1 definiert sind;

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxycarbonyl oder C₁₋₆-Alkylcarbonyl ist; und
 25 die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.

- 30 6. Verbindung nach Anspruch 4, worin B¹ -NH-SO₂R¹⁷ ist, worin R¹⁷ wie in Anspruch 1 definiert ist.
7. Verbindung nach Anspruch 4, worin X S oder O und B¹ -NH-SO₂R¹⁷ ist, worin R¹⁷ wie in Anspruch 1 definiert ist.
- 35 8. Verbindung nach Anspruch 4, die
 5-[2-(Methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridin,
 5-[2-(Trifluormethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridin,
 5-[3-(Methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridin,
 5-[3-(Trifluormethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridin,
 40 5-[3-(Methylsulfonylamino)propylthio]imidazo[1,2-a]pyridin oder
 5-[3-(Trifluormethylsulfonylamino)propylthio]imidazo[1,2-a]pyridin ist.
9. Calmodulin-Inhibitor-Zusammensetzung, umfassend eine Verbindung der Formel (I'), wie in Anspruch 4 definiert, oder ein pharmazeutisch annehmbares Salz oder Solvat davon und einen pharmazeutisch
 45 annehmbaren Träger, Verdünner oder Excipienten.
10. Verwendung einer Verbindung der Formel (I'), wie in Anspruch 4 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.

EP 0 471 236 B1

11. Verbindung der Formel (I''):



worin:

X S, S = O, SO₂, O oder NR³ ist, worin R³ Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A eine Gruppe der Formel:




25 worin alle Symbole wie in Anspruch 1 definiert sind,

oder eine Gruppe der Formel -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:



35 ist, worin o und p ganze Zahlen von 0 bis 5 sind;

B² eine Gruppe der Formel:



ist, worin alle Symbole wie in Anspruch 1 definiert sind,

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₁₋₆-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxy-carbonyl oder C₁₋₆-Alkyl-carbonyl ist;

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxy-carbonyl, Carbamoyl oder C₁₋₆-Alkyl-carbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxy-carbonyl, Carbamoyl oder C₁₋₆-Alkyl-carbamoyl ist; und

R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, An-

EP 0 471 236 B1

thryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind, oder ein Salz oder Solvat davon.

12. Verbindung nach Anspruch 11, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.


13. Verbindung nach Anspruch 11, worin X S oder O ist.

14. Verbindung nach Anspruch 11, die
5-[1-(Methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridin oder
5-[1-(Trifluormethyl)-4-piperidylthio]imidazo[1,2-a]pyridin ist.

15. Calmodulin-Inhibitor-Zusammensetzung, umfassend eine Verbindung der Formel (I''), wie in Anspruch 11 definiert, oder ein pharmazeutisch annehmbares Salz oder Solvat davon, und einen pharmazeutisch annehmbaren Träger, Verdünner oder Excipienten.

16. Verwendung einer Verbindung der Formel (I''), wie in Anspruch 11 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.


17. Verbindung der Formel (I'''):




(I''')

worin:

X S, S = O, SO₂, O oder NR³ ist, worin R³ Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;
A eine Gruppe der Formel:



worin alle Symbole wie in Anspruch 1 definiert sind,
oder eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:




ist, worin o und p ganze Zahlen von 0 bis 5 sind;

R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, An-


EP 0 471 236 B1

- thryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind; und B³ -O-CO-NR¹⁵R¹⁶ oder -O-CO-R¹⁹ ist,
- 5 worin R¹⁵, R¹⁶ und R¹⁹ wie in Anspruch 1 definiert sind,
wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxycarbonyl oder C₁₋₆-Alkylcarbonyl ist;
wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;
- 10 wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist.
- 15 18. Verbindung nach Anspruch 17, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.
19. Verbindung nach Anspruch 17, worin X S oder O und B³ -O-CONHR¹⁶ ist, worin R¹⁶ wie in Anspruch 1 definiert ist.
- 20 20. Verbindung nach Anspruch 17, die
5-[2-(Methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridin oder
5-[2-[3-(Hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridin ist.
- 25 21. Calmodulin-Inhibitor-Zusammensetzung, umfassend eine Verbindung der Formel (I'''), wie in Anspruch 17 definiert, oder ein pharmazeutisch annehmbares Salz oder Solvat davon, und einen pharmazeutisch annehmbaren Träger, Verdünner oder Excipienten.
22. Verwendung einer Verbindung der Formel (I'''), wie in Anspruch 17 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.
- 30 23. Verfahren zur Herstellung einer Verbindung nach Anspruch 4 oder 11 oder eines Salzes oder Solvats davon, das umfaßt:
Umsetzen einer Verbindung der Formel:



- 45 worin alle Symbole wie in Anspruch 1 oder 2 definiert sind, mit einer Verbindung der Formel Q¹-NR¹⁴R¹⁵, G¹-CO(O)_q-R¹⁶ oder G²-SO₂R¹⁷, worin Q¹ PhO-CO-, G-CO- oder G-CS- (worin Ph eine Phenylgruppe und G ein Halogen ist), G¹ ein Halogen oder R¹⁶(O)_q-CO-O- ist, worin q jeweils 0 oder 1 ist, G² ein Halogen oder R¹⁷SO₂O- ist und die anderen Symbole wie in Anspruch 1 definiert sind).
- 50 24. Verfahren zur Herstellung einer Verbindung nach Anspruch 4 oder eines Salzes oder Solvats davon, das umfaßt:
Umsetzen einer Verbindung der Formel:
- 55

EP 0 471 236 B1




5

10 worin E ein Halogen ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel HX^1-A-B^1 , worin X^1 S, O oder NR^3 ist und die anderen Substituenten wie in Anspruch 4 definiert sind, oder

falls X S oder O ist, Umsetzen einer Verbindung der Formel:

15



20

25 worin X^2 S oder O ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel E^1-A-B^1 , worin E^1 eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 4 definiert sind, oder

falls $X = S=O$ oder SO_2 ist, Oxidieren einer Verbindung der Formel:

30




35

40 worin alle Symbole wie in Anspruch 4 definiert sind.

25. Verfahren zur Herstellung einer Verbindung nach Anspruch 11 oder eines Salzes oder Solvats, das umfaßt:

Umsetzen einer Verbindung der Formel:

45



50


55 worin E ein Halogen ist und die anderen Symbole wie in Anspruch 11 definiert sind, mit einer Verbindung der Formel HX^1-A-B^2 , worin X^1 S, O oder NR^3 ist und die anderen Substituenten wie in Anspruch 11 definiert sind, oder

falls das Stickstoffatom der Aminogruppe B^2 mit dem Kohlenstoffatom von A einen Ring bildet,

EP 0 471 236 B1

Umsetzen einer Verbindung der Formel:

5




10

worin X^2 S oder O ist und die anderen Symbole wie in Anspruch 11 definiert sind, mit einer Verbindung der Formel E^1-A-B^2 , worin E^1 eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 11 definiert sind, oder

15

falls $X = S=O$ oder SO_2 ist, Oxidieren einer Verbindung der Formel:

20



25


worin alle Symbole wie in Anspruch 11 definiert sind.

26. Verfahren zur Herstellung einer Verbindung nach Anspruch 17 oder eines Salzes oder Solvats davon, das umfaßt:

30

Umsetzen einer Verbindung der Formel:

35




40

worin die Symbole wie in Anspruch 17 definiert sind, mit einer Verbindung der Formel $Q^1-NR^{15}R^{16}$ oder $G^1-CO(O)_q-R^{19}$, worin Q^1 , G^1 und q wie in Anspruch 23 definiert und die anderen Symbole wie in Anspruch 1 definiert sind, oder

45

Umsetzen einer Verbindung der Formel:

50




55

worin E ein Halogen ist und die anderen Symbole wie in Anspruch 17 definiert sind, mit einer Verbindung der Formel HX^1-A-B^3 , worin X^1 S, O oder NR^3 ist und die anderen Substituenten wie in Anspruch 17 definiert sind, oder

Umsetzen einer Verbindung der Formel:

EP 0 471 236 B1

5




10

worin X^2 S oder O ist und die anderen Symbole wie in Anspruch 17 definiert sind, mit einer Verbindung der Formel E^1-A-B^3 , worin E^1 eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 17 definiert sind, oder

falls X S=O oder SO_2 ist, Oxidieren einer Verbindung der Formel:

15




20

worin alle Symbole wie in Anspruch 17 definiert sind.

25

27. Angiogenese-Inhibitor-Zusammensetzung, umfassend eine Verbindung der Formel (1):

30




(1)

35

worin A' :

(a) eine Gruppe der Formel:

40



45

worin x , y und z ganze Zahlen von 0 bis 5 sind und R^e , R^f , R^g , R^h , R^i und R^j jeweils (1) ein Wasserstoff oder (2) ein C_{1-6} -Alkyl, C_{2-6} -Alkenyl, das 1 - 5 Substituenten tragen kann, oder (3) Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl C_{6-14} -Aryl oder eine aromatische, mono- oder bityklische heterozyklische Gruppe ist, die 1 - 4 Heteroatome, ausgewählt aus Schwefel, Sauerstoff und Stickstoff, enthält und 1 - 4 Substituenten tragen kann, oder worin R^e und R^f oder R^g und R^h oder R^i und R^j miteinander zu einem C_{3-8} -Cycloalkan-Ring verbunden sein können, oder worin R^e oder R^g gemeinsam mit R^f oder R^j miteinander zu einem C_{3-8} -Cycloalkan-Ring verbunden sein können, oder

55

(b) eine Gruppe der Formel: $-CH_2CH_2OCH_2CH_2-$ oder

EP 0 471 236 B1

(c) der Formel:





ist, worin a und b jeweils ganze Zahlen von 0 bis 5 sind;

10 R^a und R^b gleich oder unterschiedlich und ein Wasserstoff, eine C_{1-6} -Alkyl-, C_{2-6} -Alkenyl-, Phenyl- C_{1-6} -alkyl-, Naphthyl- C_{1-6} -alkyl- oder C_{6-14} -Aryl-Gruppe, die 1 - 4 Substituenten tragen kann; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C_{1-6} -Alkoxycarbonyl-Gruppe oder eine C_{1-6} -Alkylcarbamoyl-Gruppe sind;

R^c ein Wasserstoff ist oder R^c und R^d C_{1-6} -Alkyl, C_{3-8} -Cycloalkyl, C_{2-6} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder C_{6-14} -Aryl, die 1 - 5 Substituenten tragen können, sind;

15 R^e und R^a oder R^f , oder R^c und R^g oder R^h , oder R^c und R^i oder R^j miteinander zu



30 verbunden sein können, worin Q und R ganze Zahlen von 2 oder 3 sind;

wobei der Substituent am C_{1-6} -Alkyl, C_{3-8} -Cycloalkyl oder C_{2-6} -Alkenyl Halogen, Nitro, Amino, N-Mono- C_{1-6} -alkylamino, N,N-Di- C_{1-6} -alkylamino, C_{4-7} -zyklisches Amino, C_{1-6} -Alkyoxy, Phenoxy, 1-Naphthoxy, 2-Naphthoxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C_{1-6} -Alkoxycarbonyl oder C_{1-6} -Alkylcarbamoyl ist;

35 wobei der Substituent am Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder der heterozyklischen Gruppe Halogen, C_{1-6} -Alkyl, C_{2-6} -Alkenyl, C_{1-6} -Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C_{1-6} -Alkoxycarbonyl, Carbamoyl oder C_{1-6} -Alkylcarbamoyl ist;

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, sowie einen pharmazeutisch annehmbaren Träger, Verdünner oder Excipienten.

40 28. Angiogenese-Inhibitor-Zusammensetzung nach Anspruch 27, worin die gegebenenfalls geschützte Aminogruppe von R^a oder R^b Amino oder Acylamino ist, worin die Acylgruppe C_{1-6} -Alkylcarbonyl, C_{7-10} -Aralkylcarbonyl, C_{6-10} -Arylcarbonyl, C_{1-4} -Alkoxycarbonyl, C_{7-10} -Aralkyloxycarbonyl oder C_{6-10} -Aryloxycarbonyl ist.

45 29. Angiogenese-Inhibitor-Zusammensetzung nach Anspruch 27, worin A' Ethylen, R^c Wasserstoff und R^d C_{1-6} -Alkyl oder C_{2-6} -Alkenyl ist.


30. Angiogenese-Inhibitor-Zusammensetzung nach Anspruch 27, worin die Verbindung
50 5-[2-(Isopropoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[2-(Ethoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[2-(Methoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[2-(Propoxycarbonylamino)ethylthio]imidazo[1,2-a]pyridin oder
5-[2-(Allyloxycarbonylamino)ethylthio]imidazo[1,2-a]pyridin ist.

55 31. Verwendung einer Verbindung der Formel (1), wie in Anspruch 27 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon zur Herstellung einer Angiogenese-Inhibitor-Zusammensetzung.

EP 0 471 236 B1

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung, umfassend das Mischen einer Verbindung der Formel (I):




worin:

X S, S=O, SO₂, O oder NR³ ist, worin R³ ein Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A

(a) eine Gruppe der Formel:



worin l, m und n ganze Zahlen von 0 bis 5 sind und R⁴, R⁵, R⁶, R⁷, R⁸ und R⁹ unabhängig voneinander jeweils (1) Wasserstoff oder (2) C₁₋₆-Alkyl, C₂₋₆-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl ist, die 1 - 4 Substituenten tragen können, oder worin R⁴ und R⁵ oder R⁶ und R⁷ oder R⁸ und R⁹ miteinander zu einem Ring verbunden sein können, oder

(b) eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂-, oder


(c) eine Gruppe der Formel:



ist, worin o und p ganze Zahlen von 0 bis 5 sind;

B

(a) eine Gruppe der Formel:



worin R¹⁰ (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (3) ein Vertreter, ausgewählt aus -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ und -CS-NR¹⁴R¹⁵ ist und R¹¹ -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ oder -CS-NR¹⁴R¹⁵ ist, oder

(b) eine Gruppe der Formel:




EP 0 471 236 B1

ist, worin R^{18} (1) geradkettiges oder verzweigtes C_{1-30} -Alkyl, C_{3-8} -Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C_{2-30} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (2) $-CO-NR^{14}R^{15}$ oder $-CO-R^{19}$ ist, worin:


R^{12} , R^{14} und R^{15} unabhängig voneinander (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C_{1-30} -Alkyl, C_{3-8} -Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C_{2-30} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, sind;

R^{13} , R^{16} , R^{17} , R^{18} und R^{19} unabhängig voneinander geradkettiges oder verzweigtes C_{1-30} -Alkyl, C_{3-8} -Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C_{2-30} -Alkenyl, Phenyl- C_{1-6} -alkyl, Naphthyl- C_{1-6} -alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl sind,

R^{10} und R^3 miteinander zu einem Ring der Formel:




verbunden sein können, worin q eine ganze Zahl von 2 oder 3 ist, A und R^{11} wie zuvor definiert sind, oder R^{10} mit R^4 , R^5 oder R^8 zu einem Ring der Formel:




verbunden sein kann, worin q und r ganze Zahlen von 2 oder 3 sind und R^{11} wie zuvor definiert ist, oder R^{10} mit R^{11} zu einem Ring der Formel:


5




10



15




20



25

30

35



40

45

50

55

142

EP 0 471 236 B1

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist; und


R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind,

oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, mit einem pharmazeutisch annehmbaren Träger, Verdünner oder Exciplienten.

2. Verfahren nach Anspruch 1, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ nach Anspruch 1 ist, oder Tritylamino ist.

3. Verwendung einer Verbindung der Formel (I), wie in Anspruch 1 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.

4. Verfahren zur Herstellung einer Verbindung der Formel (I'):




(I ')

worin:


X S, S = O, SO₂, O oder NR³ ist, worin R³ ein Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A eine Gruppe der Formel:



worin alle Symbole wie in Anspruch 1 definiert sind,

oder -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:




ist, worin o und p ganze Zahlen von 0 bis 5 sind;

B¹ eine Aminogruppe ist, die mit einer Acylgruppe acyliert ist, die von einer Carbonsäure mit 2 oder mehr Kohlenstoffatomen, einer Sulfonsäure, einer Carbaminsäure oder einer Thiocarbaminsäure stammt; und

R¹ und R² gleich oder unterschiedlich und Wasserstoff, unabhängig voneinander C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl,

EP 0 471 236 B1

Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind,
 oder eines Salzes oder Solvats davon, oder
 einer Verbindung der Formel (I''):




(I'')

worin:


X S, S = O, SO₂, O oder NR³ ist, worin R³ Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A eine Gruppe der Formel:




worin alle Symbole wie in Anspruch 1 definiert sind,

oder eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:



ist, worin o und p ganze Zahlen von 0 bis 5 sind;

B² eine Gruppe der Formel:



ist, worin alle Symbole wie in Anspruch 1 definiert sind,

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxycarbonyl oder C₁₋₆-Alkylcarbonyl ist;

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino,


EP 0 471 236 B1

C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist; und

R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind, oder eines Salzes oder Solvats davon,

das umfaßt:

Umsetzen einer Verbindung der Formel:



worin alle Symbole wie in Anspruch 1 oder 2 definiert sind, mit einer Verbindung der Formel Q¹-NR¹⁴R¹⁵, G-CO(O)_q-R¹⁶ oder G²-SO₂R¹⁷, worin Q¹ = PhO-CO-, G-CO- oder G-CS- (worin Ph eine Phenylgruppe und G ein Halogen ist), G¹ ein Halogen oder R¹⁶(O)_q-CO-O- ist, worin q jeweils 0 oder 1 ist, G² ein Halogen oder R¹⁷SO₂O- ist und die anderen Symbole wie in Anspruch 1 definiert sind).

5. Verfahren nach Anspruch 4, worin
B¹ eine Gruppe der Formel:



ist, worin R¹⁰ (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (3) -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ und -CS-NR¹⁴R¹⁵ ist;

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist; und

worin R¹¹ -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ oder -CS-NR¹⁴R¹⁵ ist;

worin R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ und R¹⁷ wie in Anspruch 1 definiert sind;

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxycarbonyl oder C₁₋₆-Alkylcarbonyl ist; und

die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.

6. Verfahren nach Anspruch 4, worin B¹ -NH-SO₂R¹⁷ ist, worin R¹⁷ wie in Anspruch 1 definiert ist.

7. Verfahren nach Anspruch 4, worin X S oder O und B¹ -NH-SO₂R¹⁷ ist, worin R¹⁷ wie in Anspruch 1 definiert ist.


8. Verfahren nach Anspruch 4, worin

5-[2-(Methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[2-(Trifluormethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[3-(Methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridin,
5-[3-(Trifluormethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridin,

EP 0 471 236 B1

5-[3-(Methylsulfonylamino)propylthio]imidazo[1,2-a]pyridin oder
5-[3-(Trifluormethylsulfonylamino)propylthio]imidazo[1,2-a]pyridin hergestellt wird.

9. Verwendung einer Verbindung der Formel (I'), wie in Anspruch 4 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.
10. Verfahren nach Anspruch 4, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.
11. Verfahren nach Anspruch 4, worin X S oder O ist.
12. Verfahren nach Anspruch 4, worin
5-[1-(Methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridin oder
5-[1-(Trifluormethyl)-4-piperidylthio]imidazo[1,2-a]pyridin hergestellt wird.
13. Verwendung einer Verbindung der Formel (I''), wie in Anspruch 4 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.
14. Verbindung der Formel (I'''):




(I''')

worin:


X S, S = O, SO₂, O oder NR³ ist, worin R³ Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A eine Gruppe der Formel:



worin alle Symbole wie in Anspruch 1 definiert sind,

oder eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:



ist, worin o und p ganze Zahlen von 0 bis 5 sind;

R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind; und

B³ -O-CO-NR¹⁵R¹⁶ oder -O-CO-R¹⁹ ist,

EP 0 471 236 B1

worin R^{15} , R^{16} und R^{19} wie in Anspruch 1 definiert sind,
wobei der Substituent am C_{1-6} -Alkyl Halogen, Nitro, Amino, N-Mono- C_{1-6} -alkylamino, N,N-Di- C_{1-6} -alkylamino, 4- bis 7-gliedriges zyklisches Amino, C_{1-6} -Alkoxy, C_{6-10} -Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C_{1-6} -Alkoxycarbonyl oder C_{1-6} -Alkylcarbonyl ist;

wobei der Substituent am Phenyl- C_{1-6} -alkyl oder Naphthyl- C_{1-6} -alkyl Halogen, C_{1-6} -Alkyl, C_{1-6} -Alkoxy, Nitro, Cyano, Hydroxy, C_{1-6} -Alkoxycarbonyl, Carbamoyl oder C_{1-6} -Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothieryl oder Benzofuranyl Halogen, C_{1-6} -Alkyl, C_{1-6} -Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C_{1-6} -Alkoxycarbonyl, Carbamoyl oder C_{1-6} -Alkylcarbamoyl ist;


das umfaßt:

Umsetzen einer Verbindung der Formel:




worin die Symbole wie zuvor definiert sind, mit einer Verbindung der Formel $Q^1-NR^{15}R^{16}$ oder $G^1-CO-(O)_q-R^{19}$, worin Q^1 , G^1 und q wie in Anspruch 4 definiert und die anderen Symbole wie in Anspruch 1 definiert sind, oder

Umsetzen einer Verbindung der Formel:



worin E ein Halogen ist und die anderen Symbole wie zuvor definiert sind, mit einer Verbindung der Formel HX^1-A-B^3 , worin X^1 S, O oder NR^3 ist und die anderen Substituenten wie zuvor definiert sind, oder


Umsetzen einer Verbindung der Formel:



worin X^2 S oder O ist und die anderen Symbole wie zuvor definiert sind, mit einer Verbindung der Formel E^1-A-B^3 , worin E^1 eine Abgangsgruppe ist und die anderen Symbole wie zuvor definiert sind, oder

falls $X S=O$ oder SO_2 ist, Oxidieren einer Verbindung der Formel:

EP 0 471 236 B1



worin alle Symbole wie zuvor definiert sind.

15. Verfahren nach Anspruch 14, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.


16. Verfahren nach Anspruch 14, worin X S oder O und B³ -O-CONHR¹⁶ ist, worin R¹⁶ wie in Anspruch 1 definiert ist.

17. Verfahren nach Anspruch 14, worin
5-[2-(Methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridin oder
5-[2-[3-(Hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridin hergestellt wird.

18. Verwendung einer Verbindung der Formel (I'''), wie in Anspruch 14 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.


19. Verfahren zur Herstellung einer Verbindung nach Anspruch 4, oder eines Salzes oder Solvats davon, das umfaßt:

Umsetzen einer Verbindung der Formel:



worin E ein Halogen ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel HX¹-A-B¹, worin X¹ S, O oder NR³ ist und die anderen Substituenten wie in Anspruch 4 definiert sind, oder


falls X S oder O ist, Umsetzen einer Verbindung der Formel:



worin X² S oder O ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel E¹-A-B¹, worin E¹ eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 4 definiert sind, oder

falls X S=O oder SO₂ ist, Oxidieren einer Verbindung der Formel:

EP 0 471 236 B1




5

10 worin alle Symbole wie in Anspruch 4 definiert sind.

20. Verfahren zur Herstellung einer Verbindung nach Anspruch 4, oder eines Salzes oder Solvats davon, das umfaßt:

Umsetzen einer Verbindung der Formel:

15




20

25 worin E ein Halogen ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel HX^1-A-B^2 , worin X^1 S, O oder NR^3 ist und die anderen Substituenten wie in Anspruch 4 definiert sind, oder

falls das Stickstoffatom der Aminogruppe B^2 mit dem Kohlenstoffatom von A einen Ring bildet, Umsetzen einer Verbindung der Formel:

30




35

40 worin X^2 S oder O ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel E^1-A-B^2 , worin E^1 eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 4 definiert sind, oder

falls X S=O oder SO_2 ist, Oxidieren einer Verbindung der Formel:

45




50

55 worin alle Symbole wie in Anspruch 4 definiert sind.

EP 0 471 236 B1

21. Verwendung einer Verbindung der Formel (1):



worin A':

(a) eine Gruppe der Formel:



25 worin x, y und z ganze Zahlen von 0 bis 5 sind und R^e, R^f, R^g, R^h, Rⁱ und R^j jeweils (1) ein Wasserstoff oder (2) ein C₁₋₆-Alkyl, C₂₋₆-Alkenyl, das 1 - 5 Substituenten tragen kann, oder (3) Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl C₆₋₁₄-Aryl oder eine aromatische, mono- oder bityklische heterozyklische Gruppe ist, die 1 - 4 Heteroatome, ausgewählt aus Schwefel, Sauerstoff und Stickstoff, enthält und 1 - 4 Substituenten tragen kann, oder worin R^e und R^f oder R^g und R^h oder Rⁱ und R^j miteinander zu einem C₃₋₈-Cycloalkan-Ring verbunden sein können, oder worin R^e oder R^g gemeinsam mit Rⁱ oder R^j miteinander zu einem C₃₋₈-Cycloalkan-Ring verbunden sein können, oder
 30 (b) eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder
 (c) der Formel:



40 ist, worin a und b jeweils ganze Zahlen von 0 bis 5 sind;

worin:

45 R^a und R^b gleich oder unterschiedlich und ein Wasserstoff, eine C₁₋₆-Alkyl-, C₂₋₆-Alkenyl-, Phenyl-C₁₋₆-alkyl-, Naphthyl-C₁₋₆-alkyl- oder C₆₋₁₄-Aryl-Gruppe, die 1 - 4 Substituenten tragen kann; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxy-carbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind;


R^c ein Wasserstoff oder R^c ist und R^d C₁₋₆-Alkyl, C₃₋₈-Cycloalkyl, C₂₋₆-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder C₆₋₁₄-Aryl, die 1 - 5 Substituenten tragen kann, sind;

R^e und R^g oder R^f, oder R^e und R^h oder Rⁱ oder R^j miteinander zu

50

55

EP 0 471 236 B1



verbunden sein können, worin Q und R ganze Zahlen von 2 oder 3 sind;

15 wobei der Substituent am C₁₋₆-Alkyl, C₃₋₈-Cycloalkyl oder C₂₋₆-Alkenyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, C₄₋₇-zyklisches Amino, C₁₋₆-Alkoxy, Phenoxy, 1-Naphthoxy, 2-Naphthoxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkyoxycarbonyl oder C₁₋₆-Alkylcarbamoyl ist;

20 wobei der Substituent am Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder der heterozyklischen Gruppe Halogen, C₁₋₆-Alkyl, C₂₋₆-Alkenyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, und eines pharmazeutisch annehmbaren Trägers, Verdünners oder Excipienten zur Herstellung einer Angiogenese-Inhibitor-Zusammensetzung.


25

Patentansprüche für folgenden Vertragsstaat : GR

1. Verfahren zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung, umfassend das Mischen einer Verbindung der Formel (I):

30

35



40

worin:


X S, S=O, SO₂, O oder NR³ ist, worin R³ ein Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A

(a) eine Gruppe der Formel:

45

50



55

worin l, m und n jeweils ganze Zahlen von 0 bis 5 sind und jedes R⁴, R⁵, R⁶, R⁷, R⁸ und R⁹ unabhängig voneinander jeweils (1) Wasserstoff oder (2) C₁₋₆-Alkyl, C₂₋₆-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl ist, die 1 - 4 Substituenten tragen können, oder worin R⁴

EP 0 471 236 B1

und R⁵ oder R⁶ und R⁷ oder R⁸ und R⁹ miteinander zu einem Ring verbunden sein können, oder

(b) eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder


(c) eine Gruppe der Formel:



ist, worin o und p ganze Zahlen von 0 bis 5 sind;

B

(a) eine Gruppe der Formel:



worin R¹⁰ (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (3) ein Vertreter, ausgewählt aus -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ und -CS-NR¹⁴R¹⁵ ist, und R¹¹ -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ oder -CS-NR¹⁴R¹⁵ ist, oder


(b) eine Gruppe der Formel:



ist, worin R¹⁸ (1) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (2) -CO-NR¹⁴R¹⁵ oder -CO-R¹⁹ ist, worin:


R¹², R¹⁴ und R¹⁵ unabhängig voneinander (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, sind;

R¹³, R¹⁶, R¹⁷, R¹⁸ und R¹⁹ unabhängig voneinander geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl sind, R¹⁰ und R¹¹ miteinander zu einem Ring der Formel:




verbunden sein können, worin q eine ganze Zahl von 2 oder 3 ist, A und R¹¹ wie zuvor definiert sind, oder R¹⁰ mit R⁴, R⁶ oder R⁸ zu einem Ring der Formel:

EP 0 471 236 B1




verbunden sein kann, worin q und r ganze Zahlen von 2 oder 3 sind und R¹¹ wie zuvor definiert ist, oder R¹⁰ mit R¹¹ zu einem Ring der Formel:



verbunden sein kann,

wobei R¹⁴ und R¹⁵ gemeinsam mit dem benachbarten Stickstoffatom 1-Aziridinyl, 1-Azetidinyl, Piperidino, Perhydro-1-azepinyl, Perhydro-1-azocynyl, Morpholino, Thiomorpholino, 1-Piperazinyl, 3-Thiazolidinyl, 1-Indolyl, Perhydro-1-indolyl, 2-Isoindolyl, Perhydro-2-isoindolyl, 1,2,3,4-Tetrahydro-1-chinolyl, 1,2,3,4-Tetrahydro-2-isochinolyl, Perhydro-1-chinolyl, Perhydro-2-isochinolyl, 3-Azabicyclo[3,2,2]-non-3-yl, 9-Carbazolyl, 10-Acridanyl,



10,11-Dihydro-5H-5-dibenz[b,f]azepinyl, 5,6,11,12-Tetrahydro-5-dibenz[b,f]azocinyl, 1,2,3,4-Tetrahydro-

EP 0 471 236 B1

9-carbazolyl, 10-Phenoxadinyll oder 10-Phenothiadinyll bilden können;

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxy-carbonyl oder C₁₋₆-Alkyl-carbonyl ist,

wobei der Substituent am C₁₋₃₀-Alkyl oder C₂₋₃₀-Alkenyl (1) C₃₋₈-Cycloalkyl, (2) gegebenenfalls mit 1 - 4 Substituenten, ausgewählt aus C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Hydroxy, Nitro und Halogen, substituiertes Phenyl, (3) Naphthyl, (4) Halogen, (5) Cyano, (6) Oxo oder (7) C₁₋₆-Alkoxy ist;

wobei der Substituent am C₃₋₈-Cycloalkyl oder am gesättigten bi- oder trizyklischen Kohlenwasserstoff C₁₋₆-Alkyl, Halogen-C₁₋₆-alkyl, Hydroxy-C₁₋₆-alkyl, Acyloxy-C₁₋₆-alkyl, C₁₋₆-Alkoxy-C₁₋₆-alkyl, C₁₋₆-Alkoxy, Halogen-C₁₋₆-alkoxy, C₁₋₆-Alkoxy-carbonyl-C₁₋₆-alkoxy, C₁₋₆-Alkenyloxy, Aryloxy, C₁₋₆-Alkoxy-C₁₋₆-alkoxy, C₁₋₆-Alkoxy-carbonyl, Carboxy, Carbamoyl, N,N-Di-C₁₋₆-alkyl-carbamoyl, N-C₁₋₆-Alkyl-carbamoyl, Halogen, Cyano, Nitro, Hydroxy, Acyloxy, Amino, C₁₋₆-Alkylsulfonamino, Acylamino, C₁₋₆-Alkoxy-carbonylamino, Acyl, Mercapto, C₁₋₆-Alkylthio, C₁₋₆-Alkyl-sulfinyl, C₁₋₆-Alkylsulfonyl oder Oxo ist;

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxy-carbonyl, Carbamoyl oder C₁₋₆-Alkyl-carbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxy-carbonyl, Carbamoyl oder C₁₋₆-Alkyl-carbamoyl ist; und


R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxy-carbonyl-Gruppe oder eine C₁₋₆-Alkyl-carbamoyl-Gruppe sind,

oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, mit einem pharmazeutisch annehmbaren Träger, Verdünner oder Excipienten.

2. Verfahren nach Anspruch 1, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ nach Anspruch 1 ist, oder Tritylamino ist.

3. Verwendung einer Verbindung der Formel (I), wie in Anspruch 1 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.

4. Verbindung der Formel (I'):




(I')

worin:

X S, S=O, SO₂, O oder NR³ ist, worin R³ ein Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

A eine Gruppe der Formel:



worin alle Symbole wie in Anspruch 1 definiert sind,

EP 0 471 236 B1

oder $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ oder eine Gruppe der Formel:




ist, worin o und p ganze Zahlen von 0 bis 5 sind;

10 B¹ eine Aminogruppe ist, die mit einer Acylgruppe acyliert ist, die von einer Carbonsäure mit 2 oder mehr Kohlenstoffatomen, einer Sulfonsäure, einer Carbaminsäure oder einer Thiocarbaminsäure stammt; und

15 R¹ und R² gleich oder unterschiedlich und Wasserstoff, unabhängig voneinander C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind, oder ein Salz oder Solvat davon.

20 5. Verbindung nach Anspruch 4, worin:

B¹ eine Gruppe der Formel:



25 ist, worin R¹⁰ (1) Wasserstoff oder (2) geradkettiges oder verzweigtes C₁₋₃₀-Alkyl, C₃₋₈-Cycloalkyl, eine durch Anellieren von 5- bis 8-gliedrigen Ringen gebildete gesättigte bi- oder trizyklische Kohlenwasserstoffgruppe, C₂₋₃₀-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können, oder (3) $-\text{CO}-\text{R}^{12}$, $-\text{SO}_2\text{R}^{13}$, $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ und $-\text{CS}-\text{NR}^{14}\text{R}^{15}$ ist;

30 wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbamoyl ist; und

35 worin R¹¹ $-\text{CO}-\text{R}^{16}$, $-\text{SO}_2\text{R}^{17}$, $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ oder $-\text{CS}-\text{NR}^{14}\text{R}^{15}$ ist;

worin R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ und R¹⁷ wie in Anspruch 1 definiert sind;

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxycarbonyl oder C₁₋₆-Alkylcarbonyl ist; und

40 die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.

6. Verbindung nach Anspruch 4, worin B¹ $-\text{NH}-\text{SO}_2\text{R}^{17}$ ist, worin R¹⁷ wie in Anspruch 1 definiert ist.

45 7. Verbindung nach Anspruch 4, worin X S oder O und B¹ $-\text{NH}-\text{SO}_2\text{R}^{17}$ ist, worin R¹⁷ wie in Anspruch 1 definiert ist.


8. Verbindung nach Anspruch 4, die

50 5-[2-(Methylsulfonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[2-(Trifluormethylsulfonylamino)ethylthio]imidazo[1,2-a]pyridin,
5-[3-(Methylsulfonylamino)propyloxy]imidazo[1,2-a]pyridin,
5-[3-(Trifluormethylsulfonylamino)propyloxy]imidazo[1,2-a]pyridin,
5-[3-(Methylsulfonylamino)propylthio]imidazo[1,2-a]pyridin oder
55 5-[3-(Trifluormethylsulfonylamino)propylthio]imidazo[1,2-a]pyridin ist.

9. Verwendung einer Verbindung der Formel (I'), wie in Anspruch 4 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.

EP 0 471 236 B1

10. Verbindung der Formel (I''):



worin:

X S, S=O, SO₂, O oder NR³ ist, worin R³ Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;

15 A eine Gruppe der Formel:



25

worin alle Symbole wie in Anspruch 1 definiert sind,
oder eine Gruppe der Formel -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:


30



35

ist, worin o und p ganze Zahlen von 0 bis 5 sind;
B² eine Gruppe der Formel:

40



ist, worin alle Symbole wie in Anspruch 1 definiert sind,

50

wobei der Substituent am C₁₋₆-Alkyl Halogen, Nitro, Amino, N-Mono-C₁₋₆-alkylamino, N,N-Di-C₁₋₆-alkylamino, 4- bis 7-gliedriges zyklisches Amino, C₁₋₆-Alkoxy, C₆₋₁₀-Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C₁₋₆-Alkoxycarbonyl oder C₁₋₆-Alkylcarbonyl ist;

wobei der Substituent am Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Hydroxy, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbonyl ist;

55


wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C₁₋₆-Alkyl, C₁₋₆-Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C₁₋₆-Alkoxycarbonyl, Carbamoyl oder C₁₋₆-Alkylcarbonyl ist; und

R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-

EP 0 471 236 B1

Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind,
 5 oder ein Salz oder Solvat davon.


11. Verbindung nach Anspruch 10, worin die gegebenenfalls geschützte Aminogruppe von R¹ und R² Amino, Acylamino, worin die Acylgruppe dieselbe wie in R¹¹ ist, oder Tritylamino ist.
12. Verbindung nach Anspruch 10, worin X S oder O ist.
13. Verbindung nach Anspruch 10, die 5-[1-(Methylsulfonyl)-4-piperidylthio]imidazo[1,2-a]pyridin oder 5-[1-(Trifluormethyl)-4-piperidylthio]imidazo[1,2-a]pyridin ist.
14. Verwendung einer Verbindung der Formel (I''), wie in Anspruch 10 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.
15. Verbindung der Formel (I'''):



(I''')


30 worin:

X S, S = O, SO₂, O oder NR³ ist, worin R³ Wasserstoff oder ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl oder Naphthyl-C₁₋₆-alkyl ist, das 1 - 4 Substituenten tragen kann;
 A eine Gruppe der Formel:



40 worin alle Symbole wie in Anspruch 1 definiert sind,

oder eine Gruppe der Formel: -CH₂CH₂OCH₂CH₂- oder eine Gruppe der Formel:



50 ist, worin o und p ganze Zahlen von 0 bis 5 sind;

R¹ und R² gleich oder unterschiedlich und ein Wasserstoff, ein gegebenenfalls substituiertes C₁₋₆-Alkyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl, die 1 - 4 Substituenten tragen können; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁₋₆-Alkoxycarbonyl-Gruppe oder eine C₁₋₆-Alkylcarbamoyl-Gruppe sind; und

B³ -O-CO-NR¹⁵R¹⁶ oder -O-CO-R¹⁹ ist,

EP 0 471 236 B1

worin R^{15} , R^{16} und R^{19} wie in Anspruch 1 definiert sind,
wobei der Substituent am C_{1-6} -Alkyl Halogen, Nitro, Amino, N-Mono- C_{1-6} -alkylamino, N,N-Di- C_{1-6} -alkylamino, 4- bis 7-gliedriges zyklisches Amino, C_{1-6} -Alkoxy, C_{6-10} -Aryloxy, Carbamoyl, Cyano, Hydroxy, Carboxy, C_{1-6} -Alkoxy-carbonyl oder C_{1-6} -Alkyl-carbonyl ist;

wobei der Substituent am Phenyl- C_{1-6} -alkyl oder Naphthyl- C_{1-6} -alkyl Halogen, C_{1-6} -Alkyl, C_{1-6} -Alkoxy, Nitro, Cyano, Hydroxy, C_{1-6} -Alkoxy-carbonyl, Carbamoyl oder C_{1-6} -Alkyl-carbamoyl ist;

wobei der Substituent am Phenyl, 1-Naphthyl, 2-Naphthyl, Phenanthryl, Anthryl, Thienyl, Furyl, Benzothienyl oder Benzofuranyl Halogen, C_{1-6} -Alkyl, C_{1-6} -Alkoxy, Nitro, Cyano, Oxo, Hydroxy, Amino, C_{1-6} -Alkoxy-carbonyl, Carbamoyl oder C_{1-6} -Alkyl-carbamoyl ist.

16. Verbindung nach Anspruch 15, worin die gegebenenfalls geschützte Aminogruppe von R^1 und R^2 Amino, Acylamino, worin die Acylgruppe dieselbe wie in R^{11} ist, oder Tritylamino ist.


17. Verbindung nach Anspruch 15, worin X S oder O und B^3 -O-CONHR¹⁶ ist, worin R^{16} wie in Anspruch 1 definiert ist.

18. Verbindung nach Anspruch 15, die
5-[2-(Methylcarbamoyloxy)ethylthio]imidazo[1,2-a]pyridin oder
5-[2-[3-(Hydroxy)propylcarbamoyloxy]ethylthio]imidazo[1,2-a]pyridin ist.

19. Verwendung einer Verbindung der Formel (I'''), wie in Anspruch 15 definiert, oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Calmodulin-Inhibitor-Zusammensetzung.

20. Verfahren zur Herstellung einer Verbindung nach Anspruch 4 oder 10 oder eines Salzes oder Solvats davon, das umfaßt:


Umsetzen einer Verbindung der Formel:



worin alle Symbole wie in Anspruch 1 oder 2 definiert sind, mit einer Verbindung der Formel Q^1 -NR¹⁴R¹⁵, G^1 -CO(O)_q-R¹⁶ oder G^2 -SO₂R¹⁷, worin Q^1 PhO-CO-, G-CO- oder G-CS- (worin Ph eine Phenylgruppe und G ein Halogen ist), G^1 ein Halogen oder R^{16} (O)_q-CO-O- ist, worin q jeweils 0 oder 1 ist, G^2 ein Halogen oder R^{17} SO₂O- ist und die anderen Symbole wie in Anspruch 1 definiert sind.

21. Verfahren zur Herstellung einer Verbindung nach Anspruch 4 oder eines Salzes oder Solvats davon, das umfaßt:

Umsetzen einer Verbindung der Formel:




worin E ein Halogen ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel HX^1 -A-B¹, worin X¹ S, O oder NR³ ist und die anderen Substituenten wie in Anspruch 4 definiert sind, oder,

EP 0 471 236 B1

falls X S oder O ist, Umsetzen einer Verbindung der Formel:

5




10

worin X² S oder O ist und die anderen Symbole wie in Anspruch 4 definiert sind, mit einer Verbindung der Formel E¹-A-B¹, worin E¹ eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 4 definiert sind, oder,

15

falls X S = O oder SO₂ ist, Oxidieren einer Verbindung der Formel:

20



25


worin alle Symbole wie in Anspruch 4 definiert sind.

22. Verfahren zur Herstellung einer Verbindung nach Anspruch 10 oder eines Salzes oder Solvats davon, das umfaßt:

30

Umsetzen einer Verbindung der Formel:

35




40

worin E ein Halogen ist und die anderen Symbole wie in Anspruch 10 definiert sind, mit einer Verbindung der Formel HX¹-A-B², worin X¹ S, O oder NR³ ist und die anderen Substituenten wie in Anspruch 10 definiert sind, oder,

45

falls das Stickstoffatom der Aminogruppe B² mit einem Kohlenstoffatom von A einen Ring bildet, Umsetzen einer Verbindung der Formel:

50



55


worin X² S oder O ist und die anderen Symbole wie in Anspruch 10 definiert sind, mit einer Verbindung der Formel E¹-A-B², worin E¹ eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 10

EP 0 471 236 B1

definiert sind, oder

falls $X = S$ oder SO_2 ist, Oxidieren einer Verbindung der Formel:

5




10

worin alle Symbole wie in Anspruch 10 definiert sind.

23. Verfahren zur Herstellung einer Verbindung nach Anspruch 15 oder eines Salzes oder Solvats davon, das umfaßt:

Umsetzen einer Verbindung der Formel:

20




25

worin die Symbole wie in Anspruch 15 definiert sind, mit einer Verbindung der Formel $Q^1-NR^{15}R^{16}$ oder $G^1-CO(O)_q-R^{19}$, worin Q^1 , G^1 und q wie in Anspruch 20 definiert und die anderen Symbole wie in Anspruch 1 definiert sind, oder

30

Umsetzen einer Verbindung der Formel:

35




40

worin E ein Halogen ist und die anderen Symbole wie in Anspruch 15 definiert sind, mit einer Verbindung der Formel HX^1-A-B^3 , worin X^1 S, O oder NR^3 ist und die anderen Substituenten wie in Anspruch 15 definiert sind, oder

45

Umsetzen einer Verbindung der Formel:

50



55

worin X^2 S oder O ist und die anderen Symbole wie in Anspruch 15 definiert sind, mit einer Verbindung der Formel E^1-A-B^3 , worin E^1 eine Abgangsgruppe ist und die anderen Symbole wie in Anspruch 15 definiert sind, oder,

EP 0 471 236 B1


falls $X = S = O$ oder SO_2 ist, Oxidieren einer Verbindung der Formel:



worin alle Symbole wie in Anspruch 15 definiert sind.

24. Verwendung einer Verbindung der Formel (1):


15



worin A':

(a) eine Gruppe der Formel:

30



worin x, y und z jeweils ganze Zahlen von 0 bis 5 sind und Rᵉ, Rᶠ, Rᵍ, Rʰ, Rⁱ und Rʲ jeweils (1) ein Wasserstoff oder (2) ein C₁-₆-Alkyl, C₂-₆-Alkenyl, das 1 - 5 Substituenten tragen kann, oder (3) Phenyl-C₁-₆-alkyl, Naphthyl-C₁-₆-alkyl C₆-₁₄-Aryl oder eine aromatische, mono- oder bicyclische heterozyklische Gruppe ist, die 1 - 4 Heteroatome, ausgewählt aus Schwefel, Sauerstoff und Stickstoff, enthält und 1 - 4 Substituenten tragen kann, oder worin Rᵉ und Rᶠ oder Rᵍ und Rʰ oder Rⁱ und Rʲ miteinander zu einem C₃-₈-Cycloalkan-Ring verbunden sein können, oder worin Rᵉ oder Rᵍ gemeinsam mit Rᶠ oder Rʲ miteinander zu einem C₃-₈-Cycloalkan-Ring verbunden sein können, oder

(b) eine Gruppe der Formel: $-CH_2CH_2OCH_2CH_2-$ oder

(c) der Formel:

50




ist, worin a und b jeweils ganze Zahlen von 0 bis 5 sind;
worin:

55

Rᵃ und Rᵇ gleich oder unterschiedlich und ein Wasserstoff, eine C₁-₆-Alkyl-, C₂-₆-Alkenyl-, Phenyl-C₁-₆-alkyl-, Naphthyl-C₁-₆-alkyl- oder C₆-₁₄-Aryl-Gruppe, die 1 - 4 Substituenten tragen kann; ein Halogen, eine Nitrogruppe, eine Nitrosogruppe, eine gegebenenfalls geschützte Aminogruppe, eine C₁-₆-Alkoxycarbonyl-Gruppe oder eine C₁-₆-Alkylcarbamoyl-Gruppe sind;


R^c ein Wasserstoff oder R^c ist und R^d C₁₋₆-Alkyl, C₃₋₈-Cycloalkyl, C₂₋₆-Alkenyl, Phenyl-C₁₋₆-alkyl, Naphthyl-C₁₋₆-alkyl oder C₆₋₁₄-Aryl, das 1 - 5 Substituenten tragen kann, sind;
R^c und R^e oder Rⁱ, oder R^c und R^g oder R^h, oder R^c und Rⁱ oder R^j miteinander zu




oder eines pharmazeutisch annehmbaren Salzes oder Solvats davon, zur Herstellung einer Angiogenese-Inhibitor-Zusammensetzung.

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Composition inhibitrice de la calmoduline, comprenant un composé de formule (I) :



(a) un groupe de formule




dans laquelle l, m et n représentent des nombres entiers dont chacun vaut de 0 à 5, et chacun des symboles R^4 , R^5 , R^6 , R^7 , R^8 et R^9 représente indépendamment (1) un atome d'hydrogène ou (2) un groupe alkyle en C_1-C_6 , alcényle en C_2-C_6 , phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 , phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou bien R^4 et R^5 , ou R^6 et R^7 , ou R^8 et R^9 .

EP 0 471 236 B1

peuvent être liés l'un à l'autre pour former un cycle, ou bien R^4 ou R^6 peut être lié respectivement à R^8 ou R^9 pour former un cycle, ou

(b) un groupe de formule $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$, ou

(c) un groupe de formule :



dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

B représente


(a) un groupe de formule $-\text{NR}^{10}\text{R}^{11}$ où R^{10} représente (1) un atome d'hydrogène ou (2) un groupe alkyle en $\text{C}_1\text{-C}_{30}$ linéaire ou ramifié, un groupe cycloalkyle en $\text{C}_3\text{-C}_8$, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en $\text{C}_2\text{-C}_{30}$, phényl-alkyle en $\text{C}_1\text{-C}_6$, naphtyl-alkyle en $\text{C}_1\text{-C}_6$, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (3) un groupe choisi parmi $-\text{CO-R}^{12}$, $-\text{SO}_2\text{R}^{13}$, $-\text{CO-NR}^{14}\text{R}^{15}$ et $-\text{CS-NR}^{14}\text{R}^{15}$, et R^{11} représente $-\text{CO-R}^{16}$, $-\text{CO-OR}^{16}$, $-\text{SO}_2\text{R}^{17}$, $-\text{CO-NR}^{14}\text{R}^{15}$ ou $-\text{CS-NR}^{14}\text{R}^{15}$, ou

(b) un groupe de formule $-\text{O-R}^{18}$ où R^{18} représente (1) un groupe alkyle en $\text{C}_1\text{-C}_{30}$ linéaire ou ramifié, un groupe cycloalkyle en $\text{C}_3\text{-C}_8$, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en $\text{C}_2\text{-C}_{30}$, phényl-alkyle en $\text{C}_1\text{-C}_6$, naphtyl-alkyle en $\text{C}_1\text{-C}_6$, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (2) $-\text{CO-NR}^{14}\text{R}^{15}$ ou $-\text{CO-R}^{19}$,

où R^{12} , R^{14} et R^{15} représentent indépendamment (1) un atome d'hydrogène ou (2) un groupe alkyle en $\text{C}_1\text{-C}_{30}$ linéaire ou ramifié, un groupe cycloalkyle en $\text{C}_3\text{-C}_8$, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en $\text{C}_2\text{-C}_{30}$, phényl-alkyle en $\text{C}_1\text{-C}_6$, naphtyl-alkyle en $\text{C}_1\text{-C}_6$, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants ;


R^{13} , R^{16} , R^{17} , R^{18} et R^{19} représentent indépendamment un groupe alkyle en $\text{C}_1\text{-C}_{30}$ linéaire ou ramifié, un groupe cycloalkyle en $\text{C}_3\text{-C}_8$, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en $\text{C}_2\text{-C}_{30}$, phényl-alkyle en $\text{C}_1\text{-C}_6$, naphtyl-alkyle en $\text{C}_1\text{-C}_6$, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle,

R^{10} et R^3 pouvant être liés ensemble pour former un cycle de formule :



dans laquelle q représente un nombre entier volant 2 ou 3, et A et R^{11} ont les définitions indiquées ci-dessus,

ou R^{10} pouvant être lié avec R^4 , R^6 ou R^8 pour former un cycle de formule :



EP 0 471 236 B1

où q et r représentent respectivement un nombre entier valant 2 ou 3, et R¹¹ a la définition indiquée plus haut,
ou R¹⁰ pouvant être lié à R¹¹ pour former un cycle de formule :

5

10

15

20

25

30


35

40


45

50

55



et R¹⁴ et R¹⁵ pouvant former, conjointement avec l'atome d'azote adjacent, un groupe 1-aziridinyle, 1-azétidinyle, pipéridino, perhydro-1-azépinyle, perhydro-1-azocynyle, morpholino, thiomorpholino, 1-pipérazinyle, 3-thiazolidinyle, 1-indolyle, perhydro-1-indolyle, 2-isoindolyle, perhydro-2-isoindolyle, 1,2,3,4-tétrahydro-1-quinolyle, 1,2,3,4-tétrahydro-2-isoquinolyle, perhydro-1-quinolyle, perhydro-2-isoquinolyle, 3-azabicyclo[3.2.2]non-3-yle, 9-carbazolyle, 10-acridanyle,



10,11-dihydro-5H-5-dibenzo[b,f]azépinyle, 5,6,11,12-tétrahydro-5-dibenzo[b,f]azocinyle, 1,2,3,4-tétrahydro-9-carbazolyle, 10-phénoxazinyle ou 10-phénothiazinyle ; ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyle en C₁-C₆)amino, N,N-di(alkyle en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyle en C₁-C₆)carbonyle ;

ledit substituant placé sur un groupe alkyle en C₁-C₃₀ ou alcényle en C₂-C₃₀ pouvant être (1) un groupe cycloalkyle en C₃-C₈, (2) un groupe phényle portant éventuellement de 1 à 4 substituants choisis parmi les atomes d'halogène et les groupes alkyle en C₁-C₆, alcoxy en C₁-C₆, hydroxy et nitro, (3) un groupe naphthyle, (4) un atome d'halogène, (5) un groupe cyano, (6) un groupe oxo ou (7) un groupe alcoxy en C₁-C₆ ;

ledit substituant placé sur un groupe cycloalkyle en C₃-C₈ ou un groupe hydrocarboné saturé bicyclique ou tricyclique pouvant être un groupe alkyle en C₁-C₆, halogénoalkyle en C₁-C₆, hydroxyl-


EP 0 471 236 B1

kyle en C₁-C₆, acyloxy(alkyle en C₁-C₆), (alcoxy en C₁-C₆)-(alkyle en C₁-C₆), alcoxy en C₁-C₆, halogénoalcoxy en C₁-C₆, (alcoxy en C₁-C₆)carbonyl(alcoxy en C₁-C₆), alcényloxy en C₁-C₆, aralkyloxy, (alcoxy en C₁-C₆)-(alcoxy en C₁-C₆), (alcoxy en C₁-C₆)carbonyl, carboxy, carbamyle, N,N-di-(alkyl en C₁-C₆)carbamyle, N-(alkyl en C₁-C₆)carbamyle, cyano, nitro, hydroxy, acyloxy, amino, (alkyl en C₁-C₆)sulfonylamino, acylamino, (alcoxy en C₁-C₆)carbonylamino, acyle, mercapto, alkylthio en C₁-C₆, alkylsulfinyle en C₁-C₆, alkylsulfonyl en C₁-C₆ ou oxo, ou encore un atome d'halogène ;
 ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyl, carbamyle ou (alkyl en C₁-C₆)carbamyle ;
 ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyl, carbamyle ou (alkyl en C₁-C₆)carbamyle ;
 et R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyl ou (alkyl en C₁-C₆)carbamyle,
 ou un sel ou un solvat d'un tel composé, acceptable en pharmacie, et un véhicule, diluant ou excipient, acceptable en pharmacie.

2. Composition inhibitrice de la calmoduline, conforme à la revendication 1, dans laquelle le groupe amino éventuellement protégé représenté par R¹ ou R² est un groupe amino, acylamino où le groupe acyle est le même que celui indiqué pour R¹¹ dans la revendication 1, ou tritylamino.

3. Utilisation d'un composé de formule (I) défini dans la revendication 1 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, pour la préparation d'une composition inhibitrice de la calmoduline.


4. Composé de formule (I') :



(I ')


dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;

A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂- ou

EP 0 471 236 B1




- 5 dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;
 B¹ représente un groupe amino acylé par un groupe acyle dérivé d'un acide carboxylique comportant 2
 atomes de carbone ou plus, d'un acide sulfonique, d'un acide carbamique ou d'un acide thiocarbami-
 que ;
 10 et R¹ et R² sont identiques ou différents et représentent chacun, indépendamment, un atome
 d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, ou
 encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, thiényle, furyle, benzothiényle ou
 benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène, ou un groupe
 15 nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamide,
 ou sel ou solvat d'un tel composé.
5. Composé conforme à la revendication 4, dans lequel B¹ représente un groupe de formule -NR¹⁰R¹¹,
 où R¹⁰ représente (1) un atome d'hydrogène ou (2) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un
 groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la
 20 condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle
 en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle,
 furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (3) un groupe choisi
 parmi -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ et -CS-NR¹⁴R¹⁵ ;
 ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être
 25 un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en
 C₁-C₆)carbonyle, carbamide ou (alkyl en C₁-C₆)carbamide ;
 ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle,
 furyle, benzothiényle ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-
 30 C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamide ou
 (alkyl en C₁-C₆)carbamide ;
 et R¹¹ représente -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ ou -CS-NR¹⁴R¹⁵, où R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ et R¹⁷
 ont les définitions indiquées dans la revendication 1 ;
 ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe
 35 nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant
 de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy
 en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ; et
 le groupe amino éventuellement protégé représenté par R¹ ou R² étant un groupe amino, acylamino où
 le groupe acyle est le même que celui indiqué pour R¹¹, ou tritylamino.
- 40 6. Composé conforme à la revendication 4, dans lequel B¹ représente -NH-SO₂R¹⁷ où R¹⁷ a la définition
 indiquée dans la revendication 1.
7. Composé conforme à la revendication 4, dans lequel X représente -S- ou -O-, et B¹ représente -NH-
 SO₂R¹⁷ où R¹⁷ a la définition indiquée dans la revendication 1.
- 45 8. Composé conforme à la revendication 4, qui est
 la 5-[2-(méthylsulfonylamino)éthylthio]imidazo[1,2-a]pyridine,
 la 5-[2-(trifluorométhylsulfonylamino)éthylthio]imidazo[1,2-a]pyridine,
 la 5-[3-(méthylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
 50 la 5-[3-(trifluorométhylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
 la 5-[3-(méthylsulfonylamino)propylthio]imidazo[1,2-a]pyridine, ou
 la 5-[3-(trifluorométhylsulfonylamino)propylthio]imidazo[1,2-a]pyridine.
9. Composition inhibitrice de la calmoduline, comprenant un composé de formule (I') défini dans la
 55 revendication 4 ou un sel ou solvat d'un tel composé, acceptable en pharmacie, et un véhicule, diluant
 ou excipient, acceptable en pharmacie.

EP 0 471 236 B1

10. Utilisation d'un composé de formule (I') défini dans la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.

5 11. Composé de formule (I'') :




15 dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;
A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂-, ou un groupe de formule :



35 dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;
B² représente un groupe de formule :



où tous les symboles ont les définitions indiquées dans la revendication 1,

50 ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ;

55 ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-

EP 0 471 236 B1

C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

et R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle, ou un sel ou un solvat d'un tel composé.

12. Composé conforme à la revendication 11, dans lequel le groupe amino éventuellement protégé représenté par R¹ et R² est un groupe amino, acylamino où le groupe acyle est le même que celui de R¹¹, ou tritylamino.


13. Composé conforme à la revendication 11, dans lequel X représente -S- ou -O-.

14. Composé conforme à la revendication 11, qui est la 5-[1-(méthylsulfonyl)-4-pipéridylthio]imidazo[1,2-a]pyridine, ou la 5-[1-(trifluorométhyl)-4-pipéridylthio]imidazo[1,2-a]pyridine.

15. Composition inhibitrice de la calmoduline, comprenant un composé de formule (I'') défini dans la revendication 11 ou un sel ou solvat d'un tel composé, acceptable en pharmacie, et un véhicule, diluant ou excipient, acceptable en pharmacie.

16. Utilisation d'un composé de formule (I'') défini dans la revendication 11 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.


17. Composé de formule (I''') :



(I ' ')


dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;

A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂-, ou un groupe de formule :

EP 0 471 236 B1



5

dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène

10

ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle ; et

B³ représente -O-CO-NR¹⁵R¹⁶ ou -O-CO-R¹⁹, où R¹⁵, R¹⁶ et R¹⁹ ont les définitions indiquées dans la

15

revendication 1, ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ;

20

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

25

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle.

18. Composé conforme à la revendication 17, dans lequel le groupe amino éventuellement protégé représenté par R¹ et R² est un groupe amino, acylamino où le groupe acyle est le même que celui de R¹, ou tritylamino.

30

19. Composé conforme à la revendication 17, dans lequel X représente -S- ou -O-, et B³ représente -O-CONHR¹⁶ où R¹⁶ a la définition indiquée dans la revendication 1.

35

20. Composé conforme à la revendication 17, qui est la 5-[2-(méthylcarbamoyloxy)éthylthio]imidazo[1,2-b]pyridine, ou la 5-[2-[3-(hydroxy)propylcarbamoyloxy]éthylthio]imidazo[1,2-b]pyridine.


40

21. Composition inhibitrice de la calmoduline, comprenant un composé de formule (I''') défini dans la revendication 17 ou un sel ou solvat d'un tel composé, acceptable en pharmacie, et un véhicule, diluant ou excipient, acceptable en pharmacie.

45

22. Utilisation d'un composé de formule (I''') défini dans la revendication 17 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.

50




55

dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1 ou 2, avec un composé de formule Q¹-NR¹⁴R¹⁵, G¹-CO(O)₄-R¹⁶, ou G²-SO₂R¹⁷, où Q¹ représente PhO-CO-,

EP 0 471 236 B1


G-CO- ou G-CS- (où Ph représente un groupe phényle et G représente un atome d'halogène), G¹ représente un atome d'halogène ou un groupe R¹⁶(O)_q-CO-O- (où q vaut 0 ou 1), q vaut 0 ou 1, G² représente un atome d'halogène ou un groupe de formule R¹⁷SO₂O-, et les autres symboles ont les définitions indiquées dans la revendication 1.

24. Procédé de préparation d'un composé conforme à la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :



dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 4,


avec un composé de formule HX¹-A-B¹ dans laquelle X¹ représente -S-, -O- ou -NR³-, et les autres symboles ont les définitions indiquées dans la revendication 4, ou bien, quand X représente -S- ou -O-, le fait de faire réagir un composé de formule :



dans laquelle X² représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 4,


avec un composé de formule E¹-A-B¹ où E¹ représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 4,

ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 4.

25. Procédé de préparation d'un composé conforme à la revendication 11 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :




EP 0 471 236 B1

dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 11,

avec un composé de formule HX^1-A-B^2 où X^1 représente -S-, -O- ou -NR³- et les autres symboles ont les définitions indiquées dans la revendication 11,


ou bien, quand l'atome d'azote du groupe amino de B² forme un cycle avec un atome de carbone de A, le fait de faire réagir un composé de formule :



dans laquelle X² représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 11,


avec un composé de formule E¹-A-B² où E¹ représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 11,

ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :




dans laquelle tous les symboles ont les définitions indiquées dans la revendication 11.

26. Procédé de préparation d'un composé conforme à la revendication 17 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :



dans laquelle les symboles ont les définitions indiquées dans la revendication 17,

avec un composé de formule Q¹-NR¹⁵R¹⁶ ou G¹-CO(O)_q-R¹⁹ où Q¹, G¹ et q ont les définitions indiquées dans la revendication 23, et les autres symboles ont les définitions indiquées dans la revendication 1, ou bien le fait de faire réagir un composé de formule :




dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 17,

EP 0 471 236 B1

avec un composé de formule HX^1-A-B^3 où X^1 représente -S-, -O- ou -R³-, et les autres symboles ont les définitions indiquées dans la revendication 17, ou bien le fait de faire réagir un composé de formule :

5

10




dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 17,

15

avec un composé de formule E^1-A-B^3 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 17, ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :

20


25



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 17.

30 27. Composition inhibant l'angiogénèse, comprenant un composé de formule (1) :

35




(1)

40

dans laquelle A' représente
(a) un groupe de formule

45



50

55

dans laquelle x, y et z représentent des nombres entiers valant de 0 à 5, respectivement ; chacun des symboles R^e, R^f, R^g, R^h, Rⁱ et R^j représente (1) un atome d'hydrogène, ou (2) un groupe alkyle en C₁-C₆ ou alcényle en C₂-C₆ qui peut porter de 1 à 5 substituants, ou (3) un groupe phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, aryle en C₆-C₁₄, ou hétérocyclique aromatique monocyclique ou bicyclique comportant de 1 à 4 hétéroatomes, choisis parmi les atomes de soufre, d'oxygène et d'azote, lequel groupe peut porter de 1 à 4 substituants, ou bien R^e et R^f, R^g et R^h ou Rⁱ et R^j peuvent être raccordés pour former un cycle de type cycloalcane en C₃-C₈, ou bien R^e ou R^g peut être raccordé à R^f ou R^j pour former un cycle de type cycloalcane en C₃-C₈.


EP 0 471 236 B1

ou bien

(b) un groupe de formule $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$,

ou bien

(c) un groupe de formule :




dans laquelle a et b représentent des nombres entiers valant respectivement de 0 à 5 ;


R^a et R^b sont identiques ou différents et représentent chacun un atome d'hydrogène ou d'halogène ou un groupe alkyle en C_1-C_6 , alcényle en C_2-C_6 , phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 ou aryle en C_6-C_{14} , lequel groupe peut porter de 1 à 4 substituants, ou encore un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C_1-C_6)carbonyle ou (alkyl en C_1-C_6)carbamyle ;

R^c représente un atome d'hydrogène ou R^d , et R^d représente un groupe alkyle en C_1-C_6 , cycloalkyle en C_3-C_8 , alcényle en C_2-C_6 , phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 ou aryle en C_6-C_{14} , lequel groupe peut porter de 1 à 5 substituants ;

R^e et R^f ou R^i , ou R^e et R^g ou R^h , ou R^e et R^j ou R^l pouvant être raccordés ensemble pour former un groupe de formule :



ou



où Q et R représentent des nombres entiers valant respectivement 2 ou 3 ;

ledit substituant d'un groupe alkyle en C_1-C_6 , cycloalkyle en C_3-C_8 ou alcényle en C_2-C_6 étant un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C_1-C_6)amino, N,N-di(alkyl en C_1-C_6)amino, amino cyclique en C_4-C_7 , alcoxy en C_1-C_6 , phénoxy, 1-naphtyloxy, 2-naphtyloxy, carbamyle, cyano, hydroxy, carboxy, (alcoxy en C_1-C_6)carbonyle ou (alkyl en C_1-C_6)carbamyle ;

ledit substituant d'un groupe phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 ou hétérocyclique étant un atome d'halogène ou un groupe alkyle en C_1-C_6 , alcényle en C_2-C_6 , alcoxy en C_1-C_6 , nitro, cyano, oxo, hydroxy, amino, (alcoxy en C_1-C_6)carbonyle, carbamyle ou (alkyl en C_1-C_6)carbamyle ;

ou un sel d'un tel composé, acceptable en pharmacie, et un diluant, véhicule ou excipient, acceptable en pharmacie.

28. Composition inhibant l'angiogénèse, conforme à la revendication 27, dans laquelle le groupe amino éventuellement protégé de R^a ou R^b est un groupe amino ou acylamino, où le groupe acyle est un groupe (alkyl en C_1-C_6)carbonyle, (aralkyl en C_7-C_{10})carbonyle, (aryl en C_6-C_{10})carbonyle, (alcoxy en C_1-C_4)carbonyle, (aralkyloxy en C_7-C_{10})carbonyle ou (aryloxy en C_6-C_{10})carbonyle.

29. Composition inhibant l'angiogénèse, conforme à la revendication 27, dans laquelle A' représente un groupe éthylène, R^c représente un atome d'hydrogène et R^d représente un groupe alkyle en C_1-C_6 ou alcényle en C_2-C_6 .

30. Composition inhibant l'angiogénèse, conforme à la revendication 27, dans laquelle le composé est de la 5-[2-(isopropylloxycarbonylamino)éthylthio]imidazo[1,2-a]pyridine, de la 5-[2-(éthoxycarbonylamino)éthylthio]imidazo[1,2-a]pyridine, de la 5-[2-(méthoxycarbonylamino)éthylthio]imidazo[1,2-a]pyridine,


EP 0 471 236 B1

de la 5-[2-(propyloxycarbonylamino)éthylthio]imidazo[1,2-a]pyridine, ou
de la 5-[2-(allyloxycarbonylamino)éthylthio]imidazo[1,2-a]pyridine.

31. Utilisation d'un composé de formule (1) défini dans la revendication 27, ou d'un sel ou d'un solvat d'un
tel composé, acceptable en pharmacie, pour la préparation d'une composition inhibant l'angiogénèse.

Revendications pour l'Etat contractant suivant : ES

1. Procédé de préparation d'une composition inhibitrice de la calmoduline, comprenant le fait de mélanger
un composé de formule (I) :




(I)

dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou
un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement
substitué, qui peut porter de 1 à 4 substituants ;

A représente

(a) un groupe de formule



dans laquelle l, m et n représentent des nombres entiers dont chacun vaut de 0 à 5, et chacun
des symboles R⁴, R⁵, R⁶, R⁷, R⁸ et R⁹ représente indépendamment (1) un atome d'hydrogène
ou (2) un groupe alkyle en C₁-C₆, alcényle en C₂-C₆, phényl-alkyle en C₁-C₆, naphtyl-alkyle en
C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou
benzofurannyle, qui peut porter de 1 à 4 substituants, ou bien R⁴ et R⁵, ou R⁶ et R⁷, ou R⁸ et R⁹,
peuvent être liés l'un à l'autre pour former un cycle, ou bien R⁴ ou R⁶ peut être lié respective-
ment à R⁸ ou R⁹ pour former un cycle, ou

(b) un groupe de formule -CH₂CH₂OCH₂CH₂-, ou

(c) un groupe de formule :



dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

B représente

(a) un groupe de formule -NR¹⁰R¹¹ où R¹⁰ représente (1) un atome d'hydrogène ou (2) un groupe
alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné
bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8
chaînon, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆,
phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzo-
furannyle, qui peut porter de 1 à 4 substituants, ou (3) un groupe choisi parmi -CO-R¹², -SO₂R¹³,
-CO-NR¹⁴R¹⁵ et -CS-NR¹⁴R¹⁵, et R¹¹ représente -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ ou

EP 0 471 236 B1

-CS-NR¹⁴R¹⁵, ou

(b) un groupe de formule -O-R¹⁸ où R¹⁸ représente (1) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut


porter de 1 à 4 substituants, ou (2) -CO-NR¹⁴R¹⁵ ou -CO-R¹⁹,

où R¹², R¹⁴ et R¹⁵ représentent indépendamment (1) un atome d'hydrogène ou (2) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons,

ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants ;


R¹³, R¹⁶, R¹⁷, R¹⁸ et R¹⁹ représentent indépendamment un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle,

R¹⁰ et R³ pouvant être liés ensemble pour former un cycle de formule :



dans laquelle q représente un nombre entier valant 2 ou 3, et A et R¹¹ ont les définitions indiquées ci-dessus,


ou R¹⁰ pouvant être lié avec R⁴, R⁶ ou R⁸ pour former un cycle de formule :




où q et r représentent respectivement un nombre entier valant 2 ou 3, et R¹¹ a la définition indiquée plus haut,

ou R¹⁰ pouvant être lié à R¹¹ pour former un cycle de formule :


5




10



15




20



25

30

35



40

10,11-dihydro-5H-5-dibenzo[b,f]azépinyne, 5,6,11,12-tétrahydro-5-dibenzo[b,f]azocinyne, 1,2,3,4-tétrahydro-9-carbazolyne, 10-phénoxazinyne ou 10-phénothiazinyne ;
ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ;
ledit substituant placé sur un groupe alkyle en C₁-C₃₀ ou alcényle en C₂-C₃₀ pouvant être (1) un groupe cycloalkyle en C₃-C₈, (2) un groupe phényle portant éventuellement de 1 à 4 substituants choisis parmi les atomes d'halogène et les groupes alkyle en C₁-C₆, alcoxy en C₁-C₆, hydroxy et nitro, (3) un groupe naphthyle, (4) un atome d'halogène, (5) un groupe cyano, (6) un groupe oxo ou (7) un groupe alcoxy en C₁-C₆ ;
ledit substituant placé sur un groupe cycloalkyle en C₃-C₈ ou un groupe hydrocarboné saturé bicyclique ou tricyclique pouvant être un groupe alkyle en C₁-C₆, halogénoalkyle en C₁-C₆, hydroxyalkyle en C₁-C₆, acyloxy(alkyle en C₁-C₆), (alcoxy en C₁-C₆)-(alkyle en C₁-C₆), alcoxy en C₁-C₆, halogénoalcoxy en C₁-C₆, (alcoxy en C₁-C₆)carbonyle(alcoxy en C₁-C₆), alcényloxy en C₁-C₆, aralkyloxy, (alcoxy en C₁-C₆)(alcoxy en C₁-C₆), (alcoxy en C₁-C₆)carbonyle, carboxy, carbamyle, N,N-di(alkyl en C₁-C₆)carbamyle, N-(alkyl en C₁-C₆)carbamyle, cyano, nitro, hydroxy, acyloxy, amino, (alkyl en C₁-C₆)sulfonylamino, acylamino, (alcoxy en C₁-C₆)carbonylamino, acyle, mercapto, alkylthio en C₁-

EP 0 471 236 B1

C₆, alkylsulfinyle en C₁-C₆, alkylsulfonyle en C₁-C₆ ou oxo, ou encore un atome d'halogène ; .

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;


et R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle,

ou un sel ou un solvat d'un tel composé, acceptable en pharmacie, et un véhicule, diluant ou excipient, acceptable en pharmacie.

2. Procédé conforme à la revendication 1, dans lequel le groupe amino éventuellement protégé représenté par R¹ ou R² est un groupe amino, acylamino où le groupe acyle est le même que celui indiqué pour R¹¹ dans la revendication 1, ou tritylamino.

3. Utilisation d'un composé de formule (I) défini dans la revendication 1 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, pour la préparation d'une composition inhibitrice de la calmoduline.


4. Procédé de préparation d'un composé de formule (I') :



(I ')

dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;

A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂- ou




EP 0 471 236 B1

dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;


B¹ représente un groupe amino acylé par un groupe acyle dérivé d'un acide carboxylique comportant 2 atomes de carbone ou plus, d'un acide sulfonique, d'un acide carbamique ou d'un acide thiocarbamique ;

et R¹ et R² sont identiques ou différents et représentent chacun, indépendamment, un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène, ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle, ou d'un sel ou d'un solvat d'un tel composé, ou d'un composé de formule (I'') :




dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;

A représente un groupe de formule :




dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂-, ou un groupe de formule :



dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

B² représente un groupe de formule :



où tous les symboles ont les définitions indiquées dans la revendication 1, ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant

EP 0 471 236 B1

de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ;


ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyle, benzothiényl ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

et R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyle, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle,

ou d'un sel ou d'un solvat d'un tel composé,

lequel procédé comporte le fait de faire réagir un composé de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1 ou 2,

avec un composé de formule Q¹-NR¹⁴R¹⁵, G¹-CO(O)_q-R¹⁶, ou G²-SO₂R¹⁷, où Q¹ représente PhO-CO-, G-CO- ou G-CS- (où Ph représente un groupe phényle et G représente un atome d'halogène), G¹ représente un atome d'halogène ou un groupe R¹⁶(O)_q-CO-O- (où q vaut 0 ou 1), q vaut 0 ou 1, G² représente un atome d'halogène ou un groupe de formule R¹⁷SO₂O-, et les autres symboles ont les définitions indiquées dans la revendication 1.

5. Procédé conforme à la revendication 4, dans lequel B¹ représente un groupe de formule -NR¹⁰R¹¹, ou R¹⁰ représente (1) un atome d'hydrogène ou (2) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀; phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyle, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (3) un groupe choisi parmi -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ et -CS-NR¹⁴R¹⁵ ;

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyle, benzothiényl ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;


et R¹¹ représente -CO-R¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ ou -CS-NR¹⁴R¹⁵, où R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ et R¹⁷ ont les définitions indiquées dans la revendication 1 ;

ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ; et

le groupe amino éventuellement protégé représenté par R¹ ou R² étant un groupe amino, acylamino où le groupe acyle est le même que celui indiqué pour R¹, ou tritylamino.


EP 0 471 236 B1

6. Procédé conforme à la revendication 4, dans lequel B' représente -NH-SO₂R¹⁷ où R¹⁷ a la définition indiquée dans la revendication 1.
7. Procédé conforme à la revendication 4, dans lequel X représente -S- ou -O-, et B' représente -NH-SO₂R¹⁷ où R¹⁷ a la définition indiquée dans la revendication 1.
8. Procédé conforme à la revendication 4, dans lequel on prépare
la 5-[2-(méthylsulfonylamino)éthylthio]imidazo[1,2-a]pyridine,
la 5-[2-(trifluorométhylsulfonylamino)éthylthio]imidazo[1,2-a]pyridine,
la 5-[3-(méthylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
la 5-[3-(trifluorométhylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
la 5-[3-(méthylsulfonylamino)propylthio]imidazo[1,2-a]pyridine, ou
la 5-[3-(trifluorométhylsulfonylamino)propylthio]imidazo[1,2-a]pyridine.
9. Utilisation d'un composé de formule (I') défini dans la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.
10. Procédé conforme à la revendication 4, dans lequel le groupe amino éventuellement protégé représenté par R¹ et R² est un groupe amino, acylamino où le groupe acyle est le même que celui de R¹¹, ou tritylamino.
11. Procédé conforme à la revendication 4, dans lequel X représente -S- ou -O-.
12. Procédé conforme à la revendication 4, dans lequel on prépare
la 5-[1-(méthylsulfonyl)-4-pipéridylthio]imidazo[1,2-a]pyridine, ou
la 5-[1-trifluorométhyl]-4-pipéridylthio]imidazo[1,2-a]pyridine.
13. Utilisation d'un composé de formule (I'') défini dans la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.
14. Procédé de préparation d'un composé de formule (I''') :




(I'').

- dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;
A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂-, ou un groupe de formule :

EP 0 471 236 B1



5

dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène

10

ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle ; et

B³ représente -O-CO-NR¹⁵R¹⁶ ou -O-CO-R¹⁹, où R¹⁵, R¹⁶ et R¹⁹ ont les définitions indiquées dans la revendication 1,

15

ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ;

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

20


ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

25

à condition que le composé de formule (I''') ne soit pas de la 5-[2-(N-chloroacétylcarbamoyloxy)-éthylthio]imidazo[1,2-a]pyridine, ni l'un de ses sels, ni l'un de ses solvats,

lequel procédé comporte le fait de faire réagir un composé de formule :

30




35

dans laquelle les symboles ont les définitions indiquées ci-dessus,

avec un composé de formule Q¹-NR¹⁵R¹⁶ ou G¹-CO(O)_q-R¹⁹ où Q¹, G¹ et q ont les définitions indiquées dans la revendication 4, et les autres symboles ont les définitions indiquées dans la revendication 1, ou bien le fait de faire réagir un composé de formule :

40

45



50


dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées ci-dessus,

avec un composé de formule HX¹-A-B³ où X¹ représente -S-, -O- ou -R³-, et les autres symboles ont les définitions indiquées ci-dessus,

55


ou bien le fait de faire réagir un composé de formule :

EP 0 471 236 B1



5

10 dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées ci-dessus, avec un composé de formule E^1-A-B^3 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées ci-dessus, ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :




15

20

dans laquelle tous les symboles ont les définitions indiquées ci-dessus.

- 25 15. Procédé conforme à la revendication 14, dans lequel le groupe amino éventuellement protégé représenté par R^1 et R^2 est un groupe amino, acylamino où le groupe acyle est le même que celui de R^1 , ou tritylamino.
- 30 16. Procédé conforme à la revendication 14, dans lequel X représente -S- ou -O-, et B^3 représente -O-CONHR¹⁶ où R^{16} a la définition indiquée dans la revendication 1.
- 35 17. Procédé conforme à la revendication 14, dans lequel on prépare la 5-[2-(méthylcarbamyloxy)éthylthio]imidazo[1,2-b]pyridine, ou la 5-[2-[3-(hydroxy)propylcarbamyloxy]éthylthio]imidazo[1,2-b]pyridine.
- 40 18. Utilisation d'un composé de formule (I''') défini dans la revendication 14 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.
19. Procédé de préparation d'un composé conforme à la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :




45

50

dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 4, avec un composé de formule HX^1-A-B^1 dans laquelle X^1 représente -S-, -O- ou -NR³-, et les autres symboles ont les définitions indiquées dans la revendication 4, ou bien, quand X représente -S- ou -O-, le fait de faire réagir un composé de formule :

55


EP 0 471 236 B1



dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 4,


avec un composé de formule E^1-A-B^1 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 4,

ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 4.


20. Procédé de préparation d'un composé conforme à la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :



dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 4,

avec un composé de formule HX^1-A-B^2 où X^1 représente -S-, -O- ou -NR³- et les autres symboles ont les définitions indiquées dans la revendication 4,

ou bien, quand l'atome d'azote du groupe amino de B^2 forme un cycle avec un atome de carbone de A, le fait de faire réagir un composé de formule :




dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 4,

avec un composé de formule E^1-A-B^2 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 4,


ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :

EP 0 471 236 B1




dans laquelle tous les symboles ont les définitions indiquées dans la revendication 4.

21. Utilisation d'un composé de formule (1) :



(1)

dans laquelle A' représente
(a) un groupe de formule




dans laquelle x, y et z représentent des nombres entiers valant de 0 à 5, respectivement ; chacun des symboles Rᵉ, Rᶠ, Rᵍ, Rʰ, Rⁱ et Rʲ représente (1) un atome d'hydrogène, ou (2) un groupe alkyle en C₁-C₆ ou alcényle en C₂-C₆ qui peut porter de 1 à 5 substituants, ou (3) un groupe phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, aryle en C₆-C₁₄, ou hétérocyclique aromatique monocyclique ou bicyclique comportant de 1 à 4 hétéroatomes, choisis parmi les atomes de soufre, d'oxygène et d'azote, lequel groupe peut porter de 1 à 4 substituants, ou bien Rᵉ et Rᶠ, Rᵍ et Rʰ ou Rⁱ et Rʲ peuvent être raccordés pour former un cycle de type cycloalcane en C₃-C₈, ou bien Rᵉ ou Rᵍ peut être raccordé à Rⁱ ou Rʲ pour former un cycle de type cycloalcane en C₃-C₈, lequel peut comporter un atome d'oxygène en fonction éther en n'importe quelle position possible,

ou bien

(b) un groupe de formule -CH₂CH₂OCH₂CH₂-,

ou bien

(c) un groupe de formule :



dans laquelle a et b représentent des nombres entiers valant respectivement de 0 à 5 ;



Rᵉ et Rᵍ sont identiques ou différents et représentent chacun un atome d'hydrogène ou d'halogène ou un groupe alkyle en C₁-C₆, alcényle en C₂-C₆, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆ ou aryle en C₆-C₁₄, lequel groupe peut porter de 1 à 4 substituants, ou encore un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle ;

Rᶠ représente un atome d'hydrogène ou Rᵈ, et Rᵈ représente un groupe alkyle en C₁-C₆, cycloalkyle en C₃-C₈, alcényle en C₂-C₆, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆ ou aryle en C₆-C₁₄,

EP 0 471 236 B1

lequel groupe peut porter de 1 à 5 substituants ;

R^c et R^a ou R^f, ou R^c et R^g ou R^h, ou R^c et Rⁱ ou R^j pouvant être raccordés ensemble pour former un groupe de formule :



où Q et R représentent des nombres entiers valant respectivement 2 ou 3 ;


ledit substituant d'un groupe alkyle en C₁-C₆, cycloalkyle en C₃-C₈ ou alcényle en C₂-C₆ étant un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique en C₄-C₇, alcoxy en C₁-C₆, phénoxy, 1-naphtyloxy, 2-naphtyloxy, carbamyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant d'un groupe phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆ ou hétérocyclique étant un atome d'halogène ou un groupe alkyle en C₁-C₆, alcényle en C₂-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ou d'un sel d'un tel composé, acceptable en pharmacie, et d'un diluant, véhicule ou excipient, acceptable en pharmacie, pour la préparation d'une composition inhibant l'angiogénèse.

Revendications pour l'Etat contractant suivant : GR

1. Procédé de préparation d'une composition inhibitrice de la calmoduline, comprenant le fait de mélanger un composé de formule (I) :




(I)

dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;

A représente

(a) un groupe de formule



dans laquelle l, m et n représentent des nombres entiers dont chacun vaut de 0 à 5, et chacun des symboles R⁴, R⁵, R⁶, R⁷, R⁸ et R⁹ représente indépendamment (1) un atome d'hydrogène

EP 0 471 236 B1

ou (2) un groupe alkyle en C₁-C₆, alcényle en C₂-C₆, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou bien R⁴ et R⁵, ou R⁶ et R⁷, ou R⁸ et R⁹, peuvent être liés l'un à l'autre pour former un cycle, ou bien R⁴ ou R⁶ peut être lié respectivement à R⁸ ou R⁹ pour former un cycle, ou

(b) un groupe de formule -CH₂CH₂OCH₂CH₂-, ou

(c) un groupe de formule :



dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

B représente


(a) un groupe de formule -NR¹⁰R¹¹ où R¹⁰ représente (1) un atome d'hydrogène ou (2) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (3) un groupe choisi parmi -CO-R¹², -SO₂R¹³, -CO-NR¹⁴R¹⁵ et -CS-NR¹⁴R¹⁵, et R¹¹ représente -CO-R¹⁶, -CO-OR¹⁶, -SO₂R¹⁷, -CO-NR¹⁴R¹⁵ ou -CS-NR¹⁴R¹⁵, ou

(b) un groupe de formule -O-R¹⁸ où R¹⁸ représente (1) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (2) -CO-NR¹⁴R¹⁵ ou -CO-R¹⁹,

où R¹², R¹⁴ et R¹⁵ représentent indépendamment (1) un atome d'hydrogène ou (2) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle, qui peut porter de 1 à 4 substituants ;

R¹³, R¹⁶, R¹⁷, R¹⁸ et R¹⁹ représentent indépendamment un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényle en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle,


R¹⁰ et R³ pouvant être liés ensemble pour former un cycle de formule :



dans laquelle q représente un nombre entier valant 2 ou 3, et A et R¹¹ ont les définitions indiquées ci-dessus,


ou R¹⁰ pouvant être lié avec R⁴, R⁵ ou R⁸ pour former un cycle de formule :

EP 0 471 236 B1




où q et r représentent respectivement un nombre entier valant 2 ou 3, et R¹¹ a la définition indiquée plus haut,

ou R¹⁰ pouvant être lié à R¹¹ pour former un cycle de formule :



et R¹⁴ et R¹⁵ pouvant former, conjointement avec l'atome d'azote adjacent, un groupe 1-aziridine, 1-azétidine, pipéridine, perhydro-1-azépine, perhydro-1-azocine, morpholine, thiomorpholine, 1-pipérazine, 3-thiazolidine, 1-indole, perhydro-1-indole, 2-isindole, perhydro-2-isindole, 1,2,3,4-tétrahydro-1-quinoline, 1,2,3,4-tétrahydro-2-isoquinoline, perhydro-1-quinoline, perhydro-2-isoquinoline, 3-azabicyclo[3.2.2]non-3-yle, 9-carbazole, 10-acridanyle,




10,11-dihydro-5H-5-dibenzo[b,f]azépine, 5,6,11,12-tétrahydro-5-dibenzo[b,f]azocine, 1,2,3,4-tétrahydro-9-carbazole, 10-phénoxazine ou 10-phénothiazine ;

EP 0 471 236 B1

- ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyle en C₁-C₆)amino, N,N-di(alkyle en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyle ou (alkyle en C₁-C₆)carbonyle ;
- 5 ledit substituant placé sur un groupe alkyle en C₁-C₃₀ ou alcényle en C₂-C₃₀ pouvant être (1) un groupe cycloalkyle en C₃-C₈, (2) un groupe phényle portant éventuellement de 1 à 4 substituants choisis parmi les atomes d'halogène et les groupes alkyle en C₁-C₆, alcoxy en C₁-C₆, hydroxy et nitro, (3) un groupe naphthyle, (4) un atome d'halogène, (5) un groupe cyano, (6) un groupe oxo ou (7) un groupe alcoxy en C₁-C₆ ;
- 10 ledit substituant placé sur un groupe cycloalkyle en C₃-C₈ ou un groupe hydrocarboné saturé bicyclique ou tricyclique pouvant être un groupe alkyle en C₁-C₆, halogénoalkyle en C₁-C₆, hydroxyalkyle en C₁-C₆, acyloxy(alkyle en C₁-C₆), (alcoxy en C₁-C₆)-(alkyle en C₁-C₆), alcoxy en C₁-C₆, halogénoalcoxy en C₁-C₆, (alcoxy en C₁-C₆)carbonyle(alcoxy en C₁-C₆), alcényloxy en C₁-C₆, aralkyloxy, (alcoxy en C₁-C₆)-(alcoxy en C₁-C₆), (alcoxy en C₁-C₆)carbonyle, carboxy, carbamyle, N,N-di-
- 15 (alkyle en C₁-C₆)carbamyle, N-(alkyle en C₁-C₆)carbamyle, cyano, nitro, hydroxy, acyloxy, amino, (alkyle en C₁-C₆)sulfonylamino, acylamino, (alcoxy en C₁-C₆)carbonylamino, acyle, mercapto, alkylthio en C₁-C₆, alkylsulfinyle en C₁-C₆, alkylsulfonyl en C₁-C₆ ou oxo, ou encore un atome d'halogène ;
- ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyle en C₁-C₆)carbamyle ;
- 20 ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyle en C₁-C₆)carbamyle ;
- 25 et R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényle ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyle en C₁-C₆)carbamyle,
- 30 ou un sel ou un solvat d'un tel composé, acceptable en pharmacie, et un véhicule, diluant ou excipient, acceptable en pharmacie.
2. Procédé conforme à la revendication 1, dans lequel le groupe amino éventuellement protégé représenté par R¹ ou R² est un groupe amino, acylamino où le groupe acyle est le même que celui indiqué pour R¹¹ dans la revendication 1, ou tritylamino.
3. Utilisation d'un composé de formule (I) défini dans la revendication 1 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, pour la préparation d'une composition inhibitrice de la calmoduline.
- 40 4. Composé de formule (I') :

45




50

(I ')

- dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;
- 55 A représente un groupe de formule :

EP 0 471 236 B1



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ ou



dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

B¹ représente un groupe amino acylé par un groupe acyle dérivé d'un acide carboxylique comportant 2 atomes de carbone ou plus, d'un acide sulfonique, d'un acide carbamique ou d'un acide thiocarbamique ;

et R¹ et R² sont identiques ou différents et représentent chacun, indépendamment, un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène, ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyl ou (alkyl en C₁-C₆)carbamyle, ou sel ou solvat d'un tel composé.

5. Composé conforme à la revendication 4, dans lequel B¹ représente un groupe de formule $-\text{NR}^{10}\text{R}^{11}$, où R¹⁰ représente (1) un atome d'hydrogène ou (2) un groupe alkyle en C₁-C₃₀ linéaire ou ramifié, un groupe cycloalkyle en C₃-C₈, un groupe hydrocarboné bicyclique ou tricyclique saturé, constitué par la condensation de cycles comportant de 5 à 8 chaînons, ou un groupe alcényl en C₂-C₃₀, phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, phényl, 1-naphtyle, 2-naphtyle, phénanthryle, anthryl, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou (3) un groupe choisi parmi $-\text{CO}-\text{R}^{12}$, $-\text{SO}_2\text{R}^{13}$, $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ et $-\text{CS}-\text{NR}^{14}\text{R}^{15}$;

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyl, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryl, thiényl, furyl, benzothiényl ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyl, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

et R¹¹ représente $-\text{CO}-\text{R}^{16}$, $-\text{SO}_2\text{R}^{17}$, $-\text{CO}-\text{NR}^{14}\text{R}^{15}$ ou $-\text{CS}-\text{NR}^{14}\text{R}^{15}$, où R¹², R¹³, R¹⁴, R¹⁵, R¹⁶ et R¹⁷ ont les définitions indiquées dans la revendication 1 ;

ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyl, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyl ou (alkyl en C₁-C₆)carbonyl ; et

le groupe amino éventuellement protégé représenté par R¹ ou R² étant un groupe amino, acylamino où le groupe acyle est le même que celui indiqué pour R¹¹, ou tritylamino.

6. Composé conforme à la revendication 4, dans lequel B¹ représente $-\text{NH}-\text{SO}_2\text{R}^{17}$ où R¹⁷ a la définition indiquée dans la revendication 1.

7. Composé conforme à la revendication 4, dans lequel X représente $-\text{S}-$ ou $-\text{O}-$, et B¹ représente $-\text{NH}-\text{SO}_2\text{R}^{17}$ où R¹⁷ a la définition indiquée dans la revendication 1.


8. Composé conforme à la revendication 4, qui est la 5-[2-(méthylsulfonylamino)éthylthio]imidazo[1,2-a]pyridine.

EP 0 471 236 B1

la 5-[2-(trifluorométhylsulfonylamino)éthylthio]imidazo[1,2-a]pyridine,
 la 5-[3-(méthylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
 la 5-[3-(trifluorométhylsulfonylamino)propyloxy]imidazo[1,2-a]pyridine,
 la 5-[3-(méthylsulfonylamino)propylthio]imidazo[1,2-a]pyridine, ou
 la 5-[3-(trifluorométhylsulfonylamino)propylthio]imidazo[1,2-a]pyridine.


9. Utilisation d'un composé de formule (I') défini dans la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.

10. Composé de formule (I'') :




(I '')


dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-,
 où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;
 A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂-, ou un groupe de formule :



dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;
 B² représente un groupe de formule :



où tous les symboles ont les définitions indiquées dans la revendication 1,
 ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamoyle, cyano, hydroxy, carboxy, (alcoxy

EP 0 471 236 B1

en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbonyle ;

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyle, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

et R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényle, furyle, benzothiényne ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyle ou (alkyl en C₁-C₆)carbamyle,

ou un sel ou un solvat d'un tel composé.


11. Composé conforme à la revendication 10, dans lequel le groupe amino éventuellement protégé représenté par R¹ et R² est un groupe amino, acylamino où le groupe acyle est le même que celui de R¹, ou tritylamino.

12. Composé conforme à la revendication 10, dans lequel X représente -S- ou -O-.

13. Composé conforme à la revendication 10, qui est la 5-[1-(méthylsulfonyl)-4-pipéridylthio]imidazo[1,2-a]pyridine, ou la 5-[1-trifluorométhyl)-4-pipéridylthio]imidazo[1,2-a]pyridine.

14. Utilisation d'un composé de formule (I'') défini dans la revendication 10 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.


15. Composé de formule (I''') :



(I '' ')


dans laquelle X représente -S-, -SO-, -SO₂-, -O- ou -NR³-, où R³ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆, éventuellement substitué, qui peut porter de 1 à 4 substituants ;

A représente un groupe de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1, ou un groupe de formule -CH₂CH₂OCH₂CH₂-, ou un groupe de formule :

EP 0 471 236 B1



5

dans laquelle o et p représentent des nombres entiers valant de 0 à 5 ;

R¹ et R², qui peuvent être identiques ou différents, représentent chacun un atome d'hydrogène ou un groupe alkyle en C₁-C₆, phényl-(alkyle en C₁-C₆) ou naphtyl-(alkyle en C₁-C₆), éventuellement substitué, ou encore un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle, qui peut porter de 1 à 4 substituants, ou encore un atome d'halogène ou un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C₁-C₆)carbonyl ou (alkyl en C₁-C₆)carbamyle ; et

10

B³ représente -O-CO-NR¹⁵R¹⁶ ou -O-CO-R¹⁹, où R¹⁵, R¹⁶ et R¹⁹ ont les définitions indiquées dans la revendication 1,

15

ledit substituant placé sur un groupe alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C₁-C₆)amino, N,N-di(alkyl en C₁-C₆)amino, amino cyclique comportant de 4 à 7 chaînons, alcoxy en C₁-C₆, aryloxy en C₆-C₁₀, carbamyle, cyano, hydroxy, carboxy, (alcoxy en C₁-C₆)carbonyl ou (alkyl en C₁-C₆)carbonyl ;

20

ledit substituant placé sur un groupe phényl-alkyle en C₁-C₆ ou naphtyl-alkyle en C₁-C₆ pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, hydroxy, (alcoxy en C₁-C₆)carbonyl, carbamyle ou (alkyl en C₁-C₆)carbamyle ;

25

ledit substituant placé sur un groupe phényle, 1-naphtyle, 2-naphtyle, phénanthryle, anthryle, thiényl, furyl, benzothiényl ou benzofurannyle pouvant être un atome d'halogène ou un groupe alkyle en C₁-C₆, alcoxy en C₁-C₆, nitro, cyano, oxo, hydroxy, amino, (alcoxy en C₁-C₆)carbonyl, carbamyle ou (alkyl en C₁-C₆)carbamyle.

16. Composé conforme à la revendication 15, dans lequel le groupe amino éventuellement protégé représenté par R¹ et R² est un groupe amino, acylamino où le groupe acyle est le même que celui de R¹¹, ou tritylamino.

30

17. Composé conforme à la revendication 15, dans lequel X représente -S- ou -O-, et B³ représente -O-CONHR¹⁶ où R¹⁶ a la définition indiquée dans la revendication 1.

35

18. Composé conforme à la revendication 15, qui est
la 5-[2-(méthylcarbamoyloxy)éthylthio]imidazo[1,2-b]pyridine, ou
la 5-[2-[3-(hydroxy)propylcarbamoyloxy]éthylthio]imidazo[1,2-b]pyridine.


40

19. Utilisation d'un composé de formule (I''') défini dans la revendication 15 ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, dans la préparation d'une composition inhibitrice de la calmoduline.

40

20. Procédé de préparation d'un composé conforme à la revendication 4 ou 10, ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :

45



50

dans laquelle tous les symboles ont les définitions indiquées dans la revendication 1 ou 2,


avec un composé de formule Q¹-NR¹⁴R¹⁵, G¹-CO(O)_q-R¹⁶, ou G²-SO₂R¹⁷, où Q¹ représente PhO-CO-, G-CO- ou G-CS- (où Ph représente un groupe phényle et G représente un atome d'halogène), G¹ représente un atome d'halogène ou un groupe R¹⁶(O)_q-CO-O- (où q vaut 0 ou 1), q vaut 0 ou 1, G² représente un atome d'halogène ou un groupe de formule R¹⁷SO₂O-, et les autres symboles ont les définitions indiquées dans la revendication 1.

55

EP 0 471 236 B1

21. Procédé de préparation d'un composé conforme à la revendication 4 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :

5




10

dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 4,

15

avec un composé de formule HX^1-A-B^1 dans laquelle X^1 représente -S-, -O- ou $-NR^3$, et les autres symboles ont les définitions indiquées dans la revendication 4, ou bien, quand X représente -S- ou -O-, le fait de faire réagir un composé de formule :

20



25


dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 4,

avec un composé de formule E^1-A-B^1 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 4,

30

ou bien, quand X représente -SO- ou $-SO_2$ -, le fait d'oxyder un composé de formule :

35




40

dans laquelle tous les symboles ont les définitions indiquées dans la revendication 4.

22. Procédé de préparation d'un composé conforme à la revendication 10 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :

45

50



dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 10,

55

avec un composé de formule HX^1-A-B^2 où X^1 représente -S-, -O- ou $-NR^3$ et les autres symboles ont les définitions indiquées dans la revendication 10,

ou bien, quand l'atome d'azote du groupe amino de B^2 forme un cycle avec un atome de carbone de

EP 0 471 236 B1

A, le fait de faire réagir un composé de formule :



dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 10,

avec un composé de formule E^1-A-B^2 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 10,

ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :



dans laquelle tous les symboles ont les définitions indiquées dans la revendication 10.

23. Procédé de préparation d'un composé conforme à la revendication 15 ou d'un sel ou d'un solvat d'un tel composé, lequel procédé comporte le fait de faire réagir un composé de formule :



dans laquelle les symboles ont les définitions indiquées dans la revendication 15, avec un composé de formule $Q^1-NR^{15}R^{16}$ ou $G^1-CO(O)_q-R^{19}$ où Q^1 , G^1 et q ont les définitions indiquées dans la revendication 20, et les autres symboles ont les définitions indiquées dans la revendication 1, ou bien le fait de faire réagir un composé de formule :




dans laquelle E représente un atome d'halogène et les autres symboles ont les définitions indiquées dans la revendication 15,

avec un composé de formule HX^1-A-B^3 où X^1 représente -S-, -O- ou -R³-, et les autres symboles ont les définitions indiquées dans la revendication 15,

ou bien le fait de faire réagir un composé de formule :


EP 0 471 236 B1



dans laquelle X^2 représente -S- ou -O- et les autres symboles ont les définitions indiquées dans la revendication 15,


avec un composé de formule E^1-A-B^3 où E^1 représente un groupe partant et les autres symboles ont les définitions indiquées dans la revendication 15,

ou bien, quand X représente -SO- ou -SO₂-, le fait d'oxyder un composé de formule :




dans laquelle tous les symboles ont les définitions indiquées dans la revendication 15.

24. Utilisation d'un composé de formule (1) :



(1)

dans laquelle A' représente
(a) un groupe de formule




dans laquelle x, y et z représentent des nombres entiers valant de 0 à 5, respectivement ; chacun des symboles R^e, R^f, R^g, R^h, R^i et R^j représente (1) un atome d'hydrogène, ou (2) un groupe alkyle en C₁-C₆ ou alcényle en C₂-C₆ qui peut porter de 1 à 5 substituants, ou (3) un groupe phényl-alkyle en C₁-C₆, naphtyl-alkyle en C₁-C₆, aryle en C₆-C₁₄, ou hétérocyclique aromatique monocyclique ou bicyclique comportant de 1 à 4 hétéroatomes, choisis parmi les atomes de soufre, d'oxygène et d'azote, lequel groupe peut porter de 1 à 4 substituants, ou bien R^e et R^f , R^g et R^h ou R^i et R^j peuvent être raccordés pour former un cycle de type cycloalcane en C₃-C₈, ou bien R^e ou R^g peut être raccordé à R^f ou R^j pour former un cycle de type cycloalcane en C₃-C₈, lequel peut comporter un atome d'oxygène en fonction éther en n'importe quelle position possible, ou bien

EP 0 471 236 B1

(b) un groupe de formule $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$,
ou bien

(c) un groupe de formule :





dans laquelle a et b représentent des nombres entiers valant respectivement de 0 à 5 ;

R^a et R^b sont identiques ou différents et représentent chacun un atome d'hydrogène ou d'halogène ou un groupe alkyle en C_1-C_6 , alcényle en C_2-C_6 , phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 ou aryle en C_6-C_{14} , lequel groupe peut porter de 1 à 4 substituants, ou encore un groupe nitro, nitroso, amino éventuellement protégé, (alcoxy en C_1-C_6)carbonyle ou (alkyl en C_1-C_6)carbamyle ;

R^c représente un atome d'hydrogène ou R^d , et R^d représente un groupe alkyle en C_1-C_6 , cycloalkyle en C_3-C_8 , alcényle en C_2-C_6 , phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 ou aryle en C_6-C_{14} , lequel groupe peut porter de 1 à 5 substituants ;

R^e et R^f ou R^i , ou R^e et R^g ou R^h , ou R^e et R^j ou R^l pouvant être raccordés ensemble pour former un groupe de formule :



où Q et R représentent des nombres entiers valant respectivement 2 ou 3 ;

ledit substituant d'un groupe alkyle en C_1-C_6 , cycloalkyle en C_3-C_8 ou alcényle en C_2-C_6 étant un atome d'halogène ou un groupe nitro, amino, N-mono(alkyl en C_1-C_6)amino, N,N-di(alkyl en C_1-C_6)amino, amino cyclique en C_4-C_7 , alcoxy en C_1-C_6 , phénoxy, 1-naphtyloxy, 2-naphtyloxy, carbamyle, cyano, hydroxy, carboxy, (alcoxy en C_1-C_6)carbonyle ou (alkyl en C_1-C_6)carbamyle ;

ledit substituant d'un groupe phényl-alkyle en C_1-C_6 , naphtyl-alkyle en C_1-C_6 ou hétérocyclique étant un atome d'halogène ou un groupe alkyle en C_1-C_6 , alcényle en C_2-C_6 , alcoxy en C_1-C_6 , nitro, cyano, oxo, hydroxy, amino, (alcoxy en C_1-C_6)carbonyle, carbamyle ou (alkyl en C_1-C_6)carbamyle ;

ou d'un sel ou d'un solvat d'un tel composé, acceptable en pharmacie, pour la préparation d'une composition inhibant l'angiogénèse.